# Patent

## Title
Hepatitis C virus inhibitors

## Abstract

The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for inhibiting the function of the NS5A protein.

## Background
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims the benefit of U.S. Provisional Application Ser. No. 61/290,898 filed Dec. 30, 2009.


FIELD OF THE DISCLOSURE
The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for inhibiting the function of the NS5A protein.
BACKGROUND OF THE DISCLOSURE
The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for inhibiting the function of the NS5A protein.
HCV is a major human pathogen, infecting an estimated 170 million persons worldwide—roughly five times the number infected by human immunodeficiency virus type 1. A substantial fraction of these HCV infected individuals develop serious progressive liver disease, including cirrhosis and hepatocellular carcinoma.
The current standard of care for HCV, which employs a combination of pegylated-interferon and ribavirin, has a non-optimal success rate in achieving sustained viral response and causes numerous side effects. Thus, there is a clear and long-felt need to develop effective therapies to address this undermet medical need.
HCV is a positive-stranded RNA virus. Based on a comparison of the deduced amino acid sequence and the extensive similarity in the 5′ untranslated region, HCV has been classified as a separate genus in the Flaviviridae family. All members of the Flaviviridae family have enveloped virions that contain a positive stranded RNA genome encoding all known virus-specific proteins via translation of a single, uninterrupted, open reading frame.
Considerable heterogeneity is found within the nucleotide and encoded amino acid sequence throughout the HCV genome due to the high error rate of the encoded RNA dependent RNA polymerase which lacks a proof-reading capability. At least six major genotypes have been characterized, and more than 50 subtypes have been described with distribution worldwide. The clinical significance of the genetic heterogeneity of HCV has demonstrated a propensity for mutations to arise during monotherapy treatment, thus additional treatment options for use are desired. The possible modulator effect of genotypes on pathogenesis and therapy remains elusive.
The single strand HCV RNA genome is approximately 9500 nucleotides in length and has a single open reading frame (ORF) encoding a single large polyprotein of about 3000 amino acids. In infected cells, this polyprotein is cleaved at multiple sites by cellular and viral proteases to produce the structural and non-structural (NS) proteins. In the case of HCV, the generation of mature non-structural proteins (NS2, NS3, NS4A, NS4B, NS5A, and NS5B) is effected by two viral proteases. The first one is believed to be a metalloprotease and cleaves at the NS2-NS3 junction; the second one is a serine protease contained within the N-terminal region of NS3 (also referred to herein as NS3 protease) and mediates all the subsequent cleavages downstream of NS3, both in cis, at the NS3-NS4A cleavage site, and in trans, for the remaining NS4A-NS4B, NS4B-NS5A, NS5A-NS5B sites. The NS4A protein appears to serve multiple functions by both acting as a cofactor for the NS3 protease and assisting in the membrane localization of NS3 and other viral replicase components. The formation of a NS3-NS4A complex is necessary for proper protease activity resulting in increased proteolytic efficiency of the cleavage events. The NS3 protein also exhibits nucleoside triphosphatase and RNA helicase activities. NS5B (also referred to herein as HCV polymerase) is a RNA-dependent RNA polymerase that is involved in the replication of HCV with other HCV proteins, including NS5A, in a replicase complex.
Compounds useful for treating HCV-infected patients are desired which selectively inhibit HCV viral replication. In particular, compounds which are effective to inhibit the function of the NS5A protein are desired. The HCV NS5A protein is described, for example, in the following references: S. L. Tan, et al., Virology, 284:1-12 (2001); K.-J. Park, et al., J. Biol. Chem., 30711-30718 (2003); T. L. Tellinghuisen, et al., Nature, 435, 374 (2005); R. A. Love, et al., J. Virol, 83, 4395 (2009); N. Appel, et al., J. Biol. Chem., 281, 9833 (2006); L. Huang, J. Biol. Chem., 280, 36417 (2005); C. Rice, et al., World Patent Application WO-2006093867, Sep. 8, 2006.
SUMMARY OF THE DISCLOSURE
The present disclosure provides compounds which selectively inhibit HCV viral replication, as characterized by Formula (I):




or a stereoisomer or a pharmaceutically acceptable salt or solvate thereof, wherein:

Q1, Q2, Q3, Q4, Q5, Q6, Q7, and Q8 are each independently selected from CRw and N; wherein each RW is independently selected from hydrogen, C1-6 alkoxy, C1-4 alkyl, and halo;
L is a five-membered heterocyclyl group selected from the group consisting of




wherein Rx at each occurrence is independently hydrogen, halogen, or C1-4 alkyl optionally substituted by —C(O)OR3 or —NMe2, wherein Ry at each occurrence is independently hydrogen or C1-4 alkyl, and wherein R3 is hydrogen or C1-4 alkyl;

R1 and R2 are independently selected from cycloalkyl, heteroaryl, heterocyclyl, C1-6 alkoxy, —NHRp, and alkyl, wherein said alkyl is optionally substituted by one, two, or three substituents independently selected from aryl, alkenyl, cycloalkyl, heterocyclyl, heteroaryl, —OSi(Rq)3, —OR4, —SR5, —C(O)OR6, —NHC(O)R7, —NRaRb, and —C(O)NRcRd,
wherein Rp is heterocyclyl,
wherein Rq at each occurrence is independently C1-4 alkyl or phenyl,
wherein any said aryl or heteroaryl may optionally be substituted with one or more substituents independently selected from C1-4 alkyl, C1-4 haloalkyl, arylalkyl, heterocyclyl, heterocyclylalkyl, halogen, cyano, nitro, —OR4, —C(O)OR6, —NRaRb, (NRaRb)alkyl, and —OP(O)(OH)(OR5), and
wherein any said cycloalkyl or heterocyclyl may optionally be fused onto an aromatic ring and may optionally be substituted with one or more substituents independently selected from C1-4 alkyl, halogen, aryl, arylalkyl, heteroarylalkyl, fused cyclopropyl, —NRaRb, oxo, —OR4, —C(O)OR6, and —C(O)R7;
R4 is hydrogen, C1-6 alkyl, or benzyl;
R5 is hydrogen or C1-4 alkyl;
R6 at each occurrence is independently C1-6 alkyl, aryl, benzyl, or heteroaryl;
R7 at each occurrence is independently selected from —OR8, C1-6 alkyl, C1-6 haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, and -L1-R11, wherein said aryl and heteroaryl may optionally be substituted by one or more substituents independently selected from C1-4 alkyl, halogen, —OR9, and —NRaRb, and wherein said cycloalkyl and heterocyclyl may optionally be substituted by one or more substituents independently selected from C1-4 alkyl, —C(O)OR10, fused cyclopropyl, cyano, oxo, phenyl —NRaRb, -L1-R11, and —C(O)-L1-R11;
R8 is C1-6 alkyl, phenyl optionally substituted with a halogen, arylalkyl, —(C1-3 alkylene)-C(O)OR10, or —(C1-3 alkylene)-O—(C1-3 alkylene);
R9 is hydrogen, C1-6 alkyl, or C1-4 haloalkyl;
R10 is hydrogen, C1-6 alkyl, phenyl, or benzyl;
L1 is C1-2 alkylene optionally substituted by one or two substituents independently selected from C1-4 alkyl, —OR12, —OC(O)R13, —NRaRb, phenyl, and oxo;
R11 is C1-6 alkyl, C1-4 haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, —OR8, or —NRaRb, wherein said aryl or heteroaryl may optionally be substituted by one or more substituents independently selected from C1-4 alkyl, halogen, —OR9, nitro, cyano, and —NRaRb, and wherein said cycloalkyl or heterocyclyl may optionally be substituted by one or more substituents independently selected from C1-4 alkyl, benzyl, phenyl, halogen, —OR9, oxo, fused cyclopropyl, —NRaRb, —C(O)R10, and —C(O)OR10;
R12 is hydrogen, C1-4 alkyl, aryl, or heteroaryl, wherein said aryl or heteroaryl may optionally be substituted by one or more substituents independently selected from C1-4 alkyl, halogen, and —OR9;
R13 is C1-4 alkyl or aryl;
Ra and Rb are independently selected from hydrogen, C1-6 alkyl, cycloalkyl, arylalkyl, heteroaryl, heterocyclyl, —C(O)R14, —C(O)OR15, —C(O)NRcRd, and (NRcRd)alkyl, or alternatively, Ra and Rb, together with the nitrogen atom to which they are attached, form a five- or six-membered ring or bridged bicyclic ring structure, wherein said five- or six-membered ring or bridged bicyclic ring structure optionally may contain one or two additional heteroatoms independently selected from nitrogen, oxygen, and sulfur and may contain one, two, or three substituents independently selected from C1-6 alkyl, C1-4 haloalkyl, aryl, halogen, and —OR9;
Rc and Rd are independently selected from hydrogen, C1-4 alkyl, benzyl, and cycloalkyl;
R14 is C1-4 alkyl, arylalkyl, aryl, or heteroaryl, each optionally substituted by one, two or three substituents independently selected from C1-4 alkyl, halogen, and —OR9; and
R15 is C1-6 alkyl, arylalkyl, or C1-4 haloalkyl.
The compounds of the present disclosure can be effective to inhibit the function of the HCV NS5A protein. In particular, the compounds of the present disclosure can be effective to inhibit the HCV 1b genotype or multiple genotypes of HCV. Therefore, this disclosure also encompasses: (1) compositions comprising a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier; and (2) a method of treating an HCV infection in a patient, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof.


DETAILED DESCRIPTION OF THE DISCLOSURE
In a first aspect of the present disclosure compounds of Formula (I) are provided:




In a first embodiment of the first aspect, the present disclosure provides a compound of Formula (I), or a stereoisomer or a pharmaceutically acceptable salt or solvate thereof, wherein:
Q1, Q2, Q3, Q4, Q5, Q6, Q7, and Q8 are each independently selected from CRw and N; wherein each RW is independently selected from hydrogen, C1-6 alkoxy, C1-4 alkyl, and halo;
L is a five-membered heterocyclyl group selected from the group consisting of




wherein Rx at each occurrence is independently hydrogen, halogen, or C1-4 alkyl optionally substituted by —C(O)OR3 or —NMe2, wherein Ry at each occurrence is independently hydrogen or C1-4 alkyl, and wherein R3 is hydrogen or C1-4 alkyl;

R1 and R2 are independently selected from cycloalkyl, heteroaryl, heterocyclyl, C1-6 alkoxy, —NHRp, and alkyl, wherein said alkyl is optionally substituted by one, two, or three substituents independently selected from aryl, alkenyl, cycloalkyl, heterocyclyl, heteroaryl, —OSi(Rq)3, —OR4, —SR5, —C(O)OR6, —NHC(O)R7, —NRaRb, and —C(O)NRcRd,
wherein Rp is heterocyclyl,
wherein Rq at each occurrence is independently C1-4 alkyl or phenyl,
wherein any said aryl or heteroaryl may optionally be substituted with one or more substituents independently selected from C1-4 alkyl, C1-4 haloalkyl, arylalkyl, heterocyclyl, heterocyclylalkyl, halogen, cyano, nitro, —OR4, —C(O)OR6, —NRaRb, (NRaRb)alkyl, and —OP(O)(OH)(OR5), and
wherein any said cycloalkyl or heterocyclyl may optionally be fused onto an aromatic ring and may optionally be substituted with one or more substituents independently selected from C1-4 alkyl, halogen, aryl, arylalkyl, heteroarylalkyl, fused cyclopropyl, —NRaRb, oxo, —OR4, —C(O)OR6, and —C(O)R7;
R4 is hydrogen, C1-6 alkyl, or benzyl;
R5 is hydrogen or C1-4 alkyl;
R6 at each occurrence is independently C1-6 alkyl, aryl, benzyl, or heteroaryl;
R7 at each occurrence is independently selected from —OR8, C1-6 alkyl, C1-6 haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, and -L1-R11, wherein said aryl and heteroaryl may optionally be substituted by one or more substituents independently selected from C1-4 alkyl, halogen, —OR9, and —NRaRb, and wherein said cycloalkyl and heterocyclyl may optionally be substituted by one or more substituents independently selected from C1-4 alkyl, —C(O)OR10, fused cyclopropyl, cyano, oxo, phenyl, —NRaRb, -L1-R11, C(O)R11, and —C(O)-L1-R11;
R8 is C1-6 alkyl, phenyl optionally substituted with a halogen, arylalkyl, —(C1-3 alkylene)-C(O)OR10, or —(C1-3 alkylene)-O—(C1-3 alkylene);
R9 is hydrogen, C1-6 alkyl, or C1-4 haloalkyl;
R10 is hydrogen, C1-6 alkyl, phenyl, or benzyl;
L1 is C1-2 alkylene optionally substituted by one or two substituents independently selected from C1-4 alkyl, —OR12, —OC(O)R13, —NRaRb, phenyl, and oxo;
R11 is C1-6 alkyl, C1-4 haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, —OR8, or —NRaRb, wherein said aryl or heteroaryl may optionally be substituted by one or more substituents independently selected from C1-4 alkyl, halogen, —OR9, nitro, cyano, and —NRaRb, and wherein said cycloalkyl or heterocyclyl may optionally be substituted by one or more substituents independently selected from C1-4 alkyl, benzyl, phenyl, halogen, —OR9, oxo, fused cyclopropyl, —NRaRb, —C(O)R10, and —C(O)OR10;
R12 is hydrogen, C1-4 alkyl, aryl, or heteroaryl, wherein said aryl or heteroaryl may optionally be substituted by one or more substituents independently selected from C1-4 alkyl, halogen, and —OR9;
R13 is C1-4 alkyl or aryl;
Ra and Rb are independently selected from hydrogen, C1-6 alkyl, cycloalkyl, arylalkyl, heteroaryl, heterocyclyl, —C(O)R14, —C(O)OR15, —C(O)NRcRd, and (NRcRd)alkyl, or alternatively, Ra and Rb, together with the nitrogen atom to which they are attached, form a five- or six-membered ring or bridged bicyclic ring structure, wherein said five- or six-membered ring or bridged bicyclic ring structure optionally may contain one or two additional heteroatoms independently selected from nitrogen, oxygen, and sulfur and may contain one, two, or three substituents independently selected from C1-6 alkyl, C1-4 haloalkyl, aryl, halogen, and —OR9;
Rc and Rd are independently selected from hydrogen, C1-4 alkyl, benzyl, and cycloalkyl;
R14 is C1-4 alkyl, arylalkyl, aryl, or heteroaryl, each optionally substituted by one, two or three substituents independently selected from C1-4 alkyl, halogen, and —OR9; and
R15 is C1-6 alkyl, arylalkyl, or C1-4 haloalkyl.
In a second embodiment of the first aspect, the present disclosure provides a compound of Formula (I), or a stereoisomer or a pharmaceutically acceptable salt or solvate thereof, wherein:
L is a five-membered heterocyclyl group selected from the group consisting of




wherein Rx at each occurrence is independently hydrogen, halogen, or C1-4 alkyl optionally substituted by —C(O)OR3 or —NMe2, wherein Ry at each occurrence is independently hydrogen or C1-4 alkyl, and wherein R3 is hydrogen or C1-4 alkyl;

R1 and R2 are independently selected from the group consisting of:




wherein:

n is 0, 1, 2, or 3;
R16 at each occurrence is independently C1-4 alkyl, —OR4, or oxo;
R17 at each occurrence is independently hydrogen or —C(O)R7;
R18 is C1-6 alkyl optionally substituted by —OR4 or —SR5;
R4 is hydrogen or C1-6 alkyl;
R5 is C1-4 alkyl;
R7 at each occurrence is independently selected from —OR8, C1-6 alkyl, C1-6 haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, and -L1-R11, wherein said aryl and heteroaryl may optionally be substituted by one or more, preferably one to three, substituents independently selected from C1-4 alkyl, halogen, —OR9, and —NRaRb, and wherein said cycloalkyl and heterocyclyl may optionally be substituted by one or more, preferably one to three, substituents independently selected from C1-4 alkyl, —C(O)OR10, oxo, phenyl, fused cyclopropyl, —NRaRb, -L1-R11, —C(O)R11, and —C(O)-L1-R11;
R8 is C1-6 alkyl or arylalkyl;
R9 is hydrogen, C1-6 alkyl, or C1-4 haloalkyl;
R10 is hydrogen, phenyl, C1-6 alkyl, or benzyl;
L1 is C1-2 alkylene optionally substituted by one or two substituents independently selected from C1-4 alkyl, —OR12, —OC(O)R13, —NRaRb, phenyl, and oxo;
R11 is C1-6 alkyl, C1-4 haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, or —NRaRb, wherein said aryl or heteroaryl may optionally be substituted by one or more, preferably one to three, substituents independently selected from C1-4 alkyl, halogen, —OR9, nitro, cyano, and —NRaRb, and wherein said cycloalkyl or heterocyclyl may optionally be substituted by one or more, preferably one to three, substituents independently selected from C1-4 alkyl, benzyl, halogen, —OR9, oxo, phenyl, fused cyclopropyl, —NRaRb, —C(O)R10, and —C(O)OR10;
R12 is hydrogen, C1-4 alkyl, aryl, or heteroaryl, wherein said aryl or heteroaryl may optionally be substituted by one or more, preferably one to three, substituents independently selected from C1-4 alkyl, halogen, and —OR9;
R13 is C1-4 alkyl or aryl;
Ra and Rb are independently selected from hydrogen, C1-6 alkyl, cycloalkyl, arylalkyl, heteroaryl, heterocyclyl, —C(O)R14, —C(O)OR15, —C(O)NRcRd, and (NRcRd)alkyl, or alternatively, Ra and Rb, together with the nitrogen atom to which they are attached, form a five- or six-membered ring or bridged bicyclic ring structure, wherein said five- or six-membered ring or bridged bicyclic ring structure optionally may contain one or two additional heteroatoms independently selected from nitrogen, oxygen, and sulfur and may contain one, two, or three substituents independently selected from C1-6 alkyl, C1-4 haloalkyl, aryl, halogen, and —OR9;
Rc and Rd are independently selected from hydrogen, C1-4 alkyl, benzyl, and cycloalkyl;
R14 is C1-4 alkyl, arylalkyl, aryl, or heteroaryl, each optionally substituted by one, two or three substituents independently selected from C1-4 alkyl, halogen, and —OR9; and
R15 is C1-6 alkyl, arylalkyl, or C1-4 haloalkyl.
In a third embodiment of the first aspect, the present disclosure provides a compound of Formula (I), or a stereoisomer or a pharmaceutically acceptable salt or solvate thereof, wherein:
L is a five-membered heterocyclyl group selected from the group consisting of




wherein Rx at each occurrence is independently hydrogen, halogen, or C1-4 alkyl optionally substituted by —C(O)OR3 or —NMe2, wherein Ry at each occurrence is independently hydrogen or C1-4 alkyl, and wherein R3 is hydrogen or C1-4 alkyl;

R1 and R2 are independently selected from the group consisting of:




wherein:

n is 0, 1, 2, or 3;
R16 at each occurrence is independently C1-4 alkyl, —OR4, or oxo;
R17 at each occurrence is independently hydrogen or —C(O)R7;
R18 is C1-6 alkyl optionally substituted by —OR4 or —SR5;
R4 is hydrogen or C1-6 alkyl;
R5 is C1-4 alkyl;
R7 at each occurrence is independently selected from the group consisting of —OCH2Ph, —OC(CH3)3, methyl, ethyl, isopropyl, —CH2Ph, cyclopropyl, cyclobutyl, phenyl,



















In a fourth embodiment of the first aspect, the present disclosure provides a compound of Formula (Ia):




or a stereoisomer or a pharmaceutically acceptable salt or solvate thereof, wherein:

Rx is hydrogen, methyl, —CH2C(O)OR3, or —CH2NMe2, wherein R3 is hydrogen or C1-4 alkyl;
R1 and R2 are each independently




R17 at each occurrence is independently hydrogen or —C(O)R7;
R7 at each occurrence is independently —OR8 or benzyl; and
R8 is C1-4 alkyl or benzyl.
In a fifth embodiment of the first aspect, the present disclosure provides a compound of Formula (Ib):




or a stereoisomer or a pharmaceutically acceptable salt or solvate thereof, wherein:

Rx is hydrogen or C1-4 alkyl;
R1 and R2 are independently selected from:




wherein:

R16 is hydrogen, OH, or —OR4, wherein R4 is hydrogen or C1-4 alkyl;
R17 at each occurrence is independently hydrogen or —C(O)R7;
R7 at each occurrence is independently selected from —OR8, C1-6 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, heterocyclyl, aryl, heteroaryl, and -L1-R11, wherein said aryl and heteroaryl may optionally be substituted by one, two, or three substituents independently selected from C1-4 alkyl, halogen, —OR9, and —NRaRb, and wherein said cycloalkyl and heterocyclyl may optionally be substituted by one, two, or three substituents independently selected from C1-4 alkyl, —C(O)OR10, oxo, phenyl, fused cyclopropyl, —NRaRb, -L1-R11, —C(O)R11, and —C(O)-L1-R11;
R8 is C1-4 alkyl or benzyl;
R9 is hydrogen or C1-4 alkyl;
R10 is C1-4 alkyl, phenyl, or benzyl;
L1 is C1-2 alkylene optionally substituted by one or two substituents independently selected from C1-4 alkyl, —OR12, —OC(O)R13, —NRaRb, phenyl, and oxo;
R11 is C1-4 alkyl, C1-4 haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, or —NRaRb, wherein said aryl or heteroaryl may optionally be substituted by one, two, or three substituents independently selected from C1-4 alkyl, halogen, —OR9, and —NRaRb, and wherein said cycloalkyl or heterocyclyl may optionally be substituted by one, two, or three substituents independently selected from C1-4 alkyl, benzyl, phenyl, halogen, —OR9, oxo, fused cyclopropyl, —NRaRb, —C(O)R10, and —C(O)OR10;
R12 is hydrogen, C1-4 alkyl, aryl, or heteroaryl, wherein said aryl or heteroaryl may optionally be substituted by one or more, preferably one to three, substituents independently selected from C1-4 alkyl, halogen, and —OR9;
R13 is C1-4 alkyl;
Ra and Rb are independently selected from hydrogen, C1-4 alkyl, —C(O)R14, or alternatively, Ra and Rb, together with the nitrogen atom to which they are attached, form a five- or six-membered ring, wherein said five- or six-membered ring optionally may contain one additional heteroatom selected from nitrogen, oxygen, and sulfur and may contain one, two, or three substituents independently selected from C1-4 alkyl, C1-4 haloalkyl, aryl, halogen, and —OR9;
R14 is C1-4 alkyl;
R17a is heteroarylalkyl; and
R18 is C1-4 alkyl optionally substituted by —OR4 or —SR5, wherein R4 and R5 are each independently C1-4 alkyl.
In a sixth embodiment of the first aspect, the present disclosure provides a compound of Formula (Ib), or a stereoisomer or a pharmaceutically acceptable salt or solvate thereof, wherein:
Rx is hydrogen;
R1 and R2 are independently selected from:




wherein:

R16 is hydrogen, OH, or —OR4, wherein R4 is hydrogen or C1-4 alkyl;
R17 at each occurrence is independently hydrogen or —C(O)R7;
R7 is selected from the group consisting of —OCH2Ph, —OC(CH3)3, methyl, ethyl, —CH2Ph, cyclopropyl, cyclobutyl, phenyl,



















R17a is




In a seventh embodiment of the first aspect, the present disclosure provides a compound of Formula (Ic):




or a stereoisomer or a pharmaceutically acceptable salt or solvate thereof, wherein:

R1 and R2 are independently selected from:




R17 at each occurrence is independently hydrogen or —C(O)R7;
R7 at each occurrence is independently selected from the group consisting of —OR8, C1-4 alkyl, C3-6 cycloalkyl, benzyl, aryl, heterocyclyl, heteroaryl, and -L1-R11, wherein said aryl and heteroaryl may optionally be substituted by one, two, or three substituents independently selected from C1-4 alkyl, halogen, —OR9, and —NRaRb, and wherein said cycloalkyl and heterocyclyl may optionally be substituted by one or more, preferably one to three, substituents independently selected from C1-4 alkyl, —OR9, —NRaRb, and oxo;
R8 is C1-4 alkyl or benzyl;
R9 is hydrogen or C1-4 alkyl;
R10 is hydrogen, C1-4 alkyl, or benzyl;
L1 is C1-2 alkylene optionally substituted by one or two substituents independently selected from C1-4 alkyl, —OR12, —OC(O)R13, —NRaRb, and oxo;
R11 is C1-4 alkyl, cycloalkyl, aryl, or heteroaryl, wherein said aryl or heteroaryl may optionally be substituted by one, two, or three substituents independently selected from C1-4 alkyl, halogen, —OR9, and —NRaRb, and wherein said cycloalkyl or heterocyclyl may optionally be substituted by one, two, or three substituents independently selected from C1-4 alkyl, halogen, —OR9, oxo, and —NRaRb;
R12 is hydrogen or C1-4 alkyl;
R13 is C1-4 alkyl;
R17b is —OR8; and
Ra and Rb are each independently hydrogen or C1-4 alkyl.
In an eighth embodiment of the first aspect, the present disclosure provides a compound of Formula (Ic), or a stereoisomer or a pharmaceutically acceptable salt or solvate thereof, wherein:
Rx is hydrogen;
R7 at each occurrence is selected from the group consisting of —OCH2Ph,
—OC(CH3)3, —CH2Ph, cyclopropyl, cyclobutyl,







R17b is —OC(CH3)3 or —OCH2Ph.
In a ninth embodiment of the first aspect, the present disclosure provides a compound of Formula (Id):




or a stereoisomer or a pharmaceutically acceptable salt or solvate thereof, wherein:

Rx is hydrogen or C1-4 alkyl;
R1 and R2 are each independently




R16 is hydrogen or —OH;
R17 at each occurrence is independently hydrogen or —C(O)R7;
R7 at each occurrence is independently selected from the group consisting of —OR8, C1-4 alkyl, heteroaryl, and -L1-R11, wherein said heteroaryl may optionally be substituted by one, two, or three substituents independently selected from C1-4 alkyl, halogen, and —OR9;
R8 is C1-4 alkyl or benzyl;
R9 is hydrogen or C1-4 alkyl;
L1 is C1-2 alkylene optionally substituted by one or two substituents independently selected from C1-4 alkyl, —OR12, and oxo;
R11 is aryl, C1-4 alkyl, cycloalkyl, aryl, or heteroaryl, wherein said aryl or heteroaryl may optionally be substituted by one, two, or three substituents independently selected from C1-4 alkyl, halogen, and —OR9; and
R12 is hydrogen or C1-4 alkyl.
In a tenth embodiment of the first aspect, the present disclosure provides a compound of Formula (Ie):




or a pharmaceutically acceptable salt or solvate thereof, wherein:

Rx and Ry are each independently hydrogen or C1-4 alkyl;
R1 and R2 are each independently selected from




R16 is hydrogen or —OR4, wherein R4 is hydrogen or C1-4 alkyl;
R17 at each occurrence is independently hydrogen or —C(O)R7;
R7 at each occurrence is independently selected from the group consisting of: —OR8, C1-4 alkyl, aryl, C3-6 cycloalkyl, heterocyclyl, heteroaryl, and -L1-R11, wherein said aryl and heteroaryl may optionally be substituted by one, two, or three substituents independently selected from C1-4 alkyl, halogen, —OR9, and —NRaRb, and wherein said cycloalkyl and heterocyclyl may optionally be substituted by one or more, preferably one to three, substituents independently selected from C1-4 alkyl, —OR9, —NRaRb, and oxo;
R8 is C1-4 alkyl or benzyl;
R9 is hydrogen or C1-4 alkyl;
L1 is C1-2 alkylene optionally substituted by one or two substituents independently selected from C1-4 alkyl, —OR12, —OC(O)R13, —NRaRb, and oxo;
R11 is C1-4 alkyl, cycloalkyl, aryl, or heteroaryl, wherein said aryl or heteroaryl may be optionally substituted by one, two, or three substituents independently selected from C1-4 alkyl, halogen, —OR9, and —NRaRb, and wherein said cycloalkyl or heterocyclyl may optionally be substituted by one or more, preferably one to three, substituents independently selected from C1-4 alkyl, halogen, —OR9, oxo, and —NRaRb;
R9 is hydrogen, C1-4 alkyl, or C1-4 haloalkyl;
R10 is C1-4 alkyl or benzyl;
R12 is hydrogen or C1-4 alkyl;
R13 is C1-4 alkyl;
Ra and Rb are each independently hydrogen, C1-4 alkyl, or —C(O)R14; and
R14 is C1-4 alkyl.
In an eleventh embodiment of the first aspect, the present disclosure provides a compound of Formula (Ie), or a stereoisomer or a pharmaceutically acceptable salt or solvate thereof, wherein:
Rx is hydrogen;
Ry is hydrogen or C1-4 alkyl; and
R7 at each occurrence is independently selected from the group consisting of —OCH2Ph, —OC(CH3)3, methyl, ethyl, isopropyl, benzyl, cyclopropyl, cyclobutyl,




In a twelfth embodiment of the first aspect, the present disclosure provides a compound of Formula (If):




or a stereoisomer or a pharmaceutically acceptable salt or solvate thereof, wherein:

Rx is hydrogen or C1-4 alkyl;




R1 and R2 are each independently
R16 is hydrogen or —OH;
R17 at each occurrence is independently hydrogen or —C(O)R7;
R7 at each occurrence is independently —OR8 or —CH2Ph; and
R8 is C1-4 alkyl or benzyl.
In a thirteenth embodiment of the first aspect, the present disclosure provides a compound of Formula (Ig):




or a stereoisomer or a pharmaceutically acceptable salt or solvate thereof, wherein:

Ry is hydrogen or C1-4 alkyl;
R1 and R2 are each independently




R17 at each occurrence is independently hydrogen or —C(O)R7; and
R7 at each occurrence is independently —OR8; and
R8 is C1-4 alkyl or benzyl.
In a fourteenth embodiment of the first aspect, the present disclosure provides a compound of Formula (Ih):




or a stereoisomer or a pharmaceutically acceptable salt or solvate thereof, wherein:

Ry is hydrogen or C1-4 alkyl;
R1 and R2 are each independently




R16 is hydrogen or —OH; and
R17 at each occurrence is independently hydrogen or —C(O)R7;
R7 at each occurrence is independently —OR8 or benzyl; and
R8 is C1-4 alkyl or benzyl.
In a fifteenth embodiment of the first aspect, the present disclosure provides a compound of Formula (Ii):




or a stereoisomer or a pharmaceutically acceptable salt or solvate thereof, wherein:

Q is S or O;
R1 and R2 are each independently




R17 at each occurrence is independently hydrogen or —C(O)R7; and
R7 at each occurrence is independently selected from the group consisting of —OR8, C1-4 alkyl, and benzyl; and
R8 is C1-4 alkyl or benzyl.
In a sixteenth embodiment of the first aspect, the present disclosure provides a compound of Formula (Ij):




or a stereoisomer or a pharmaceutically acceptable salt or solvate thereof, wherein:

Rx is hydrogen or C1-4 alkyl;
R1 and R2 are each independently




R17 at each occurrence is independently hydrogen or —C(O)R7; and
R7 at each occurrence is independently C1-4 alkyl or benzyl.
In a seventeenth embodiment of the first aspect, the present disclosure provides a compound of Formula (Ik):




or a stereoisomer or a pharmaceutically acceptable salt or solvate thereof, wherein:

Rx is hydrogen or C1-4 alkyl;
R1 and R2 are independently selected from:




R17 at each occurrence is independently hydrogen or —C(O)R7;
R7 at each occurrence is independently C1-4 alkyl, phenyl, C1-6 alkoxy, thienyl, isoxazolyl, tetrahydrofuryl, or benzyl; and
R17a is




In a second aspect the present disclosure provides a composition comprising a compound of Formula (I):




or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier, wherein Formula (I) is defined according to any of the embodiments described above in the first aspect of the present disclosure.

In a first embodiment of the second aspect the composition further comprises at least one additional compound having anti-HCV activity.
In a second embodiment of the second aspect at least one of the additional compounds is an interferon or a ribavirin.
In a third embodiment of the second aspect the interferon is selected from interferon alpha 2B, pegylated interferon alpha, consensus interferon, interferon alpha 2A, and lymphoblastiod interferon tau.
In a fourth embodiment of the second aspect the present disclosure provides a composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, a pharmaceutically acceptable carrier, and at least one additional compound having anti-HCV activity, wherein at least one of the additional compounds is selected from interleukin 2, interleukin 6, interleukin 12, a compound that enhances the development of a type 1 helper T cell response, interfering RNA, anti-sense RNA, Imiqimod, ribavirin, an inosine 5′-monophospate dehydrogenase inhibitor, amantadine, and rimantadine.
In a fifth embodiment of the second aspect the present disclosure provides a composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, a pharmaceutically acceptable carrier, and at least one additional compound having anti-HCV activity, wherein at least one of the additional compounds is effective to inhibit the function of a target selected from HCV metalloprotease, HCV serine protease, HCV polymerase, HCV helicase, HCV NS4B protein, HCV entry, HCV assembly, HCV egress, HCV NS5A protein, and IMPDH for the treatment of an HCV infection.
In a third aspect the present disclosure provides a method of treating an HCV infection in a patient, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I):




or a pharmaceutically acceptable salt or solvate thereof, wherein Formula (I) is defined according to any of the embodiments described above in the first aspect of the present disclosure.

In a first embodiment of the third aspect the method further comprises administering at least one additional compound having anti-HCV activity prior to, after or simultaneously with the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof.
In a second embodiment of the third aspect at least one of the additional compounds is an interferon or a ribavirin.
In a third embodiment of the third aspect the interferon is selected from interferon alpha 2B, pegylated interferon alpha, consensus interferon, interferon alpha 2A, and lymphoblastiod interferon tau.
In a fourth embodiment of the third aspect the present disclosure provides a method of treating an HCV infection in a patient, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, and at least one additional compound having anti-HCV activity prior to, after or simultaneously with the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein at least one of the additional compounds is selected from interleukin 2, interleukin 6, interleukin 12, a compound that enhances the development of a type 1 helper T cell response, interfering RNA, anti-sense RNA, Imiqimod, ribavirin, an inosine 5′-monophospate dehydrogenase inhibitor, amantadine, and rimantadine.
In a fifth embodiment of the third aspect the present disclosure provides a method of treating an HCV infection in a patient, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, and at least one additional compound having anti-HCV activity prior to, after or simultaneously with the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein at least one of the additional compounds is effective to inhibit the function of a target selected from HCV metalloprotease, HCV serine protease, HCV polymerase, HCV helicase, HCV NS4B protein, HCV entry, HCV assembly, HCV egress, HCV NS5A protein, and IMPDH for the treatment of an HCV infection.
In another aspect the present disclosure provides a compound of Formula (X):




or a stereoisomer or a pharmaceutically acceptable salt or solvate thereof, wherein:

L is a five-membered heterocyclyl group selected from the group consisting




wherein Rx at each occurrence is independently hydrogen, halogen, or C1-4 alkyl optionally substituted by —C(O)OR3 or —NMe2, wherein Ry at each occurrence is independently hydrogen or C1-4 alkyl, and wherein R3 is hydrogen or C1-4 alkyl;

R1 and R2 are independently selected from cycloalkyl, heteroaryl, heterocyclyl, C1-6 alkoxy, —NHRp, and alkyl, wherein said alkyl is optionally substituted by one, two, or three substituents independently selected from aryl, alkenyl, cycloalkyl, heterocyclyl, heteroaryl, —OSi(Rq)3, —OR4, —SR5, —C(O)OR6, —NHC(O)R7, —NRaRb, and —C(O)NRcRd,
wherein Rp is heterocyclyl,
wherein Rq at each occurrence is independently C1-4 alkyl or phenyl,
wherein any said aryl or heteroaryl may optionally be substituted with one or more, preferably one to three, substituents independently selected from C1-4 alkyl, C1-4 haloalkyl, arylalkyl, heterocyclyl, heterocyclylalkyl, halogen, cyano, nitro, —OR4, —C(O)OR6, —NRaRb, (NRaRb)alkyl, and —OP(O)(OH)(OR5), and
wherein any said cycloalkyl or heterocyclyl may optionally be fused onto an aromatic ring and may optionally be substituted with one or more, preferably one to three, substituents independently selected from C1-4 alkyl, halogen, aryl, arylalkyl, heteroarylalkyl, fused cyclopropyl, —NRaRb, oxo, —OR4, —C(O)OR6, and —C(O)R7;
R4 is hydrogen, C1-6 alkyl, or benzyl;
R5 is hydrogen or C1-4 alkyl;
R6 at each occurrence is independently C1-6 alkyl, aryl, benzyl, or heteroaryl;
R7 at each occurrence is independently selected from —OR8, C1-6 alkyl, C1-6 haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, and -L1-R11, wherein said aryl and heteroaryl may optionally be substituted by one or more, preferably one to three, substituents independently selected from C1-4 alkyl, halogen, —OR9, and —NRaRb, and wherein said cycloalkyl and heterocyclyl may optionally be substituted by one or more, preferably one to three, substituents independently selected from C1-4 alkyl, —C(O)OR10, oxo, phenyl, fused cyclopropyl, —NRaRb, -L1-R11, —C(O)R11, and —C(O)-L1-R11;
R8 is C1-6 alkyl or arylalkyl;
R9 is hydrogen, C1-6 alkyl, or C1-4 haloalkyl;
R10 is hydrogen, C1-6 alkyl, phenyl, or benzyl;
L1 is C1-2 alkylene optionally substituted by one or two substituents independently selected from C1-4 alkyl, —OR12, —OC(O)R13, —NRaRb, phenyl, and oxo;
R11 is C1-6 alkyl, C1-4 haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, or —NRaRb, wherein said aryl or heteroaryl may optionally be substituted by one or more, preferably one to three, substituents independently selected from C1-4 alkyl, halogen, —OR9, nitro, cyano, and —NRaRb, and wherein said cycloalkyl or heterocyclyl may optionally be substituted by one or more, preferably one to three, substituents independently selected from C1-4 alkyl, benzyl, phenyl, halogen, —OR9, oxo, fused cyclopropyl, —NRaRb, —C(O)R10, and —C(O)OR10;
R12 is hydrogen, C1-4 alkyl, aryl, or heteroaryl, wherein said aryl or heteroaryl may optionally be substituted by one or more, preferably one to three, substituents independently selected from C1-4 alkyl, halogen, and —OR9;
R13 is C1-4 alkyl or aryl;
Ra and Rb are independently selected from hydrogen, C1-6 alkyl, cycloalkyl, arylalkyl, heteroaryl, heterocyclyl, —C(O)R14, —C(O)OR15, —C(O)NRcRd, and (NRcRd)alkyl, or alternatively, Ra and Rb, together with the nitrogen atom to which they are attached, form a five- or six-membered ring or bridged bicyclic ring structure, wherein said five- or six-membered ring or bridged bicyclic ring structure optionally may contain one or two additional heteroatoms independently selected from nitrogen, oxygen, and sulfur and may contain one, two, or three substituents independently selected from C1-6 alkyl, C1-4 haloalkyl, aryl, halogen, and —OR9;
Rc and Rd are independently selected from hydrogen, C1-4 alkyl, benzyl, and cycloalkyl;
R14 is C1-4 alkyl, arylalkyl, aryl, or heteroaryl, each optionally substituted by one, two or three substituents independently selected from C1-4 alkyl, halogen, and —OR9; and
R15 is C1-6 alkyl, arylalkyl, or C1-4 haloalkyl.
Other aspects of the present disclosure may include suitable combinations of embodiments disclosed herein.
Yet other aspects and embodiments may be found in the description provided herein.
The description of the present disclosure herein should be construed in congruity with the laws and principals of chemical bonding. In some instances it may be necessary to remove a hydrogen atom in order to accommodate a substituent at any given location.
Certain features of the structure of Formula (I) are further illustrated below:




In Formula (I), R1 and R2 are independent from each other, although in some circumstances they are preferably the same.
R1C(O)— and R2C(O)— can be derived from any of the “Caps” disclosed herein, and in principle can be derived from any carboxylic acid or derivatives. When R1 or R2 contains a nitrogen that can be “capped” with an acyl group, for example, when R1 or R2 is an amino alkyl group or a nitrogen-containing heterocyclyl group, such an acyl group can also be derived from any of the “Caps” disclosed herein.
When a “cap” contains a stereogenic center, the stereogeneic center can take either (R)— or (S)— configuration. For example, a pyrrolidine-containing “cap” can take either (R)— or (S)— configuration as depicted below:




When a cyclopropyl ring is fused onto a cycloalkyl or heterocyclyl ring, the CH2 group of the fused cyclopropyl ring can take either α- or β-position. For example, a pyrrolidine ring with a fused cyclopropyl group may take either of the two forms depicted below:




Thus, this disclosure is intended to cover all possible stereoisomers even when a single stereoisomer, or no stereochemistry, is described in a structure. It should be understood that the compounds encompassed by the present disclosure are those that are suitably stable for use as pharmaceutical agent.
It is intended that the definition of any substituent or variable at a particular location in a molecule be independent of its definitions elsewhere in that molecule. For example, for substituent (R16)n, when n is 2, each of the two R16 groups may be the same or different.
All patents, patent applications, and literature references cited in the specification are herein incorporated by reference in their entirety. In the case of inconsistencies, the present disclosure, including definitions, will prevail.
DEFINITIONS
Definitions have been provided above for each of the groups defined. In addition, the following definitions shall be used.
As used herein, the singular forms “a”, “an”, and “the” include plural reference unless the context clearly dictates otherwise.
Unless stated otherwise, all aryl, cycloalkyl, heteroaryl, and heterocyclyl groups of the present disclosure may be substituted as described in each of their respective definitions. For example, the aryl part of an arylalkyl group may be substituted as described in the definition of the term “aryl.”
The term “acetyl,” as used herein, refers to —C(O)CH3.
The term “alkenyl,” as used herein, refers to a monovalent, straight or branched hydrocarbon chain having one or more, preferably one to two, double bonds therein. The double bond of an alkenyl group can be unconjugated or conjugated to another unsaturated group. Suitable alkenyl groups include, but are not limited to, C2 to C10 alkenyl groups, such as vinyl, allyl, butenyl, pentenyl, hexenyl, butadienyl, pentadienyl, hexadienyl, 2-ethylhexenyl, 2-propyl-2-butenyl, 4-(2-methyl-3-butene)-pentenyl. An alkenyl group can be unsubstituted or substituted with one or two suitable substituents.
The term “alkoxy,” as used herein, refers to an alkyl group attached to the parent molecular moiety through an oxygen atom. Representative examples of alkoxy group include, but are not limited to, methoxy(CH3O—), ethoxy (CH3CH2O—), and t-butoxy ((CH3)3CO—).
The term “alkyl,” as used herein, refers to a group derived from a straight or branched chain saturated hydrocarbon by removal of a hydrogen from one of the saturated carbons. The alkyl group preferably contains from one to ten carbon atoms. Representative examples of alkyl group include, but are not limited to, methyl, ethyl, isopropyl, and tert-butyl.
The term “alkylcarbonyl,” as used herein, refers to an alkyl group attached to the parent molecular moiety through a carbonyl group. Representative examples of alkylcarbonyl group include, but are not limited to, acetyl (—C(O)CH3), propanoyl (—C(O)CH2CH3), n-butyryl (—C(O)CH2CH2CH3), and 2,2-dimethylpropanoyl or pivaloyl (—C(O)C(CH3)3).
The term “allyl,” as used herein, refers to the —CH2CH═CH2 group.
The term “aryl,” as used herein, refers to a group deived from an aromatic carbocycle by removal of a hydrogen atom from an aromatic ring. The aryl group can be monocyclic, bicyclic or polycyclic, wherein in bicyclic or polycyclic aryl group, the aromatic carbocycle can be fused onto another four- to six-membered aromatic or non-aromatic carbocycle. Representative examples of aryl groups include, but are not limited to, phenyl, indanyl, indenyl, naphthyl, and 1,2,3,4-tetrahydronaphth-5-yl.
The term “arylalkyl,” as used herein, refers to an alkyl group substituted with one, two, or three aryl groups, wherein aryl part of the arylalkyl group may optionally be substituted by one to five substituents independently selected from C1 to C6 alkyl, C1 to C4 haloalkyl, C1 to C6 alkoxy, halogen, cyano, and nitro groups. Represented examples of arylalkyl include, but are not limited to, benzyl, 2-phenyl-1-ethyl (PhCH2CH2—), (naphth-1-yl)methyl, and (naphth-2-yl)methyl.
The term “benzyl,” as used herein, refers to a methyl group on which one of the hydrogen atoms is replaced by a phenyl group, wherein said phenyl group may optionally be substituted by one to five substituents independently selected from methyl, trifluoromethyl (—CF3), methoxy (—OCH3), halogen, and nitro (—NO2). Representative examples of benzyl group include, but are not limited to, PhCH2—, 4-MeO—C6H4—CH2—, and 2,4,6-tri-methyl-C6H4—CH2—.
The term “bridged bicyclic ring,” as used herein, refers to a ring structure comprising a bridgehead between two of the ring members, wherein the ring and the bridgehead optionally may independently comprise one or more, preferably one to two, heteroatoms independently selected from nitrogen, oxygen, and sulfur. Illustrated examples of a bridged bicyclic ring structure include, but are not limited to:




The terms “Cap” and “cap,” as used herein, refer to a group that can be used to replace the R1C(O)— or R2C(O)— group in formula (I) or an acyl group residing at a nitrogen atom in the R1 or R2 group, for example, the R7C(O)— group. It should be understood that “Cap” or “cap” can also refer to a reagent which is a precursor to the final “cap” in a compound of formula (I), for example, a carboxylic acid or its derivatives that can react with an amino group to form an amide bond, such as an ester, acyl halide, acyl azide, and so on.
The term “carbonyl,” as used herein, refers to —C(O)—.
The term “carboxyl,” as used herein, refers to —CO2H.
The term “cyano,” as used herein, refers to —CN.
The term “cycloalkyl,” as used herein, refers to a group derived from a saturated carbocycle, having preferably three to eight carbon atoms, by removal of a hydrogen atom from the saturated carbocycle, wherein the saturated carbocyle can optionally be fused onto one or two other aromatic or nonaromatic carbocycles. Representative examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclopentyl, cyclohexyl, and 1,2,3,4-tetrahydronaphth-1-yl.
The term “formyl,” as used herein, refers to —CHO.
The term “fused cyclopropyl,” as used herein, refers to a cyclopropyl ring fused onto another ring structure, i.e., a methylene group (—CH2—) attached to two




adjacent carbon atoms, as illustrated in the group:

The terms “halo” and “halogen,” as used herein, refer to F, Cl, Br, or I.
The term “haloalkoxy,” as used herein, refers to a haloalkyl group attached to the parent molecular moiety through an oxygen atom.
The term “haloalkyl,” as used herein, refers to an alkyl group substituted by at least one halogen atom. The haloalkyl group can be an alkyl group of which all hydrogen atoms are substituted by halogens. Representative examples of haloalkyl include, but are not limited to, trifluoromethyl (CF3—), 1-chloroethyl (C1CH2CH2—), and 2,2,2-trifluoroethyl (CF3CH2—).
The term “heteroaryl,” as used herein, refers to group derived from a monocyclic, bicyclic, or polycyclic compound comprising at least one aromatic ring comprising one or more, preferably one to three, heteroatoms independently selected from nitrogen, oxygen, and sulfur, by removal of a hydrogen atom from an aromatic ring thereof. As is well known to those skilled in the art, heteroaryl rings have less aromatic character than their all-carbon counterparts. Thus, for the purposes of the disclosure, a heteroaryl group need only have some degree of aromatic character. Illustrative examples of heteroaryl groups include, but are not limited to, pyridyl, pyridazinyl, pyrimidyl, pyrazyl, triazinyl, pyrrolyl, pyrazolyl, imidazolyl, (1,2,3,)- and (1,2,4)-triazolyl, pyrazinyl, pyrimidinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, isoxazolyl, oxazolyl, indolyl, quinolinyl, isoquinolinyl, benzisoxazolyl, benzothiazolyl, benzothienyl, and pyrrolopyridinyl.
The term “heteroarylalkyl,” as used herein, refers to an alkyl group substituted with one, two, or three heteroaryl groups.
The term “heterobicyclyl,” as used herein, refers to a ring structure comprising two fused, bridged, or spirocyclic rings that include carbon and one or more, preferably one to three, heteroatoms independently selected from nitrogen, oxygen, and sulfur. The heterobicyclic ring structure is a subset of heterocyclic ring and can be saturated or unsaturated. Examples of heterobicyclic ring structures include, but are not limited to, tropane, quinuclidine, and 7-azabicyclo[2.2.1]heptane.
The term “heterocyclyl,” as used herein, refers to a group derived from a monocyclic, bicyclic, or polycyclic compound comprising at least one nonaromatic ring comprising one or more, preferably one to three, heteroatoms independently selected from nitrogen, oxygen, and sulfur, by removal of a hydrogen atom from the nonaromatic ring. The heterocyclyl group encompasses the heterobicyclyl group. The heterocyclyl groups of the present disclosure can be attached to the parent molecular moiety through a carbon atom or a nitrogen atom in the group. Examples of heterocyclyl groups include, but are not limited to, morpholinyl, oxazolidinyl, piperazinyl, piperidinyl, pyrrolidinyl, tetrahydrofuryl, thiomorpholinyl, and indolinyl.
The term “heterocyclylalkyl,” as used herein, refers to an alkyl group substituted with one, two, or three heterocyclyl groups.
The terms “hydroxy” or “hydroxyl,” as used herein, refer to —OH.
The term “nitro,” as used herein, refers to —NO2.
The term “—NRaRb,” as used herein, refers to two groups, Ra and Rb, which are attached to the parent molecular moiety through a nitrogen atom, or alternatively Ra and Rb, together with the nitrogen atom to which they are attached, form a 5- or 6-membered ring or a fused- or bridged-bicyclic ring structure optionally containing one, two, or three additional heteroatom independently selected from nitrogen, oxygen, and sulfur. The term “—NRcRd” is defined similarly.
The term “(NRaRb)alkyl,” as used herein, refers to an alkyl group substituted with one, two, or three —NRaRb groups. The term “(NRcRd)alkyl” is defined similarly.
The term “oxo,” as used herein, refers to ═O.
The term “sulfonyl,” as used herein, refers to —SO2—.
The term “trialkylsilyl,” as used herein, refers to —SiR3, wherein each R is C1 to C4 alkyl or phenyl. The three R groups may be the same or different. Representative examples of “trialkylsilyl” include, but are not limited to, trimethylsilyl (TMS), tert-butyldiphenylsilyl (TBDPS), tert-butyldimethylsilyl (TBS or TBDMS), and triisopropylsilyl (TIPS).
Asymmetric centers exist in the compounds of the present disclosure. These centers are designated by the symbols “R” or “S”, depending on the configuration of substituents around the chiral carbon atom. It should be understood that the disclosure encompasses all stereochemical isomeric forms, or mixtures thereof, which possess the ability to inhibit NS5A. Individual stereoisomers of compounds can be prepared synthetically from commercially available starting materials which contain chiral centers or by preparation of mixtures of enantiomeric products followed by separation such as conversion to a mixture of diastereomers followed by separation or recrystallization, chromatographic techniques, or direct separation of enantiomers on chiral chromatographic columns. Starting compounds of particular stereochemistry are either commercially available or can be made and resolved by techniques known in the art.
Certain compounds of the present disclosure may also exist in different stable conformational forms which may be separable. Torsional asymmetry due to restricted rotation about an asymmetric single bond, for example because of steric hindrance or ring strain, may permit separation of different conformers. The present disclosure includes each conformational isomer of these compounds and mixtures thereof.
The term “compounds of the present disclosure”, and equivalent expressions, are meant to embrace compounds of Formula (I), and pharmaceutically acceptable enantiomers, diastereomers, and salts thereof. Similarly, references to intermediates are meant to embrace their salts where the context so permits.
The present disclosure is intended to include all isotopes of atoms occurring in the present compounds. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include deuterium and tritium. Isotopes of carbon include 13C and 14C. Isotopically-labeled compounds of the invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein, using an appropriate isotopically-labeled reagent in place of the non-labeled reagent otherwise employed. Such compounds may have a variety of potential uses, for example as standards and reagents in determining biological activity. In the case of stable isotopes, such compounds may have the potential to favorably modify biological, pharmacological, or pharmacokinetic properties.
The compounds of the present disclosure can exist as pharmaceutically acceptable salts or solvates. The term “pharmaceutically acceptable salt,” as used herein, represents salts or zwitterionic forms of the compounds of the present disclosure which are water or oil-soluble or dispersible, which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of patients without excessive toxicity, irritation, allergic response, or other problem or complication commensurate with a reasonable benefit/risk ratio, and are effective for their intended use The salts can be prepared during the final isolation and purification of the compounds or separately by reacting a suitable nitrogen atom with a suitable acid. Representative acid addition salts include acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate; digluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate, formate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylproprionate, picrate, pivalate, propionate, succinate, tartrate, trichloroacetate, trifluoroacetate, phosphate, glutamate, bicarbonate, para-toluenesulfonate, and undecanoate. Examples of acids which can be employed to form pharmaceutically acceptable addition salts include inorganic acids such as hydrochloric, hydrobromic, sulfuric, and phosphoric, and organic acids such as oxalic, maleic, succinic, and citric.
Basic addition salts can be prepared during the final isolation and purification of the compounds by reacting a carboxy group with a suitable base such as the hydroxide, carbonate, or bicarbonate of a metal cation or with ammonia or an organic primary, secondary, or tertiary amine. The cations of pharmaceutically acceptable salts include lithium, sodium, potassium, calcium, magnesium, and aluminum, as well as nontoxic quaternary amine cations such as ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine, tributylamine, pyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylmorpholine, dicyclohexylamine, procaine, dibenzylamine, N,N-dibenzylphenethylamine, and N,N′-dibenzylethylenediamine. Other representative organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine, and piperazine.
When it is possible that, for use in therapy, therapeutically effective amounts of a compound of Formula (I), as well as pharmaceutically acceptable salts or solvates thereof, may be administered as the raw chemical, it is possible to present the active ingredient as a pharmaceutical composition. Accordingly, the disclosure further provides pharmaceutical compositions, which include therapeutically effective amounts of compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof, and one or more, preferably one to three, pharmaceutically acceptable carriers, diluents, or excipients. The term “therapeutically effective amount,” as used herein, refers to the total amount of each active component that is sufficient to show a meaningful patient benefit, e.g., a sustained reduction in viral load. When applied to an individual active ingredient, administered alone, the term refers to that ingredient alone. When applied to a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially, or simultaneously. The compounds of Formula (I) and pharmaceutically acceptable salts or solvates thereof, are as described above. The carrier(s), diluent(s), or excipient(s) must be acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. In accordance with another aspect of the present disclosure there is also provided a process for the preparation of a pharmaceutical formulation including admixing a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, with one or more, preferably one to three, pharmaceutically acceptable carriers, diluents, or excipients. The term “pharmaceutically acceptable,” as used herein, refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of patients without excessive toxicity, irritation, allergic response, or other problem or complication commensurate with a reasonable benefit/risk ratio, and are effective for their intended use.
Pharmaceutical formulations may be presented in unit dose forms containing a predetermined amount of active ingredient per unit dose. Dosage levels of between about 0.01 and about 250 milligram per kilogram (“mg/kg”) body weight per day, preferably between about 0.05 and about 100 mg/kg body weight per day of the compounds of the present disclosure are typical in a monotherapy for the prevention and treatment of HCV mediated disease. Typically, the pharmaceutical compositions of this disclosure will be administered from about 1 to about 5 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy. The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending on the condition being treated, the severity of the condition, the time of administration, the route of administration, the rate of excretion of the compound employed, the duration of treatment, and the age, gender, weight, and condition of the patient. Preferred unit dosage formulations are those containing a daily dose or sub-dose, as herein above recited, or an appropriate fraction thereof, of an active ingredient. Generally, treatment is initiated with small dosages substantially less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. In general, the compound is most desirably administered at a concentration level that will generally afford antivirally effective results without causing any harmful or deleterious side effects.
When the compositions of this disclosure comprise a combination of a compound of the present disclosure and one or more, preferably one or two, additional therapeutic or prophylactic agent, both the compound and the additional agent are usually present at dosage levels of between about 10 to 150%, and more preferably between about 10 and 80% of the dosage normally administered in a monotherapy regimen.
Pharmaceutical formulations may be adapted for administration by any appropriate route, for example by the oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual, or transdermal), vaginal, or parenteral (including subcutaneous, intracutaneous, intramuscular, intra-articular, intrasynovial, intrasternal, intrathecal, intralesional, intravenous, or intradermal injections or infusions) route. Such formulations may be prepared by any method known in the art of pharmacy, for example by bringing into association the active ingredient with the carrier(s) or excipient(s). Oral administration or administration by injection are preferred.
Pharmaceutical formulations adapted for oral administration may be presented as discrete units such as capsules or tablets; powders or granules; solutions or suspensions in aqueous or non-aqueous liquids; edible foams or whips; or oil-in-water liquid emulsions or water-in-oil emulsions.
For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. Powders are prepared by comminuting the compound to a suitable fine size and mixing with a similarly comminuted pharmaceutical carrier such as an edible carbohydrate, as, for example, starch or mannitol. Flavoring, preservative, dispersing, and coloring agent can also be present.
Capsules are made by preparing a powder mixture, as described above, and filling formed gelatin sheaths. Glidants and lubricants such as colloidal silica, talc, magnesium stearate, calcium stearate, or solid polyethylene glycol can be added to the powder mixture before the filling operation. A disintegrating or solubilizing agent such as agar-agar, calcium carbonate, or sodium carbonate can also be added to improve the availability of the medicament when the capsule is ingested.
Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents, and coloring agents can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, and the like. Lubricants used in these dosage forms include sodium oleate, sodium chloride, and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, betonite, xanthan gum, and the like. Tablets are formulated, for example, by preparing a powder mixture, granulating or slugging, adding a lubricant and disintegrant, and pressing into tablets. A powder mixture is prepared by mixing the compound, suitable comminuted, with a diluent or base as described above, and optionally, with a binder such as carboxymethylcellulose, an aliginate, gelating, or polyvinyl pyrrolidone, a solution retardant such as paraffin, a resorption accelerator such as a quaternary salt and/or and absorption agent such as betonite, kaolin, or dicalcium phosphate. The powder mixture can be granulated by wetting with a binder such as syrup, starch paste, acadia mucilage, or solutions of cellulosic or polymeric materials and forcing through a screen. As an alternative to granulating, the powder mixture can be run through the tablet machine and the result is imperfectly formed slugs broken into granules. The granules can be lubricated to prevent sticking to the tablet forming dies by means of the addition of stearic acid, a stearate salt, talc, or mineral oil. The lubricated mixture is then compressed into tablets. The compounds of the present disclosure can also be combined with a free flowing inert carrier and compressed into tablets directly without going through the granulating or slugging steps. A clear or opaque protective coating consisting of a sealing coat of shellac, a coating of sugar or polymeric material, and a polish coating of wax can be provided. Dyestuffs can be added to these coatings to distinguish different unit dosages.
Oral fluids such as solution, syrups, and elixirs can be prepared in dosage unit form so that a given quantity contains a predetermined amount of the compound. Syrups can be prepared by dissolving the compound in a suitably flavored aqueous solution, while elixirs are prepared through the use of a non-toxic vehicle. Solubilizers and emulsifiers such as ethoxylated isostearyl alcohols and polyoxyethylene sorbitol ethers, preservatives, flavor additive such as peppermint oil or natural sweeteners, or saccharin or other artificial sweeteners, and the like can also be added.
Where appropriate, dosage unit formulations for oral administration can be microencapsulated. The formulation can also be prepared to prolong or sustain the release as for example by coating or embedding particulate material in polymers, wax, or the like.
The compounds of Formula (I), and pharmaceutically acceptable salts or solvates thereof, can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles. Liposomes can be formed from a variety of phopholipids, such as cholesterol, stearylamine, or phophatidylcholines.
The compounds of Formula (I) and pharmaceutically acceptable salts or solvates thereof may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled. The compounds may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamidephenol, polyhydroxyethylaspartamidephenol, or polyethyleneoxidepolylysine substituted with palitoyl residues. Furthermore, the compounds may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates, and cross-linked or amphipathic block copolymers of hydrogels.
Pharmaceutical formulations adapted for transdermal administration may be presented as discrete patches intended to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. For example, the active ingredient may be delivered from the patch by iontophoresis as generally described in Pharmaceutical Research 1986, 3(6), 318.
Pharmaceutical formulations adapted for topical administration may be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols, or oils.
For treatments of the eye or other external tissues, for example mouth and skin, the formulations are preferably applied as a topical ointment or cream. When formulated in an ointment, the active ingredient may be employed with either a paraffinic or a water-miscible ointment base. Alternatively, the active ingredient may be formulated in a cream with an oil-in-water cream base or a water-in oil base.
Pharmaceutical formulations adapted for topical administrations to the eye include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent.
Pharmaceutical formulations adapted for topical administration in the mouth include lozenges, pastilles, and mouth washes.
Pharmaceutical formulations adapted for rectal administration may be presented as suppositories or as enemas.
Pharmaceutical formulations adapted for nasal administration wherein the carrier is a solid include a course powder having a particle size for example in the range 20 to 500 microns which is administered in the manner in which snuff is taken, i.e., by rapid inhalation through the nasal passage from a container of the powder held close up to the nose. Suitable formulations wherein the carrier is a liquid, for administration as a nasal spray or nasal drops, include aqueous or oil solutions of the active ingredient.
Pharmaceutical formulations adapted for administration by inhalation include fine particle dusts or mists, which may be generated by means of various types of metered, dose pressurized aerosols, nebulizers, or insufflators.
Pharmaceutical formulations adapted for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams, or spray formulations.
Pharmaceutical formulations adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats, and soutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules, and tablets.
It should be understood that in addition to the ingredients particularly mentioned above, the formulations may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavoring agents.
The term “patient” includes both human and other mammals.
The term “treating” refers to: (i) preventing a disease, disorder or condition from occurring in a patient that may be predisposed to the disease, disorder, and/or condition but has not yet been diagnosed as having it; (ii) inhibiting the disease, disorder, or condition, i.e., arresting its development; and (iii) relieving the disease, disorder, or condition, i.e., causing regression of the disease, disorder, and/or condition.
The compounds of the present disclosure can also be administered with a cyclosporin, for example, cyclosporin A. Cyclosporin A has been shown to be active against HCV in clinical trials (Hepatology 2003, 38, 1282; Biochem. Biophys. Res. Commun. 2004, 313, 42; J. Gastroenterol. 2003, 38, 567).
Table 1 below lists some illustrative examples of compounds that can be administered with the compounds of this disclosure. The compounds of the disclosure can be administered with other anti-HCV activity compounds in combination therapy, either jointly or separately, or by combining the compounds into a composition.










TABLE 1







Type of Inhibitor



Brand Name
Physiological Class
or Target
Source Company







NIM811

Cyclophilin
Novartis


Debio-025

inhibitors
Debiopharm


Zadaxin

Immuno-
Sciclone




modulator


Suvus

Methylene blue
Bioenvision


Actilon (CPG10101)

TLR9 agonist
Coley


Batabulin (T67)
Anticancer
β-Tubulin
Tularik Inc., South




inhibitor
San Francisco, CA


ISIS 14803
Antiviral
Antisense
ISIS





Pharmaceuticals Inc,





Carlsbad, CA/Elan





Pharmaceuticals





Inc., New York, NY


Summetrel
Antiviral
Antiviral
Endo





Pharmaceuticals





Holdings Inc.,





Chadds Ford, PA


GS-9132 (ACH-806)
Antiviral
HCV inhibitor
Achillion/Gilead


Pyrazolopyrimidine
Antiviral
HCV inhibitors
Arrow Therapeutics


compounds and salts


Ltd.


From


WO2005/047288


26 May 2005


Levovirin
Antiviral
IMPDH inhibitor
Ribapharm Inc.,





Costa Mesa, CA


Merimepodib
Antiviral
IMPDH inhibitor
Vertex


(VX-497)


Pharmaceuticals





Inc., Cambridge,





MA


XTL-6865 (XTL-002)
Antiviral
Monoclonal
XTL




antibody
Biopharmaceuticals





Ltd., Rehovot, Israel


Telaprevir
Antiviral
NS3 serine
Vertex


(VX-950, LY-570310)

protease inhibitor
Pharmaceuticals





Inc., Cambridge,





MA/Eli Lilly and





Co. Inc.,





Indianapolis, IN


HCV-796
Antiviral
NS5B replicase
Wyeth/Viropharma




inhibitor


NM-283
Antiviral
NS5B replicase
Idenix/Novartis




inhibitor


GL-59728
Antiviral
NS5B replicase
Gene Labs/Novartis




inhibitor


GL-60667
Antiviral
NS5B replicase
Gene Labs/Novartis




inhibitor


2′C MeA
Antiviral
NS5B replicase
Gilead




inhibitor


PSI 6130
Antiviral
NS5B replicase
Roche




inhibitor


R1626
Antiviral
NS5B replicase
Roche




inhibitor


2′C Methyl adenosine
Antiviral
NS5B replicase
Merck




inhibitor


JTK-003
Antiviral
RdRp inhibitor
Japan Tobacco Inc.,





Tokyo, Japan


Levovirin
Antiviral
Ribavirin
ICN





Pharmaceuticals,





Costa Mesa, CA


Ribavirin
Antiviral
Ribavirin
Schering-Plough





Corporation,





Kenilworth, NJ


Viramidine
Antiviral
Ribavirin prodrug
Ribapharm Inc.,





Costa Mesa, CA


Heptazyme
Antiviral
Ribozyme
Ribozyme





Pharmaceuticals





Inc., Boulder, CO


BILN-2061
Antiviral
Serine protease
Boehringer




inhibitor
Ingelheim Pharma





KG, Ingelheim,





Germany


SCH 503034
Antiviral
Serine protease
Schering Plough




inhibitor


Zadazim
Immune modulator
Immune
SciClone




modulator
Pharmaceuticals





Inc., San Mateo, CA


Ceplene
Immunomodulator
Immune
Maxim




modulator
Pharmaceuticals





Inc., San Diego, CA


CellCept
Immunosuppressant
HCV IgG
F. Hoffmann-La




immuno-
Roche LTD, Basel,




suppressant
Switzerland


Civacir
Immunosuppressant
HCV IgG
Nabi




immuno-
Biopharmaceuticals




suppressant
Inc., Boca Raton, FL


Albuferon-α
Interferon
Albumin IFN-α2b
Human Genome





Sciences Inc.,





Rockville, MD


Infergen A
Interferon
IFN alfacon-1
InterMune





Pharmaceuticals





Inc., Brisbane, CA


Omega IFN
Interferon
IFN-ω
Intarcia Therapeutics


IFN-β and EMZ701
Interferon
IFN-β and
Transition




EMZ701
Therapeutics Inc.,





Ontario, Canada


Rebif
Interferon
IFN-β1a
Serono, Geneva,





Switzerland


Roferon A
Interferon
IFN-α2a
F. Hoffmann-La





Roche LTD, Basel,





Switzerland


Intron A
Interferon
IFN-α2b
Schering-Plough





Corporation,





Kenilworth, NJ


Intron A and Zadaxin
Interferon
IFN-α2b/α1-
RegeneRx




thymosin
Biopharma. Inc.,





Bethesda, MD/





SciClone





Pharmaceuticals Inc,





San Mateo, CA


Rebetron
Interferon
IFN-α2b/
Schering-Plough




ribavirin
Corporation,





Kenilworth, NJ


Actimmune
Interferon
INF-γ
InterMune Inc.,





Brisbane, CA


Interferon-β
Interferon
Interferon-β-1a
Serono


Multiferon
Interferon
Long lasting IFN
Viragen/Valentis


Wellferon
Interferon
Lymphoblastoid
GlaxoSmithKline




IFN-αn1
plc, Uxbridge, UK


Omniferon
Interferon
natural IFN-α
Viragen Inc.,





Plantation, FL


Pegasys
Interferon
PEGylated IFN-
F. Hoffmann-La




α2a
Roche LTD, Basel,





Switzerland


Pegasys and Ceplene
Interferon
PEGylated IFN-
Maxim




α2a/immune
Pharmaceuticals




modulator
Inc., San Diego, CA


Pegasys and Ribavirin
Interferon
PEGylated IFN-
F. Hoffmann-La




α2a/ribavirin
Roche LTD, Basel,





Switzerland


PEG-Intron
Interferon
PEGylated IFN-
Schering-Plough




α2b
Corporation,





Kenilworth, NJ


PEG-Intron/Ribavirin
Interferon
PEGylated IFN-
Schering-Plough




α2b/ribavirin
Corporation,





Kenilworth, NJ


IP-501
Liver protection
Antifibrotic
Indevus





Pharmaceuticals





Inc., Lexington, MA


IDN-6556
Liver protection
Caspase inhibitor
Idun





Pharmaceuticals





Inc., San Diego, CA


ITMN-191 (R-7227)
Antiviral
Serine protease
InterMune




inhibitor
Pharmaceuticals





Inc., Brisbane, CA


GL-59728
Antiviral
NS5B replicase
Genelabs




inhibitor


ANA-971
Antiviral
TLR-7 agonist
Anadys


Boceprevir
Antiviral
Serine protease
Schering Plough




inhibitor


TMS-435
Antiviral
Serine protease
Tibotec BVBA,




inhibitor
Mechelen, Belgium


BI-201335
Antiviral
Serine protease
Boehringer




inhibitor
Ingelheim Pharma





KG, Ingelheim,





Germany


MK-7009
Antiviral
Serine protease
Merck




inhibitor


PF-00868554
Antiviral
Replicase
Pfizer




inhibitor


ANA598
Antiviral
Non-Nucleoside
Anadys




NS5B polymerase
Pharmaceuticals,




inhibitor
Inc., San Diego, CA,





USA


IDX375
Antiviral
Non-Nucleoside
Idenix




replicase inhibitor
Pharmaceuticals,





Cambridge, MA,





USA


BILB 1941
Antiviral
NS5B polymerase
Boehringer




inhibitor
Ingelheim Canada





Ltd R&D, Laval,





QC, Canada


PSI-7851
Antiviral
Nucleoside
Pharmasset,




polymerase
Princeton, NJ, USA




inhibitor


VCH-759
Antiviral
NS5B polymerase
ViroChem Pharma




inhibitor


VCH-916
Antiviral
NS5B polymerase
ViroChem Pharma




inhibitor


GS-9190
Antiviral
NS5B polymerase
Gilead




inhibitor


Peg-interferon lamda
Antiviral
Interferon
ZymoGenetics/





Bristol-Myers





Squibb









The compounds of the present disclosure may also be used as laboratory reagents. Compounds may be instrumental in providing research tools for designing of viral replication assays, validation of animal assay systems and structural biology studies to further enhance knowledge of the HCV disease mechanisms. Further, the compounds of the present disclosure are useful in establishing or determining the binding site of other antiviral compounds, for example, by competitive inhibition.
The compounds of this disclosure may also be used to treat or prevent viral contamination of materials and therefore reduce the risk of viral infection of laboratory or medical personnel or patients who come in contact with such materials, e.g., blood, tissue, surgical instruments and garments, laboratory instruments and garments, and blood collection or transfusion apparatuses and materials.
This disclosure is intended to encompass compounds having Formula (I) when prepared by synthetic processes or by metabolic processes including those occurring in the human or animal body (in vivo) or processes occurring in vitro.
The abbreviations used in the present application, including particularly in the illustrative examples which follow, are well-known to those skilled in the art. Some of the abbreviations used are as follows:













Me
methyl


Et
ethyl;


t-Bu
tert-butyl;


iPr
isopropyl;


min
minutes;


rt or RT
room temperature or retention time (context will dictate);


TFA
trifluoroacetic acid;


h or hr 
hours;


DMSO
dimethylsulfoxide;


DME
dimethyl ether;


LDA
Lithium diisopropylamide;


NBS
N-Bromosuccinimide;


SEM-Cl
2-(Trimethylsilyl)ethoxymethyl chloride;


TBAF
tetrabutylammonium fluoride;


HATU
O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium



hexafluorophosphate;


iPr2EtN 
diisopropylethylamine;


DIEA
diisopropylethylamine;


DIPEA
diisopropylethylamine;


Hunig's
diisopropylethylamine;


Boc or BOC
tert-butoxycarbonyl;


DMAP
4-dimethylaminopyridine;


HCl
hydrochloric acid;


Na2SO4
sodium sulfate;


MgSO4
magnesium sulfate;


PdCl2(PPh3)2
bis(triphenylphosphine)palladium(II)dichloride; MCX


cartridge
Waters Oasis ® MCX LP extraction cartridge.









The present disclosure will now be described in connection with certain embodiments which are not intended to limit its scope. On the contrary, the present disclosure covers all alternatives, modifications, and equivalents as can be included within the scope of the claims. Thus, the following examples, which include specific embodiments, will illustrate one practice of the present disclosure, it being understood that the examples are for the purposes of illustration of certain embodiments and are presented to provide what is believed to be the most useful and readily understood description of its procedures and conceptual aspects.
Starting materials can be obtained from commercial sources or prepared by well-established literature methods known to those of ordinary skill in the art.
Synthetic Methods
Scheme 1: Substituted Phenylglycine Derivatives
Substituted phenylglycine derivatives can be prepared by a number of methods shown below. Phenylglycine t-butyl ester can be reductively alkylated (pathyway A) with an appropriate aldehyde and a reductant such as sodium cyanoborohydride in acidic medium. Hydrolysis of the t-butyl ester can be accomplished with strong acid such as HCl or trifluoroacetic acid. Alternatively, phenylglycine can be alkylated with an alkyl halide such as ethyl iodide and a base such as sodium bicarbonate or potassium carbonate (pathway B). Pathway C illustrates reductive alkylation of phenylglycine as in pathway A followed by a second reductive alkylation with an alternate aldehyde such as formaldehyde in the presence of a reducing agent and acid. Pathway D illustrates the synthesis of substituted phenylglycines via the corresponding mandelic acid analogs. Conversion of the secondary alcohol to a competent leaving group can be accomplished with p-toluensulfonyl chloride. Displacement of the tosylate group with an appropriate amine followed by reductive removal of the benzyl ester can provide substituted phenylglycine derivatives. In pathway E a racemic substituted phenylglycine derivative is resolved by esterification with an enantiomerically pure chiral auxiliary such as but not limited to (+)-1-phenylethanol, (−)-1-phenylethanol, an Evan's oxazolidinone, or enantiomerically pure pantolactone. Separation of the diastereomers is accomplished via chromatography (silica gel, HPLC, crystallization, etc) followed by removal of the chiral auxiliary providing enantiomerically pure phenylglycine derivatives. Pathway H illustrates a synthetic sequence which intersects with pathway E wherein the aforementioned chiral auxiliary is installed prior to amine addition. Alternatively, an ester of an arylacetic acid can be brominated with a source of bromonium ion such as bromine, N-bromosuccinimide, or CBr4. The resultant benzylic bromide can be displaced with a variety of mono- or disubstituted amines in the presence of a tertiary amine base such as triethylamine or Hunig's base. Hydrolysis of the methyl ester via treatment with lithium hydroxide at low temperature or 6N HCl at elevated temperature provides the substituted phenylglycine derivatives. Another method is shown in pathway G. Glycine analogs can be derivatized with a variety of aryl halides in the presence of a source of palladium (0) such as palladium bis(tributylphosphine) and base such as potassium phosphate. The resultant ester can then be hydrolyzed by treatment with base or acid. It should be understood that other well known methods to prepare phenylglycine derivatives exist in the art and can be amended to provide the desired compounds in this description. It should also be understood that the final phenylglycine derivatives can be purified to enantiomeric purity greater than 98% ee via preparative HPLC.




In another embodiment of the present disclosure, acylated phenylglycine derivatives may be prepared as illustrated below. Phenylglycine derivatives wherein the carboxylic acid is protected as an easily removed ester, may be acylated with an acid chloride in the presence of a base such as triethylamine to provide the corresponding amides (pathway A). Pathway B illustrates the acylation of the starting phenylglycine derivative with an appropriate chloroformate while pathway C shows reaction with an appropriate isocyanate or carbamoyl chloride. Each of the three intermediates shown in pathways A-C may be deprotected by methods known by those skilled in the art (ie; treatment of the t-butyl ester with strong base such as HCl or trifluoroacetic acid).




Amino-substituted phenylacetic acids may be prepared by treatment of a chloromethylphenylacetic acid with an excess of an amine




Synthesis of Common Caps
Compound Analysis Conditions
Purity assessment and low resolution mass analysis were conducted on a Shimadzu LC system coupled with Waters MICROMASS® ZQ MS system. It should be noted that retention times may vary slightly between machines. Additional LC conditions applicable to the current section, unless noted otherwise.
















Cond.-MS-W1 




Column =
XTERRA ® 3.0 × 50 mm S7 



Start % B =
0 



Final % B =
100 



Gradient time =
2 min 



Stop time =
3 min 



Flow Rate =
5 mL/min 



Wavelength =
220 nm 



Solvent A =
0.1% TFA in 10% methanol/90% H2O 



Solvent B =
0.1% TFA in 90% methanol/10% H2O 



Cond.-MS-W2 




Column =
XTERRA ® 3.0 × 50 mm S7 



Start % B =
0 



Final % B =
100 



Gradient time =
3 min 



Stop time =
4 min 



Flow Rate =
4 mL/min 



Wavelength =
220 nm 



Solvent A =
0.1% TFA in 10% methanol/90% H2O



Solvent B =
0.1% TFA in 90% methanol/10% H2O 



Cond.-MS-W5 




Column =
XTERRA ® 3.0 × 50 mm S7 



Start % B =
0 



Final % B =
30 



Gradient time =
2 min 



Stop time =
3 min 



Flow Rate =
5 mL/min 



Wavelength =
220 nm 



Solvent A =
0.1% TFA in 10% methanol/90% H2O



Solvent B =
0.1% TFA in 90% methanol/10% H2O 



Cond.-D1 




Column =
XTERRA ® C18 3.0 × 50 mm S7 



Start % B =
0 



Final % B =
100 



Gradient time =
3 min 



Stop time = 
4 min 



Flow Rate = 
4 mL/min 



Wavelength =
220 nm 



Solvent A = 
0.1% TFA in 10% methanol/90% H2O



Solvent B = 
0.1% TFA in 90% methanol/10% H2O



Cond.-D2 




Column =
PHENOMENEX ® Luna 4.6 × 50 mm S10 



Start % B =
0 



Final % B =
100 



Gradient time =
3 min 



Stop time = 
4 min



Flow Rate = 
4 mL/min



Wavelength =
220 nm 



Solvent A = 
0.1% TFA in 10% methanol/90% H2O 



Solvent B = 
0.1% TFA in 90% methanol/10% H2O 



Cond.-M3 




Column =
XTERRA ® C18 3.0 × 50 mm S7 



Start % B =
0 



Final % B =
40 



Gradient time =
2 min 



Stop time = 
3 min 



Flow Rate = 
5 mL/min 



Wavelength =
220 nm 



Solvent A = 
0.1% TFA in 10% methanol/90% H2O



Solvent B = 
0.1% TFA in 90% methanol/10% H2O



Condition I 




Column =
PHENOMENEX ® Luna 3.0 × 50 mm S10 



Start % B =
0 



Final % B =
100 



Gradient time =
2 min 



Stop time = 
3 min 



Flow Rate = 
4 mL/min 



Wavelength =
220 nm 



Solvent A = 
0.1% TFA in 10% methanol/90% H2O



Solvent B = 
0.1% TFA in 90% methanol/10% H2O



Condition II 




Column =
PHENOMENEX ® Luna 4.6 × 50 mm S10 



Start % B =
0 



Final % B =
100 



Gradient time =
2 min 



Stop time = 
3 min



Flow Rate = 
5 mL/min



Wavelength =
220 nm 



Solvent A = 
0.1% TFA in 10% methanol/90% H2O



Solvent B = 
0.1% TFA in 90% methanol/10% H2O



Condition III 




Column =
XTERRA ® C18 3.0 × 50 mm S7 



Start % B =
0 



Final % B =
100 



Gradient time =
3 min 



Stop time = 
4 min 



Flow Rate = 
4 mL/min



Wavelength =
220 nm 



Solvent A = 
0.1% TFA in 10% methanol/90% H2O



Solvent B = 
0.1% TFA in 90% methanol/10% H2O










Cap-1




(R)-2-(Dimethylamino)-2-phenylacetic acid
A suspension of 10% Pd/C (2.0 g) in methanol (10 mL) was added to a mixture of (R)-2-phenylglycine (10 g, 66.2 mmol), formaldehyde (33 mL of 37% wt. in water), 1N HCl (30 mL) and methanol (30 mL), and exposed to H2 (60 psi) for 3 hours. The reaction mixture was filtered through diatomaceous earth (CELITE®), and the filtrate was concentrated in vacuo. The resulting crude material was recrystallized from isopropanol to provide the HCl salt of Cap-1 as a white needle (4.0 g). Optical rotation: —117.1° [c=9.95 mg/mL in H2O; λ=589 nm]. 1H NMR (DMSO-d6, δ=2.5 ppm, 500 MHz): δ 7.43-7.34 (m, 5H), 4.14 (s, 1H), 2.43 (s, 6H); LC (Condition I): RT=0.25; LC-MS: Anal. Calcd. for [M+H]+ C10H14NO2 180.10; found 180.17; HRMS: Anal. Calcd. for [M+H]+ C10H14NO2 180.1025; found 180.1017.
Cap-2




(R)-2-(Diethylamino)-2-phenylacetic acid
NaBH3CN (6.22 g, 94 mmol) was added in portions over a few minutes to a cooled (ice/water) mixture of (R)-2-Phenylglycine (6.02 g, 39.8 mmol) and methanol (100 mL), and stirred for 5 minutes. Acetaldehyde (10 mL) was added dropwise over 10 minutes and stirring was continued at the same cooled temperature for 45 minutes and at ambient temperature for  ̃6.5 hours. The reaction mixture was cooled back with ice-water bath, treated with water (3 mL) and then quenched with a dropwise addition of concentrated HCl over  ̃45 minutes until the pH of the mixture was  ̃1.5-2.0. The cooling bath was removed and the stirring was continued while adding concentrated HCl in order to maintain the pH of the mixture around 1.5-2.0. The reaction mixture was stirred overnight, filtered to remove the white suspension, and the filtrate was concentrated in vacuo. The crude material was recrystallized from ethanol to afford the HCl salt of Cap-2 as a shining white solid in two crops (crop-1: 4.16 g; crop-2: 2.19 g). 1H NMR (DMSO-d6, δ=2.5 ppm, 400 MHz): 10.44 (1.00, br s, 1H), 7.66 (m, 2H), 7.51 (m, 3H), 5.30 (s, 1H), 3.15 (br m, 2H), 2.98 (br m, 2H), 1.20 (app br s, 6H). Crop-1: [α]25-102.21° (c=0.357, H2O); crop-2: [α]25-99.7° (c=0.357, H2O). LC (Condition I): RT=0.43 min; LC-MS: Anal. Calcd. for [M+H]+ C12H18NO2: 208.13; found 208.26.
Cap-3




Acetaldehyde (5.0 mL, 89.1 mmol) and a suspension of 10% Pd/C (720 mg) in methanol/H2O (4 mL/1 mL) was sequentially added to a cooled ( ̃15° C.) mixture of (R)-2-phenylglycine (3.096 g, 20.48 mmol), 1N HCl (30 mL) and methanol (40 mL). The cooling bath was removed and the reaction mixture was stirred under a balloon of H2 for 17 hours. An additional acetaldehyde (10 mL, 178.2 mmol) was added and stirring continued under H2 atmosphere for 24 hours [Note: the supply of H2 was replenished as needed throughout the reaction]. The reaction mixture was filtered through diatomaceous earth (CELITE®), and the filtrate was concentrated in vacuo. The resulting crude material was recrystallized from isopropanol to provide the HCl salt of (R)-2-(ethylamino)-2-phenylacetic acid as a shining white solid (2.846 g). 1H NMR (DMSO-d6, δ=2.5 ppm, 400 MHz): δ 14.15 (br s, 1H), 9.55 (br s, 2H), 7.55-7.48 (m, 5H), 2.88 (br m, 1H), 2.73 (br m, 1H), 1.20 (app t, J=7.2, 3H). LC (Condition I): RT=0.39 min; >95% homogeneity index; LC-MS: Anal. Calcd. for [M+H]+ C10H14NO2: 180.10; found 180.18.
A suspension of 10% Pd/C (536 mg) in methanol/H2O (3 mL/1 mL) was added to a mixture of (R)-2-(ethylamino)-2-phenylacetic acid/HCl (1.492 g, 6.918 mmol), formaldehyde (20 mL of 37% wt. in water), 1N HCl (20 mL) and methanol (23 mL). The reaction mixture was stirred under a balloon of H2 for  ̃72 hours, where the H2 supply was replenished as needed. The reaction mixture was filtered through diatomaceous earth (CELITE®) and the filtrate was concentrated in vacuo. The resulting crude material was recrystallized from isopropanol (50 mL) to provide the HCl salt of Cap-3 as a white solid (985 mg). 1H NMR (DMSO-d6, δ=2.5 ppm, 400 MHz): δ 10.48 (br s, 1H), 7.59-7.51 (m, 5H), 5.26 (s, 1H), 3.08 (app br s, 2H), 2.65 (br s, 3H), 1.24 (br m, 3H). LC (Condition I): RT=0.39 min; >95% homogeneity index; LC-MS: Anal. Calcd. for [M+H]+ C11H16NO2: 194.12; found 194.18; HRMS: Anal. Calcd. for [M+H]+ C11H16NO2: 194.1180; found 194.1181.
Cap-4




(R)-2-(Methoxycarbonylamino)-2-phenylacetic acid
ClCO2Me (3.2 mL, 41.4 mmol) was added dropwise to a cooled (ice/water) THF (410 mL) semi-solution of (R)-tert-butyl 2-amino-2-phenylacetate/HCl (9.877 g, 40.52 mmol) and diisopropylethylamine (14.2 mL, 81.52 mmol) over 6 min, and stirred at similar temperature for 5.5 hours. The volatile component was removed in vacuo, and the residue was partitioned between water (100 mL) and ethyl acetate (200 mL). The organic layer was washed with 1N HCl (25 mL) and saturated NaHCO3 solution (30 mL), dried (MgSO4), filtered, and concentrated in vacuo. The resultant colorless oil was triturated from hexanes, filtered and washed with hexanes (100 mL) to provide (R)-tert-butyl 2-(methoxycarbonylamino)-2-phenylacetate as a white solid (7.7 g). 1H NMR (DMSO-d6, 8=2.5 ppm, 400 MHz): 7.98 (d, J=8.0, 1H), 7.37-7.29 (m, 5H), 5.09 (d, J=8, 1H), 3.56 (s, 3H), 1.33 (s, 9H). LC (Condition I): RT=1.53 min;  ̃90% homogeneity index; LC-MS: Anal. Calcd. for [M+Na]+ C14H19NNaO4: 288.12; found 288.15.
TFA (16 mL) was added dropwise to a cooled (ice/water) CH2Cl2 (160 mL) solution of the above product over 7 minutes, and the cooling bath was removed and the reaction mixture was stirred for 20 hours. Since the deprotection was still not complete, an additional TFA (1.0 mL) was added and stirring continued for an additional 2 hours. The volatile component was removed in vacuo, and the resulting oil residue was treated with diethyl ether (15 mL) and hexanes (12 mL) to provide a precipitate. The precipitate was filtered and washed with diethyl ether/hexanes ( ̃1:3 ratio; 30 mL) and dried in vacuo to provide Cap-4 as a fluffy white solid (5.57 g). Optical rotation: −176.9° [c=3.7 mg/mL in H2O; 2=589 nm]. 1H NMR (DMSO-d6, δ=2.5 ppm, 400 MHz): δ 12.84 (br s, 1H), 7.96 (d, J=8.3, 1H), 7.41-7.29 (m, 5H), 5.14 (d, J=8.3, 1H), 3.55 (s, 3H). LC (Condition I): RT=1.01 min; >95% homogeneity index; LC-MS: Anal. Calcd. for [M+H]+ C10H12NO4 210.08; found 210.17; HRMS: Anal. Calcd. for [M+H]+ C10H12NO4 210.0766; found 210.0756.
Cap-5




A mixture of (R)-2-phenylglycine (1.0 g, 6.62 mmol), 1,4-dibromobutane (1.57 g, 7.27 mmol) and Na2CO3 (2.10 g, 19.8 mmol) in ethanol (40 mL) was heated at 100° C. for 21 hours. The reaction mixture was cooled to ambient temperature and filtered, and the filtrate was concentrated in vacuo. The residue was dissolved in ethanol and acidified with 1N HCl to pH 3-4, and the volatile component was removed in vacuo. The resulting crude material was purified by a reverse phase HPLC (water/methanol/TFA) to provide the TFA salt of Cap-5 as a semi-viscous white foam (1.0 g). 1H NMR (DMSO-d6, δ=2.5, 500 MHz) δ 10.68 (br s, 1H), 7.51 (m, 5H), 5.23 (s, 1H), 3.34 (app br s, 2H), 3.05 (app br s, 2H), 1.95 (app br s, 4H); RT=0.30 minutes (Condition I); >98% homogeneity index; LC-MS: Anal. Calcd. for [M+H]+ C12H16NO2: 206.12; found 206.25.
Cap-6




The TFA salt of Cap-6 was synthesized from (R)-2-phenylglycine and 1-bromo-2-(2-bromoethoxy)ethane by using the method of preparation of Cap-5. 1H NMR (DMSO-d6, δ=2.5, 500 MHz) δ 12.20 (br s, 1H), 7.50 (m, 5H), 4.92 (s, 1H), 3.78 (app br s, 4H), 3.08 (app br s, 2H), 2.81 (app br s, 2H); RT=0.32 minutes (Condition I); >98%; LC-MS: Anal. Calcd. for [M+H]+ C12H16NO3: 222.11; found 222.20; HRMS: Anal. Calcd. for [M+H]+ C12H16NO3: 222.1130; found 222.1121.
Cap-7




A CH2Cl2 (200 mL) solution of p-toluenesulfonyl chloride (8.65 g, 45.4 mmol) was added dropwise to a cooled (−5° C.) CH2Cl2 (200 mL) solution of (S)-benzyl 2-hydroxy-2-phenylacetate (10.0 g, 41.3 mmol), triethylamine (5.75 mL, 41.3 mmol) and 4-dimethylaminopyridine (0.504 g, 4.13 mmol), while maintaining the temperature between −5° C. and 0° C. The reaction was stirred at 0° C. for 9 hours, and then stored in a freezer (−25° C.) for 14 hours. It was allowed to thaw to ambient temperature and washed with water (200 mL), 1N HCl (100 mL) and brine (100 mL), dried (MgSO4), filtered, and concentrated in vacuo to provide benzyl 2-phenyl-2-(tosyloxy)acetate as a viscous oil which solidified upon standing (16.5 g). The chiral integrity of the product was not checked and that product was used for the next step without further purification. 1H NMR (DMSO-d6, δ=2.5, 500 MHz) δ 7.78 (d, J=8.6, 2H), 7.43-7.29 (m, 10H), 7.20 (m, 2H), 6.12 (s, 1H), 5.16 (d, J=12.5, 1H), 5.10 (d, J=12.5, 1H), 2.39 (s, 3H). RT=3.00 (Condition III); >90% homogeneity index; LC-MS: Anal. Calcd. for [M+H]+ C22H20NaO5S: 419.09; found 419.04.
A THF (75 mL) solution of benzyl 2-phenyl-2-(tosyloxy)acetate (6.0 g, 15.1 mmol), 1-methylpiperazine (3.36 mL, 30.3 mmol) and N,N-diisopropylethylamine (13.2 mL, 75.8 mmol) was heated at 65° C. for 7 hours. The reaction was allowed to cool to ambient temperature and the volatile component was removed in vacuo. The residue was partitioned between ethylacetate and water, and the organic layer was washed with water and brine, dried (MgSO4), filtered, and concentrated in vacuo. The resulting crude material was purified by flash chromatography (silica gel, ethyl acetate) to provide benzyl 2-(4-methylpiperazin-1-yl)-2-phenylacetate as an orangish-brown viscous oil (4.56 g). Chiral HPLC analysis (CHIRALCEL® OD-H) indicated that the sample is a mixture of stereoisomers in a 38.2 to 58.7 ratio. The separation of the stereoisomers were effected as follow: the product was dissolved in 120 mL of ethanol/heptane (1:1) and injected (5 mL/injection) on chiral HPLC column (Chiracel OJ, 5 cm ID×50 cm L, 20 μm) eluting with 85:15 Heptane/ethanol at 75 mL/min, and monitored at 220 nm. Stereoisomer-1 (1.474 g) and stereoisomer-2 (2.2149 g) were retrieved as viscous oil. 1H NMR (CDCl3, δ=7.26, 500 MHz) 7.44-7.40 (m, 2H), 7.33-7.24 (m, 6H), 7.21-7.16 (m, 2H), 5.13 (d, J=12.5, 1H), 5.08 (d, J=12.5, 1H), 4.02 (s, 1H), 2.65-2.38 (app br s, 8H), 2.25 (s, 3H). RT=2.10 (Condition III); >98% homogeneity index; LC-MS: Anal. Calcd. for [M+H]+ C26H25N2O2: 325.19; found 325.20.
A methanol (10 mL) solution of either stereoisomer of benzyl 2-(4-methylpiperazin-1-yl)-2-phenylacetate (1.0 g, 3.1 mmol) was added to a suspension of 10% Pd/C (120 mg) in methanol (5.0 mL). The reaction mixture was exposed to a balloon of hydrogen, under a careful monitoring, for <50 minutes. Immediately after the completion of the reaction, the catalyst was filtered through diatomaceous earth (CELITE®) and the filtrate was concentrated in vacuo to provide Cap-7, contaminated with phenylacetic acid as a tan foam (867.6 mg; mass is above the theoretical yield). The product was used for the next step without further purification. 1H NMR (DMSO-d6, δ=2.5, 500 MHz) δ 7.44-7.37 (m, 2H), 7.37-7.24 (m, 3H), 3.92 (s, 1H), 2.63-2.48 (app. br s, 2H), 2.48-2.32 (m, 6H), 2.19 (s, 3H); RT=0.31 (Condition II); >90% homogeneity index; LC-MS: Anal. Calcd. for [M+H]+ C13H19N2O2: 235.14; found 235.15; HRMS: Anal. Calcd. for [M+H]+ C13H19N2O2: 235.1447; found 235.1440.
The synthesis of Cap-8 and Cap-9 was conducted according to the synthesis of Cap-7 by using appropriate amines for the SN2 displacement step (i.e., 4-hydroxypiperidine for Cap-8 and (S)-3-fluoropyrrolidine for Cap-9) and modified conditions for the separation of the respective stereoisomeric intermediates, as described below.
Cap-8




The stereoisomeric separation of the intermediate benzyl 2-(4-hydroxypiperidin-1-yl)-2-phenyl acetate was effected by employing the following conditions: the compound (500 mg) was dissolved in ethanol/heptane (5 mL/45 mL). The resulting solution was injected (5 mL/injection) on a chiral HPLC column (Chiracel OJ, 2 cm ID×25 cm L, 10 μm) eluting with 80:20 heptane/ethanol at 10 mL/min, monitored at 220 nm, to provide 186.3 mg of stereoisomer-1 and 209.1 mg of stereoisomer-2 as light-yellow viscous oils. These benzyl ester was hydrogenolysed according to the preparation of Cap-7 to provide Cap-8: 1H NMR (DMSO-d6, δ=2.5, 500 MHz) 7.40 (d, J=7, 2H), 7.28-7.20 (m, 3H), 3.78 (s 1H), 3.46 (m, 1H), 2.93 (m, 1H), 2.62 (m, 1H), 2.20 (m, 2H), 1.70 (m, 2H), 1.42 (m, 2H). RT=0.28 (Condition II); >98% homogeneity index; LC-MS: Anal. Calcd. for [M+H]+ C13H18NO3: 236.13; found 236.07; HRMS: Calcd. for [M+H]+ C13H18NO3: 236.1287; found 236.1283.
Cap-9




The diastereomeric separation of the intermediate benzyl 2-((S)-3-fluoropyrrolidin-1-yl)-2-phenylacetate was effected by employing the following conditions: the ester (220 mg) was separated on a chiral HPLC column (Chiracel OJ-H, 0.46 cm ID×25 cm L, 5 μm) eluting with 95% CO2/5% methanol with 0.1% TFA, at 10 bar pressure, 70 mL/min flow rate, and a temperature of 35° C. The HPLC elute for the respective stereoisomers was concentrated, and the residue was dissolved in CH2Cl2 (20 mL) and washed with an aqueous medium (10 mL water+1 mL saturated NaHCO3 solution). The organic phase was dried (MgSO4), filtered, and concentrated in vacuo to provide 92.5 mg of fraction-1 and 59.6 mg of fraction-2. These benzyl esters were hydrogenolysed according to the preparation of Cap-7 to prepare Cap-9a and Cap-9b. Cap-9a (diastereomer-1; the sample is a TFA salt as a result of purification on a reverse phase HPLC using H2O/methanol/TFA solvent): 1H NMR (DMSO-d6, δ=2.5, 400 MHz) 7.55-7.48 (m, 5H), 5.38 (d of m, J=53.7, 1H), 5.09 (br s, 1H), 3.84-2.82 (br m, 4H), 2.31-2.09 (m, 2H). RT=0.42 (Condition I); >95% homogeneity index; LC-MS: Anal. Calcd. for [M+H]+ C12H15FNO2: 224.11; found 224.14; Cap-9b (diastereomer-2): 1H NMR (DMSO-d6, δ=2.5, 400 MHz) 7.43-7.21 (m, 5H), 5.19 (d of m, J=55.9, 1H), 3.97 (s, 1H), 2.95-2.43 (m, 4H), 2.19-1.78 (m, 2H). RT=0.44 (Condition I); LC-MS: Anal. Calcd. for [M+H]+ C12H15FNO2: 224.11; found 224.14.
Cap-10




To a solution of D-proline (2.0 g, 17 mmol) and formaldehyde (2.0 mL of 37% wt. in H2O) in methanol (15 mL) was added a suspension of 10% Pd/C (500 mg) in methanol (5 mL). The mixture was stirred under a balloon of hydrogen for 23 hours. The reaction mixture was filtered through diatomaceous earth (CELITE®) and concentrated in vacuo to provide Cap-10 as an off-white solid (2.15 g). 1H NMR (DMSO-d6, δ=2.5, 500 MHz) 3.42 (m, 1H), 3.37 (dd, J=9.4, 6.1, 1H), 2.85-2.78 (m, 1H), 2.66 (s, 3H), 2.21-2.13 (m, 1H), 1.93-1.84 (m, 2H), 1.75-1.66 (m, 1H). RT=0.28 (Condition II); >98% homogeneity index; LC-MS: Anal. Calcd. for [M+H]+ C6H12NO2: 130.09; found 129.96.
Cap-11




A mixture of (2S,4R)-4-fluoropyrrolidine-2-carboxylic acid (0.50 g, 3.8 mmol), formaldehyde (0.5 mL of 37% wt. in H2O), 12 N HCl (0.25 mL) and 10% Pd/C (50 mg) in methanol (20 mL) was stirred under a balloon of hydrogen for 19 hours. The reaction mixture was filtered through diatomaceous earth (CELITE®) and the filtrate was concentrated in vacuo. The residue was recrystallized from isopropanol to provide the HCl salt of Cap-11 as a white solid (337.7 mg). 1H NMR (DMSO-d6, δ=2.5, 500 MHz) 5.39 (d m, J=53.7, 1H), 4.30 (m, 1H), 3.90 (ddd, J=31.5, 13.5, 4.5, 1H), 3.33 (dd, J=25.6, 13.4, 1H), 2.85 (s, 3H), 2.60-2.51 (m, 1H), 2.39-2.26 (m, 1H). RT=0.28 (Condition II); >98% homogeneity index; LC-MS: Anal. Calcd. for [M+H]+ C6H11FNO2: 148.08; found 148.06.
Cap-12 (Aame as Cap-52)




(S)-2-(Methoxycarbonylamino)propanoic acid
L-Alanine (2.0 g, 22.5 mmol) was dissolved in 10% aqueous sodium carbonate solution (50 mL), and a THF (50 mL) solution of methyl chloroformate (4.0 mL) was added to it. The reaction mixture was stirred under ambient conditions for 4.5 hours and concentrated in vacuo. The resulting white solid was dissolved in water and acidified with 1N HCl to a pH  ̃2-3. The resulting solutions was extracted with ethyl acetate (3×100 mL), and the combined organic phase was dried (Na2SO4), filtered, and concentrated in vacuo to provide a colorless oil (2.58 g). 500 mg of this material was purified by a reverse phase HPLC(H2O/methanol/TFA) to provide 150 mg of Cap-12 as a colorless oil. 1H NMR (DMSO-d6, δ=2.5, 500 MHz) 7.44 (d, J=7.3, 0.8H), 7.10 (br s, 0.2H), 3.97 (m, 1H), 3.53 (s, 3H), 1.25 (d, J=7.3, 3H).
Cap-13




A mixture of L-alanine (2.5 g, 28 mmol), formaldehyde (8.4 g, 37 wt. %), 1N HCl (30 mL) and 10% Pd/C (500 mg) in methanol (30 mL) was stirred under a hydrogen atmosphere (50 psi) for 5 hours. The reaction mixture was filtered through diatomaceous earth (CELITE®) and the filtrate was concentrated in vacuo to provide the HCl salt of Cap-13 as an oil which solidified upon standing under vacuum (4.4 g; the mass is above theoretical yield). The product was used without further purification. 1H NMR (DMSO-d6, δ=2.5, 500 MHz) δ 12.1 (br s, 1H), 4.06 (q, J=7.4, 1H), 2.76 (s, 6H), 1.46 (d, J=7.3, 3H).
Cap-14




(R)-2-Phenyl-2-(piperidin-1-yl)acetic acid
Step 1: A mixture of (R)-(−)-D-phenylglycine tert-butyl ester (3.00 g, 12.3 mmol), NaBH3CN (0.773 g, 12.3 mmol), KOH (0.690 g, 12.3 mmol) and acetic acid (0.352 mL, 6.15 mmol) were stirred in methanol at 0° C. To this mixture was added glutaric dialdehyde (2.23 mL, 12.3 mmol) dropwise over 5 minutes. The reaction mixture was stirred as it was allowed to warm to ambient temperature and stirring was continued at the same temperature for 16 hours. The solvent was subsequently removed and the residue was partitioned with 10% aqueous NaOH and ethyl acetate. The organic phase was separated, dried (MgSO4), filtered and concentrated to dryness to provide a clear oil. This material was purified by reverse-phase preparative HPLC (Primesphere C-18, 30×100 mm; CH3CN—H2O-0.1% TFA) to give the intermediate ester (2.70 g, 56%) as a clear oil. 1H NMR (400 MHz, CDCl3) δ 7.53-7.44 (m, 3H), 7.40-7.37 (m, 2H), 3.87 (d, J=10.9 Hz, 1H), 3.59 (d, J=10.9 Hz, 1H), 2.99 (t, J=11.2 Hz, 1H), 2.59 (t, J=11.4 Hz, 1H), 2.07-2.02 (m, 2H), 1.82 (d, J=1.82 Hz, 3H), 1.40 (s, 9H). LC-MS: Anal. Calcd. for C17H25NO2: 275; found: 276 (M+H)+.
Step 2: To a stirred solution of the intermediate ester (1.12 g, 2.88 mmol) in dichloromethane (10 mL) was added TFA (3 mL). The reaction mixture was stirred at ambient temperature for 4 hours and then it was concentrated to dryness to give a light yellow oil. The oil was purified using reverse-phase preparative HPLC (Primesphere C-18, 30×100 mm; CH3CN—H2O-0.1% TFA). The appropriate fractions were combined and concentrated to dryness in vacuo. The residue was then dissolved in a minimum amount of methanol and applied to applied to MCX LP extraction cartridges (2×6 g). The cartridges were rinsed with methanol (40 mL) and then the desired compound was eluted using 2M ammonia in methanol (50 mL). Product-containing fractions were combined and concentrated and the residue was taken up in water. Lyophilization of this solution provided the title compound (0.492 g, 78%) as a light yellow solid. 1H NMR (DMSO-d6) δ 7.50 (s, 5H), 5.13 (s, 1H), 3.09 (br s, 2H), 2.92-2.89 (m, 2H), 1.74 (m, 4H), 1.48 (br s, 2H). LC-MS: Anal. Calcd. for C13H17NO2: 219; found: 220 (M+H)+.
Cap-15




Step 1: (S)-1-Phenylethyl 2-bromo-2-phenylacetate. To a mixture of α-bromophenylacetic acid (10.75 g, 0.050 mol), (S)-(−)-1-phenylethanol (7.94 g, 0.065 mol) and DMAP (0.61 g, 5.0 mmol) in dry dichloromethane (100 mL) was added solid EDCI (12.46 g, 0.065 mol) all at once. The resulting solution was stirred at room temperature under Ar for 18 hours and then it was diluted with ethyl acetate, washed (H2O×2, brine), dried (Na2SO4), filtered, and concentrated to give a pale yellow oil. Flash chromatography (SiO2/hexane-ethyl acetate, 4:1) of this oil provided the title compound (11.64 g, 73%) as a white solid. 1H NMR (400 MHz, CDCl3) δ 7.53-7.17 (m, 10H), 5.95 (q, J=6.6 Hz, 0.5H), 5.94 (q, J=6.6 Hz, 0.5H), 5.41 (s, 0.5H), 5.39 (s, 0.5H), 1.58 (d, J=6.6 Hz, 1.5H), 1.51 (d, J=6.6 Hz, 1.5H).
Step 2: (S)-1-Phenylethyl (R)-2-(4-hydroxy-4-methylpiperidin-1-yl)-2-phenylacetate. To a solution of (S)-1-phenylethyl 2-bromo-2-phenylacetate (0.464 g, 1.45 mmol) in THF (8 mL) was added triethylamine (0.61 mL, 4.35 mmol), followed by tetrabutylammonium iodide (0.215 g, 0.58 mmol). The reaction mixture was stirred at room temperature for 5 minutes and then a solution of 4-methyl-4-hydroxypiperidine (0.251 g, 2.18 mmol) in THF (2 mL) was added. The mixture was stirred for 1 hour at room temperature and then it was heated at 55-60° C. (oil bath temperature) for 4 hours. The cooled reaction mixture was then diluted with ethyl acetate (30 mL), washed (H2O×2, brine), dried (MgSO4), filtered and concentrated. The residue was purified by silica gel chromatography (0-60% ethyl acetate-hexane) to provide first the (S,R)-isomer of the title compound (0.306 g, 60%) as a white solid and then the corresponding (S,S)-isomer (0.120 g, 23%), also as a white solid. (S,R)-isomer: 1H NMR (CD3OD) δ 7.51-7.45 (m, 2H), 7.41-7.25 (m, 8H), 5.85 (q, J=6.6 Hz, 1H), 4.05 (s, 1H), 2.56-2.45 (m, 2H), 2.41-2.29 (m, 2H), 1.71-1.49 (m, 4H), 1.38 (d, J=6.6 Hz, 3H), 1.18 (s, 3H). LC-MS: Anal. Calcd. for C22H27NO3: 353; found: 354 (M+H)+. (S,S)-isomer: 1H NMR (CD3OD) δ 7.41-7.30 (m, 5H), 7.20-7.14 (m, 3H), 7.06-7.00 (m, 2H), 5.85 (q, J=6.6 Hz, 1H), 4.06 (s, 1H), 2.70-2.60 (m, 1H), 2.51 (dt, J=6.6, 3.3 Hz, 1H), 2.44-2.31 (m, 2H), 1.75-1.65 (m, 1H), 1.65-1.54 (m, 3H), 1.50 (d, J=6.8 Hz, 3H), 1.20 (s, 3H). LC-MS: Anal. Calcd. for C22H27NO3: 353; found: 354 (M+H)+.
Step 3: (R)-2-(4-Hydroxy-4-methylpiperidin-1-yl)-2-phenylacetic acid. To a solution of (S)-1-phenylethyl (R)-2-(4-hydroxy-4-methylpiperidin-1-yl)-2-phenylacetate (0.185 g, 0.52 mmol) in dichloromethane (3 mL) was added trifluoroacetic acid (1 mL) and the mixture was stirred at room temperature for 2 hours. The volatiles were subsequently removed in vacuo and the residue was purified by reverse-phase preparative HPLC (Primesphere C-18, 20×100 mm; CH3CN—H2O-0.1% TFA) to give the title compound (as TFA salt) as a pale bluish solid (0.128 g, 98%). LC-MS: Anal. Calcd. for C14H19NO3: 249; found: 250 (M+H)+.
Cap-16




Step 1: (S)-1-Phenylethyl 2-(2-fluorophenyl)acetate. A mixture of 2-fluorophenylacetic acid (5.45 g, 35.4 mmol), (S)-1-phenylethanol (5.62 g, 46.0 mmol), EDCI (8.82 g, 46.0 mmol) and DMAP (0.561 g, 4.60 mmol) in CH2Cl2 (100 mL) was stirred at room temperature for 12 hours. The solvent was then concentrated and the residue partitioned with H2O-ethyl acetate. The phases were separated and the aqueous layer back-extracted with ethyl acetate (2×). The combined organic phases were washed (H2O, brine), dried (Na2SO4), filtered, and concentrated in vacuo. The residue was purified by silica gel chromatography (BIOTAGE®/0-20% ethyl acetate-hexane) to provide the title compound as a colorless oil (8.38 g, 92%). 1H NMR (400 MHz, CD3OD) δ 7.32-7.23 (m, 7H), 7.10-7.04 (m, 2), 5.85 (q, J=6.5 Hz, 1H), 3.71 (s, 2H), 1.48 (d, J=6.5 Hz, 3H).
Step 2: (R)—((S)-1-Phenylethyl) 2-(2-fluorophenyl)-2-(piperidin-1-yl)acetate. To a solution of (S)-1-phenylethyl 2-(2-fluorophenyl)acetate (5.00 g, 19.4 mmol) in THF (1200 mL) at 0° C. was added DBU (6.19 g, 40.7 mmol) and the solution was allowed to warm to room temperature while stirring for 30 minutes. The solution was then cooled to −78° C. and a solution of CBr4 (13.5 g, 40.7 mmol) in THF (100 mL) was added and the mixture was allowed to warm to −10° C. and stirred at this temperature for 2 hours. The reaction mixture was quenched with saturated aq. NH4Cl and the layers were separated. The aqueous layer was back-extracted with ethyl acetate (2×) and the combined organic phases were washed (H2O, brine), dried (Na2SO4), filtered, and concentrated in vacuo. To the residue was added piperidine (5.73 mL, 58.1 mmol) and the solution was stirred at room temperature for 24 hours. The volatiles were then concentrated in vacuo and the residue was purified by silica gel chromatography (BIOTAGE®/0-30% diethyl ether-hexane) to provide a pure mixture of diastereomers (2:1 ratio by 1H NMR) as a yellow oil (2.07 g, 31%), along with unreacted starting material (2.53 g, 51%). Further chromatography of the diastereomeric mixture (BIOTAGE®/0-10% diethyl ether-toluene) provided the title compound as a colorless oil (0.737 g, 11%). 1H NMR (400 MHz, CD3OD) δ 7.52 (ddd, J=9.4, 7.6, 1.8 Hz, 1H), 7.33-7.40 (m, 1), 7.23-7.23 (m, 4H), 7.02-7.23 (m, 4H), 5.86 (q, J=6.6 Hz, 1H), 4.45 (s, 1H), 2.39-2.45 (m, 4H), 1.52-1.58 (m, 4H), 1.40-1.42 (m, 1H), 1.38 (d, J=6.6 Hz, 3H). LC-MS: Anal. Calcd. for C21H24FNO2: 341; found: 342 (M+H)+.
Step 3: (R)-2-(2-Fluorophenyl)-2-(piperidin-1-yl)acetic acid. A mixture of (R)—((S)-1-phenylethyl) 2-(2-fluorophenyl)-2-(piperidin-1-yl)acetate (0.737 g, 2.16 mmol) and 20% Pd(OH)2/C (0.070 g) in ethanol (30 mL) was hydrogenated at room temperature and atmospheric pressure (H2 balloon) for 2 hours. The solution was then purged with Ar, filtered through diatomaceous earth (CELITE®), and concentrated in vacuo. This provided the title compound as a colorless solid (0.503 g, 98%). 1H NMR (400 MHz, CD3OD) δ 7.65 (ddd, J=9.1, 7.6, 1.5 Hz, 1H), 7.47-7.53 (m, 1H), 7.21-7.30 (m, 2H), 3.07-3.13 (m, 4H), 1.84 (br s, 4H), 1.62 (br s, 2H). LC-MS: Anal. Calcd. for C13H16FNO2: 237; found: 238 (M+H)+.
Cap-17




Step 1: (S)-1-Phenylethyl (R)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-2-phenylacetate. To a solution of (S)-1-phenylethyl 2-bromo-2-phenylacetate (1.50 g, 4.70 mmol) in THF (25 mL) was added triethylamine (1.31 mL, 9.42 mmol), followed by tetrabutylammonium iodide (0.347 g, 0.94 mmol). The reaction mixture was stirred at room temperature for 5 minutes and then a solution of 4-phenyl-4-hydroxypiperidine (1.00 g, 5.64 mmol) in THF (5 mL) was added. The mixture was stirred for 16 hours and then it was diluted with ethyl acetate (100 mL), washed (H2O×2, brine), dried (MgSO4), filtered and concentrated. The residue was purified on a silica gel column (0-60% ethyl acetate-hexane) to provide an approximately 2:1 mixture of diastereomers, as judged by 1H NMR. Separation of these isomers was performed using supercritical fluid chromatography (CHIRALCEL® OJ-H, 30×250 mm; 20% ethanol in CO2 at 35° C.), to give first the (R)-isomer of the title compound (0.534 g, 27%) as a yellow oil and then the corresponding (S)-isomer (0.271 g, 14%), also as a yellow oil. (S,R)-isomer: 1H NMR (400 MHz, CD3OD) δ 7.55-7.47 (m, 4H), 7.44-7.25 (m, 10H), 7.25-7.17 (m, 1H), 5.88 (q, J=6.6 Hz, 1H), 4.12 (s, 1H), 2.82-2.72 (m, 1H), 2.64 (dt, J=11.1, 2.5 Hz, 1H), 2.58-2.52 (m, 1H), 2.40 (dt, J=11.1, 2.5 Hz, 1H), 2.20 (dt, J=12.1, 4.6 Hz, 1H), 2.10 (dt, J=12.1, 4.6 Hz, 1H), 1.72-1.57 (m, 2H), 1.53 (d, J=6.5 Hz, 3H). LC-MS: Anal. Calcd. for C27H29NO3: 415; found: 416 (M+H)+; (S,S)-isomer: 1H NMR (400 MHz, CD3OD) δ 7.55-7.48 (m, 2H), 7.45-7.39 (m, 2H), 7.38-7.30 (m, 5H), 7.25-7.13 (m, 4H), 7.08-7.00 (m, 2H), 5.88 (q, J=6.6 Hz, 1H), 4.12 (s, 1H), 2.95-2.85 (m, 1H), 2.68 (dt, J=11.1, 2.5 Hz, 1H), 2.57-2.52 (m, 1H), 2.42 (dt, J=11.1, 2.5 Hz, 1H), 2.25 (dt, J=12.1, 4.6 Hz, 1H), 2.12 (dt, J=12.1, 4.6 Hz, 1H), 1.73 (dd, J=13.6, 3.0 Hz, 1H), 1.64 (dd, J=13.6, 3.0 Hz, 1H), 1.40 (d, J=6.6 Hz, 3H). LC-MS: Anal. Calcd. for C22H29NO3: 415; found: 416 (M+H)+.
The following esters were prepared in similar fashion:














Intermediate-17a




Diastereomer 1: 1H NMR  (500 MHz, DMSO-d6) δ ppm  1.36 (d, J = 6.41 Hz, 3H) 2.23- 2.51 (m, 4H) 3.35 (s, 4H) 4.25  (s, 1H) 5.05 (s, 2H) 5.82 (d, J =  6.71 Hz, 1H) 7.15-7.52 (m, 15H).  LC-MS: Anal. Calcd. for:  C28H30N2O4 458.22; found:  459.44 (M + H)+. Diastereomer 2: 1H NMR  (500 MHz, DMSO-d6) δ ppm  1.45 (d, J = 6.71 Hz, 3H) 2.27- 2.44 (m, 4H) 3.39 (s, 4H) 4.23  (s, 1H) 5.06 (s, 2H) 5.83 (d, J =  6.71 Hz, 1H) 7.12 (dd, J = 6.41,  3.05 Hz, 2H) 7.19-7.27 (m, 3H)  7.27-7.44 (m, 10H). LC-MS:  Anal. Calcd. for: C28H30N2O4  458.22; found: 459.44 (M + H)+.


 


Intermediate-17b




Diastereomer 1: RT = 11.76  minutes (Condition II); LC-MS:  Anal. Calcd. for: C20H22N2O3  338.16; found: 339.39 (M + H)+. Diastereomer 2: RT = 10.05  minutes (Condition II). LC-MS:  Anal. Calcd. for: C20H22N2O3  338.16; found: 339.39 (M + H)+.


 


Intermediate-17c




Diastereomer 1: TR = 4.55  minutes (Condition I); LC-MS:  Anal. Calcd. for: C21H26N2O2  338.20; found: 339.45 (M + H)+. Diastereomer 2: TR = 6.00  minutes (Condition I). LC-MS:  Anal. Calcd. for: C21H26N2O2  338.20; found: 339.45 (M + H)+.


 


Intermediate-17d




Diastereomer 1: RT = 7.19  minutes (Condition I); LC-MS:  Anal. Calcd. for: C27H29NO2  399.22; found: 400.48 (M + H)+. Diastereomer 2: RT = 9.76  minutes (Condition I); LC-MS:  Anal. Calcd. for: C27H29NO2  399.22; found: 400.48 (M + H)+.









Chiral SFC Conditions for determining retention time:

Condition I

Column: CHIRALPAK® AD-H Column, 4.62×50 mm, 5 μm

Solvents: 90% CO2—10% methanol with 0.1% DEA

Temp: 35° C.

Pressure: 150 bar

Flow rate: 2.0 mL/min.

UV monitored at 220 nm

Injection: 1.0 mg/3 mL methanol

Condition II

Column: CHIRALCEL® OD-H Column, 4.62×50 mm, 5 μm

Solvents: 90% CO2—10% methanol with 0.1% DEA

Temp: 35° C.

Pressure: 150 bar

Flow rate: 2.0 mL/min.

UV monitored at 220 nm

Injection: 1.0 mg/mL methanol

Cap-17, Step 2: (R)-2-(4-Hydroxy-4-phenylpiperidin-1-yl)-2-phenylacetic acid. To a solution of (S)-1-phenylethyl (R)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-2-phenylacetate (0.350 g, 0.84 mmol) in dichloromethane (5 mL) was added trifluoroacetic acid (1 mL) and the mixture was stirred at room temperature for 2 hours. The volatiles were subsequently removed in vacuo and the residue was purified by reverse-phase preparative HPLC (Primesphere C-18, 20×100 mm; CH3CN—H2O-0.1% TFA) to give the title compound (as TFA salt) as a white solid (0.230 g, 88%). LC-MS: Anal. Calcd. for C19H21NO3: 311.15; found: 312 (M+H)+.
The following carboxylic acids were prepared in optically pure form in a similar fashion:














Cap-17a




RT = 2.21 (Condition II);  1H NMR (500 MHz,  DMSO-d6) δ ppm 2.20- 2.35 (m, 2H) 2.34-2.47  (m, 2H) 3.37 (s, 4H) 3.71  (s, 1H) 5.06 (s, 2H) 7.06- 7.53 (m, 10H). LC-MS:  Anal. Calcd. for:  C20H22N2O4 354.16 found: 355.38 (M + H)+.


 


Cap-17b 




RT = 0.27 (Condition III);  LC-MS: Anal. Calcd. for:  C12H14N2O3 234.10; found: 235.22 (M + H)+.


 


Cap-17c




RT = 0.48 (Condition II);  LC-MS: Anal. Calcd. for:  C13H18N2O2 234.14; found: 235.31 (M + H)+.


 


Cap-17d




RT = 2.21 (Condition I);  LC-MS: Anal. Calcd. for:  C19H21NO2 295.16; found:  296.33 (M + H)+.









LC-MS Conditions for determining retention time:

Condition I

Column: PHENOMENEX® Luna 4.6×50 mm S10

Start % B=0

Final % B=100

Gradient Time=4 min

Flow Rate=4 mL/min

Wavelength=220

Solvent A=10% methanol-90% H2O-0.1% TFA

Solvent B=90% methanol-10% H2O-0.1% TFA

Condition II

Column: Waters SunFire 4.6×50 mm S5

Start % B=0

Final % B=100

Gradient Time=2 min

Flow Rate=4 mL/min

Wavelength=220

Solvent A=10% methanol-90% H2O-0.1% TFA

Solvent B=90% methanol-10% H2O-0.1% TFA

Condition III

Column: PHENOMENEX® 10μ 3.0×50 mm

Start % B=0

Final % B=100

Gradient Time=2 min

Flow Rate=4 mL/min

Wavelength=220

Solvent A=10% methanol-90% H2O-0.1% TFA

Solvent B=90% methanol-10% H2O-0.1% TFA

Cap-18




Step 1: (R,S)-Ethyl 2-(4-pyridyl)-2-bromoacetate. To a solution of ethyl 4-pyridylacetate (1.00 g, 6.05 mmol) in dry THF (150 mL) at 0° C. under argon was added DBU (0.99 mL, 6.66 mmol). The reaction mixture was allowed to warm to room temperature over 30 minutes and then it was cooled to −78° C. To this mixture was added CBr4 (2.21 g, 6.66 mmol) and stirring was continued at −78° C. for 2 hours. The reaction mixture was then quenched with sat. aq. NH4Cl and the phases were separated. The organic phase was washed (brine), dried (Na2SO4), filtered, and concentrated in vacuo. The resulting yellow oil was immediately purified by flash chromatography (SiO2/hexane-ethyl acetate, 1:1) to provide the title compound (1.40 g, 95%) as a somewhat unstable yellow oil. 1H NMR (400 MHz, CDCl3) δ 8.62 (dd, J=4.6, 1.8 Hz, 2H), 7.45 (dd, J=4.6, 1.8 Hz, 2H), 5.24 (s, 1H), 4.21-4.29 (m, 2H), 1.28 (t, J=7.1 Hz, 3H). LC-MS: Anal. Calcd. for C9H10BrNO2: 242, 244; found: 243, 245 (M+H)+.
Step 2: (R,S)-Ethyl 2-(4-pyridyl)-2-(N,N-dimethylamino)acetate. To a solution of (R,S)-ethyl 2-(4-pyridyl)-2-bromoacetate (1.40 g, 8.48 mmol) in DMF (10 mL) at room temperature was added dimethylamine (2M in THF, 8.5 mL, 17.0 mmol). After completion of the reaction (as judged by thin layer chromatography) the volatiles were removed in vacuo and the residue was purified by flash chromatography (BIOTAGE®, 40+M SiO2 column; 50%-100% ethyl acetate-hexane) to provide the title compound (0.539 g, 31%) as a light yellow oil. 1H NMR (400 MHz, CDCl3) δ 8.58 (d, J=6.0 Hz, 2H), 7.36 (d, J=6.0 Hz, 2H), 4.17 (m, 2H), 3.92 (s, 1H), 2.27 (s, 6H), 1.22 (t, J=7.0 Hz). LC-MS: Anal. Calcd. for C11H16N2O2: 208; found: 209 (M+H)+.
Step 3: (R,S)-2-(4-Pyridyl)-2-(N,N-dimethylamino)acetic acid. To a solution of (R,S)-ethyl 2-(4-pyridyl)-2-(N,N-dimethylamino)acetate (0.200 g, 0.960 mmol) in a mixture of THF-methanol-H2O (1:1:1, 6 mL) was added powdered LiOH (0.120 g, 4.99 mmol) at room temperature. The solution was stirred for 3 hours and then it was acidified to pH 6 using 1N HCl. The aqueous phase was washed with ethyl acetate and then it was lyophilized to give the dihydrochloride of the title compound as a yellow solid (containing LiCl). The product was used as such in subsequent steps.
1H NMR (400 MHz, DMSO-d6) δ 8.49 (d, J=5.7 Hz, 2H), 7.34 (d, J=5.7 Hz, 2H), 3.56 (s, 1H), 2.21 (s, 6H).
The following examples were prepared in similar fashion using the method described above:














Cap-19




LC-MS: Anal. Calcd.  for C9H12N2O2: 180;  found: 181 (M + H)+.


 


Cap-20




LC-MS: no  ionization. 1H NMR  (400 MHz, CD3OD)  δ 8.55 (d, J = 4.3  Hz, 1H), 7.84 (app t, J = 5.3 Hz, 1H),  7.61 (d, J = 7.8 Hz, 1H), 7.37 (app t, J = 5.3 Hz, 1H), 4.35 (s, 1H), 2.60 (s, 6H).


 


Cap-21




LC-MS: Anal. Calcd.  for C9H11ClN2O2:  214, 216; found:  215, 217 (M + H)+.


 


Cap-22




LC-MS: Anal. Calcd.  for C10H12N2O4:  224; found: 225  (M + H)+.


 


Cap-23




LC-MS: Anal. Calcd.  for C14H15NO2:  229; found: 230  (M + H)+.


 


Cap-24




LC-MS: Anal. Calcd.  for C11H12F3NO2:  247; found: 248  (M + H)+.


 


Cap-25




LC-MS: Anal. Calcd.  for C11H12F3NO2:  247; found: 248  (M + H)+.


 


Cap-26




LC-MS: Anal. Calcd.  for C10H12FNO2:  197; found: 198  (M + H)+.


 


Cap-27




LC-MS: Anal. Calcd.  for C10H12FNO2:  247; found: 248  (M + H)+.


 


Cap-28




LC-MS: Anal. Calcd.  for C10H12ClNO2:  213; found: 214  (M + H)+.


 


Cap-29




LC-MS: Anal. Calcd.  for C10H12ClNO2:  213; found: 214  (M + H)+.


 


Cap-30




LC-MS: Anal. Calcd.  for C10H12ClNO2:  213; found: 214  (M + H)+.


 


Cap-31




LC-MS: Anal. Calcd.  for C8H12N2O2S:  200; found: 201  (M + H)+.


 


Cap-32




LC-MS: Anal. Calcd.  for C8H11NO2S:  185; found: 186  (M + H)+.


 


Cap-33




LC-MS: Anal. Calcd.  for C8H11NO2S:  185; found: 186  (M + H)+.


 


Cap-34




LC-MS: Anal. Calcd.  for C11H12N2O3:  220; found: 221  (M + H)+.


 


Cap-35




LC-MS: Anal. Calcd.  for C12H13NO2S:  235; found: 236  (M + H)+.


 


Cap-36




LC-MS: Anal. Calcd.  for C12H14N2O2S:  250; found: 251  (M + H)+.









Cap-37




Step 1: (R,S)-Ethyl 2-(quinolin-3-yl)-2-(N,N-dimethylamino)-acetate. A mixture of ethyl N,N-dimethylaminoacetate (0.462 g, 3.54 mmol), K3PO4 (1.90 g, 8.95 mmol), Pd(t-Bu3P)2 (0.090 g, 0.176 mmol), 3-bromoquinoline and toluene (10 mL) was degassed with a stream of Ar bubbles for 15 minutes. The reaction mixture was then heated at 100° C. for 12 hours, after which it was cooled to room temperature and poured into H2O. The mixture was extracted with ethyl acetate (2×) and the combined organic phases were washed (H2O, brine), dried (Na2SO4), filtered, and concentrated in vacuo. The residue was purified first by reverse-phase preparative HPLC (Primesphere C-18, 30×100 mm; CH3CN—H2O-5 mM NH4OAc) and then by flash chromatography (SiO2/hexane-ethyl acetate, 1:1) to provide the title compound (0.128 g, 17%) as an orange oil. 1H NMR (400 MHz, CDCl3) δ 8.90 (d, J=2.0 Hz, 1H), 8.32 (d, J=2.0 Hz, 1H), 8.03-8.01 (m, 2H), 7.77 (ddd, J=8.3, 6.8, 1.5 Hz, 1H), 7.62 (ddd, J=8.3, 6.8, 1.5 Hz, 1H), 4.35 (s, 1H), 4.13 (m, 2H), 2.22 (s, 6H), 1.15 (t, J=7.0 Hz, 3H). LC-MS: Anal. Calcd. for C15H18N2O2: 258; found: 259 (M+H)+.
Step 2: (R,S) 2-(Quinolin-3-yl)-2-(N,N-dimethylamino)acetic acid. A mixture of (R,S)-ethyl 2-(quinolin-3-yl)-2-(N,N-dimethylamino)acetate (0.122 g, 0.472 mmol) and 6M HCl (3 mL) was heated at 100° C. for 12 hours. The solvent was removed in vacuo to provide the dihydrochloride of the title compound (0.169 g, >100%) as a light yellow foam. The unpurified material was used in subsequent steps without further purification. LC-MS: Anal. Calcd. for C13H14N2O2: 230; found: 231 (M+H)+.
Cap-38




Step 1: (R)—((S)-1-Phenylethyl) 2-(dimethylamino)-2-(2-fluorophenyl)acetate and (S)—((S)-1-Phenylethyl) 2-(dimethylamino)-2-(2-fluorophenyl)acetate. To a mixture of (RS)-2-(dimethylamino)-2-(2-fluorophenyl)acetic acid (2.60 g, 13.19 mmol), DMAP (0.209 g, 1.71 mmol) and (S)-1-phenylethanol (2.09 g, 17.15 mmol) in CH2Cl2 (40 mL) was added EDCI (3.29 g, 17.15 mmol) and the mixture was allowed to stir at room temperature for 12 hours. The solvent was then removed in vacuo and the residue partitioned with ethyl acetate-H2O. The layers were separated, the aqueous layer was back-extracted with ethyl acetate (2×) and the combined organic phases were washed (H2O, brine), dried (Na2SO4), filtered, and concentrated in vacuo. The residue was purified by silica gel chromatography (BIOTAGE®/0-50% diethyl ether-hexane). The resulting pure diastereomeric mixture was then separated by reverse-phase preparative HPLC (Primesphere C-18, 30×100 mm; CH3CN—H2O-0.1% TFA) to give first (S)-1-phenethyl (R)-2-(dimethylamino)-2-(2-fluorophenyl)acetate (0.501 g, 13%) and then (S)-1-phenethyl (S)-2-(dimethylamino)-2-(2-fluorophenyl)-acetate (0.727 g. 18%), both as their TFA salts. (S,R)-isomer: 1H NMR (400 MHz, CD3OD) δ 7.65-7.70 (m, 1H), 7.55-7.60 (ddd, J=9.4, 8.1, 1.5 Hz, 1H), 7.36-7.41 (m, 2H), 7.28-7.34 (m, 5H), 6.04 (q, J=6.5 Hz, 1H), 5.60 (s, 1H), 2.84 (s, 6H), 1.43 (d, J=6.5 Hz, 3H). LC-MS: Anal. Calcd. for C18H20FNO2: 301; found: 302 (M+H)+; (S,S)-isomer: 1H NMR (400 MHz, CD3OD) δ 7.58-7.63 (m, 1H), 7.18-7.31 (m, 6H), 7.00 (dd, J=8.5, 1.5 Hz, 2H), 6.02 (q, J=6.5 Hz, 1H), 5.60 (s, 1H), 2.88 (s, 6H), 1.54 (d, J=6.5 Hz, 3H). LC-MS: Anal. Calcd. for C18H20FNO2: 301; found: 302 (M+H)+.
Step 2: (R)-2-(Dimethylamino)-2-(2-fluorophenyl)acetic acid. A mixture of (R)—((S)-1-phenylethyl) 2-(dimethylamino)-2-(2-fluorophenyl)acetate TFA salt (1.25 g, 3.01 mmol) and 20% Pd(OH)2/C (0.125 g) in ethanol (30 mL) was hydrogenated at room temperature and atmospheric pressure (H2 balloon) for 4 hours. The solution was then purged with Ar, filtered through diatomaceous earth (CELITE®), and concentrated in vacuo. This gave the title compound as a colorless solid (0.503 g, 98%). 1H NMR (400 MHz, CD3OD) δ 7.53-7.63 (m, 2H), 7.33-7.38 (m, 2H), 5.36 (s, 1H), 2.86 (s, 6H). LC-MS: Anal. Calcd. for C10H12FNO2: 197; found: 198 (M+H)+.
The S-isomer could be obtained from (S)—((S)-1-phenylethyl) 2-(dimethylamino)-2-(2-fluorophenyl)acetate TFA salt in similar fashion.
Cap-39




A mixture of (R)-(2-chlorophenyl)glycine (0.300 g, 1.62 mmol), formaldehyde (35% aqueous solution, 0.80 mL, 3.23 mmol) and 20% Pd(OH)2/C (0.050 g) was hydrogenated at room temperature and atmospheric pressure (H2 balloon) for 4 hours. The solution was then purged with Ar, filtered through diatomaceous earth (CELITE®) and concentrated in vacuo. The residue was purified by reverse-phase preparative HPLC (Primesphere C-18, 30×100 mm; CH3CN—H2O-0.1% TFA) to give the TFA salt of the title compound (R)-2-(dimethylamino)-2-(2-chlorophenyl)acetic acid as a colorless oil (0.290 g, 55%). 1H NMR (400 MHz, CD3OD) δ 7.59-7.65 (m, 2H), 7.45-7.53 (m, 2H), 5.40 (s, 1H), 2.87 (s, 6H). LC-MS: Anal. Calcd. for C10H12ClNO2: 213; found: 214 (M+H)+.
Cap-40




To an ice-cold solution of (R)-(2-chlorophenyl)glycine (1.00 g, 5.38 mmol) and NaOH (0.862 g, 21.6 mmol) in H2O (5.5 mL) was added methyl chloroformate (1.00 mL, 13.5 mmol) dropwise. The mixture was allowed to stir at 0° C. for 1 hour and then it was acidified by the addition of conc. HCl (2.5 mL). The mixture was extracted with ethyl acetate (2×) and the combined organic phase was washed (H2O, brine), dried (Na2SO4), filtered, and concentrated in vacuo to give the title compound (R)-2-(methoxycarbonylamino)-2-(2-chlorophenyl)acetic acid as a yellow-orange foam (1.31 g, 96%). 1H NMR (400 MHz, CD3OD) δ 7.39-7.43 (m, 2H), 7.29-7.31 (m, 2H), 5.69 (s, 1H), 3.65 (s, 3H). LC-MS: Anal. Calcd. for C10H10ClNO4: 243; found: 244 (M+H)+.
Cap-41




To a suspension of 2-(2-(chloromethyl)phenyl)acetic acid (2.00 g, 10.8 mmol) in THF (20 mL) was added morpholine (1.89 g, 21.7 mmol) and the solution was stirred at room temperature for 3 hours. The reaction mixture was then diluted with ethyl acetate and extracted with H2O (2×). The aqueous phase was lyophilized and the residue was purified by silica gel chromatography (BIOTAGE®/0-10% methanol-CH2Cl2) to give the title compound 2-(2-(morpholinomethyl)phenyl)acetic acid as a colorless solid (2.22 g, 87%). 1H NMR (400 MHz, CD3OD) δ 7.37-7.44 (m, 3H), 7.29-7.33 (m, 1H), 4.24 (s, 2H), 3.83 (br s, 4H), 3.68 (s, 2H), 3.14 (br s, 4H). LC-MS: Anal. Calcd. for C13H17NO3: 235; found: 236 (M+H)+.
The following examples were similarly prepared using the method described for Cap-41:

















Cap-42




LC-MS: Anal. Calcd. for  C14H19NO2: 233; found:  234 (M + H)+.



 



Cap-43




LC-MS: Anal. Calcd. for  C13H17NO2: 219; found:  220 (M + H)+.



 



Cap-44




LC-MS: Anal. Calcd. for  C11H15NO2: 193; found:  194 (M + H)+.



 



Cap-45




LC-MS: Anal. Calcd. for  C14H20N2O2: 248; found:  249 (M + H)+.










Cap-45a




HMDS (1.85 mL, 8.77 mmol) was added to a suspension of (R)-2-amino-2-phenylacetic acid p-toluenesulfonate (2.83 g, 8.77 mmol) in CH2Cl2 (10 mL) and the mixture was stirred at room temperature for 30 minutes. Methyl isocyanate (0.5 g, 8.77 mmol) was added in one portion stirring continued for 30 minutes. The reaction was quenched by addition of H2O (5 mL) and the resulting precipitate was filtered, washed with H2O and n-hexanes, and dried under vacuum. (R)-2-(3-methylureido)-2-phenylacetic acid (1.5 g; 82%) was recovered as a white solid and it was used without further purification. 1H NMR (500 MHz, DMSO-d6) δ ppm 2.54 (d, J=4.88 Hz, 3H) 5.17 (d, J=7.93 Hz, 1H) 5.95 (q, J=4.48 Hz, 1H) 6.66 (d, J=7.93 Hz, 1H) 7.26-7.38 (m, 5H) 12.67 (s, 1H). LC-MS: Anal. Calcd. for C10H12N2O3 208.08 found 209.121 (M+H)+; HPLC PHENOMENEX® C-18 3.0×46 mm, 0 to 100% B over 2 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, RT=1.38 min, 90% homogeneity index.
Cap-46




The desired product was prepared according to the method described for Cap-45a. 1H NMR (500 MHz, DMSO-d6) δ ppm 0.96 (t, J=7.17 Hz, 3H) 2.94-3.05 (m, 2H) 5.17 (d, J=7.93 Hz, 1H) 6.05 (t, J=5.19 Hz, 1H) 6.60 (d, J=7.63 Hz, 1H) 7.26-7.38 (m, 5H) 12.68 (s, 1H). LC-MS: Anal. Calcd. for C11H14N2O3 222.10 found 223.15 (M+H)+. HPLC XTERRA® C-18 3.0×506 mm, 0 to 100% B over 2 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.2% H3PO4, B=10% water, 90% methanol, 0.2% H3PO4, RT=0.87 min, 90% homogeneity index.
Cap-47




Step 1: (R)-tert-Butyl 2-(3,3-dimethylureido)-2-phenylacetate. To a stirred solution of (R)-tert-butyl-2-amino-2-phenylacetate (1.0 g, 4.10 mmol) and Hunig's base (1.79 mL, 10.25 mmol) in DMF (40 mL) was added dimethylcarbamoyl chloride (0.38 mL, 4.18 mmol) dropwise over 10 minutes. After stirring at room temperature for 3 hours, the reaction was concentrated under reduced pressure and the resulting residue was dissolved in ethyl acetate. The organic layer was washed with H2O, 1N aq. HCl and brine, dried (MgSO4), filtered and concentrated under reduced pressure. (R)-tert-butyl 2-(3,3-dimethylureido)-2-phenylacetate was obtained as a white solid (0.86 g; 75%) and used without further purification. 1H NMR (500 MHz, DMSO-d6) δ ppm 1.33 (s, 9H) 2.82 (s, 6H) 5.17 (d, J=7.63 Hz, 1H) 6.55 (d, J=7.32 Hz, 1H) 7.24-7.41 (m, 5H). LC-MS: Anal. Calcd. for C15H22N2O3 278.16 found 279.23 (M+H)+; HPLC PHENOMENEX® Luna C-18 4.6×50 mm, 0 to 100% B over 4 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, RT=2.26 min, 97% homogeneity index.
Step 2: (R)-2-(3,3-Dimethylureido)-2-phenylacetic acid. To a stirred solution of ((R)-tert-butyl 2-(3,3-dimethylureido)-2-phenylacetate (0.86 g, 3.10 mmol) in CH2Cl2 (250 mL) was added TFA (15 mL) dropwise and the resulting solution was stirred at rt for 3 hours. The desired compound was then precipitated out of solution with a mixture of EtOAC:Hexanes (5:20), filtered off and dried under reduced pressure. (R)-2-(3,3-dimethylureido)-2-phenylacetic acid was isolated as a white solid (0.59 g, 86%) and used without further purification. 1H NMR (500 MHz, DMSO-d6) δ ppm 2.82 (s, 6H) 5.22 (d, J=7.32 Hz, 1H) 6.58 (d, J=7.32 Hz, 1H) 7.28 (t, J=7.17 Hz, 1H) 7.33 (t, J=7.32 Hz, 2H) 7.38-7.43 (m, 2H) 12.65 (s, 1H). LC-MS: Anal. Calcd. for C11H14N2O3: 222.24; found: 223.21 (M+H)+. HPLC XTERRA® C-18 3.0×50 mm, 0 to 100% B over 2 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.2% H3PO4, B=10% water, 90% methanol, 0.2% H3PO4, RT=0.75 min, 93% homogeneity index.
Cap-48




Step 1: (R)-tert-Butyl 2-(3-cyclopentylureido)-2-phenylacetate. To a stirred solution of (R)-2-amino-2-phenylacetic acid hydrochloride (1.0 g, 4.10 mmol) and Hunig's base (1.0 mL, 6.15 mmol) in DMF (15 mL) was added cyclopentyl isocyanate (0.46 mL, 4.10 mmol) dropwise and over 10 minutes. After stirring at room temperature for 3 hours, the reaction was concentrated under reduced pressure and the resulting residue was taken up in ethyl acetate. The organic layer was washed with H2O and brine, dried (MgSO4), filtered, and concentrated under reduced pressure. (R)-tert-butyl 2-(3-cyclopentylureido)-2-phenylacetate was obtained as an opaque oil (1.32 g; 100%) and used without further purification. 1H NMR (500 MHz, CD3C1-D) δ ppm 1.50-1.57 (m, 2H) 1.58-1.66 (m, 2H) 1.87-1.97 (m, 2H) 3.89-3.98 (m, 1H) 5.37 (s, 1H) 7.26-7.38 (m, 5H). LC-MS: Anal. Calcd. for C18H26N2O3 318.19 found 319.21 (M+H)+; HPLC XTERRA® C-18 3.0×50 mm, 0 to 100% B over 4 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA, RT=2.82 min, 96% homogeneity index.
Step 2: (R)-2-(3-Cyclopentylureido)-2-phenylacetic acid. To a stirred solution of (R)-tert-butyl 2-(3-cyclopentylureido)-2-phenylacetate (1.31 g, 4.10 mmol) in CH2Cl2 (25 mL) was added TFA (4 mL) and triethylsilane (1.64 mL; 10.3 mmol) dropwise, and the resulting solution was stirred at room temperature for 6 hours. The volatile components were removed under reduced pressure and the crude product was recrystallized in ethyl acetate/pentanes to yield (R)-2-(3-cyclopentylureido)-2-phenylacetic acid as a white solid (0.69 g, 64%). 1H NMR (500 MHz, DMSO-d6) δ ppm 1.17-1.35 (m, 2H) 1.42-1.52 (m, 2H) 1.53-1.64 (m, 2H) 1.67-1.80 (m, 2H) 3.75-3.89 (m, 1H) 5.17 (d, J=7.93 Hz, 1H) 6.12 (d, J=7.32 Hz, 1H) 6.48 (d, J=7.93 Hz, 1H) 7.24-7.40 (m, 5H) 12.73 (s, 1H). LC-MS: Anal. Calcd. for C14H18N2O3: 262.31; found: 263.15 (M+H)+. HPLC XTERRA® C-18 3.0×50 mm, 0 to 100% B over 2 minutes, 1 minute hold time, A=90% water, 10% methanol, 0.2% H3PO4, B=10% water, 90% methanol, 0.2% H3PO4, RT=1.24 min, 100% homogeneity index.
Cap-49




To a stirred solution of 2-(benzylamino)acetic acid (2.0 g, 12.1 mmol) in formic acid (91 mL) was added formaldehyde (6.94 mL, 93.2 mmol). After five hours at 70° C., the reaction mixture was concentrated under reduced pressure to 20 mL and a white solid precipitated. Following filtration, the mother liquors were collected and further concentrated under reduced pressure providing the crude product. Purification by reverse-phase preparative HPLC(XTERRA® 30×100 mm, detection at 220 nm, flow rate 35 mL/min, 0 to 35% B over 8 min; A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA) provided the title compound 2-(benzyl(methyl)-amino)acetic acid as its TFA salt (723 mg, 33%) as a colorless wax. 1H NMR (300 MHz, DMSO-d6) δ ppm 2.75 (s, 3H) 4.04 (s, 2H) 4.34 (s, 2H) 7.29-7.68 (m, 5H). LC-MS: Anal. Calcd. for: C10H13NO2 179.09; found: 180.20 (M+H)+.
Cap-50




To a stirred solution of 3-methyl-2-(methylamino)butanoic acid (0.50 g, 3.81 mmol) in water (30 mL) was added K2CO3 (2.63 g, 19.1 mmol) and benzyl chloride (1.32 g, 11.4 mmol). The reaction mixture was stirred at ambient temperature for 18 hours. The reaction mixture was extracted with ethyl acetate (30 mL×2) and the aqueous layer was concentrated under reduced pressure providing the crude product which was purified by reverse-phase preparative HPLC(XTERRA® 30×100 mm, detection at 220 nm, flow rate 40 mL/min, 20 to 80% B over 6 min; A=90% water, 10% methanol, 0.1% TFA, B=10% water, 90% methanol, 0.1% TFA) to provide 2-(benzyl(methyl)amino)-3-methylbutanoic acid, TFA salt (126 mg, 19%) as a colorless wax. 1H NMR (500 MHz, DMSO-d6) δ ppm 0.98 (d, 3H) 1.07 (d, 3H) 2.33-2.48 (m, 1H) 2.54-2.78 (m, 3H) 3.69 (s, 1H) 4.24 (s, 2H) 7.29-7.65 (m, 5H). LC-MS: Anal. Calcd. for: C13H19NO2 221.14; found: 222.28 (M+H)+.
Cap-51




(S)-2-(Methoxycarbonylamino)-3-methylbutanoic acid
Na2CO3 (1.83 g, 17.2 mmol) was added to NaOH (33 mL of 1M/H2O, 33 mmol) solution of L-valine (3.9 g, 33.29 mmol) and the resulting solution was cooled with ice-water bath. Methyl chloroformate (2.8 mL, 36.1 mmol) was added dropwise over 15 min, the cooling bath was removed and the reaction mixture was stirred at ambient temperature for 3.25 hr. The reaction mixture was washed with ether (50 mL, 3×), and the aqueous phase was cooled with ice-water bath and acidified with concentrated HCl to a pH region of 1-2, and extracted with CH2Cl2 (50 mL, 3×). The organic phase was dried (MgSO4) and evaporated in vacuo to afford Cap-51 as a white solid (6 g). 1H NMR for the dominant rotamer (DMSO-d6, δ=2.5 ppm, 500 MHz): 12.54 (s, 1H), 7.33 (d, J=8.6, 1H), 3.84 (dd, J=8.4, 6.0, 1H), 3.54 (s, 3H), 2.03 (m, 1H), 0.87 (m, 6H). HRMS: Anal. Calcd. for [M+H]+ C7H14NO4: 176.0923; found 176.0922.
Cap-51 (alternate route)




(S)-2-(Methoxycarbonylamino)-3-methylbutanoic acid
DIEA (137.5 mL, 0.766 mol) was added to a suspension of (S)-tert-butyl 2-amino-3-methylbutanoate hydrochloride (75.0 g, 0.357 mol) in THF (900 mL), and the mixture was cooled to 0° C. (ice/water bath). Methyl chloroformate (29.0 mL, 0.375 mol) was added dropwise over 45 min, the cooling bath was removed and the heterogeneous mixture was stirred at ambient temperature for 3 h. The solvent was removed under diminished pressure and the residue partitioned between EtOAc and water (1 L each). The organic layer was washed with H2O (1 L) and brine (1 L), dried (MgSO4), filtered and concentrated under diminished pressure. The crude material was passed through a plug of silica gel (1 kg), eluting with hexanes (4 L) and 15:85 EtOAc/hexanes (4 L) to afford (S)-tert-butyl 2-(methoxycarbonylamino)-3-methylbutanoate as a clear oil (82.0 g, 99% yield). 1H NMR (500 MHz, DMSO-d6, δ=2.5 ppm) 7.34 (d, J=8.6, 1H), 3.77 (dd, J=8.6, 6.1, 1H), 3.53 (s, 3H), 1.94-2.05 (m, 1H), 1.39 (s, 9H), 0.83-0.92 (m, 6H). 13C-NMR (126 MHz, DMSO-d6, δ=39.2 ppm) 170.92, 156.84, 80.38, 60.00, 51.34, 29.76, 27.62, 18.92, 17.95. LC-MS: [M+Na]+254.17.
Trifluoroacetic acid (343 mL, 4.62 mol) and Et3SiH (142 mL, 0.887 mol) were added sequentially to a solution of (S)-tert-butyl 2-(methoxycarbonylamino)-3-methylbutanoate (82.0 g, 0.355 mol) in CH2Cl2 (675 mL), and the mixture was stirred at ambient temperature for 4 h. The volatile component was removed under diminished pressure and the resultant oil triturated with petroleum ether (600 mL) to afford a white solid, which was filtered and washed with hexanes (500 mL) and petroleum ether (500 mL). Recrystallization from EtOAc/petroleum ether afforded Cap-51 as white flaky crystals (54.8 g, 88% yield). MP=108.5-109.5° C. 1H NMR (500 MHz, DMSO-d6, δ=2.5 ppm) 12.52 (s, 1H), 7.31 (d, J=8.6, 1H), 3.83 (dd, J=8.6, 6.1, 1H), 3.53 (s, 3H), 1.94-2.07 (m, 1H), 0.86 (dd, J=8.9, 7.0, 6H). 13C NMR (126 MHz, DMSO-d6, δ=39.2 ppm) 173.30, 156.94, 59.48, 51.37, 29.52, 19.15, 17.98. LC-MS: [M+H]+=176.11. Anal. Calcd. for C7H13NO4: C, 47.99; H, 7.48; N, 7.99. Found: C, 48.17; H, 7.55; N, 7.99. Optical Rotation: [α]D=−4.16 (12.02 mg/mL; MeOH). Optical purity: >99.5% ee. Note: the optical purity assessment was made on the methyl ester derivative of Cap-51, which was prepared under a standard TMSCHN2 (benzene/MeOH) esterification protocol. HPLC analytical conditions: column, CHIRALPAK® AD-H (4.6×250 mm, 5 μm); solvent, 95% heptane/5% IPA (isocratic); flow rate, 1 mL/min; temperature, 35° C.; UV monitored at 205 nm.
[Note: Cap-51 could also be purchased from Flamm.]
Cap-52 (same as Cap-12)




(S)-2-(Methoxycarbonylamino)propanoic acid
Cap-52 was synthesized from L-alanine according to the procedure described for the synthesis of Cap-51. For characterization purposes, a portion of the crude material was purified by a reverse phase HPLC(H2O/methanol/TFA) to afford Cap-52 as a colorless viscous oil. 1H NMR (DMSO-d6, δ=2.5 ppm, 500 MHz): 12.49 (br s, 1H), 7.43 (d, J=7.3, 0.88H), 7.09 (app br s, 0.12H), 3.97 (m, 1H), 3.53 (s, 3H), 1.25 (d, J=7.3, 3H).
Cap-53 to Cap-64
Cap-53 to Cap-64 were prepared from appropriate starting materials according to the procedure described for the synthesis of Cap-51, with noted modifications if any.












Cap
Structure
Data







Cap-53a: (R) Cap-53b: (S)  ((S)-2- (methoxy- carbonyl- amino) butanoic acid)




1H NMR (DMSO- d6, δ = 2.5 ppm,  500 MHz): δ 12.51 (br s, 1H), 7.4  (d, J = 7.9, 0.9H),  7.06 (app s, 0.1H),  3.86-3.82 (m,  1H), 3.53 (s, 3H),  1.75-1.67 (m, 1H),  1.62-1.54 (m, 1H),  0.88 (d, J = 7.3,  3H). RT = 0.77  minutes (Cond. 2);  LC-MS: Anal.  Calcd. for [M + Na]+  C6H11NNaO4:  184.06; found  184.07. HRMS  Calcd. for [M + Na]+  C6H11NNaO4:  184.0586; found  184.0592.


 


Cap-54a: (R) Cap-54b: (S)  ((S)-2- cyclopropyl- 2-(methoxy- carbonyl- amino)acetic  acid)




1H NMR (DMSO- d6, δ = 2.5 ppm,  500 MHz): δ 12.48  (s, 1H), 7.58 (d,  J = 7.6, 0.9H), 7.25  (app s, 0.1H), 3.52  (s, 3H), 3.36-3.33  (m, 1H), 1.10-1.01  (m, 1H), 0.54-0.49 (m, 1H), 0.46-0.40  (m, 1H), 0.39-0.35  (m, 1H), 0.31-0.21  (m, 1H). HRMS  Calcd. for [M + H]+  C7H12NO4:  174.0766; found  174.0771


 


Cap-55




1H NMR (DMSO- d6, δ = 2.5 ppm,  500 MHz): δ  12.62 (s, 1H), 7.42  (d, J = 8.2, 0.9H),  7.07 (app s, 0.1H),  5.80-5.72 (m, 1H),  5.10 (d, J= 17.1,  1H), 5.04 (d, J =  10.4, 1H), 4.01- 3.96 (m, 1H), 3.53  (s, 3H), 2.47-2.42  (m, 1H), 2.35-2.29  (m, 1H).


 


Cap-56 (S)-3-methoxy- 2-(methoxy- carbonyl- amino)  propanoic acid




1H NMR (DMSO- d6, δ = 2.5 ppm,  500 MHz): δ  12.75 (s, 1H), 7.38  (d, J = 8.3, 0.9H),  6.96 (app s, 0.1H),  4.20-4.16 (m, 1H),  3.60-3.55 (m, 2H),  3.54 (s, 3H), 3.24  (s, 3H).


 


Cap-57




1H NMR (DMSO- d6, δ = 2.5 ppm,  500 MHz): δ 12.50  (s, 1H), 8.02 (d, J = 7.7, 0.08H), 7.40  (d, J = 7.9, 0.76H), 7.19 (d, J = 8.2,  0.07H), 7.07 (d, J = 6.7, 0.09H), 4.21- 4.12 (m, 0.08H), 4.06-3.97 (m, 0.07H),  3.96-3.80 (m, 0.85H), 3.53 (s, 3H), 1.69- 1.51 (m, 2H), 1.39- 1.26 (m, 2H), 0.85 (t, J = 7.4, 3H). LC  (Cond. 2): RT = 1.39 LC-MS: Anal. Calcd. for [M + H]+  C7H14NO4: 176.09; found 176.06.


 


Cap-58




1H NMR (DMSO- d6, δ = 2.5 ppm,  500 MHz): δ 12.63  (br s, 1H), 7.35 (s,  1H), 7.31 (d, J = 8.2, 1H), 6.92 (s,  1H), 4.33-4.29  (m, 1H), 3.54 (s,  3H), 2.54(dd, J =  15.5, 5.4, 1H), 2.43 (dd, J = 15.6, 8.0, 1H). RT = 0.16 min (Cond. 2); LC-MS: Anal. Calcd. for  [M + H]+ C6H11N2O5:  191.07; found 191.14.


 


Cap-59a: (R) Cap-59B: (S)




1H NMR (DMSO- d6, δ = 2.5 ppm,  400 MHz): δ  12.49 (br s, 1H),  7.40 (d, J = 7.3,  0.89H), 7.04 (br s,  0.11H), 4.00-3.95  (m, 3H), 1.24 (d,  J = 7.3, 3H), 1.15  (t, J = 7.2, 3H).  HRMS: Anal.  Calcd. for [M + H]+  C6H12NO4: 162.0766;  found 162.0771. 


 


Cap-60




The crude material  was purified with  a reverse phase  HPLC (H2O/ MeOH/TFA)  to afford a colorless viscous oil that  crystallized to a  white solid upon  exposure to high  vacuum.  1H NMR (DMSO- d6, δ = 2.5 ppm,  400 MHz): δ 12.38 (br s, 1H), 7.74  (s, 0.82H), 7.48 (s, 0.18H), 3.54/3.51  (two s, 3H), 1.30  (m, 2H), 0.98 (m,  2H). HRMS: Anal.  Calcd. for [M + H]+  C6H10NO4: 160.0610;  found 160.0604.


 


Cap-61




1H NMR (DMSO- d6, δ = 2.5 ppm,  400 MHz): δ  12.27 (br s, 1H),  7.40 (br s, 1H),  3.50 (s, 3H), 1.32  (s, 6H). HRMS:  Anal. Calcd. for  [M + H]+ C6H12NO4:  162.0766;  found 162.0765.


 


Cap-62




1H NMR (DMSO- d6, δ = 2.5 ppm,  400 MHz): δ  12.74 (br s, 1H),  4.21 (d, J = 10.3,  0.6H), 4.05 (d, J =  10.0, 0.4H),  3.62/3.60 (two  singlets, 3H), 3.0  (s, 3H), 2.14-2.05  (m, 1H), 0.95 (d,  J = 6.3, 3H), 0.81  (d, J = 6.6, 3H).  LC-MS: Anal.  Calcd. for [M − H]−  C8H14NO4: 188.09; found 188.05.


 


Cap-63




[Note: the reaction  was allowed to run  for longer than  what was noted  for the general  procedure.] 1H  NMR (DMSO-d6,  δ = 2.5 ppm, 400  MHz): 12.21 (br s,  1H), 7.42 (br s,  1H), 3.50 (s, 3H),  2.02-1.85 (m, 4H),  1.66-1.58 (m, 4H).  LC-MS: Ana1.  Calcd. for [M + H]+  C8H14NO4: 188.09; found 188.19.


 


Cap-64




[Note: the reaction  was allowed to run  for longer than  what was noted  for the general  procedure.] 1H  NMR (DMSO-d6,  δ = 2.5 ppm, 400  MHz): 12.35 (br s,  1H), 7.77 (s,  0.82H), 7.56/7.52  (overlapping br s,  0.18H), 3.50 (s, 3H), 2.47-2.40 (m, 2H), 2.14-2.07 (m, 2H),  1.93-1.82 (m, 2H).









Cap-65




Methyl chloroformate (0.65 mL, 8.39 mmol) was added dropwise over 5 min to a cooled (ice-water) mixture of Na2CO3 (0.449 g, 4.23 mmol), NaOH (8.2 mL of 1M/H2O, 8.2 mmol) and (S)-2-amino-3-hydroxy-3-methylbutanoic acid (1.04 g, 7.81 mmol). The reaction mixture was stirred for 45 min, and then the cooling bath was removed and stirring was continued for an additional 3.75 hr. The reaction mixture was washed with CH2Cl2, and the aqueous phase was cooled with ice-water bath and acidified with concentrated HCl to a pH region of 1-2. The volatile component was removed in vacuo and the residue was taken up in a 2:1 mixture of MeOH/CH2Cl2 (15 mL) and filtered, and the filterate was rotervaped to afford Cap-65 as a white semi-viscous foam (1.236 g). 1H NMR (DMSO-d6, δ=2.5 ppm, 400 MHz): δ 6.94 (d, J=8.5, 0.9H), 6.53 (br s, 0.1H), 3.89 (d, J=8.8, 1H), 2.94 (s, 3H), 1.15 (s, 3H), 1.13 (s, 3H).
Cap-66 and Cap-67 were prepared from appropriate commercially available starting materials by employing the procedure described for the synthesis of Cap-65.
Cap-66




1H NMR (DMSO-d6, δ=2.5 ppm, 400 MHz): δ 12.58 (br s, 1H), 7.07 (d, J=8.3, 0.13H), 6.81 (d, J=8.8, 0.67H), 4.10-4.02 (m, 1.15H), 3.91 (dd, J=9.1, 3.5, 0.85H), 3.56 (s, 3H), 1.09 (d, J=6.2, 3H). [Note: only the dominant signals of NH were noted].
Cap-67




1H NMR (DMSO-d6, δ=2.5 ppm, 400 MHz): 12.51 (br s, 1H), 7.25 (d, J=8.4, 0.75H), 7.12 (br d, J=0.4, 0.05H), 6.86 (br s, 0.08H), 3.95-3.85 (m, 2H), 3.54 (s, 3H), 1.08 (d, J=6.3, 3H). [Note: only the dominant signals of NH were noted].
Cap-68




Methyl chloroformate (0.38 ml, 4.9 mmol) was added drop-wise to a mixture of 1N NaOH (aq) (9.0 ml, 9.0 mmol), 1M NaHCO3 (aq) (9.0 ml, 9.0 mol), L-aspartic acid β-benzyl ester (1.0 g, 4.5 mmol) and dioxane (9 ml). The reaction mixture was stirred at ambient conditions for 3 hr, and then washed with ethyl acetate (50 ml, 3×). The aqueous layer was acidified with 12N HCl to a pH  ̃1-2, and extracted with ethyl acetate (3×50 ml). The combined organic layers were washed with brine, dried (Na2SO4), filtered, and concentrated in vacuo to afford Cap-68 as a light yellow oil (1.37 g; mass is above theoretical yield, and the product was used without further purification). 1H NMR (DMSO-d6, δ=2.5 ppm, 500 MHz): δ 12.88 (br s, 1H), 7.55 (d, J=8.5, 1H), 7.40-7.32 (m, 5H), 5.13 (d, J=12.8, 1H), 5.10 (d, J=12.9, 1H), 4.42-4.38 (m, 1H), 3.55 (s, 3H), 2.87 (dd, J=16.2, 5.5, 1H), 2.71 (dd, J=16.2, 8.3, 1H). LC (Cond. 2): RT=1.90 min; LC-MS: Anal. Calcd. for [M+H]+ C13H16NO6: 282.10; found 282.12.
Cap-69a and Cap-69b




NaCNBH3 (2.416 g, 36.5 mmol) was added in batches to a chilled ( ̃15° C.) water (17 mL)/MeOH (10 mL) solution of alanine (1.338 g, 15.0 mmol). A few minutes later acetaldehyde (4.0 mL, 71.3 mmol) was added drop-wise over 4 min, the cooling bath was removed, and the reaction mixture was stirred at ambient condition for 6 hr. An additional acetaldehyde (4.0 mL) was added and the reaction was stirred for 2 hr. Concentrated HCl was added slowly to the reaction mixture until the pH reached  ̃1.5, and the resulting mixture was heated for 1 hr at 40° C. Most of the volatile component was removed in vacuo and the residue was purified with a DOWEX® 50WX8-100 ion-exchange resin (column was washed with water, and the compound was eluted with dilute NH4OH, prepared by mixing 18 ml of NH4OH and 282 ml of water) to afford Cap-69 (2.0 g) as an off-white soft hygroscopic solid. 1H NMR (DMSO-d6, δ=2.5 ppm, 400 MHz): δ 3.44 (q, J=7.1, 1H), 2.99-2.90 (m, 2H), 2.89-2.80 (m, 2H), 1.23 (d, J=7.1, 3H), 1.13 (t, J=7.3, 6H).
Cap-70 to Cap-74x
Cap-70 to Cap-74x were prepared according to the procedure described for the synthesis of Cap-69 by employing appropriate starting materials.














Cap-70a: (R) Cap-70b: (S)




1H NMR (DMSO-d6, δ = 2.5 ppm, 400 MHz): δ 3.42 (q, J = 7.1, 1H), 2.68- 2.60 (m, 4H), 1.53-1.44  (m, 4H), 1.19 (d, J = 7.3, 3H), 0.85 (t, J = 7.5, 6H). LC-MS: Anal. Calcd. for [M + H]+ C9H20NO2:  174.15; found 174.13.


 


Cap-71a: (R) Cap-71b: (S) 




1H NMR (DMSO-d6, δ =  2.5 ppm, 500 MHz): δ 3.18-3.14 (m, 1H), 2.84- 2.77 (m, 2H), 2.76-2.68 (m, 2H), 1.69-1.54 (m,  2H), 1.05 (t, J = 7.2, 6H), 0.91 (t, J = 7.3, 3H). LC- MS: Anal. Calcd. for [M + H]+ C8H18NO2:  160.13; found 160.06.


 


Cap-72




1H NMR (DMSO-d6, δ = 2.5 ppm, 400 MHz): δ 2.77-2.66 (m, 3H), 2.39- 2.31 (m, 2H), 1.94-1.85 (m, 1H), 0.98 (t, J = 7.1,  6H), 0.91 (d, J = 6.5, 3H), 0.85 (d, J = 6.5, 3H). LC-MS: Anal. Calcd. for [M + H]+ C9H20NO2: 174.15; found 174.15.


 


Cap-73




1H NMR (DMSO-d6, δ =  2.5 ppm, 500 MHz): δ 9.5 (br s, 1H), 3.77 (dd,  J = 10.8, 4.1, 1H), 3.69- 3.61 (m, 2H), 3.26 (s, 3H), 2.99-2.88 (m, 4H), 1.13 (t, J = 7.2, 6H).


 


Cap-74




1H NMR (DMSO-d6, δ = 2.5 ppm, 500 MHz): δ 7.54 (s, 1H), 6.89 (s, 1H), 3.81 (t, J = 6.6, k, 1H), 2.82-2.71 (m, 4H), 2.63  (dd, J = 15.6, 7.0, 1H), 2.36 (dd, J = 15.4, 6.3,  1H), 1.09 (t, J = 7.2, 6H). RT = 0.125 minutes  (Cond. 2); LC-MS: Anal. Calcd. for [M + H]+  C8H17N2O3: 189.12;  found 189.13.


 


Cap-74x




LC-MS: Anal. Calcd.  for [M + H]+ C10H22NO2: 188.17; found 188.21.









Cap-75




Cap-75, Step a




NaBH3CN (1.6 g, 25.5 mmol) was added to a cooled (ice/water bath) water (25 ml)/methanol (15 ml) solution of H-D-Ser-OBzl HCl (2.0 g, 8.6 mmol). Acetaldehyde (1.5 ml, 12.5 mmol) was added drop-wise over 5 min, the cooling bath was removed, and the reaction mixture was stirred at ambient condition for 2 hr. The reaction was carefully quenched with 12N HCl and concentrated in vacuo. The residue was dissolved in water and purified with a reverse phase HPLC (MeOH/H2O/TFA) to afford the TFA salt of (R)-benzyl 2-(diethylamino)-3-hydroxypropanoate as a colorless viscous oil (1.9 g). 1H NMR (DMSO-d6, δ=2.5 ppm, 500 MHz): δ 9.73 (br s, 1H), 7.52-7.36 (m, 5H), 5.32 (d, J=12.2, 1H), 5.27 (d, J=12.5, 1H), 4.54-4.32 (m, 1H), 4.05-3.97 (m, 2H), 3.43-3.21 (m, 4H), 1.23 (t, J=7.2, 6H). LC-MS (Cond. 2): RT=1.38 min; LC-MS: Anal. Calcd. for [M+H]+ C14H22NO3: 252.16; found 252.19.
Cap-75
NaH (0.0727 g, 1.82 mmol, 60%) was added to a cooled (ice-water) THF (3.0 mL) solution of the TFA salt (R)-benzyl 2-(diethylamino)-3-hydroxypropanoate (0.3019 g, 0.8264 mmol) prepared above, and the mixture was stirred for 15 min. Methyl iodide (56 mL, 0.90 mmol) was added and stirring was continued for 18 hr while allowing the bath to thaw to ambient condition. The reaction was quenched with water and loaded onto a MeOH pre-conditioned MCX (6 g) cartridge, and washed with methanol followed by compound elution with 2N NH3/Methanol. Removal of the volatile component in vacuo afforded Cap-75, contaminated with (R)-2-(diethylamino)-3-hydroxypropanoic acid, as a yellow semi-solid (100 mg). The product was used as is without further purification.
Cap-76




NaCNBH3 (1.60 g, 24.2 mmol) was added in batches to a chilled ( ̃15° C.) water/MeOH (12 mL each) solution of (S)-4-amino-2-(tert-butoxycarbonylamino) butanoic acid (2.17 g, 9.94 mmol). A few minutes later acetaldehyde (2.7 mL, 48.1 mmol) was added drop-wise over 2 min, the cooling bath was removed, and the reaction mixture was stirred at ambient condition for 3.5 hr. An additional acetaldehyde (2.7 mL, 48.1 mmol) was added and the reaction was stirred for 20.5 hr. Most of the MeOH component was removed in vacuo, and the remaining mixture was treated with concentrated HCl until its pH reached  ̃1.0 and then heated for 2 hr at 40° C. The volatile component was removed in vacuo, and the residue was treated with 4 M HCl/dioxane (20 mL) and stirred at ambient condition for 7.5 hr. The volatile component was removed in vacuo and the residue was purified with DOWEX® 50WX8-100 ion-exchange resin (column was washed with water and the compound was eluted with dilute NH4OH, prepared from 18 ml of NH4OH and 282 ml of water) to afford intermediate (S)-2-amino-4-(diethylamino)butanoic acid as an off-white solid (1.73 g).
Methyl chloroformate (0.36 mL, 4.65 mmol) was added drop-wise over 11 min to a cooled (ice-water) mixture of Na2CO3 (0.243 g, 2.29 mmol), NaOH (4.6 mL of 1M/H2O, 4.6 mmol) and the above product (802.4 mg). The reaction mixture was stirred for 55 min, and then the cooling bath was removed and stirring was continued for an additional 5.25 hr. The reaction mixture was diluted with equal volume of water and washed with CH2Cl2 (30 mL, 2×), and the aqueous phase was cooled with ice-water bath and acidified with concentrated HCl to a pH region of 2. The volatile component was then removed in vacuo and the crude material was free-based with MCX resin (6.0 g; column was washed with water, and sample was eluted with 2.0 M NH3/MeOH) to afford impure Cap-76 as an off-white solid (704 mg). 1H NMR (MeOH-d4, δ=3.29 ppm, 400 MHz): δ 3.99 (dd, J=7.5, 4.7, 1H), 3.62 (s, 3H), 3.25-3.06 (m, 6H), 2.18-2.09 (m, 1H), 2.04-1.96 (m, 1H), 1.28 (t, J=7.3, 6H). LC-MS: Anal. Calcd. for [M+H]+ C10H21N2O4: 233.15; found 233.24.
Cap-77a and Cap-77b




The synthesis of Cap-77 was conducted according to the procedure described for Cap-7 by using 7-azabicyclo[2.2.1]heptane for the SN2 displacement step, and by effecting the stereoisomeric separation of the intermediate benzyl 2-(7-azabicyclo[2.2.1]heptan-7-yl)-2-phenylacetate using the following condition: the intermediate (303.7 mg) was dissolved in ethanol, and the resulting solution was injected on a chiral HPLC column (Chiracel AD-H column, 30×250 mm, 5 um) eluting with 90% CO2—10% EtOH at 70 mL/min, and a temperature of 35° C. to provide 124.5 mg of stereoisomer-1 and 133.8 mg of stereoisomer-2. These benzyl esters were hydrogenolysed according to the preparation of Cap-7 to provide Cap-77:
1H NMR (DMSO-d6, δ=2.5 ppm, 400 MHz): δ 7.55 (m, 2H), 7.38-7.30 (m, 3H), 4.16 (s, 1H), 3.54 (app br s, 2H), 2.08-1.88 (m, 4H), 1.57-1.46 (m, 4H). LC (Cond. 1): RT=0.67 min; LC-MS: Anal. Calcd. for [M+H]+ C14H18NO2: 232.13; found 232.18. HRMS: Anal. Calcd. for [M+H]+ C14H18NO2: 232.1338; found 232.1340.
Cap-78




NaCNBH3 (0.5828 g, 9.27 mmol) was added to a mixture of the HCl salt of (R)-2-(ethylamino)-2-phenylacetic acid (an intermediate in the synthesis of Cap-3; 0.9923 mg, 4.60 mmol) and (1-ethoxycyclopropoxy)trimethylsilane (1.640 g, 9.40 mmol) in MeOH (10 mL), and the semi-heterogeneous mixture was heated at 50° C. with an oil bath for 20 hr. More (1-ethoxycyclopropoxy)trimethylsilane (150 mg, 0.86 mmol) and NaCNBH3 (52 mg, 0.827 mmol) were added and the reaction mixture was heated for an additional 3.5 hr. It was then allowed to cool to ambient temperature and acidified to a  ̃pH region of 2 with concentrated HCl, and the mixture was filtered and the filtrate was rotervaped. The resulting crude material was taken up in i-PrOH (6 mL) and heated to effect dissolution, and the non-dissolved part was filtered off and the filtrate concentrated in vacuo. About 1⁄3 of the resultant crude material was purified with a reverse phase HPLC (H2O/MeOH/TFA) to afford the TFA salt of Cap-78 as a colorless viscous oil (353 mg). 1H NMR (DMSO-d6, δ=2.5 ppm, 400 MHz; after D2O exchange): δ 7.56-7.49 (m, 5H), 5.35 (S, 1H), 3.35 (m, 1H), 3.06 (app br s, 1H), 2.66 (m, 1H), 1.26 (t, J=7.3, 3H), 0.92 (m, 1H), 0.83-0.44 (m, 3H). LC (Cond. 1): RT=0.64 min; LC-MS: Anal. Calcd. for [M+H]+ C13H18NO2: 220.13; found 220.21. HRMS: Anal. Calcd. for [M+H]+ C13H18NO2: 220.1338; found 220.1343.
Cap-79




Ozone was bubbled through a cooled (−78° C.) CH2Cl2 (5.0 mL) solution Cap-55 (369 mg, 2.13 mmol) for about 50 min until the reaction mixture attained a tint of blue color. Me2S (10 pipette drops) was added, and the reaction mixture was stirred for 35 min. The −78° C. bath was replaced with a −10° C. bath and stirring continued for an additional 30 min, and then the volatile component was removed in vacuo to afford a colorless viscous oil.
NaBH3CN (149 mg, 2.25 mmol) was added to a MeOH (5.0 mL) solution of the above crude material and morpholine (500 mL, 5.72 mmol) and the mixture was stirred at ambient condition for 4 hr. It was cooled to ice-water temperature and treated with concentrated HCl to bring its pH to  ̃2.0, and then stirred for 2.5 hr. The volatile component was removed in vacuo, and the residue was purified with a combination of MCX resin (MeOH wash; 2.0 N NH3/MeOH elution) and a reverse phase HPLC (H2O/MeOH/TFA) to afford Cap-79 containing unknown amount of morpholine.
In order to consume the morpholine contaminant, the above material was dissolved in CH2Cl2 (1.5 mL) and treated with Et3N (0.27 mL, 1.94 mmol) followed by acetic anhydride (0.10 mL, 1.06 mmol) and stirred at ambient condition for 18 hr. THF (1.0 mL) and H2O (0.5 mL) were added and stirring continued for 1.5 hr. The volatile component was removed in vacuo, and the resultant residue was passed through MCX resin (MeOH wash; 2.0 N NH3/MeOH elution) to afford impure Cap-79 as a brown viscous oil, which was used for the next step without further purification.
Cap-80a and Cap-80b




SOCl2 (6.60 mL, 90.5 mmol) was added drop-wise over 15 min to a cooled (ice-water) mixture of (S)-3-amino-4-(benzyloxy)-4-oxobutanoic acid (10.04 g, 44.98 mmol) and MeOH (300 mL), the cooling bath was removed and the reaction mixture was stirred at ambient condition for 29 hr. Most of the volatile component was removed in vacuo and the residue was carefully partitioned between EtOAc (150 mL) and saturated NaHCO3 solution. The aqueous phase was extracted with EtOAc (150 mL, 2×), and the combined organic phase was dried (MgSO4), filtered, and concentrated in vacuo to afford (S)-1-benzyl 4-methyl 2-aminosuccinate as a colorless oil (9.706 g). 1H NMR (DMSO-d6, δ=2.5 ppm, 400 MHz): δ 7.40-7.32 (m, 5H), 5.11 (s, 2H), 3.72 (app t, J=6.6, 1H), 3.55 (s, 3H), 2.68 (dd, J=15.9, 6.3, 1H), 2.58 (dd, J=15.9, 6.8, 1H), 1.96 (s, 2H). LC (Cond. 1): RT=0.90 min; LC-MS: Anal. Calcd. for [M+H]+ C12H16NO4: 238.11; found 238.22.
Pb(NO3)2 (6.06 g, 18.3 mmol) was added over 1 min to a CH2Cl2 (80 mL) solution of (S)-1-benzyl 4-methyl 2-aminosuccinate (4.50 g, 19.0 mmol), 9-bromo-9-phenyl-9H-fluorene (6.44 g, 20.0 mmol) and Et3N (3.0 mL, 21.5 mmol), and the heterogeneous mixture was stirred at ambient condition for 48 hr. The mixture was filtered and the filtrate was treated with MgSO4 and filtered again, and the final filtrate was concentrated. The resulting crude material was submitted to a BIOTAGE® purification (350 g silica gel, CH2Cl2 elution) to afford (S)-1-benzyl 4-methyl 2-(9-phenyl-9H-fluoren-9-ylamino)succinate as highly viscous colorless oil (7.93 g). 1H NMR (DMSO-d6, δ=2.5 ppm, 400 MHz): δ 7.82 (m, 2H), 7.39-7.13 (m, 16H), 4.71 (d, J=12.4, 1H), 4.51 (d, J=12.6, 1H), 3.78 (d, J=9.1, NH), 3.50 (s, 3H), 2.99 (m, 1H), 2.50-2.41 (m, 2H, partially overlapped with solvent). LC (Cond. 1): RT=2.16 min; LC-MS: Anal. Calcd. for [M+H]+ C31H28NO4: 478.20; found 478.19.
LiHMDS (9.2 mL of 1.0 M/THF, 9.2 mmol) was added drop-wise over 10 min to a cooled (−78° C.) THF (50 mL) solution of (S)-1-benzyl 4-methyl 2-(9-phenyl-9H-fluoren-9-ylamino)succinate (3.907 g, 8.18 mmol) and stirred for  ̃1 hr. MeI (0.57 mL, 9.2 mmol) was added drop-wise over 8 min to the mixture, and stirring was continued for 16.5 hr while allowing the cooling bath to thaw to room temperature. After quenching with saturated NH4Cl solution (5 mL), most of the organic component was removed in vacuo and the residue was partitioned between CH2Cl2 (100 mL) and water (40 mL). The organic layer was dried (MgSO4), filtered, and concentrated in vacuo, and the resulting crude material was purified with a BIOTAGE® (350 g silica gel; 25% EtOAc/hexanes) to afford 3.65 g of a 2S/3S and 2S/3R diastereomeric mixtures of 1-benzyl 4-methyl 3-methyl-2-(9-phenyl-9H-fluoren-9-ylamino)succinate in  ̃1.0:0.65 ratio (1H NMR). The stereochemistry of the dominant isomer was not determined at this juncture, and the mixture was submitted to the next step without separation. Partial 1H NMR data (DMSO-d6, δ=2.5 ppm, 400 MHz): major diastereomer, δ 4.39 (d, J=12.3, 1H of CH2), 3.33 (s, 3H, overlapped with H2O signal), 3.50 (d, J=10.9, NH), 1.13 (d, J=7.1, 3H); minor diastereomer, δ 4.27 (d, J=12.3, 1H of CH2), 3.76 (d, J=10.9, NH), 3.64 (s, 3H), 0.77 (d, J=7.0, 3H). LC (Cond. 1): RT=2.19 min; LC-MS: Anal. Calcd. for [M+H]+ C32H30NO4: 492.22; found 492.15.
Diisobutylaluminum hydride (20.57 ml of 1.0 M in hexanes, 20.57 mmol) was added drop-wise over 10 min to a cooled (−78° C.) THF (120 mL) solution of (2S)-1-benzyl 4-methyl 3-methyl-2-(9-phenyl-9H-fluoren-9-ylamino)succinate (3.37 g, 6.86 mmol) prepared above, and stirred at −78° C. for 20 hr. The reaction mixture was removed from the cooling bath and rapidly poured into  ̃1M H3PO4/H2O (250 mL) with stirring, and the mixture was extracted with ether (100 mL, 2×). The combined organic phase was washed with brine, dried (MgSO4), filtered and concentrated in vacuo. A silica gel mesh of the crude material was prepared and submitted to chromatography (25% EtOAc/hexanes; gravity elution) to afford 1.1 g of (2S,3S)-benzyl 4-hydroxy-3-methyl-2-(9-phenyl-9H-fluoren-9-ylamino)butanoate, contaminated with benzyl alcohol, as a colorless viscous oil and (2S,3R)-benzyl 4-hydroxy-3-methyl-2-(9-phenyl-9H-fluoren-9-ylamino)butanoate containing the (2S,3R) stereoisomer as an impurity. The later sample was resubmitted to the same column chromatography purification conditions to afford 750 mg of purified material as a white foam. [Note: the (2S,3S) isomer elutes before the (2S,3R) isomer under the above condition]. (2S,3S) isomer: 1H NMR (DMSO-d6, δ=2.5 ppm, 400 MHz): 7.81 (m, 2H), 7.39-7.08 (m, 16H), 4.67 (d, J=12.3, 1H), 4.43 (d, J=12.4, 1H), 4.21 (app t, J=5.2, OH), 3.22 (d, J=10.1, NH), 3.17 (m, 1H), 3.08 (m, 1H),  ̃2.5 (m, 1H, overlapped with the solvent signal), 1.58 (m, 1H), 0.88 (d, J=6.8, 3H). LC (Cond. 1): RT=2.00 min; LC-MS: Anal. Calcd. for [M+H]+ C31H30NO3: 464.45; found 464.22. (2S,3R) isomer: 1H NMR (DMSO-d6, δ=2.5 ppm, 400 MHz): 7.81 (d, J=7.5, 2H), 7.39-7.10 (m, 16H), 4.63 (d, J=12.1, 1H), 4.50 (app t, J=4.9, 1H), 4.32 (d, J=12.1, 1H), 3.59-3.53 (m, 2H), 3.23 (m, 1H), 2.44 (dd, J=9.0, 8.3, 1H), 1.70 (m, 1H), 0.57 (d, J=6.8, 3H). LC (Cond. 1): RT=1.92 min; LC-MS: Anal. Calcd. for [M+H]+ C31H30NO3: 464.45; found 464.52.
The relative stereochemical assignments of the DIBAL-reduction products were made based on NOE studies conducted on lactone derivatives prepared from each isomer by employing the following protocol: LiHMDS (50 μL of 1.0 M/THF, 0.05 mmol) was added to a cooled (ice-water) THF (2.0 mL) solution of (2S,3S)-benzyl 4-hydroxy-3-methyl-2-(9-phenyl-9H-fluoren-9-ylamino)butanoate (62.7 mg, 0.135 mmol), and the reaction mixture was stirred at similar temperature for  ̃2 hr. The volatile component was removed in vacuo and the residue was partitioned between CH2Cl2 (30 mL), water (20 mL) and saturated aqueous NH4Cl solution (1 mL). The organic layer was dried (MgSO4), filtered, and concentrated in vacuo, and the resulting crude material was submitted to a BIOTAGE® purification (40 g silica gel; 10-15% EtOAc/hexanes) to afford (3S,4S)-4-methyl-3-(9-phenyl-9H-fluoren-9-ylamino)dihydrofuran-2(3H)-one as a colorless film of solid (28.1 mg). (2S,3R)-benzyl 4-hydroxy-3-methyl-2-(9-phenyl-9H-fluoren-9-ylamino)butanoate was elaborated similarly to (3S,4R)-4-methyl-3-(9-phenyl-9H-fluoren-9-ylamino)dihydrofuran-2(3H)-one. (3S,4S)-lactone isomer: 1H NMR (DMSO-d6, δ=2.5 ppm, 400 MHz), 7.83 (d, J=7.5, 2H), 7.46-7.17 (m, 11H), 4.14 (app t, J=8.3, 1H), 3.60 (d, J=5.8, NH), 3.45 (app t, J=9.2, 1H),  ̃2.47 (m, 1H, partially overlapped with solvent signal), 2.16 (m, 1H), 0.27 (d, J=6.6, 3H). LC (Cond. 1): RT=1.98 min; LC-MS: Anal. Calcd. for [M+Na]+ C24H21NNaO2: 378.15; found 378.42. (3S,4R)-lactone isomer: 1H NMR (DMSO-d6, δ=2.5 ppm, 400 MHz), 7.89 (d, J=7.6, 1H), 7.85 (d, J=7.3, 1H), 7.46-7.20 (m, 11H), 3.95 (dd, J=9.1, 4.8, 1H), 3.76 (d, J=8.8, 1H), 2.96 (d, J=3.0, NH), 2.92 (dd, J=6.8, 3, NCH), 1.55 (m, 1H), 0.97 (d, J=7.0, 3H). LC (Cond. 1): RT=2.03 min; LC-MS: Anal. Calcd. for [M+Na]+ C24H21NNaO2: 378.15; found 378.49.
TBDMS-Cl (48 mg, 0.312 mmol) followed by imidazole (28.8 mg, 0.423 mmol) were added to a CH2Cl2 (3 ml) solution of (2S,3S)-benzyl 4-hydroxy-3-methyl-2-(9-phenyl-9H-fluoren-9-ylamino)butanoate (119.5 mg, 0.258 mmol), and the mixture was stirred at ambient condition for 14.25 hr. The reaction mixture was then diluted with CH2Cl2 (30 mL) and washed with water (15 mL), and the organic layer was dried (MgSO4), filtered, and concentrated in vacuo. The resultant crude material was purified with a BIOTAGE® (40 g silica gel; 5% EtOAc/hexanes) to afford (2S,3S)-benzyl 4-(tert-butyldimethylsilyloxy)-3-methyl-2-(9-phenyl-9H-fluoren-9-ylamino)butanoate, contaminated with TBDMS based impurities, as a colorless viscous oil (124.4 mg). (2S,3R)-benzyl 4-hydroxy-3-methyl-2-(9-phenyl-9H-fluoren-9-ylamino)butanoate was elaborated similarly to (2S,3R)-benzyl 4-(tert-butyldimethylsilyloxy)-3-methyl-2-(9-phenyl-9H-fluoren-9-ylamino)butanoate. (2S,3S)-silyl ether isomer: 1H NMR (DMSO-d6, δ=2.5 ppm, 400 MHz), 7.82 (d, J=4.1, 1H), 7.80 (d, J=4.0, 1H), 7.38-7.07 (m, 16H), 4.70 (d, J=12.4, 1H), 4.42 (d, J=12.3, 1H), 3.28-3.19 (m, 3H), 2.56 (dd, J=10.1, 5.5, 1H), 1.61 (m, 1H), 0.90 (d, J=6.8, 3H), 0.70 (s, 9H), −0.13 (s, 3H), −0.16 (s, 3H). LC (Cond. 1, where the run time was extended to 4 min): RT=3.26 min; LC-MS: Anal. Calcd. for [M+H]+ C37H44NO3Si: 578.31; found 578.40. (2S,3R)-silyl ether isomer: 1H NMR (DMSO-d6, δ=2.5 ppm, 400 MHz), 7.82 (d, J=3.0, 1H), 7.80 (d, J=3.1, 1H), 7.39-7.10 (m, 16H), 4.66 (d, J=12.4, 1H), 4.39 (d, J=12.4, 1H), 3.61 (dd, J=9.9, 5.6, 1H), 3.45 (d, J=9.5, 1H), 3.41 (dd, J=10, 6.2, 1H), 2.55 (dd, J=9.5, 7.3, 1H), 1.74 (m, 1H), 0.77 (s, 9H), 0.61 (d, J=7.1, 3H), −0.06 (s, 3H), −0.08 (s, 3H).
A balloon of hydrogen was attached to a mixture of (2S,3S)-benzyl 4-(tert-butyldimethylsilyloxy)-3-methyl-2-(9-phenyl-9H-fluoren-9-ylamino)butanoate (836 mg, 1.447 mmol) and 10% Pd/C (213 mg) in EtOAc (16 mL) and the mixture was stirred at room temperature for  ̃21 hr, where the balloon was recharged with H2 as necessary. The reaction mixture was diluted with CH2Cl2 and filtered through a pad of diatomaceous earth (CELITE®-545), and the pad was washed with EtOAc (200 mL), EtOAc/MeOH (1:1 mixture, 200 mL) and MeOH (750 mL). The combined organic phase was concentrated, and a silica gel mesh was prepared from the resulting crude material and submitted to a flash chromatography (8:2:1 mixture of EtOAc/1-PrOH/H2O) to afford (2S,3S)-2-amino-4-(tert-butyldimethylsilyloxy)-3-methylbutanoic acid as a white fluffy solid (325 mg). (2S,3R)-benzyl 4-(tert-butyldimethylsilyloxy)-3-methyl-2-(9-phenyl-9H-fluoren-9-ylamino)butanoate was similarly elaborated to (2S,3R)-2-amino-4-(tert-butyldimethylsilyloxy)-3-methylbutanoic acid. (2S,3S)-amino acid isomer: 1H NMR (methanol-d4, δ=3.29 ppm, 400 MHz), 3.76 (dd, J=10.5, 5.2, 1H), 3.73 (d, J=3.0, 1H), 3.67 (dd, J=10.5, 7.0, 1H), 2.37 (m, 1H), 0.97 (d, J=7.0, 3H), 0.92 (s, 9H), 0.10 (s, 6H). LC-MS: Anal. Calcd. for [M+H]+ C11H26NO3Si: 248.17; found 248.44. (2S,3R)-amino acid isomer: 1H NMR (methanol-d4, δ=3.29 ppm, 400 MHz), 3.76-3.75 (m, 2H), 3.60 (d, J=4.1, 1H), 2.16 (m, 1H), 1.06 (d, J=7.3, 3H), 0.91 (s, 9H), 0.09 (s, 6H). Anal. Calcd. for [M+H]+ C11H26NO3Si: 248.17; found 248.44.
Water (1 mL) and NaOH (0.18 mL of 1.0 M/H2O, 0.18 mmol) were added to a mixture of (2S,3S)-2-amino-4-(tert-butyldimethylsilyloxy)-3-methylbutanoic acid (41.9 mg, 0.169 mmol) and Na2CO3 (11.9 mg, 0.112 mmol), and sonicated for about 1 min to effect dissolution of reactants. The mixture was then cooled with an ice-water bath, methyl chloroformate (0.02 mL, 0.259 mmol) was added over 30 s, and vigorous stirring was continued at similar temperature for 40 min and then at ambient temperature for 2.7 hr. The reaction mixture was diluted with water (5 mL), cooled with ice-water bath and treated drop-wise with 1.0 N HCl aqueous solution ( ̃0.23 mL). The mixture was further diluted with water (10 mL) and extracted with CH2Cl2 (15 mL, 2×). The combined organic phase was dried (MgSO4), filtered, and concentrated in vacuo to afford Cap-80a as an off-white solid. (2S,3R)-2-amino-4-(tert-butyldimethylsilyloxy)-3-methylbutanoic acid was similarly elaborated to Cap-80b. Cap-80a: 1H NMR (DMSO-d6, δ=2.5 ppm, 400 MHz), 12.57 (br s, 1H), 7.64 (d, J=8.3, 0.3H), 7.19 (d, J=8.8, 0.7H), 4.44 (dd, J=8.1, 4.6, 0.3H), 4.23 (dd, J=8.7, 4.4, 0.7H), 3.56/3.53 (two singlets, 3H), 3.48-3.40 (m, 2H), 2.22-2.10 (m, 1H), 0.85 (s, 9H),  ̃0.84 (d, 0.9H, overlapped with t-Bu signal), 0.79 (d, J=7, 2.1H), 0.02/0.01/0.00 (three overlapping singlets, 6H). LC-MS: Anal. Calcd. for [M+Na]+ C13H27NNaO5Si: 328.16; found 328.46. Cap-80b: 1H NMR (CDCl3, δ=7.24 ppm, 400 MHz), 6.00 (br d, J=6.8, 1H), 4.36 (dd, J=7.1, 3.1, 1H), 3.87 (dd, J=10.5, 3.0, 1H), 3.67 (s, 3H), 3.58 (dd, J=10.6, 4.8, 1H), 2.35 (m, 1H), 1.03 (d, J=7.1, 3H), 0.90 (s, 9H), 0.08 (s, 6H). LC-MS: Anal. Calcd. for [M+Na]+ C13H27NNaO5Si: 328.16; found 328.53. The crude products were utilized without further purification.
Cap-81




Prepared according to the protocol described by Falb et al., Synthetic Communications, 23:2839 (1993).
Cap-82 to Cap-85
Cap-82 to Cap-85 were synthesized from appropriate starting materials according to the procedure described for Cap-51 or Cap-13. The samples exhibited similar spectral profiles as that of their stereoisomers (i.e., Cap-4, Cap-13, Cap-51 and Cap-52, respectively).








(2S,3R)-3-Methoxy-2-(methoxycarbonylamino)butanoic acid
To a mixture of O-methyl-L-threonine (3.0 g, 22.55 mmol), NaOH (0.902 g, 22.55 mmol) in H2O (15 mL) was added ClCO2Me (1.74 mL, 22.55 mmol) dropwise at 0° C. The mixture was allowed to stir for 12 h and acidified to pH 1 using 1N HCl. The aqueous phase was extracted with EtOAc and (2×250 mL) and 10% MeOH in CH2Cl2 (250 mL) and the combined organic phases were concentrated under in vacuo to afford a colorless oil (4.18 g, 97%) which was of sufficient purity for use in subsequent steps. 1H NMR (400 MHz, CDCl3) δ 4.19 (s, 1H), 3.92-3.97 (m, 1H), 3.66 (s, 3H), 1.17 (d, J=7.7 Hz, 3H). LC-MS: Anal. Calcd. for C7H13NO5: 191; found: 190 (M−H)−.
Cap-87




To a mixture of L-homoserine (2.0 g, 9.79 mmol), Na2CO3 (2.08 g, 19.59 mmol) in H2O (15 mL) was added ClCO2Me (0.76 mL, 9.79 mmol) dropwise at 0° C. The mixture was allowed to stir for 48 h and acidified to pH 1 using 1N HCl. The aqueous phase was extracted with EtOAc and (2×250 mL) and the combined organic phases were concentrated in vacuo to afford a colorless solid (0.719 g, 28%) which was of sufficient purity for use in subsequent steps. 1H NMR (400 MHz, CDCl3) δ 4.23 (dd, J=4.5, 9.1 Hz, 1H), 3.66 (s, 3H), 3.43-3.49 (m, 2H), 2.08-2.14 (m, 1H), 1.82-1.89 (m, 1H). LC-MS: Anal. Calcd. for C7H13NO5: 191; found: 192 (M+H)+.
Cap-88




A mixture of L-valine (1.0 g, 8.54 mmol), 3-bromopyridine (1.8 mL, 18.7 mmol), K2CO3 (2.45 g, 17.7 mmol) and CuI (169 mg, 0.887 mmol) in DMSO (10 mL) was heated at 100° C. for 12 h. The reaction mixture was cooled to rt, poured into H2O (ca. 150 mL) and washed with EtOAc (×2). The organic layers were extracted with a small amount of H2O and the combined aq phases were acidified to ca. pH 2 with 6N HCl. The volume was reduced to about one-third and 20 g of cation exchange resin (Strata) was added. The slurry was allowed to stand for 20 min and loaded onto a pad of cation exchange resin (Strata) (ca. 25 g). The pad was washed with H2O (200 mL), MeOH (200 mL), and then NH3 (3M in MeOH, 2×200 mL). The appropriate fractions was concentrated in vacuo and the residue (ca. 1.1 g) was dissolved in H2O, frozen and lyophyllized. The title compound was obtained as a foam (1.02 g, 62%). 1H NMR (400 MHz, DMSO-d6) δ 8.00 (s, br, 1H), 7.68-7.71 (m, 1H), 7.01 (s, br, 1H), 6.88 (d, J=7.5 Hz, 1H), 5.75 (s, br, 1H), 3.54 (s, 1H), 2.04-2.06 (m, 1H), 0.95 (d, J=6.0 Hz, 3H), 0.91 (d, J=6.6 Hz, 3H). LC-MS: Anal. Calcd. for C10H14N2O2: 194; found: 195 (M+H)+.
Cap-89




A mixture of L-valine (1.0 g, 8.54 mmol), 5-bromopyrimidine (4.03 g, 17.0 mmol), K2CO3 (2.40 g, 17.4 mmol) and CuI (179 mg, 0.94 mmol) in DMSO (10 mL) was heated at 100° C. for 12 h. The reaction mixture was cooled to RT, poured into H2O (ca. 150 mL) and washed with EtOAc (×2). The organic layers were extracted with a small amount of H2O and the combined aq phases were acidified to ca. pH 2 with 6N HCl. The volume was reduced to about one-third and 20 g of cation exchange resin (Strata) was added. The slurry was allowed to stand for 20 min and loaded onto a pad of cation exchange resin (Strata) (ca. 25 g). The pad was washed with H2O (200 mL), MeOH (200 mL), and then NH3 (3M in MeOH, 2×200 mL). The appropriate fractions was concentrated in vacuo and the residue (ca. 1.1 g) was dissolved in H2O, frozen and lyophyllized. The title compound was obtained as a foam (1.02 g, 62%). 1H NMR (400 MHz, CD3OD) showed the mixture to contain valine and the purity could not be estimated. The material was used as is in subsequent reactions. LC-MS: Anal. Calcd. for C9H13N3O2: 195; found: 196 (M+H)+.
Cap-90




Cap-90 was prepared according to the method described for the preparation of Cap-1. The crude material was used as is in subsequent steps. LC-MS: Anal. Calcd. for C11H15NO2: 193; found: 192 (M−H)−.
Cap-91 to Cap-116
The following Caps were prepared according to the method used for preparation of Cap-51 unless noted otherwise:












Cap
Structure
LC-MS







Cap-91




LC-MS: Anal. Calcd.  for C11H13NO4: 223;  found: 222 (M − H)−.


 


Cap-92




LC-MS: Anal. Calcd.  for C11H13NO4: 223;  found: 222 (M − H)−.


 


Cap-93




LC-MS: Anal. Calcd.  for C10H12N2O4: 224;  found: 225 (M + H)+.


 


Cap-94




LC-MS: Anal. Calcd.  for C8H11N3O4: 213;  found: 214 (M + H)+.


 


Cap-95




LC-MS: Anal. Calcd.  for C13H17NO4: 251;  found: 250 (M − H)−.


 


Cap-96




LC-MS: Anal. Calcd.  for C12H15NO4: 237;  found: 236 (M − H)−.


 


Cap-97




LC-MS: Anal. Calcd.  for C9H15NO4: 201;  found: 200 (M − H)−.


 


Cap-98




LC-MS: Anal. Calcd.  for C9H15NO4: 201;  found: 202 (M + H)+.


 


Cap-99




1H NMR (400 MHz,  CD3OD) δ 3.88 -3.94  (m, 1H), 3.60, 3.61  (s, 3H), 2.80 (m,  1H), 2.20 (m 1H),  1.82-1.94 (m, 3H),  1.45-1.71 (m, 2H).


 


Cap-99a




1H NMR (400 MHz,  CD3OD) δ 3.88-3.94  (m, 1H), 3.60, 3.61  (s, 3H), 2.80 (m,  1H), 2.20 (m 1H),  1.82-1.94 (m, 3H),  1.45-1.71 (m, 2H).


 


Cap-100




LC-MS: Ana1. Calcd.  for C12H14NO4F: 255;  found: 256 (M + H)+.


 


Cap-101




LC-MS: Ana1. Calcd.  for C11H13NO4: 223;  found: 222 (M − H)−.


 


Cap-102




LC-MS: Ana1. Calcd.  for C11H13NO4: 223;  found: 222 (M − H)−


 


Cap-103




LC-MS: Ana1. Calcd.  for C10H12N2O4: 224;  found: 225 (M + H)+.


 


Cap-104




1H NMR (400 MHz,  CD3OD) δ 3.60 (s,  3H), 3.50-3.53 (m,  1H), 2.66-2.69 and  2.44-2.49 (m, 1H),  1.91-2.01 (m, 2H),  1.62-1.74 (m, 4H),  1.51-1.62 (m, 2H).


 


Cap-105




1H NMR (400 MHz,  CD3OD) δ 3.60 (s,  3H), 3.33-3.35 (m,  1H, partially  obscured by solvent),  2.37-2.41 and 2.16- 2.23 (m, 1H), 1.94- 2.01 (m, 4H), 1.43- 1.53 (m, 2H), 1.17- 1.29 (m, 2H).


 


Cap-106



   Prepared from cis-4- aminocyclohexane carboxylic acid and acetaldehyde by employing a similar procedure described for the synthesis of Cap-2. The crude HCl salt was passed through MCX (MeOH/H2O/CH2Cl2 wash; 2N NH3/MeOH elution) to afford an oil, which was dissolved in CH3CN/H2O and lyophilized to afford a tan solid.
1H NMR (400 MHz,  CD3OD) δ 3.16 (q,  J = 7.3 Hz, 4H),  2.38-2.41 (m, 1H),  2.28-2.31 (m, 2H),  1.79-1.89 (m, 2H),  1.74 (app, ddd J =  3.5, 12.5, 15.9 Hz,  2H), 1.46 (app dt J =  4.0, 12.9 Hz, 2H),  1.26 (t, J = 7.3 Hz,  6H)


 


Cap-107




LC-MS: Anal. Calcd.  for C8H10N2O4S: 230;  found: 231 (M + H)+.


 


Cap-108




LC-MS: Ana1. Calcd.  for C15H17N3O4: 303;  found: 304 (M + H)+.


 


Cap-109




LC-MS: Ana1. Calcd.  for C10H12N2O4: 224;  found: 225 (M + H)+.


 


Cap-110




LC-MS: Ana1. Calcd.  for C10H12N2O4: 224;  found: 225 (M + H)+.


 


Cap-111




LC-MS: Ana1. Calcd.  for C12H16NO8P: 333;  found: 334 (M + H)+.


 


Cap-112




LC-MS: Ana1. Calcd.  for C13H14N2O4: 262;  found: 263 (M + H)+.


 


Cap-113




LC-MS: Ana1. Calcd.  for C18H19NO5: 329;  found: 330 (M + H)+.


 


Cap-114




1H NMR (400 MHz,  CDCl3) δ 4.82-4.84  (m, 1H), 4.00-4.05  (m, 2H), 3.77 (s,  3H), 2.56 (s, br, 2H)


 


Cap-115




1H NMR (400 MHz,  CDCl3) δ 5.13 (s, br,  1H), 4.13 (s, br, 1H),  3.69 (s, 3H), 2.61 (d,  J = 5.0 Hz, 2H), 1.28  (d, J = 9.1 Hz, 3H).


 


Cap-116




1H NMR (400 MHz,  CDCl3) δ 5.10 (d, J =  8.6 Hz, 1H), 3.74- 3.83 (m, 1H), 3.69  (s, 3H), 2.54-2.61 (m,  2H), 1.88 (sept, J =  7.0 Hz, 1H), 0.95 (d,  J = 7.0 Hz, 6H).









Cap-117 to Cap-123
For the preparation of Cap-117 to Cap-123 the Boc amino acids were obtained from commercially sources and were deprotected by treatment with 25% TFA in CH2Cl2. After complete reaction as judged by LC-MS the solvents were removed in vacuo and the corresponding TFA salt of the amino acid was carbamoylated with methyl chloroformate according to the procedure described for Cap-51.












Cap
Structure
LC-MS







Cap-117




LC-MS: Anal. Calcd. for C12H15NO4: 237; found: 238 (M + H)+.


 


Cap-118




LC-MS: Anal. Calcd. for C10H13NO4S: 243; found: 244 (M + H)+.


 


Cap-119




LC-MS: Anal. Calcd. for C10H13NO4S: 243; found: 244 (M + H)+.


 


Cap-120




LC-MS: Anal. Calcd. for C10H13NO4S: 243; found: 244 (M + H)+.


 


Cap-121




1H NMR (400 MHz, CDCl3) δ 4.06-4.16 (m, 1H), 3.63 (s, 3H), 3.43 (s, 1H), 2.82 and 2.66 (s, br, 1H), 1.86-2.10 (m, 3H), 1.64-1.76 (m, 2H), 1.44-1.53 (m, 1H).


 


Cap-122




1H NMR profile is similar to that of its stereoisomer, Cap-121.


 


Cap-123




LC-MS: Anal. Calcd. for C27H26N2O6: 474; found: 475 (M + H)+.









Cap-124




The hydrochloride salt of L-threonine tert-butyl ester was carbamoylated according to the procedure for Cap-51. The crude reaction mixture was acidified with 1N HCl to pH ̃1 and the mixture was extracted with EtOAc (2×50 mL). The combined organic phases were concentrated in vacuo to give a colorless oil which solidified on standing. The aqueous layer was concentrated in vacuo and the resulting mixture of product and inorganic salts was triturated with EtOAc—CH2Cl2—MeOH (1:1:0.1) and then the organic phase concentrated in vacuo to give a colorless oil which was shown by LC-MS to be the desired product. Both crops were combined to give 0.52 g of a solid. 1H NMR (400 MHz, CD3OD) δ 4.60 (m, 1H), 4.04 (d, J=5.0 Hz, 1H), 1.49 (d, J=6.3 Hz, 3H). LC-MS: Anal. Calcd. for C5H7NO4: 145; found: 146 (M+H)+.
Cap-125




To a suspension of Pd(OH)2, (20%, 100 mg), aqueous formaldehyde (37% wt, 4 ml), acetic acid, (0.5 mL) in methanol (15 mL) was added (S)-4-amino-2-(tert-butoxycarbonylamino)butanoic acid (1 g, 4.48 mmol). The reaction was purged several times with hydrogen and was stirred overnight with an hydrogen balloon room temperature. The reaction mixture was filtered through a pad of diatomaceous earth (CELITE®), and the volatile component was removed in vacuo. The resulting crude material was used as is for the next step. LC-MS: Anal. Calcd. for C11H22N2O4: 246; found: 247 (M+H)+.
Cap-126




This procedure is a modification of that used to prepare Cap-51. To a suspension of 3-methyl-L-histidine (0.80 g, 4.70 mmol) in THF (10 mL) and H2O (10 mL) at 0° C. was added NaHCO3 (0.88 g, 10.5 mmol). The resulting mixture was treated with ClCO2Me (0.40 mL, 5.20 mmol) and the mixture allowed to stir at 0° C. After stirring for ca. 2 h LC-MS showed no starting material remaining. The reaction was acidified to pH 2 with 6 N HCl.
The solvents were removed in vacuo and the residue was suspended in 20 mL of 20% MeOH in CH2Cl2. The mixture was filtered and concentrated to give a light yellow foam (1.21 g,). LC-MS and 1H NMR showed the material to be a 9:1 mixture of the methyl ester and the desired product. This material was taken up in THF (10 mL) and H2O (10 mL), cooled to 0° C. and LiOH (249.1 mg, 10.4 mmol) was added. After stirring ca. 1 h LC-MS showed no ester remaining. Therefore the mixture was acidified with 6N HCl and the solvents removed in vacuo. LC-MS and 1H NMR confirm the absence of the ester. The title compound was obtained as its HCl salt contaminated with inorganic salts (1.91 g, >100%). The compound was used as is in subsequent steps without further purification. 1H NMR (400 MHz, CD3OD) δ 8.84, (s, 1H), 7.35 (s, 1H), 4.52 (dd, J=5.0, 9.1 Hz, 1H), 3.89 (s, 3H), 3.62 (s, 3H), 3.35 (dd, J=4.5, 15.6 Hz, 1H, partially obscured by solvent), 3.12 (dd, J=9.0, 15.6 Hz, 1H). LC-MS: Anal. Calcd. for C9H13N3O4: 227.09; found: 228.09 (M+H)+.
Cap-127




Cap-127 was prepared according to the method for Cap-126 above starting from (S)-2-amino-3-(1-methyl-1H-imidazol-4-yl)propanoic acid (1.11 g, 6.56 mmol), NaHCO3 (1.21 g, 14.4 mmol) and ClCO2Me (0.56 mL, 7.28 mmol). The title compound was obtained as its HCl salt (1.79 g, >100%) contaminated with inorganic salts. LC-MS and 1H NMR showed the presence of ca. 5% of the methyl ester. The crude mixture was used as is without further purification. 1H NMR (400 MHz, CD3OD) δ 8.90 (s, 1H), 7.35 (s, 1H), 4.48 (dd, J=5.0, 8.6 Hz, 1H), 3.89 (s, 3H), 3.62 (s, 3H), 3.35 (m, 1H), 3.08 (m, 1H); LC-MS: Anal. Calcd. for C9H13N3O4: 227.09; found: 228 (M+H)+.
Preparation of Cap-128




Step 1. Preparation of (S)-benzyl 2-(tert-butoxycarbonylamino)pent-4-ynoate (cj-27b)




To a solution of cj-27a (1.01 g, 4.74 mmol), DMAP (58 mg, 0.475 mmol) and iPr2NEt (1.7 mL, 9.8 mmol) in CH2Cl2 (100 mL) at 0° C. was added Cbz-Cl (0.68 mL, 4.83 mmol). The solution was allowed to stir for 4 h at 0° C., washed (1N KHSO4, brine), dried (Na2SO4), filtered, and concentrated in vacuo. The residue was purified by flash column chromatography (TLC 6:1 hex:EtOAc) to give the title compound (1.30 g, 91%) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.35 (s, 5H), 5.35 (d, br, J=8.1 Hz, 1H), 5.23 (d, J=12.2 Hz, 1H), 5.17 (d, J=12.2 Hz, 1H), 4.48-4.53 (m, 1H), 2.68-2.81 (m, 2H), 2.00 (t, J=2.5 Hz, 1H), 1.44 (s, 9H). LC-MS: Anal. Calcd. for C17H21NO4: 303; found: 304 (M+H)+.
Step 2. Preparation of (S)-benzyl 3-(1-benzyl-1H-1,2,3-triazol-4-yl)-2-(tert-butoxycarbonylamino)propanoate (cj-28)




To a mixture of (S)-benzyl 2-(tert-butoxycarbonylamino)pent-4-ynoate (0.50 g, 1.65 mmol), sodium ascorbate (0.036 g, 0.18 mmol), CuSO4-5H2O (0.022 g, 0.09 mmol) and NaN3 (0.13 g, 2.1 mmol) in DMF-H2O (5 mL, 4:1) at rt was added BnBr (0.24 mL, 2.02 mmol) and the mixture was warmed to 65° C. After 5 h LC-MS indicated low conversion. A further portion of NaN3 (100 mg) was added and heating was continued for 12 h. The reaction was poured into EtOAc and H2O and shaken. The layers were separated and the aqueous layer extracted 3× with EtOAc and the combined organic phases washed (H2O×3, brine), dried (Na2SO4), filtered, and concentrated. The residue was purified by flash (BIOTAGE®, 40+M 0-5% MeOH in CH2Cl2; TLC 3% MeOH in CH2Cl2) to afford a light yellow oil which solidified on standing (748.3 mg, 104%). The NMR was consistent with the desired product but suggests the presence of DMF. The material was used as is without further purification. 1H NMR (400 MHz, DMSO-d6) δ 7.84 (s, 1H), 7.27-7.32 (m, 10H), 5.54 (s, 2H), 5.07 (s, 2H), 4.25 (m, 1H), 3.16 (dd, J=1.0, 5.3 Hz, 1H), 3.06 (dd, J=5.3, 14.7 Hz), 2.96 (dd, J=9.1, 14.7 Hz, 1H), 1.31 (s, 9H). LC-MS: Anal. Calcd. for C24H28N4O4: 436; found: 437 (M+H)+.
Step 3. Preparation of (S)-benzyl 3-(1-benzyl-1H-1,2,3-triazol-4-yl)-2-(methoxycarbonylamino)propanoate (cj-29)




A solution of (S)-benzyl 3-(1-benzyl-1H-1,2,3-triazol-4-yl)-2-(tert-butoxycarbonylamino)propanoate (0.52 g, 1.15 mmol) in CH2Cl2 was added TFA (4 mL). The mixture was allowed to stir at room temperature for 2 h. The mixture was concentrated in vacuo to give a colorless oil which solidified on standing. This material was dissolved in THF—H2O and cooled to 0° C. Solid NaHCO3 (0.25 g, 3.00 mmol) was added followed by ClCO2Me (0.25 mL, 3.25 mmol). After stirring for 1.5 h the mixture was acidified to pH ̃2 with 6N HCl and then poured into H2O-EtOAc. The layers were separated and the aq phase extracted 2× with EtOAc. The combined org layers were washed (H2O, brine), dried (Na2SO4), filtered, and concentrated in vacuo to give a colorless oil (505.8 mg, 111%, NMR suggested the presence of an unidentified impurity) which solidified while standing on the pump. The material was used as is without further purification. 1H NMR (400 MHz, DMSO-d6) δ 7.87 (s, 1H), 7.70 (d, J=8.1 Hz, 1H), 7.27-7.32 (m, 10H), 5.54 (s, 2H), 5.10 (d, J=12.7 Hz, 1H), 5.06 (d, J=12.7 Hz, 1H), 4.32-4.37 (m, 1H), 3.49 (s, 3H), 3.09 (dd, J=5.6, 14.7 Hz, 1H), 2.98 (dd, J=9.6, 14.7 Hz, 1H). LC-MS: Anal. Calcd. for C21H22N4O4: 394; found: 395 (M+H)+.
Step 4. Preparation of (S)-2-(methoxycarbonylamino)-3-(1H-1,2,3-triazol-4-yl)propanoic acid (Cap-128)




(S)-Benzyl 3-(1-benzyl-1H-1,2,3-triazol-4-yl)-2-(methoxycarbonylamino)propanoate (502 mg, 1.11 mmol) was hydrogenated in the presence of Pd—C (82 mg) in MeOH (5 mL) at atmospheric pressure for 12 h. The mixture was filtered through diatomaceous earth (CELITE®) and concentrated in vacuo. (S)-2-(methoxycarbonylamino)-3-(1H-1,2,3-triazol-4-yl)propanoic acid was obtained as a colorless gum (266 mg, 111%) which was contaminated with ca. 10% of the methyl ester. The material was used as is without further purification. 1H NMR (400 MHz, DMSO-d6) δ 12.78 (s, br, 1H), 7.59 (s, 1H), 7.50 (d, J=8.0 Hz, 1H), 4.19-4.24 (m, 1H), 3.49 (s, 3H), 3.12 (dd, J=4.8 Hz, 14.9 Hz, 1H), 2.96 (dd, J=9.9, 15.0 Hz, 1H). LC-MS: Anal. Calcd. for C7H10N4O4: 214; found: 215 (M+H)+.
Preparation of Cap-129




Step 1. Preparation of (S)-2-(benzyloxycarbonylamino)-3-(1H-pyrazol-1-yl)propanoic acid (cj-31)




A suspension of (S)-benzyl 2-oxooxetan-3-ylcarbamate (0.67 g, 3.03 mmol), and pyrazole (0.22 g, 3.29 mmol) in CH3CN (12 mL) was heated at 50° C. for 24 h. The mixture was cooled to rt overnight and the solid filtered to afford (S)-2-(benzyloxycarbonylamino)-3-(1H-pyrazol-1-yl)propanoic acid (330.1 mg). The filtrate was concentrated in vacuo and then triturated with a small amount of CH3CN (ca. 4 mL) to afford a second crop (43.5 mg). Total yield 370.4 mg (44%). m.p. 165.5-168° C. lit m.p. 168.5-169.5 [Vederas et al., J. Am. Chem. Soc., 107:7105 (1985)]. 1H NMR (400 MHz, CD3OD) δ 7.51 (d, J=2.0, 1H), 7.48 (s, J=1.5 Hz, 1H), 7.24-7.34 (m, 5H), 6.23 m, 1H), 5.05 (d, 12.7 Hz, 1H), 5.03 (d, J=12.7 Hz, 1H), 4.59-4.66 (m, 2H), 4.42-4.49 (m, 1H). LC-MS: Anal. Calcd. for C14H15N3O4: 289; found: 290 (M+H)+.
Step 2. Preparation of (S)-2-(methoxycarbonylamino)-3-(1H-pyrazol-1-yl)propanoic acid (Cap-129)




(S)-2-(Benzyloxycarbonylamino)-3-(1H-pyrazol-1-yl)propanoic acid (0.20 g, 0.70 mmol) was hydrogenated in the presence of Pd—C (45 mg) in MeOH (5 mL) at atmospheric pressure for 2 h. The product appeared to be insoluble in MeOH, therefore the reaction mixture was diluted with 5 mL H2O and a few drops of 6N HCl. The homogeneous solution was filtered through diatomaceous earth (CELITE®), and the MeOH removed in vacuo. The remaining solution was frozen and lyophyllized to give a yellow foam (188.9 mg). This material was suspended in THF—H2O (1:1, mL) and then cooled to 0° C. To the cold mixture was added NaHCO3 (146.0 mg, 1.74 mmol) carefully (evolution of CO2). After gas evolution had ceased (ca. 15 min) ClCO2Me (0.06 mL, 0.78 mmol) was added dropwise. The mixture was allowed to stir for 2 h and was acidified to pH ̃2 with 6N HCl and poured into EtOAc. The layers were separated and the aqueous phase extracted with EtOAC (×5). The combined organic layers were washed (brine), dried (Na2SO4), filtered, and concentrated to give the title compound as a colorless solid (117.8 mg, 79%). 1H NMR (400 MHz, DMSO-d6) δ 13.04 (s, 1H), 7.63 (d, J=2.6 Hz, 1H), 7.48 (d, J=8.1 Hz, 1H), 7.44 (d, J=1.5 Hz, 1H), 6.19 (app t, J=2.0 Hz, 1H), 4.47 (dd, J=3.0, 12.9 Hz, 1H), 4.29-4.41 (m, 2H), 3.48 (s, 3H). LC-MS: Anal. Calcd. for C8H11N3O4: 213; found: 214 (M+H)+.
Cap-130




Cap-130 was prepared by acylation of commercially available (R)-phenylglycine analogous to the procedure given in: Calmes, M. et al., Tetrahedron, 43(10):2285 (1987).
Cap-131




Step a: Dimethylcarbamoyl chloride (0.92 mL, 10 mmol) was added slowly to a solution of (S)-benzyl 2-amino-3-methylbutanoate hydrochloride (2.44 g; 10 mmol) and Hunig's base (3.67 mL, 21 mmol) in THF (50 mL). The resulting white suspension was stirred at room temperature overnight (16 hours) and concentrated under reduced pressure. The residue was partitioned between ethyl acetate and water. The organic layer was washed with brine, dried (MgSO4), filtered, and concentrated under reduced pressure. The resulting yellow oil was purified by flash chromatography, eluting with ethyl acetate:hexanes (1:1). Collected fractions were concentrated under vacuum providing 2.35 g (85%) of clear oil. 1H NMR (300 MHz, DMSO-d6) δ ppm 0.84 (d, J=6.95 Hz, 3H), 0.89 (d, J=6.59 Hz, 3H), 1.98-2.15 (m, 1H), 2.80 (s, 6H), 5.01-5.09 (m, J=12.44 Hz, 1H), 5.13 (d, J=12.44 Hz, 1H), 6.22 (d, J=8.05 Hz, 1H), 7.26-7.42 (m, 5H). LC (Cond. 1): RT=1.76 min; MS: Anal. Calcd. for [M+H]+ C16H22N2O3: 279.17; found 279.03.
Step b: To an MeOH (50 mL) solution of the intermediate prepared above (2.35 g; 8.45 mmol) was added Pd/C (10%; 200 mg) and the resulting black suspension was flushed with N2 (3×) and placed under 1 atm of H2. The mixture was stirred at room temperature overnight and filtered though a microfiber filter to remove the catalyst. The resulting clear solution was then concentrated under reduced pressure to obtain 1.43 g (89%) of Cap-131 as a white foam, which was used without further purification. 1H NMR (500 MHz, DMSO-d6) δ ppm 0.87 (d, J=4.27 Hz, 3H), 0.88 (d, J=3.97 Hz, 3H), 1.93-2.11 (m, 1H), 2.80 (s, 6H), 3.90 (dd, J=8.39, 6.87 Hz, 1H), 5.93 (d, J=8.54 Hz, 1H), 12.36 (s, 1H). LC (Cond. 1): RT=0.33 min; MS: Anal. Calcd. for [M+H]+ C8H17N2O3: 189.12; found 189.04.
Cap-132




Cap-132 was prepared from (S)-benzyl 2-aminopropanoate hydrochloride according to the method described for Cap-131. 1H NMR (500 MHz, DMSO-d6) δ ppm 1.27 (d, J=7.32 Hz, 3H), 2.80 (s, 6H), 4.06 (qt, 1H), 6.36 (d, J=7.32 Hz, 1H), 12.27 (s, 1H). LC (Cond. 1): RT=0.15 min; MS: Anal. Calcd. for [M+H]+ C6H13N2O3: 161.09; found 161.00.
Cap-133




Cap-133 was prepared from (S)-tert-butyl 2-amino-3-methylbutanoate hydrochloride and 2-fluoroethyl chloroformate according to the method described for Cap-47. 1H NMR (500 MHz, DMSO-d6) δ ppm 0.87 (t, J=6.71 Hz, 6H), 1.97-2.10 (m, 1H), 3.83 (dd, J=8.39, 5.95 Hz, 1H), 4.14-4.18 (m, 1H), 4.20-4.25 (m, 1H), 4.50-4.54 (m, 1H), 4.59-4.65 (m, 1H), 7.51 (d, J=8.54 Hz, 1H), 12.54 (s, 1H).
Cap-134




Cap-134 was prepared from (S)-diethyl alanine and methyl chloroformate according to the method described for Cap-51. 1H NMR (500 MHz, DMSO-d6) δ ppm 0.72-0.89 (m, 6H), 1.15-1.38 (m, 4H), 1.54-1.66 (m, 1H), 3.46-3.63 (m, 3H), 4.09 (dd, J=8.85, 5.19 Hz, 1H), 7.24 (d, J=8.85 Hz, 1H), 12.55 (s, 1H). LC (Cond. 2): RT=0.66 min; LC-MS: Anal. Calcd. for [M+H]+ C9H18NO4: 204.12; found 204.02.
Cap-135




A solution of D-2-amino-(4-fluorophenyl)acetic acid (338 mg, 2.00 mmol), 1N HCl in diethylether (2.0 mL, 2.0 mmol) and formalin (37%, 1 mL) in methanol (5 mL) was subjected to balloon hydrogenation over 10% palladium on carbon (60 mg) for 16 h at 25° C. The mixture was then filtered through CELITE® to afford the HCl salt of Cap-135 as a white foam (316 mg, 80%). 1H NMR (300 MHz, MeOH-d4) δ 7.59 (dd, J=8.80, 5.10 Hz, 2H), 7.29 (t, J=8.6 Hz, 2H), 5.17 (s, 1H), 3.05 (v br s, 3H), 2.63 (v br s, 3H); Rt=0.19 min (Cond.-MS-W5); 95% homogenity index; LRMS: Anal. Calcd. for [M+H]+ C10H13FNO2: 198.09; found: 198.10.
Cap-136




To a cooled (−50° C.) suspension of 1-benzyl-1H-imidazole (1.58 g, 10.0 mmol) in anhydrous diethyl ether (50 mL) under nitrogen was added n-butyl lithium (2.5 M in hexanes, 4.0 mL, 10.0 mmol) dropwise. After being stirred for 20 min at −50° C., dry carbon dioxide (passed through Drierite) was bubbled into the reaction mixture for 10 min before it was allowed to warm up to 25° C. The heavy precipitate which formed on addition of carbon dioxide to the reaction mixture was filtered to yield a hygroscopic, white solid which was taken up in water (7 mL), acidified to pH 3, cooled, and induced to crystallize with scratching. Filtration of this precipitate gave a white solid which was suspended in methanol, treated with 1N HCl/diethyl ether (4 mL) and concentrated in vacuo. Lyophilization of the residue from water (5 mL) afforded the HCl salt of Cap-136 as a white solid (817 mg, 40%). 1H NMR (300 MHz, DMSO-d6) δ 7.94 (d, J=1.5 Hz, 1H), 7.71 (d, J=1.5 Hz, 1H), 7.50-7.31 (m, 5H), 5.77 (s, 2H); Rt=0.51 min (Cond.-MS-W5); 95% homogenity index; LRMS: Anal. Calc. for [M+H]+ C11H12N2O2: 203.08; found: 203.11.
Cap-137




Cap-137, Step a




A suspension of 1-chloro-3-cyanoisoquinoline (188 mg, 1.00 mmol; prepared according to the procedure in WO 2003/099274) (188 mg, 1.00 mmol), cesium fluoride (303.8 mg, 2.00 mmol), bis(tri-tert-butylphosphine)palladium dichloride (10 mg, 0.02 mmol) and 2-(tributylstannyl)furan (378 μL, 1.20 mmol) in anhydrous dioxane (10 mL) under nitrogen was heated at 80° C. for 16 h before it was cooled to 25° C. and treated with saturated, aqueous potassium fluoride solution with vigorous stirring for 1 h. The mixture was partitioned between ethyl acetate and water and the organic phase was separated, washed with brine, dried over Na2SO4, filtered and concentrated. Purification of the residue on silica gel (elution with 0% to 30% ethyl acetate/hexanes) afforded Cap-137, Step a as a white solid which was used as is (230 mg, 105%). Rt=1.95 min (Cond.-MS-W2); 90% homogeneity index; LRMS: Anal. Calc. for [M+H]+ C14H8N2O: 221.07; found: 221.12.
Cap-137




To a suspension of Cap-137, Step a (110 mg, 0.50 mmol) and sodium periodate (438 mg, 2.05 mmol) in carbon tetrachloride (1 mL), acetonitrile (1 mL) and water (1.5 mL) was added ruthenium trichloride hydrate (2 mg, 0.011 mmol). The mixture was stirred at 25° C. for 2 h and then partitioned between dichloromethane and water. The aqueous layer was separated, extracted twice more with dichloromethane and the combined dichloromethane extracts were dried over Na2SO4, filtered and concentrated. Trituration of the residue with hexanes afforded Cap-137 (55 mg, 55%) as a grayish-colored solid. Rt=1.10 min (Cond.-MS-W2); 90% homogeneity index; LC-MS: Anal. Calc. for [M+H]+ C11H8N2O2: 200.08; found: 200.08.
Cap-138 to Cap-158
Synthetic Strategy. Method A.




Cap-138




Cap-138, Step a




To a stirred suspension of 5-hydroxisoquinoline (prepared according to the procedure in WO 2003/099274) (2.0 g, 13.8 mmol) and triphenylphosphine (4.3 g, 16.5 mmol) in dry tetrahydrofuran (20 mL) was added dry methanol (0.8 mL) and diethyl azodicarboxylate (3.0 mL, 16.5 mmol) portionwise. The mixture was stirred at room temperature for 20 h before it was diluted with ethyl acetate and washed with brine, dried over Na2SO4, filtered and concentrated. The residue was preabsorbed onto silica gel and purified (elution with 40% ethyl acetate/hexanes) to afford Cap-138, Step a as a light yellow solid (1.00 g, 45%). 1H NMR (CDCl3, 500 MHz) δ 9.19 (s, 1H), 8.51 (d, J=6.0 Hz, 1H), 7.99 (d, J=6.0 Hz, 1H), 7.52-7.50 (m, 2H), 7.00-6.99 (m, 1H), 4.01 (s, 3H); Rt=0.66 min (Cond. D2); 95% homogeneity index; LC-MS: Anal. Calc. for [M+H]+ C10H10NO: 160.08; found 160.10.
Cap-138, Step b




To a stirred solution of Cap-138, Step a (2.34 g, 14.7 mmol) in anhydrous dichloromethane (50 mL) at room temperature was added meta-chloroperbenzoic acid (77%, 3.42 g, 19.8 mmol) in one portion. After being stirred for 20 h, powdered potassium carbonate (2.0 g) was added and the mixture was stirred for 1 h at room temperature before it was filtered and concentrated to afford Cap-138, Step b as a pale, yellow solid which was sufficiently pure to carry forward (2.15 g, 83.3%). 1H NMR (CDCl3, 400 MHz) δ 8.73 (d, J=1.5 Hz, 1H), 8.11 (dd, J=7.3, 1.7 Hz, 1H), 8.04 (d, J=7.1 Hz, 1H), 7.52 (t, J=8.1 Hz, 1H), 7.28 (d, J=8.3 Hz, 1H), 6.91 (d, J=7.8 Hz, 1H), 4.00 (s, 3H); Rt=0.92 min, (Cond.-D1); 90% homogenity index; LC-MS: Anal. Calc. for [M+H]+ C10H10NO2: 176.07; found: 176.0.
Cap-138, Step c




To a stirred solution of Cap-138, Step b (0.70 g, 4.00 mmol) and triethylamine (1.1 mL, 8.00 mmol) in dry acetonitrile (20 mL) at room temperature under nitrogen was added trimethylsilylcyanide (1.60 mL, 12.00 mmol). The mixture was heated at 75° C. for 20 h before it was cooled to room temperature, diluted with ethyl acetate and washed with saturated sodium bicarbonate solution and brine prior to drying over Na2SO4 and solvent concentration. The residue was flash chromatographed on silica gel (elution with 5% ethyl acetate/hexanes) to 25% ethyl acetate/hexanes to afford Cap-138, Step c (498.7 mg) as a white, crystalline solid along with 223 mg of additional Cap-138, Step c recovered from the filtrate. 1H NMR (CDCl3, 500 MHz) δ 8.63 (d, J=5.5 Hz, 1H), 8.26 (d, J=5.5 Hz, 1H), 7.88 (d, J=8.5 Hz, 1H), 7.69 (t, J=8.0 Hz, 1H), 7.08 (d, J=7.5 Hz, 1H), 4.04 (s, 3H); Rt=1.75 min, (Cond.-D1); 90% homogeneity index; LC-MS: Anal. Calc. for [M+H]+ C11H9N2O: 185.07; found: 185.10.
Cap-138




Cap-138, Step c (0.45 g, 2.44 mmol) was treated with 5N sodium hydroxide solution (10 mL) and the resulting suspension was heated at 85° C. for 4 h, cooled to 25° C., diluted with dichloromethane and acidified with 1N hydrochloric acid. The organic phase was separated, washed with brine, dried over Na2SO4, concentrated to 1⁄4 volume and filtered to afford Cap-138 as a yellow solid (0.44 g, 88.9%). 1H NMR (DMSO-d6, 400 MHz) δ 13.6 (br s, 1H), 8.56 (d, J=6.0 Hz, 1H), 8.16 (d, J=6.0 Hz, 1H), 8.06 (d, J=8.8 Hz, 1H), 7.71-7.67 (m, 1H), 7.30 (d, J=8.0 Hz, 1H), 4.02 (s, 3H); Rt=0.70 min (Cond.-D1); 95% homogenity index; LC-MS: Anal. Calc. for [M+H]+ C11H10NO3: 204.07; found: 204.05.
Synthetic Strategy. Method B (derived from Tetrahedron Letters, 42:6707 (2001)).




Cap-139




Cap-139, Step a




To a thick-walled, screw-top vial containing an argon-degassed suspension of 1-chloro-6-methoxyisoquinoline (1.2 g, 6.2 mmol; prepared according to the procedure in WO 2003/099274), potassium cyanide (0.40 g, 6.2 mmol), 1,5-bis(diphenylphosphino)pentane (0.27 g, 0.62 mmol) and palladium (II) acetate (70 mg, 0.31 mmol) in anhydrous toluene (6 mL) was added N,N,N′,N′-tetramethylethylenediamine (0.29 mL, 2.48 mmol). The vial was sealed, heated at 150° C. for 22 h and then allowed to cool to 25° C. The reaction mixture was diluted with ethyl acetate, washed with water and brine, dried over Na2SO4, filtered and concentrated. The residue was purified on silica gel eluting with 5% ethyl acetate/hexanes to 25% ethyl acetate/hexanes to afford Cap-139, Step a as a white solid (669.7 mg). 1H NMR (CDCl3, 500 MHz) δ 8.54 (d, J=6.0 Hz, 1H), 8.22 (d, J=9.0 Hz, 1H), 7.76 (d, J=5.5 Hz, 1H), 7.41-7.39 (m, 1H), 7.13 (d, J=2.0 Hz, 1H), 3.98 (s, 3H); Rt=1.66 min (Cond.-D1); 90% homogenity index; LC-MS: Anal. Calc. for [M+H]+ C11H9N2O: 185.07; found: 185.20.
Cap-139




Cap-139 was prepared from the basic hydrolysis of Cap-139, Step a with 5N NaOH according to the procedure described for Cap-138. 1H NMR (400 MHz, DMSO-d6) δ 13.63 (v br s, 1H), 8.60 (d, J=9.3 Hz, 1H), 8.45 (d, J=5.6 Hz, 1H), 7.95 (d, J=5.9 Hz, 1H), 7.49 (d, J=2.2 Hz, 1H), 7.44 (dd, J=9.3, 2.5 Hz, 1H), 3.95 (s, 3H); Rt=0.64 min (Cond.-D1); 90% homogenity index; LC-MS: Anal. Calc. for [M+H]+ C11H10NO3: 204.07; found: 204.05.
Cap-140




Cap-140, Step a




To a vigorously-stirred mixture of 1,3-dichloro-5-ethoxyisoquinoline (482 mg, 2.00 mmol; prepared according to the procedure in WO 2005/051410), palladium (II) acetate (9 mg, 0.04 mmol), sodium carbonate (223 mg, 2.10 mmol) and 1,5-bis(diphenylphosphino)pentane (35 mg, 0.08 mmol) in dry dimethylacetamide (2 mL) at 25° C. under nitrogen was added N,N,N′,N′-tetramethylethylenediamine (60 mL, 0.40 mmol). After 10 min, the mixture was heated to 150° C., and then a stock solution of acetone cyanohydrin (prepared from 457 μL of acetone cyanohydrin in 4.34 mL DMA) was added in 1 mL portions over 18 h using a syringe pump. The mixture was then partitioned between ethyl acetate and water and the organic layer was separated, washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified on silica gel eluting with 10% ethyl acetate/hexanes to 40% ethyl acetate/hexanes to afford Cap-140, Step a as a yellow solid (160 mg, 34%). Rt=2.46 min (Cond.-MS-W2); 90% homogenity index; LC-MS: Anal. Calc. for [M+H]+ C12H9ClN2O: 233.05; found: 233.08.
Cap-140




Cap-140 was prepared by the acid hydrolysis of Cap-140, Step a with 12N HCl as described in the procedure for the preparation of Cap-141, described below. Rt=2.24 min (Cond.-MS-W2); 90% homogenity index; LC-MS: Anal. Calc. for [M+H]+ C12H11ClNO3: 252.04; found: 252.02.
Cap-141




Cap-141, Step a




Cap-141, Step a was prepared from 1-bromo-3-fluoroisoquinoline (prepared from 3-amino-1-bromoisoquinoline using the procedure outlined in J. Med. Chem., 13:613 (1970)) as described in the procedure for the preparation of Cap-140, Step a (vide supra). 1H NMR (500 MHz, CDCl3) δ 8.35 (d, J=8.5 Hz, 1H), 7.93 (d, J=8.5 Hz, 1H), 7.83 (t, J=7.63 Hz, 1H), 7.77-7.73 (m, 1H), 7.55 (s, 1H); Rt=1.60 min (Cond.-D1); 90% homogenity index; LC-MS: Anal. Calc. for [M+H]+ C10H6FN2: 173.05; found: 172.99.
Cap-141




Cap-141, Step a (83 mg, 0.48 mmol) was treated with 12N HCl (3 mL) and the resulting slurry was heated at 80° C. for 16 h before it was cooled to room temperature and diluted with water (3 mL). The mixture was stirred for 10 min and then filtered to afford Cap-141 as an off-white solid (44.1 mg, 47.8%). The filtrate was diluted with dichloromethane and washed with brine, dried over Na2SO4, and concentrated to afford additional Cap-141 which was sufficiently pure to be carried forward directly (29.30 mg, 31.8%). 1H NMR (DMSO-d6, 500 MHz) δ 14.0 (br s, 1H), 8.59-8.57 (m, 1H), 8.10 (d, J=8.5 Hz, 1H), 7.88-7.85 (m, 2H), 7.74-7.71 (m, 1H); Rt=1.33 min (Cond.-D1); 90% homogenity index; LC-MS: Anal. Calc. for [M+H]+ C10H2FNO2: 192.05; found: 191.97.
Cap-142




Cap-142, Step a




Cap-142, Step a was prepared from 4-bromoisoquinoline N-oxide as described in the two-step procedure for the preparation of Cap-138, steps b and c. Rt=1.45 min (Cond.-MS-W1); 90% homogenity index; LC-MS: Anal. Calc. for [M+H]+ C10H6BrN2: 232.97; found: 233.00.
Cap-142, Step b




To an argon-degassed suspension of Cap-142, Step a (116 mg, 0.50 mmol), potassium phosphate tribasic (170 mg, 0.80 mmol), palladium (II) acetate (3.4 mg, 0.015 mmol) and 2-(dicyclohexylphosphino)biphenyl (11 mg, 0.03 mmol) in anhydrous toluene (1 mL) was added morpholine (61 μL, 0.70 mmol). The mixture was heated at 100° C. for 16 h, cooled to 25° C. and filtered through diatomaceous earth (CELITE®). Purification of the residue on silica gel, eluting with 10% to 70% ethyl acetate/hexanes afforded Cap-142, Step b (38 mg, 32%) as a yellow solid, which was carried forward directly. Rt=1.26 min (Cond.-MS-W1); 90% homogenity index; LC-MS: Anal. Calc. for [M+H]+ C14H14N3O: 240.11; found: 240.13.
Cap-142




Cap-142 was prepared from Cap-142, Step b with 5N sodium hydroxide as described in the procedure for Cap-138. Rt=0.72 min (Cond.-MS-W1); 90% homogenity index; LC-MS: Anal. Calc. for [M+H]+ C14H15N2O3: 259.11; found: 259.08.
Cap-143




Cap-143, Step a




To a stirred solution of 3-amino-1-bromoisoquinoline (444 mg, 2.00 mmol) in anhydrous dimethylformamide (10 mL) was added sodium hydride (60%, unwashed, 96 mg, 2.4 mmol) in one portion. The mixture was stirred at 25° C. for 5 min before 2-bromoethyl ether (90%, 250 mL, 2.00 mmol) was added. The mixture was stirred further at 25° C. for 5 h and at 75° C. for 72 h before it was cooled to 25° C., quenched with saturated ammonium chloride solution and diluted with ethyl acetate. The organic layer was separated, washed with water and brine, dried over Na2SO4, filtered and concentrated. Purification of the residue on silica gel eluting with 0% to 70% ethyl acetate/hexanes afforded Cap-143, Step a as a yellow solid (180 mg, 31%). Rt=1.75 min (Cond.-MS-W1); 90% homogenity index; LC-MS: Anal. Calc. for [M+H]+ C13H14BrN2O: 293.03; found: 293.04.
Cap-143




To a cold (−60° C.) solution of Cap-143, Step a (154 mg, 0.527 mmol) in anhydrous tetrahydrofuran (5 mL) was added a solution of n-butyllithium in hexanes (2.5 M, 0.25 mL, 0.633 mmol). After 10 min, dry carbon dioxide was bubbled into the reaction mixture for 10 min before it was quenched with 1N HCl and allowed to warm to 25° C. The mixture was then extracted with dichloromethane (3×30 mL) and the combined organic extracts were concentrated in vacuo. Purification of the residue by a reverse phase HPLC (MeOH/water/TFA) afforded Cap-143 (16 mg, 12%). Rt=1.10 min (Cond.-MS-W1); 90% homogenity index; LC-MS: Anal. Calc. for [M+H]+ C14H15N2O3: 259.11; found: 259.08.
Cap-144




Cap-144, Step a




1,3-Dichloroisoquinoline (2.75 g, 13.89 mmol) was added in small portions to a cold (0° C.) solution of fuming nitric acid (10 mL) and concentrated sulfuric acid (10 mL). The mixture was stirred at 0° C. for 0.5 h before it was gradually warmed to 25° C. where it stirred for 16 h. The mixture was then poured into a beaker containing chopped ice and water and the resulting suspension was stirred for 1 h at 0° C. before it was filtered to afford Cap-144, Step a (2.73 g, 81%) as a yellow solid which was used directly. Rt=2.01 min. (Cond.-D1); 95% homogenity index; LC-MS: Anal. Calc. for [M+H]+ C9H5Cl2N2O2: 242.97; found: 242.92.
Cap-144, Step b




Cap-144, Step a (0.30 g, 1.23 mmol) was taken up in methanol (60 mL) and treated with platinum oxide (30 mg), and the suspension was subjected to Parr hydrogenation at 7 psi H2 for 1.5 h. Then formalin (5 mL) and additional platinum oxide (30 mg) were added, and the suspension was resubjected to Parr hydrogenation at 45 psi H2 for 13 h. It was then suction-filtered through diatomaceous earth (CELITE®) and concentrated down to 1⁄4 volume. Suction-filtration of the ensuing precipitate afforded the title compound as a yellow solid which was flash chromatographed on silica gel eluting with 5% ethyl acetate in hexanes to 25% ethyl acetate in hexanes to afford Cap-144, Step b (231 mg, 78%) as a pale yellow solid. Rt=2.36 min (Cond.-D1); 95% homogenity index; 1H NMR (400 MHz, CDCl3) δ 8.02 (s, 1H), 7.95 (d, J=8.6 Hz, 1H), 7.57-7.53 (m, 1H), 7.30 (d, J=7.3 Hz, 1H), 2.88 (s, 6H); LC-MS: Anal. Calc. for [M+H]+ C11H11Cl2N2: 241.03; found: 241.02. HRMS: Anal. Calc. for [M+H]+ C11H11Cl2N2: 241.0299; found: 241.0296.
Cap-144, Step c




Cap-144, Step c was prepared from Cap-144, Step b according to the procedure described for the preparation of Cap-139, Step a. Rt=2.19 min (Cond.-D1); 95% homogenity index; LC-MS: Anal. Calc. for [M+H]+ C12H11ClN3: 232.06; found: 232.03. HRMS: Anal. Calc. for [M+H]+ C12H11ClN3: 232.0642; found: 232.0631.
Cap-144




Cap-144 was prepared according to the procedure described for Cap-141. Rt=2.36 min (Cond.-D1); 90%; LC-MS: Anal. Calc. for [M+H]+ C12H12ClN2O2: 238.01; found: 238.09.
Cap-145 to Cap-162
Cap-145 to Cap-162 were prepared from the appropriate 1-chloroisoquinolines according to the procedure described for the preparation of Cap-138 (Method A) or Cap-139 (Method B) unless noted otherwise as outlined below.


















Rt (LC-






Cond.); %






homogeneity






index; MS


Cap-#
Cap
Method
Hydrolysis
data







Cap-145



   Prepared from commercially available 1,3-dichloroisoquinoline
B
12N HCl
1.14 min (Cond.-MS- W1); 90%; LC-MS: Anal. Calc. for [M + H]+ C10H7ClNO2: 208.02; found: 208.00.


 


Cap-146



   Prepared from commercially available 3-hydroxyisoquinoline
A
5N NaOH
1.40 min (Cond.-D1); 95%; LC-MS: Anal. Calc. for [M + H]+ C11H10NO3: 204.07; found: 204.06.


 


Cap-147



   Prepared from commercially available 1-chloro-4- hydroxyisoquinoline
B
5N NaOH
0.87 min (Cond.-D1); 95%; LC-MS: Anal. Calc. for [M + H]+ C11H10NO3: 204.07; found: 204.05.


 


Cap-148



   Prepared from commercially available 7-hydroxyisoquinoline
A
5N NaOH
0.70 min (Cond.-D1); 95%; LC-MS: Anal. Calc. for [M + H]+ C11H10NO3: 204.07; found: 204.05.


 


Cap-149



   Prepared from commercially available 5-hydroxyisoquinoline
A
5N NaOH
0.70 min (Cond.-D1); 95%; LC-MS: Anal. Calc. for [M + H]+ C11H10NO3: 204.07; found: 204.05.


 


Cap-150



   Prepared from 8- methoxy-1- chloroisoquinoline, which can be synthesized following the procedure in WO 2003/099274
A
12N HCl
0.26 min (Cond.-D1); 95%; LC-MS: Anal. Calc. for [M + H]+ C11H10NO3: 204.07; found: 204.04.


 


Cap-151 3-chloro-5- methoxyisoquino- line-1-carboxylic acid



   Prepared from 5- methoxy-1,3- dichloroisoquinoline, which can be synthesized following the procedure in WO 2005/051410
B
12N HCl
1.78 min (Cond.-D1); 90%; LC-MS: Anal. Calc. for [M + H]+ C11H9ClNO3: 238.03; found: 238.09.


 


Cap-152



   Prepared from commercially available 6-methoxy-1,3- dichloroisoquinoline
B
12N HCl
1.65 min (Cond.-D1); 95%; LC-MS: Anal. Calc. for [M + H]+ C11H9ClNO3: 238.00; found: 238.09.


 


Cap-153



   Prepared from 4- bromoisoquinoline, which can be synthesized following the procedure in WO 2003/062241
A
6N HCl
1.18 min (Cond.-MS- W1); 95%; LC-MS: Anal. Calc. for [M + H]+ C10H7BrNO2: 251.97; found: 251.95.


 


Cap-154



   Prepared from 7-fluoro- 1-chloroisoquinoline, which can be synthesized following the procedure in WO 2003/099274
B
5N NaOH
0.28 min (Cond.-MS- W1); 90%; LC-MS: Anal. Calc. for [M + H]+ C10H7FNO2: 192.05; found: 192.03.


 


Cap-155



   Prepared from 1,7- dichloroisoquinoline, which can be synthesized following the procedure in WO 2003/099274
B
5N NaOH
0.59 min (Cond.-MS- W1); 90%; LC-MS: Anal. Calc. for [M + H]+ C10H7ClNO2: 208.02; found: 208.00.


 


Cap-156



   Prepared from 1,6- dichloroisoquinoline, which can be synthesized following the procedure in WO 2003/099274
B
5N NaOH
0.60 min (Cond.-MS- W1); 90%; LC-MS: Anal. Calc. for [M + H]+ C10H7ClNO2: 208.02; found: 208.03.


 


Cap-157



   Prepared from 1,4- dichloroisoquinoline, which can be synthesized following the procedure in WO 2003/062241
B
12N HCl
1.49 min (Cond.-D1); 95%; LC-MS: Anal. Calc. for [M + H]+ C10H17ClNO: 208.02; found: 208.00.


 


Cap-158



   Prepared from 1,5- dichloroisoquinoline, which can be synthesized following the procedure in WO 2003/099274
B
5N NaOH
0.69 min (Cond.-MS- W1); 90%; LC-MS: Anal. Calc. for [M + H]+ C10H7ClNO2: 208.02; found: 208.01.


 


Cap-159



   Prepared from 5-fluoro- 1-chloroisoquinoline, which can be synthesized following the procedure in WO 2003/099274
B
5N NaOH
0.41 min (Cond.-MS- W1); 90%; LC-MS: Anal. Calc. for [M + H]+ C10H7FNO2: 192.05; found: 192.03.


 


Cap-160



   Prepared from 6-fluoro- 1-chloroisoquinoline, which can be synthesized following the procedure in WO 2003/099274
B
5N NaOH
0.30 min (Cond.-MS- W1); 90%; LC-MS: Anal. Calc. for [M + H]+ C10H7FNO2: 192.05; found: 192.03.


 


Cap-161



   Prepared from 4- bromoquinoline-2- carboxylic acid and dimethylamine (DMSO, 100 °C.)
—
—
0.70 min (Cond. D1); 95%; LC-MS: Anal. Calc. for [M + H]+ C12H13N2O2: 217.10; found: 217.06.


 


Cap-162



   Prepared from m- anisidinc following the procedure described in J. Hetero. Chem., 17 (1993) and Heterocycles, 60: 953 (2003).
—
—
0.65 min (Cond. -M3); 95%; LC-MS: Anal. Calc. for [M + H]+ C11H10NO23: 204.07; found: 203.94.









Cap-163




To a solution of 2-ketobutyric acid (1.0 g, 9.8 mmol) in diethylether (25 ml) was added phenylmagnesium bromide (22 ml, 1M in THF) dropwise. The reaction was stirred at  ̃25° C. under nitrogen for 17.5 h. The reaction was acidified with 1N HCl and the product was extracted with ethyl acetate (3×100 ml). The combined organic layer was washed with water followed by brine and dried over MgSO4. After concentration in vacuo, a white solid was obtained. The solid was recrystallized from hexanes/ethyl acetate to afford Cap-163 as white needles (883.5 mg). 1H NMR (DMSO-d6, δ=2.5 ppm, 500 MHz): 12.71 (br s, 1H), 7.54-7.52 (m, 2H), 7.34-7.31 (m, 2H), 7.26-7.23 (m, 1H), 5.52-5.39 (br s, 1H), 2.11 (m, 1H), 1.88 (m, 1H), 0.79 (app t, J=7.4 Hz, 3H).
Cap-164




A mixture of 2-amino-2-phenylbutyric acid (1.5 g, 8.4 mmol), formaldehyde (14 mL, 37% in water), 1N HCl (10 mL) and 10% Pd/C (0.5 mg) in MeOH (40 mL) was exposed to H2 at 50 psi in a Parr bottle for 42 h. The reaction was filtered over CELITE® and concentrated in vacuo, the residue was taken up in MeOH (36 mL) and the product was purified with a reverse phase HPLC (MeOH/H2O/TFA) to afford the TFA salt of Cap-164 as a white solid (1.7 g). 1H NMR (DMSO-d6, δ=2.5 ppm, 500 MHz) 7.54-7.47 (m, 5H), 2.63 (m, 1H), 2.55 (s, 6H), 2.31 (m, 1H), 0.95 (app t, J=7.3 Hz, 3H).
Cap-165




To a mixture of 2-amino-2-indanecarboxylic acid (258.6 mg, 1.46 mmol) and formic acid (0.6 ml, 15.9 mmol) in 1,2-dichloroethane (7 ml) was added formaldehyde (0.6 ml, 37% in water). The mixture was stirred at  ̃25° C. for 15 min then heated at 70° C. for 8 h. The volatile component was removed in vacuo, and the residue was dissolved in DMF (14 mL) and purified by a reverse phase HPLC (MeOH/H2O/TFA) to afford the TFA salt of Cap-165 as a viscous oil (120.2 mg). 1H NMR (DMSO-d6, δ=2.5 ppm, 500 MHz): 7.29-7.21 (m, 4H), 3.61 (d, J=17.4 Hz, 2H), 3.50 (d, J=17.4 Hz, 2H), 2.75 (s, 6H). LC-MS: Anal. Calcd. for [M+H]+ C12H16NO2: 206.12; found: 206.07.
Cap-166a and Cap-166b




Cap-166a and Cap-166b were prepared from (1S, 4S)-(+)-2-methyl-2,5-diazabicyclo[2.2.1]heptane (2HBr) according to the method described for the synthesis of Cap-7a and Cap-7b, with the exception that the benzyl ester intermediate was separated using a semi-prep Chrialcel OJ column, 20×250 mm, 10 μm eluting with 85:15 heptane/ethanol mixture at 10 mL/min elution rate for 25 min. Cap-166b: 1H NMR (DMSO-d6, δ=2.5 ppm, 500 MHz): 7.45 (d, J=7.3 Hz, 2H), 7.27-7.19 (m, 3H), 4.09 (s, 1H), 3.34 (app br s, 1H), 3.16 (app br s, 1H), 2.83 (d, J=10.1 Hz, 1H), 2.71 (m, 2H), 2.46 (m, 1H), 2.27 (s, 3H), 1.77 (d, J=9.8 Hz, 1H), 1.63 (d, J=9.8 Hz, 1H). LC-MS: Anal. Calcd. for [M+H]+ C14H19N2O2: 247.14; found: 247.11.
Cap-167




A solution of racemic Boc-1,3-dihydro-2H-isoindole carboxylic acid (1.0 g, 3.8 mmol) in 20% TFA/CH2Cl2 was stirred at  ̃25° C. for 4 h. All the volatile component was removed in vacuo. A mixture of the resultant crude material, formaldehyde (15 mL, 37% in water), 1N HCl (10 mL) and 10% Pd/C (10 mg) in MeOH was exposed to H2 (40 PSI) in a Parr bottle for 23 h. The reaction mixture was filtered over CELITE® and concentrated in vacuo to afford Cap-167 as a yellow foam (873.5 mg). 1H NMR (DMSO-d6, δ=2.5 ppm, 500 MHz) 7.59-7.38 (m, 4H), 5.59 (s, 1H), 4.84 (d, J=14 Hz, 1H), 4.50 (d, J=14.1 Hz, 1H), 3.07 (s, 3H). LC-MS: Anal. Calcd. for [M+H]+ C10H12NO2: 178.09; found: 178.65.
Cap-168




Racemic Cap-168 was prepared from racemic Boc-aminoindane-1-carboxylic acid according to the procedure described for the preparation of Cap-167. The crude material was employed as such.
Cap-169




A mixture of 2-amino-2-phenylpropanoic acid hydrochloride (5.0 g, 2.5 mmol), formaldehyde (15 ml, 37% in water), 1N HCl (15 ml), and 10% Pd/C (1.32 g) in MeOH (60 mL) was placed in a Parr bottle and shaken under hydrogen (55 PSI) for 4 days. The reaction mixture was filtered over CELITE® and concentrated in vacuo. The residue was taken up in MeOH and purified by reverse phase prep-HPLC (MeOH/water/TFA) to afford the TFA salt of Cap-169 as a viscous semi-solid (2.1 g). 1H NMR (CDCl3, δ=7.26 ppm, 500 MHz): 7.58-7.52 (m, 2H), 7.39-7.33 (m, 3H), 2.86 (br s, 3H), 2.47 (br s, 3H), 1.93 (s, 3H). LC-MS: Anal. Calcd. for [M+H]+ C11H16NO2: 194.12; found: 194.12.
Cap-170




(S)-2-(Methoxycarbonylamino)-2-(tetrahydro-2H-pyran-4-yl)acetic acid
To (S)-2-amino-2-(tetrahydro-2H-pyran-4-yl)acetic acid (505 mg; 3.18 mmol; obtained from Astatech) in water (15 ml) was added sodium carbonate (673 mg; 6.35 mmol), and the resultant mixture was cooled to 0° C. and then methyl chloroformate (0.26 ml; 3.33 mmol) was added dropwise over 5 minutes. The reaction was allowed to stir for 18 hours while allowing the bath to thaw to ambient temperature. The reaction mixture was then partitioned between 1N HCl and ethyl acetate. The organic layer was removed and the aqueous layer was further extracted with 2 additional portions of ethyl acetate. The combined organic layers were washed with brine, dried over magnesium sulfate, filtered and concentrated in vacuo to afford Cap-170a colorless residue. 1H NMR (500 MHz, DMSO-d6) δ ppm 12.65 (1H, br s), 7.44 (1H, d, J=8.24 Hz), 3.77-3.95 (3H, m), 3.54 (3H, s), 3.11-3.26 (2H, m), 1.82-1.95 (1H, m), 1.41-1.55 (2H, m), 1.21-1.39 (2H, m); LC-MS: Anal. Calcd. for [M+H]+ C9H16NO5: 218.1; found 218.1.
Cap-171




A solution of methyl 2-(benzyloxycarbonylamino)-2-(oxetan-3-ylidene)acetate (200 mg, 0.721 mmol; Il Farmaco, 56:609-613 (2001)) in ethyl acetate (7 ml) and CH2Cl2 (4.00 ml) was degassed by bubbling nitrogen for 10 min. Dimethyl dicarbonate (0.116 ml, 1.082 mmol) and Pd/C (20 mg, 0.019 mmol) were then added, the reaction mixture was fitted with a hydrogen balloon and allowed to stir at ambient temperature overnight at which time TLC (95:5 CH2Cl2/MeOH: visualized with stain made from 1 g Ce(NH4)2SO4, 6 g ammonium molybdate, 6 ml sulfuric acid, and 100 ml water) indicated complete conversion. The reaction was filtered through CELITE® and concentrated. The residue was purified via BIOTAGE® (load with dichloromethane on 25 samplet; elute on 25S column with dichloromethane for 3CV then 0 to 5% MeOH/dichloromethane over 250 ml then hold at 5% MeOH/dichloromethane for 250 ml; 9 ml fractions). Collected fractions containing desired material and concentrated to 120 mg (81%) of methyl 2-(methoxycarbonylamino)-2-(oxetan-3-yl)acetate as a colorless oil. 1H NMR (500 MHz, chloroform-d) δ ppm 3.29-3.40 (m, J=6.71 Hz, 1H) 3.70 (s, 3H) 3.74 (s, 3H) 4.55 (t, J=6.41 Hz, 1H) 4.58-4.68 (m, 2H) 4.67-4.78 (m, 2H) 5.31 (br s, 1H). LC-MS: Anal. Calcd. for [M+H]+ C8H14NO5: 204.2; found 204.0.
To methyl 2-(methoxycarbonylamino)-2-(oxetan-3-yl)acetate (50 mg, 0.246 mmol) in THF (2 mL) and water (0.5 mL) was added lithium hydroxide monohydrate (10.33 mg, 0.246 mmol). The resultant solution was allowed to stir overnight at ambient temperature. TLC (1:1 EA/Hex; Hanessian stain [1 g Ce(NH4)2SO4, 6 g ammonium molybdate, 6 ml sulfuric acid, and 100 ml water]) indicated  ̃10% starting material remaining. Added an additional 3 mg LiOH and allowed to stir overnight at which time TLC showed no starting material remaining. Concentrated in vacuo and placed on high vac overnight providing 55 mg lithium 2-(methoxycarbonylamino)-2-(oxetan-3-yl)acetate as a colorless solid. 1H NMR (500 MHz, MeOD) δ ppm 3.39-3.47 (m, 1H) 3.67 (s, 3H) 4.28 (d, J=7.93 Hz, 1H) 4.64 (t, J=6.26 Hz, 1H) 4.68 (t, J=7.02 Hz, 1H) 4.73 (d, J=7.63 Hz, 2H).
Cap-172




Cap-172, Step a




The following diazotization step was adapted from Barton, A. et al., J.C.S. Perkin Trans 1, 159-164 (1982): A solution of NaNO2 (166 mg, 2.4 mmol) in water (0.6 mL) was added slowly to a stirred, cold (0° C.) solution of methyl 2-amino-5-ethyl-1,3-thiazole-4-carboxylate (186 mg, 1.0 mmol), CuSO4.5H2O (330 mg, 1.32 mmol), NaCl (260 mg, 4.45 mmol) and H2SO4 (5.5 mL) in water (7.5 mL). The mixture was stirred at 0° C. for 45 min and allowed to warm up to room temperature where it stirred further for 1 h before CuCl (118 mg) was added. This mixture was stirred further at room temperature for 16 h before it was diluted with brine and extracted with ether twice. The organic layers were combined, dried over MgSO4 and concentrated to give methyl 2-chloro-5-ethylthiazole-4-carboxylate (i.e., Cap-172, Step a) (175 mg, 85%) as an orange oil (80% pure) which was used directly in the next reaction. Rt=1.99 min (Cond.-MD1); LC-MS: Anal. Calcd. for [M+H]+ C7H9ClNO2S: 206.01; found: 206.05.
Cap-172
To a solution of methyl 2-chloro-5-ethylthiazole-4-carboxylate (175 mg) in THF/H2O/MeOH (20 mL/3 mL/12 mL) was added LiOH (305 mg, 12.76 mmol). The mixture was stirred at room temperature overnight before it was concentrated down and neutralized with 1N HCl in ether (25 mL). The residue was extracted twice with ethyl acetate and the organic layers were combined, dried over MgSO4 and evaporated to yield Cap-172 (60 mg, 74%) as a red solid which was used without further purification. 1H NMR (300 MHz, DMSO-d6) δ ppm 13.03-13.42 (1H, m), 3.16 (2H, q, J=7.4 Hz), 1.23 (3H, t, J=7.5 Hz). Rt=1.78 min (Cond.-MD1); LC-MS: Anal. Calcd. for [M+H]+ C6H7ClNO2S: 191.99; found: 191.99.
Cap-173




Cap-173, Step a




The following diazotization step was adapted from Barton, A. et al., J.C.S. Perkin Trans I, 159-164 (1982): A solution of NaNO2 (150 mg, 2.17 mmol) in water (1.0 mL) was added dropwise to a stirred, cold (0° C.) solution of methyl 2-amino-5-ethyl-1,3-thiazole-4-carboxylate (186 mg, 1.0 mmol) in 50% H3PO2 (3.2 mL). The mixture was stirred at 0° C. for 1 h and allowed to warm up to room temperature where it stirred further for 2 h. After recooling to 0° C., the mixture was treated slowly with a solution of NaOH (85 mg) in water (10 mL). The mixture was then diluted with saturated NaHCO3 solution and extracted twice with ether. The organic layers were combined, dried over MgSO4 and concentrated to give methyl 5-ethylthiazole-4-carboxylate (i.e., Cap-173, Step a) (134 mg, 78%) as an orange oil (85% pure) which was used directly in the next reaction. Rt=1.58 min (Cond.-MD1); LC-MS: Anal. Calcd. for [M+H]+ C2H10NO2S: 172.05; found: 172.05.
Cap-173
To a solution of methyl 5-ethylthiazole-4-carboxylate (134 mg) in THF/H2O/MeOH (18 mL/2.7 mL/11 mL) was added LiOH (281 mg, 11.74 mmol). The mixture was stirred at room temperature overnight before it was concentrated down and neutralized with 1N HCl in ether (25 mL). The residue was extracted twice with ethyl acetate and the organic layers were combined, dried over MgSO4 and evaporated to yield Cap-173 (90 mg, 73%) as an orange solid which was used without further purification. 1H NMR (300 MHz, DMSO-d6) δ ppm 12.74-13.04 (1 H, m), 3.20 (2H, q, J=7.3 Hz), 1.25 (3H, t, J=7.5 Hz). Rt=1.27 min (Cond.-MD1); LC-MS: Anal. Calcd. for [M+H]+ C6H8NO2S: 158.03; found: 158.04.
Cap-174




Cap-174, Step a




Triflic anhydride (5.0 g, 18.0 mmol) was added dropwise to a cold (0° C.) solution of methyl 3-hydroxypicolinate (2.5 g, 16.3 mmol) and TEA (2.5 mL, 18.0 mmol) in CH2Cl2 (80 mL). The mixture was stirred at 0° C. for 1 h before it was allowed to warm up to room temperature where it stirred for an additional 1 h. The mixture was then quenched with saturated NaHCO3 solution (40 mL) and the organic layer was separated, washed with brine, dried over MgSO4 and concentrated to give methyl 3-(trifluoromethylsulfonyloxy)picolinate (i.e., Cap-174, Step a) (3.38 g, 73%) as a dark brown oil (>95% pure) which was used directly without further purification. 1H NMR (300 MHz, CDCl3) δ ppm 8.72-8.79 (1H, m), 7.71 (1H, d, J=1.5 Hz), 7.58-7.65 (1H, m), 4.04 (3H, s). Rt=1.93 min (Cond.-MD1); LC-MS: Anal. Calcd. for [M+H]+ C8H7F3NO5S: 286.00; found: 286.08.
Cap-174
To a solution of methyl 3-(trifluoromethylsulfonyloxy)picolinate (570 mg, 2.0 mmol) in DMF (20 mL) was added LiCl (254 mg, 6.0 mmol), tributyl(vinyl)stannane (761 mg, 2.4 mmol) and bis(triphenylphosphine)palladium dichloride (42 mg, 0.06 mmol). The mixture was heated at 100° C. overnight before a saturated solution of KF (20 mL) was added to the reaction mixture at room temperature. This mixture was stirred for 4 h before it was filtered through CELITE® and the pad of CELITE® was washed with ethyl acetate. The aqueous phase of the filtrate was then separated and concentrated down in vacuo. The residue was treated with 4N HCl in dioxanes (5 mL) and the resulting mixture was extracted with methanol, filtered and evaporated to afford Cap-174 (260 mg) as a green solid which was slightly contaminated with inorganic salts but was used without further purification. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.21 (1H, d, J=3.7 Hz), 7.81-7.90 (1H, m), 7.09 (1H, dd, J=7.7, 4.8 Hz), 6.98 (1H, dd, J=17.9, 11.3 Hz), 5.74 (1H, dd, J=17.9, 1.5 Hz), 5.20 (1H, d, J=11.0 Hz). Rt=0.39 min (Cond.-MD1); LC-MS: Anal. Calcd. for [M+H]+ C8H8NO2: 150.06; found: 150.07.
Cap-175




Cap-175, Step a




To a solution of methyl 3-(trifluoromethylsulfonyloxy)picolinate (i.e., Cap-174, Step a) (570 mg, 2.0 mmol), an intermediate in the preparation of Cap-174, in DMF (20 mL) was added LiCl (254 mg, 6.0 mmol), tributyl(vinyl)stannane (761 mg, 2.4 mmol) and bis(triphenylphosphine)palladium dichloride (42 mg, 0.06 mmol). The mixture was heated at 100° C. for 4 h before the solvent was removed in vacuo. The residue was taken up in acetonitrile (50 mL) and hexanes (50 mL) and the resulting mixture was washed twice with hexanes. The acetonitrile layer was then separated, filtered through CELITE®, and evaporated. Purification of the residue by flash chromatography on a Horizon instrument (gradient elution with 25% ethyl acetate in hexanes to 65% ethyl acetate in hexanes) afforded methyl 3-vinylpicolinate (i.e., Cap-175, Step a) (130 mg, 40%) as a yellow oil. 1H NMR (300 MHz, CDCl3) δ ppm 8.60 (1H, dd, J=4.6, 1.7 Hz), 7.94 (1H, d, J=7.7 Hz), 7.33-7.51 (2H, m), 5.72 (1H, d, J=17.2 Hz), 5.47 (1H, d, J=11.0 Hz), 3.99 (3H, s). Rt=1.29 min (Cond.-MD1); LC-MS: Anal. Calcd. for [M+H]+ C9H10NO2: 164.07; found: 164.06.
Cap-175, Step b




Palladium on carbon (10%, 25 mg) was added to a solution of methyl 3-vinylpicolinate (120 mg, 0.74 mmol) in ethanol (10 mL). The suspension was stirred at room temperature under an atmosphere of hydrogen for 1 h before it was filtered through CELITE® and the pad of CELITE® was washed with methanol. The filtrate was concentrated down to dryness to yield methyl 3-ethylpicolinate (i.e., Cap-175, Step b) which was taken directly into the next reaction. Rt=1.15 min (Cond.-MD1); LC-MS: Anal. Calcd. for [M+H]+ C9H12NO2: 166.09; found: 166.09.
Cap-175
To a solution of methyl 3-ethylpicolinate in THF/H2O/MeOH (5 mL/0.75 mL/3 mL) was added LiOH (35 mg, 1.47 mmol). The mixture was stirred at room temperature for 2 d before additional LiOH (80 mg) was added. After an additional 24 h at room temperature, the mixture was filtered and the solvent was removed in vacuo. The residue was then treated with 4N HCl in dioxanes (5 mL) and the resulting suspension was concentrated down to dryness to yield Cap-175 as a yellow solid which was used without further purification. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.47 (1H, dd, J=4.8, 1.5 Hz), 7.82-7.89 (1H, m), 7.53 (1H, dd, J=7.7, 4.8 Hz), 2.82 (2H, q, J=7.3 Hz), 1.17 (3H, t, J=7.5 Hz). Rt=0.36 min (Cond.-MD1); LC-MS: Anal. Calcd. for [M+H]+ C8H10NO2: 152.07; found: 152.10.
Cap-176




(S)-2-(4,4-Difluorocyclohexyl)-2-(methoxycarbonylamino)acetic acid
Cap-176, Step a




A solution of 1,4-dioxaspiro[4.5]decan-8-one (15 g, 96 mmol) in EtOAc (150 mL) was added to a solution of methyl 2-(benzyloxycarbonylamino)-2-(dimethoxyphosphoryl)acetate (21.21 g, 64.0 mmol) in 1,1,3,3-tetramethylguanidine (10.45 mL, 83 mmol) and EtOAc (150 mL). The resulting solution was the stirred at ambient temperature for 72 h and then it was diluted with EtOAc (25 mL). The organic layer was washed with 1N HCl (75 mL), H2O (100 mL) and brine (100 mL), dried (MgSO4), filtered and concentrated. The residue was purified via BIOTAGE® (5% to 25% EtOAc/Hexanes; 300 g column). The combined fractions containing the product were then concentrated under vacuum and the residue was re-crystallized from hexanes/EtOAc to give white crystals that corresponded to methyl 2-(benzyloxycarbonylamino)-2-(1,4-dioxaspiro[4.5]decan-8-ylidene)acetate (6.2 g) 1H NMR (400 MHz, CDCl3-d) δ ppm 7.30-7.44 (5H, m), 6.02 (1H, br. s.), 5.15 (2H, s), 3.97 (4H, s), 3.76 (3H, br. s.), 2.84-2.92 (2H, m), 2.47 (2H, t, J=6.40 Hz), 1.74-1.83 (4H, m). LC (Cond. OL1): Rt=2.89 min. LC-MS: Anal. Calcd. for [M+Na]+ C19H23NNaO6: 745.21; found: 745.47.
Cap-176, Step b




Ester Cap-176, Step b was prepared from alkene Cap-176, Step a according to the method of Burk, M. J. et al. (J. Am. Chem. Soc., 117:9375-9376 (1995)) and references therein): A 500 mL high-pressure bottle was charged with alkene Cap-176, Step a (3.5 g, 9.68 mmol) in degassed MeOH (200 mL) under a blanket of N2. The solution was then charged with (−)-1,2-Bis((2S,5S)-2,5-dimethylphospholano)ethane(cyclooctadiene) rhodium (I) tetrafluoroborate (0.108 g, 0.194 mmol) and the resulting mixture was flushed with N2 (3×) and charged with H2 (3×). The solution was shaken vigorously under 70 psi of H2 at ambient temperature for 72 h. The solvent was removed under reduced pressure and the remaining residue was taken up in EtOAc. The brownish solution was then filtered through a plug of Silica Gel and eluted with EtOAc. The solvent was concentrated under vacuum to afford a clear oil corresponding to ester Cap-176, Step b (3.4 g). 1H NMR (500 MHz, CDCl3-d) δ ppm 7.28-7.43 (5H, m), 5.32 (1H, d, J=9.16 Hz), 5.06-5.16 (2H, m), 4.37 (1H, dd, J=9.00, 5.04 Hz), 3.92 (4H, t, J=3.05 Hz), 3.75 (3H, s), 1.64-1.92 (4H, m), 1.37-1.60 (5H, m). LC (Cond. OL1): Rt=1.95 min. LC-MS: Anal. Calcd. for [M+H]+ C19H26NO6: 364.18; found: 364.27.
Cap-176, Step c




Ester Cap-176, Step b (4.78 g, 13.15 mmol) was dissolved in THF (15 mL) followed by sequential addition of water (10 mL), glacial acetic acid (26.4 mL, 460 mmol) and dichloroacetic acid (5.44 mL, 65.8 mmol). The resulting mixture was stirred for 72 h at ambient temperature, and the reaction was quenched by slow addition of solid Na2CO3 with vigorous stirring until the release of gas was no longer visible. Crude product was extracted into 10% ethyl acetate-dichloromethane and the organic layers were combined, dried (MgSO4) filtered and concentrated. The resulting residue was purified via BIOTAGE® (0 to 30% EtOAc/Hex; 25 g column) to afford ketone Cap-176, Step c (3.86 g) as a clear oil. 1H NMR (400 MHz, CDCl3-d) δ ppm 7.28-7.41 (5H, m), 5.55 (1H, d, J=8.28 Hz), 5.09 (2H, s), 4.46 (1H, dd, J=8.16, 5.14 Hz), 3.74 (3H, s), 2.18-2.46 (5H, m), 1.96-2.06 (1H, m), 1.90 (1H, ddd, J=12.99, 5.96, 2.89 Hz), 1.44-1.68 (2H, m, J=12.36, 12.36, 12.36, 12.36, 4.77 Hz). LC (Cond. OL1): Rt=1.66 min. LC-MS: Anal. Calcd. for [M+Na]+ C17H21NNaO5: 342.13; found: 342.10.
Cap-176, Step d




DEOXO-FLUOR® (3.13 mL, 16.97 mmol) was added to a solution of ketone Cap-176, Step c (2.71 g, 8.49 mmol) in CH2Cl2 (50 mL) followed by addition of a catalytic amount of EtOH (0.149 mL, 2.55 mmol). The resulting yellowish solution was stirred at rt overnight. The reaction was quenched by addition of sat. aq. NaHCO3 (25 mL) and the mixture was extracted with EtOAc (3×75 mL)). The combined organic layers were dried (MgSO4), filtered and dried to give a yellowish oil. The residue was purified via BIOTAGE® chromatography (2% to 15% EtOAc/Hex; 90 g column) and a white solid corresponding to the difluoro amino acid difluoride Cap-176, Step d (1.5 g) was recovered. 1H NMR (400 MHz, CDCl3-d) δ ppm 7.29-7.46 (5H, m), 5.34 (1H, d, J=8.28 Hz), 5.12 (2H, s), 4.41 (1H, dd, J=8.66, 4.89 Hz), 3.77 (3H, s), 2.06-2.20 (2H, m), 1.83-1.98 (1H, m), 1.60-1.81 (4H, m), 1.38-1.55 (2H, m). 19F NMR (376 MHz, CDCl3-d) δ ppm −92.15 (1F, d, J=237.55 Hz), −102.44 (1F, d, J=235.82 Hz). LC (Cond. OL1): Rt=1.66 min. LC-MS: Anal. Calcd. for [2M+Na]+ C34H42F4N2NaO8: 705.28; found: 705.18.
Cap-176, Step e




Difluoride Cap-176, Step d (4 g, 11.72 mmol) was dissolved in MeOH (120 mL) and charged with Pd/C (1.247 g, 1.172 mmol). The suspension was flushed with N2 (3×) and the reaction mixture was placed under 1 atm of H2 (balloon). The mixture was stirred at ambient temperature for 48 h. The suspension was then filtered though a plug of CELITE® and concentrated under vacuum to give an oil that corresponded to amino acid Cap-176, Step e (2.04 g) and that was used without further purification. 1H NMR (400 MHz, DMSO-d6) δ ppm 3.62 (3H, s), 3.20 (1H, d, J=5.77 Hz), 1.91-2.09 (2H, m), 1.50-1.88 (7H, m), 1.20-1.45 (2H, m). 19F NMR (376 MHz, DMSO-d6) δ ppm −89.39 (1F, d, J=232.35 Hz), −100.07 (1F, d, J=232.35 Hz). 13C NMR (101 MHz, DMSO-d6) δ ppm 175.51 (1C, s), 124.10 (1C, t, J=241.21, 238.90 Hz), 57.74 (1C, s), 51.39 (1C, s), 39.23 (1C, br. s.), 32.02-33.83 (2C, m), 25.36 (1C, d, J=10.02 Hz), 23.74 (1C, d, J=9.25 Hz). LC (Cond. OL2): Rt=0.95 min. LC-MS: Anal. Calcd. for [2M+H]+ C18H31F4N2O2: 415.22; found: 415.40.
Cap-176, Step f




Methyl chloroformate (1.495 mL, 19.30 mmol) was added to a solution of amino acid Cap-176, Step e (2 g, 9.65 mmol) and DIEA (6.74 mL, 38.6 mmol) in CH2Cl2 (100 mL). The resulting solution was stirred at rt for 3 h and volatiles were removed under reduced pressure. The residue was purified via BIOTAGE® (0% to 20% EtOAc/Hex; 90 g column). A clear oil that solidified upon standing under vacuum and corresponding to carbamate Cap-176, Step f (2.22 g) was recovered. 1H NMR (500 MHz, CDCl3-d) δ ppm 5.27 (1H, d, J=8.55 Hz), 4.39 (1H, dd, J=8.85, 4.88 Hz), 3.77 (3H, s), 3.70 (3H, s), 2.07-2.20 (2H, m), 1.84-1.96 (1H, m), 1.64-1.82 (4H, m), 1.39-1.51 (2H, m). 19F NMR (471 MHz, CDCl3-d) δ ppm −92.55 (1F, d, J=237.13 Hz), −102.93 (1F, d, J=237.12 Hz). 13C NMR (126 MHz, CDCl3-d) δ ppm 171.97 (1C, s), 156.69 (1C, s), 119.77-125.59 (1C, m), 57.24 (1C, br. s.), 52.48 (1C, br. s.), 52.43 (1C, s), 39.15 (1C, s), 32.50-33.48 (2C, m), 25.30 (1C, d, J=9.60 Hz), 24.03 (1C, d, J=9.60 Hz). LC (Cond. OL1): Rt=1.49 min. LC-MS: Anal. Calcd. for [M+Na]+ C11H17F2NNaO4: 288.10; found: 288.03.
Cap-176




(S)-2-(4,4-Difluorocyclohexyl)-2-(methoxycarbonylamino)acetic acid
A solution of LiOH (0.379 g, 15.83 mmol) in water (25 mL) was added to a solution of carbamate Cap-176, Step f (2.1 g, 7.92 mmol) in THF (75 mL) and the resulting mixture was stirred at ambient temperature for 4 h. THF was removed under vacuum and the remaining aqueous phase was acidified with 1N HCl solution (2 mL) and then extracted with EtOAc (2×50 mL). The combined organic layers were dried (MgSO4), filtered and concentrated to give a white foam corresponding to Cap-176 (1.92 g). 1H NMR (400 MHz, DMSO-d6) δ ppm 12.73 (1H, s), 7.50 (1H, d, J=8.78 Hz), 3.97 (1H, dd, J=8.53, 6.02 Hz), 3.54 (3H, s), 1.92-2.08 (2H, m), 1.57-1.90 (5H, m), 1.34-1.48 (1H, m), 1.27 (1H, qd, J=12.72, 3.26 Hz). 19F NMR (376 MHz, DMSO-d6) δ ppm −89.62 (1F, d, J=232.35 Hz), −99.93 (1F, d, J=232.35 Hz). LC (Cond. OL2): Rt=0.76 min. LC-MS: Anal. Calcd. for [M−H]+ C10H14F2NO4: 250.09; found: 250.10.
Cap-177a-d




Cap-177a-d, Step a




1,1,3,3-Tetramethylguanidine (0.985 mL, 7.85 mmol) was added to a stirred solution of methyl 2-(benzyloxycarbonylamino)-2-(dimethoxyphosphoryl)acetate (2.0 g, 6.0 mmol) in EtOAc (40 mL) and the mixture was stirred at rt under N2 for 10 min. Then dihydro-2H-pyran-3(4H)-one [23462-75-1] (0.604 g, 6.04 mmol) was added and the mixture was stirred at rt for 16 h. The reaction mixture was then cooled in freezer for 10 min and neutralized with aq. citric acid (1.5 g in 20 mL water). The two phases were partitioned and the organic layer was washed with 0.25 N aq. HCl and brine, and then dried (MgSO4) and concentrated to a colorless oil. The crude material was purified by flash silica chromatography (loading solvent: DCM, eluted with EtOAc/Hexanes, gradient from 20% to 30% EtOAc) to yield two isomeric products: The first eluted product was (Z)-methyl 2-(benzyloxycarbonylamino)-2-(2H-pyran-3(4H,5H,6H)-ylidene)acetate (490 mg) (white solid), and the second was (E)-methyl 2-(benzyloxycarbonylamino)-2-(2H-pyran-3(4H,5H,6H)-ylidene)acetate (433 mg) (white solid). LC-MS retention time 1.398 min (for Z-isomer) and 1.378 min (for E-isomer); m/z 304.08 (for Z-isomer) and 304.16 (for E-isomer) (MH−). LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a PHENOMENEX® Luna 10 u C18 3.0×50 mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220 nM. The elution conditions employed a flow rate of 4 mL/min, a gradient of 100% Solvent A/0% Solvent B to 0% Solvent A/100% Solvent B, a gradient time of 3 min, a hold time of 1 min, and an analysis time of 4 min where Solvent A was 5% MeOH/95% H2O/10 mM ammonium acetate and Solvent B was 5% H2O/95% MeOH/10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode. 1H NMR (400 MHz, chloroform-d) (for Z-isomer) δ ppm 7.30-7.44 (m, 5H), 6.18 (br. s., 1H), 5.10-5.17 (m, 2H), 4.22 (s, 2H), 3.78 (br. s., 3H), 2.93-3.02 (m, 2H), 1.80 (dt, J=11.7, 5.8 Hz, 2H), 1.62 (s, 2H). 1H NMR (400 MHz, chloroform-d) (for E-isomer) δ ppm 7.31-7.44 (m, 5H), 6.12 (br. s., 1H), 5.13-5.17 (m, 2H), 4.64 (br. s., 2H), 3.70-3.82 (m, 5H), 2.49 (t, J=6.5 Hz, 2H), 1.80 (br. s., 2H). (Note: the absolute regiochemistry was determined by 1H NMR shifts and coupling constants).
Cap-177a-d, Step b




(−)-1,2-Bis((2S,5S)-2,5-dimethylphospholano)ethane(cyclooctadiene)-rhodium(I)tetrafluoroborate (28.2 mg, 0.051 mmol) was added to a stirred solution of (Z)-methyl 2-(benzyloxycarbonylamino)-2-(2H-pyran-3 (4H,5H,6H)-ylidene)acetate (310 mg, 1.015 mmol) in MeOH (10 mL) and the mixture was vacuum flushed with N2, followed by H2, and then the reaction was stirred under H2 (60 psi) at rt for 2d. The reaction mixture was concentrated and the residue was purified by flash silica chromatography (loading solvent: DCM, eluted with 20% EtOAc in hexanes) to yield (S)-methyl 2-(benzyloxycarbonylamino)-2-((S)-tetrahydro-2H-pyran-3-yl)acetate (204 mg) as clear colorless oil. LC-MS retention time 1.437 min; m/z 307.89 (MH+). LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a PHENOMENEX® Luna 10 u C18 3.0×50 mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220 nM. The elution conditions employed a flow rate of 4 mL/min, a gradient of 100% Solvent A/0% Solvent B to 0% Solvent A/100% Solvent B, a gradient time of 3 min, a hold time of 1 min, and an analysis time of 4 min where Solvent A was 5% MeOH/95% H2O/10 mM ammonium acetate and Solvent B was 5% H2O/95% MeOH/10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode. 1H NMR (400 MHz, chloroform-d) δ ppm 7.30-7.46 (m, 5H), 5.32 (d, J=8.8 Hz, 1H), 5.12 (s, 2H), 4.36 (dd, J=8.9, 5.6 Hz, 1H), 3.84-3.98 (m, 2H), 3.77 (s, 3H), 3.28-3.37 (m, 1H), 3.23 (dd, J=11.3, 10.5 Hz, 1H), 2.04-2.16 (m, 1H), 1.61-1.75 (m, 3H), 1.31-1.43 (m, 1H).
The other stereoisomer ((E)-methyl 2-(benzyloxycarbonylamino)-2-(2H-pyran-3(4H,5H,6H)-ylidene)acetate) (360 mg, 1.18 mmol) was reduced in a similar manner to yield (S)-methyl 2-(benzyloxycarbonylamino)-2-((R)-tetrahydro-2H-pyran-3-yl)acetate (214 mg) as clear colorless oil. LC-MS retention time 1.437 min; m/z 308.03 (MH+). LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a PHENOMENEX® Luna 10 u C18 3.0×50 mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220 nM. The elution conditions employed a flow rate of 4 mL/min, a gradient of 100% Solvent A/0% Solvent B to 0% Solvent A/100% Solvent B, a gradient time of 3 min, a hold time of 1 min, and an analysis time of 4 min where Solvent A was 5% MeOH/95% H2O/10 mM ammonium acetate and Solvent B was 5% H2O/95% MeOH/10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode. 1H NMR (400 MHz, chloroform-d) δ ppm 7.30-7.44 (m, 5H), 5.31 (d, J=9.0 Hz, 1H), 5.12 (s, 2H), 4.31 (dd, J=8.7, 6.9 Hz, 1H), 3.80-3.90 (m, 2H), 3.77 (s, 3H), 3.37 (td, J=10.8, 3.5 Hz, 1H), 3.28 (dd, J=11.3, 9.8 Hz, 1H), 1.97-2.10 (m, 1H), 1.81 (d, J=11.5 Hz, 1H), 1.61-1.72 (m, 2H), 1.33-1.46 (m, 1H).
The individual enantiomers of Cap-177a, Step b (Cap-177c, Step b) and Cap-177b, Step b (Cap-177d, Step b) were prepared in the same manner and in similar yields utilizing (−)-1,2-Bis((2R,5R)-2,5-dimethylphospholano)ethane (cyclooctadiene)-rhodium(I)tetrafluoroborate as the hydrogenation catalyst for the olefin reductions of the individual stereoisomer starting materials.
Cap-177a and Cap-177b, Step c




10% Pd/C (69.3 mg, 0.065 mmol) was added to a solution of (S)-methyl 2-(benzyloxycarbonylamino)-2-((S)-tetrahydro-2H-pyran-3-yl)acetate (200 mg, 0.651 mmol) and dimethyl dicarbonate [4525-33-1] (0.104 mL, 0.976 mmol) in MeOH (10 mL). The reaction mixture was vacuum flushed with N2, followed by Hz, and then the reaction was stirred under H2 (55 psi) at rt for 5 h. The reaction mixture was filtered through CELITE®/silica pad and the filtrate was concentrated to a colorless oil. The crude oil was purified by flash silica chromatography (loading solvent: DCM, eluted with 30% EtOAc in hexanes) to yield product (S)-methyl 2-(methoxycarbonylamino)-2-((S)-tetrahydro-2H-pyran-3-yl)acetate (132 mg) as colorless oil. LC-MS retention time 0.92 min; m/z 231.97 (MH+). LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a PHENOMENEX® Luna 10 u C18 3.0×50 mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220 nM. The elution conditions employed a flow rate of 4 mL/min, a gradient of 100% Solvent A/0% Solvent B to 0% Solvent A/100% Solvent B, a gradient time of 3 min, a hold time of 1 min, and an analysis time of 4 min where Solvent A was 5% MeOH/95% H2O/10 mM ammonium acetate and Solvent B was 5% H2O/95% MeOH/10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode.
1H NMR (400 MHz, chloroform-d) δ ppm 5.24 (d, J=8.5 Hz, 1H), 4.34 (dd, J=8.9, 5.6 Hz, 1H), 3.84-3.97 (m, 2H), 3.77 (s, 3H), 3.70 (s, 3H), 3.29-3.38 (m, 1H), 3.23 (dd, J=11.2, 10.4 Hz, 1H), 2.03-2.14 (m, 1H), 1.56-1.75 (m, 3H), 1.32-1.43 (m, 1H).
Another diastereomer ((S)-methyl 2-(benzyloxycarbonylamino)-2-((R)-tetrahydro-2H-pyran-3-yl)acetate) was transformed in a similar manner to yield (S)-methyl 2-(methoxycarbonylamino)-2-((R)-tetrahydro-2H-pyran-3-yl)acetate as clear colorless oil. LC-MS retention time 0.99 min; m/z 231.90 (MH+). LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a PHENOMENEX® Luna 10 u C18 3.0×50 mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220 nM. The elution conditions employed a flow rate of 4 mL/min, a gradient of 100% Solvent A/0% Solvent B to 0% Solvent A/100% Solvent B, a gradient time of 3 min, a hold time of 1 min, and an analysis time of 4 min where Solvent A was 5% MeOH/95% H2O/10 mM ammonium acetate and Solvent B was 5% H2O/95% MeOH/10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode.
1H NMR (400 MHz, chloroform-d) δ ppm 5.25 (d, J=8.0 Hz, 1H), 4.29 (dd, J=8.4, 7.2 Hz, 1H), 3.82-3.90 (m, 2H), 3.77 (s, 3H), 3.70 (s, 3H), 3.37 (td, J=10.8, 3.3 Hz, 1H), 3.28 (t, J=10.5 Hz, 1H), 1.96-2.08 (m, 1H), 1.81 (dd, J=12.9, 1.6 Hz, 1H), 1.56-1.72 (m, 2H), 1.33-1.46 (m, 1H).
The individual enantiomers of Cap-177a, Step c (Cap-177c, Step c) and Cap-177b, Step c (Cap-177d, Step c) were prepared in a similar manner and is similar yields using the appropriate starting materials from Cap-177a-d, Step b.
Cap-177a and Cap-177b, Step d




To a solution of (S)-methyl 2-(methoxycarbonylamino)-2-((S)-tetrahydro-2H-pyran-3-yl)acetate (126 mg, 0.545 mmol) in THF (4 mL) stirring at rt was added a solution of 1M LiOH (1.090 mL, 1.090 mmol) in water. The reaction was stirred at rt for 3 h, neutralized with 1M HCl (1.1 mL) and extracted with EtOAc (3×10 mL). The organics were dried, filtered and concentrated to yield (S)-2-(methoxycarbonylamino)-2-((S)-tetrahydro-2H-pyran-3-yl)acetic acid (Cap-177a) (125 mg) as a clear colorless oil. LC-MS retention time 0.44 min; m/z 218.00 (MH+). LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a PHENOMENEX® Luna 10 u C18 3.0×50 mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220 nM. The elution conditions employed a flow rate of 4 mL/min, a gradient of 100% Solvent A/0% Solvent B to 0% Solvent A/100% Solvent B, a gradient time of 3 min, a hold time of 1 min, and an analysis time of 4 min where Solvent A was 5% MeOH/95% H2O/10 mM ammonium acetate and Solvent B was 5% H2O/95% MeOH/10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode. 1H NMR (400 MHz, chloroform-d) δ ppm 5.28 (d, J=8.8 Hz, 1H), 4.38 (dd, J=8.7, 5.6 Hz, 1H), 3.96-4.04 (m, 1H), 3.91 (d, J=11.0 Hz, 1H), 3.71 (s, 3H), 3.33-3.41 (m, 1H), 3.24-3.32 (m, 1H), 2.10-2.24 (m, 1H), 1.74-1.83 (m, 1H), 1.63-1.71 (m, 2H), 1.35-1.49 (m, 1H).
Another diastereomer ((S)-methyl 2-(methoxycarbonylamino)-2-((R)-tetrahydro-2H-pyran-3-yl)acetate) was transformed in a similar manner to yield (S)-2-(methoxycarbonylamino)-2-((R)-tetrahydro-2H-pyran-3-yl)acetic acid (Cap-177b) as clear colorless oil. LC-MS retention time 0.41 min; m/z 217.93 (MH+). LC data was recorded on a Shimadzu LC-10AS liquid chromatograph equipped with a PHENOMENEX® Luna 10 u C18 3.0×50 mm column using a SPD-10AV UV-Vis detector at a detector wave length of 220 nM. The elution conditions employed a flow rate of 4 mL/min, a gradient of 100% Solvent A/0% Solvent B to 0% Solvent A/100% Solvent B, a gradient time of 3 min, a hold time of 1 min, and an analysis time of 4 min where Solvent A was 5% MeOH/95% H2O/10 mM ammonium acetate and Solvent B was 5% H2O/95% MeOH/10 mM ammonium acetate. MS data was determined using a MICROMASS® Platform for LC in electrospray mode.
1H NMR (400 MHz, chloroform-d) δ ppm 6.18 (br. s., 1H), 5.39 (d, J=8.5 Hz, 1H), 4.27-4.37 (m, 1H), 3.82-3.96 (m, 2H), 3.72 (s, 3H), 3.42 (td, J=10.8, 3.3 Hz, 1H), 3.35 (t, J=10.4 Hz, 1H), 2.01-2.18 (m, 1H), 1.90 (d, J=11.8 Hz, 1H), 1.59-1.76 (m, 2H), 1.40-1.54 (m, 1H).
The individual enantiomers of Cap-177a (Cap-177c) and Cap-177b (Cap-177d) were prepared in a similar manner and is similar yields using the appropriate starting materials from Cap-177a-d, Step c.
Cap-178




Cap-178, Step a




To a solution of (2S,3S,4S)-2-methyl-3,4-dihydro-2H-pyran-3,4-diyl diacetate (5 g, 23.34 mmol) in 20 mL of MeOH in a hydrogenation tank was added Pd/C (150 mg, 0.141 mmol). The resulting mixture was hydrogenated at 40 psi on Parr Shaker for 1 hour. The mixture was then filtered and the filtrate was concentrated to afford Cap-178, Step a (5.0 g) as a clear oil, which solidified while standing. 1H NMR (500 MHz, CDCl3) δ ppm 4.85-4.94 (1H, m), 4.69 (1H, t, J=9.46 Hz), 3.88-3.94 (1H, m), 3.44 (1H, td, J=12.21, 1.83 Hz), 3.36 (1H, dq, J=9.42, 6.12 Hz), 2.03-2.08 (1 H, m), 2.02 (3H, s), 2.00 (3H, s), 1.70-1.80 (1H, m), 1.16 (3H, d, J=6.10 Hz).
Cap-178, Step b




To a solution of Cap-178, Step a (5.0 g, 23 mmol) in 50 mL of MeOH was added several drops of sodium methoxide. After stirring at room temperature for 30 min, sodium methoxide (0.1 mL, 23.12 mmol) was added and the solution was stirred at room temperature overnight. The solvent was then removed under vacuum. The residue was diluted with benzene and concentrated to afford the corresponding diol as a yellow solid. The solid was dissolved in 50 mL of pyridine and to this solution at −35° C. was added benzoyl chloride (2.95 mL, 25.4 mmol) dropwise. The resulting mixture was stirred at −35° C. for 1 hour then at room temperature overnight. The mixture was diluted with Et2O and washed with water. The aqueous layer was extracted with EtOAc (2×). The combined organic layers were dried with MgSO4 and concentrated. The crude product was purified by flash chromatography (silica gel, 5%-15% EtOAc/Hex) to afford Cap-178, Step b (4.5 g) as clear oil which slowly crystallized upon prolonged standing. LC-MS: Anal. Calcd. for [M+Na]+ C13H16NaO4 259.09; found 259.0; 1H NMR (500 MHz, CDCl3) δ ppm 8.02-8.07 (2 H, m), 7.55-7.61 (1H, m), 7.45 (2H, t, J=7.78 Hz), 5.01 (1H, ddd, J=11.44, 8.70, 5.49 Hz), 3.98 (1H, ddd, J=11.90, 4.88, 1.53 Hz), 3.54 (1H, td, J=12.36, 2.14 Hz), 3.41 (1H, t, J=9.00 Hz), 3.31-3.38 (1H, m), 2.13-2.19 (1H, m), 1.83-1.94 (1H, m), 1.36 (3H, d, J=5.80 Hz).
Cap-178, Step c




To a mixture of NaH (1.143 g, 28.6 mmol) (60% in mineral oil) in 6 mL of CS2 was added Cap-178, Step b (4.5 g, 19 mmol) in 40 mL of CS2 dropwise over 15 min. The resulting mixture was stirred at room temperature for 30 min. The mixture turned light orange with some solid. MeI (14.29 mL, 229 mmol) was then added dropwise over 20 min. The mixture was then stirred at room temperature overnight. The reaction was carefully quenched with saturated NH4Cl solution. The mixture was extracted with EtOAc (3×). The combined organic layers were dried with MgSO4 and concentrated. The crude product was purified by flash chromatography (silica gel, 6% EtOAc/Hex) to afford Cap-178, Step c (3.13 g) as clear oil. LC-MS: Anal. Calcd. for [M+Na]+ C15H18NaO4S2 349.05; found 349.11; 1H NMR (500 MHz, CDCl3) δ ppm 7.94-8.00 (2H, m), 7.50-7.58 (1H, m), 7.41 (2H, t, J=7.78 Hz), 5.96 (1H, t, J=9.46 Hz), 5.28 (1H, ddd, J=11.37, 9.38, 5.49 Hz), 4.02 (1H, ddd, J=11.98, 4.96, 1.68 Hz), 3.54-3.68 (2H, m), 2.48 (3H, s), 2.31 (1H, dd), 1.88-1.99 (1H, m), 1.28 (3H, d).
Cap-178, Step d




To a mixture of Cap-178, Step c (3.13 g, 9.59 mmol) and AIBN (120 mg, 0.731 mmol) in 40 mL of benzene at 80° C. was added tri-n-butyltin hydride (10.24 mL, 38.4 mmol). The resulting mixture was stirred at reflux temperature for 20 min then cooled to room temperature. The mixture was diluted with diethyl ether and 100 mL of KF (10 g) aqueous solution was added and the mixture was stirred vigorously for 30 min. The two layers were then separated and the aqueous phase was extracted with EtOAc (2×). The organic layer was dried with MgSO4 and concentrated. The crude product was purified by flash chromatography (silica gel, deactivated with 3% Et3N in Hexanes and flushed with 3% Et3N in Hexanes to remove tributyltin derivative and then eluted with 15% EtOAc/Hex) to afford Cap-178, Step d (1.9 g) as clear oil. 1H NMR (500 MHz, CDCl3) δ ppm 7.98-8.07 (2H, m), 7.52-7.58 (1H, m), 7.43 (2H, t, J=7.63 Hz), 5.08-5.17 (1H, m), 4.06 (1H, ddd, J=11.90, 4.88, 1.53 Hz), 3.50-3.59 (2H, m), 2.08-2.14 (1H, m), 1.99-2.06 (1H, m), 1.69-1.80 (1H, m), 1.41-1.49 (1H, m), 1.24 (3H, d, J=6.10 Hz).
Cap-178, Step e




To a mixture of Cap-178, Step d (1.9 g, 8.63 mmol) in 10 mL of MeOH was added sodium methoxide (2 mL, 4.00 mmol) (2 M in methanol). The resulting mixture was stirred at room temperature for 5 hours. The solvent was removed under vacuum. The mixture was neutralized with saturated NH4Cl solution and extracted with EtOAc (3×). The organic layers were dried with MgSO4 and concentrated to afford Cap-178, Step e (0.8 g) as clear oil. The product was used in the next step without further purification. 1H NMR (400 MHz, CDCl3) δ ppm 4.01 (1H, ddd, J=11.80, 5.02, 1.76 Hz), 3.73-3.83 (1H, m), 3.36-3.46 (2H, m), 1.92-2.00 (1H, m), 1.88 (1H, m), 1.43-1.56 (1H, m), 1.23 (3H, d), 1.15-1.29 (1H, m).
Cap-178, Step f




Tosyl-Cl (2.63 g, 13.77 mmol) was added to a solution of Cap-178, Step e (0.8 g, 6.89 mmol) and pyridine (2.23 mL, 27.5 mmol) in 100 mL of CH2Cl2. The resulting mixture was stirred at room temperature for 3 days. 10 mL of water was then added into the reaction mixture and the mixture was stirred at room temperature for an hour. The two layers were separated and the organic phase was washed with water and 1 N HCl aq. solution. The organic phase was dried with MgSO4 and concentrated to afford Cap-178, Step f (1.75 g) as a light yellow solid. The product was used in the next step without further purification. Anal. Calcd. for [M+H]+ C13H19O4S 271.10; found 270.90; 1H NMR (400 MHz, CDCl3) δ ppm 7.79 (2H, d, J=8.24 Hz), 7.34 (2H, d, J=7.93 Hz), 4.53-4.62 (1H, m), 3.94 (1H, ddd, J=12.13, 4.96, 1.83 Hz), 3.29-3.41 (2H, m), 2.45 (3H, s), 1.90-1.97 (1H, m), 1.79-1.85 (1H, m), 1.64-1.75 (1H, m), 1.38-1.48 (1H, m), 1.17 (3H, d, J=6.10 Hz).
Cap-178, Step g




To a microwave tube was placed ethyl 2-(diphenylmethyleneamino)acetate (1.6 g, 5.92 mmol) and Cap-178, Step f (1.6 g, 5.92 mmol). 10 mL of toluene was added. The tube was sealed and LiHMDS (7.1 mL, 7.10 mmol) (1 N in toluene) was added dropwise under N2. The resulting dark brown solution was heated at 100° C. under microwave radiation for 6 hours. To the mixture was then added water and the mixture was extracted with EtOAc (3×). The combined organic layers were washed with brine, dried with MgSO4 and concentrated to afford a diastereomeric mixture of Cap-3, Step g (3.1 g) as an orange oil. The crude mixture was submitted to the next step without separation. LC-MS: Anal. Calcd. for [M+H]+ C23H28NO3 366.21; found 366.3.
Cap-178, Step h




To a solution of the diastereomeric mixture of ethyl Cap-178, Step g in 20 mL of THF was added HCl (30 ml, 60.0 mmol) (2 N aqueous). The resulting mixture was stirred at room temperature for 1 hour. The mixture was extracted with EtOAc and the aqueous layer was concentrated to afford an HCl salt of Cap-178, Step h (1.9 g) as an orange oil. The salt was used in the next step without further purification. LC-MS: Anal. Calcd. for [M+H]+ C10H20NO3 202.14; found 202.1.
Cap-178, Step i




A solution of 1.9 g Cap-178, Step h (HCl salt), DiPEA (4.19 mL, 24.0 mmol) and methyl chloroformate (1.24 mL, 16.0 mmol) in 20 mL of CH2Cl2 was stirred at room temperature for 1 hour. The mixture was diluted with CH2Cl2 and washed with water. The organic layer was dried with Na2SO4 and concentrated. The crude product was purified by flash chromatography (silica gel, 0-20% EtOAc/Hex) to afford Cap-178, Step i (1.1 g) as a yellow oil. Anal. Calcd. for [M+Na]+ C12H21NNaO5 282.13; found 282.14; 1H NMR (400 MHz, CDCl3) δ ppm 5.16 (1H, br. s.), 4.43-4.58 (1H, m), 4.17-4.28 (2H, m), 3.89-4.03 (1H, m), 3.72-3.78 (2 H, m), 3.67-3.72 (3H, m), 2.07-2.19 (1H, m), 1.35-1.77 (4H, m), 1.30 (3H, td, J=7.09, 2.89 Hz), 1.19 (3H, d, J=6.53 Hz).
Cap-178, Step j




To a mixture of Cap-178, Step i (1.1 g, 4.2 mmol) in 5 mL of THF and 2 mL of water was added LiOH (6.36 mL, 12.7 mmol) (2 N aq.). The resulting mixture was stirred at room temperature overnight. The mixture was then neutralized with 1 N HCl aq. and extracted with EtOAc (3×). The combined organic layers were dried with MgSO4 and concentrated to afford Cap-178, Step j (0.8 g) as a clear oil. LC-MS: Anal. Calcd. for [M+H]+ C10H18NO5 232.12; found 232.1; 1H NMR (400 MHz, CDCl3) δ ppm 5.20 (1H, d, J=8.28 Hz), 4.54 (1H, t, J=8.16 Hz), 3.95-4.10 (1H, m), 3.66-3.85 (5H, m), 2.15-2.29 (1H, m), 1.41-1.85 (4H, m), 1.23 (3H, dd, J=6.53, 1.76 Hz).
Cap-178, Step k




To a solution of Cap-178, Step j (240 mg, 1.04 mmol), (S)-1-phenylethanol (0.141 mL, 1.142 mmol) and EDC (219 mg, 1.14 mmol) in 10 mL of CH2Cl2 was added DMAP (13.95 mg, 0.114 mmol). The resulting solution was stirred at room temperature overnight and the solvent was removed under vacuum. The residue was taken up into EtOAc, washed with water, dried with MgSO4 and concentrated. The crude product was purified by chromatography (silica gel, 0-15% EtOAc/Hexanes) to afford Cap-178, Step k as a mixture of two diastereomers. The mixture was separated by chiral HPLC (CHIRALPAK® AS column, 21×250 mm, 10 um) eluting with 90% 0.1% diethylamine/Heptane-10% EtOH at 15 mL/min to afford Cap-178, Step k stereoisomer 1 (eluted first) and Cap-178, Step k stereoisomer 2 (eluted second) as white solids. The stereochemistry of the isomers was not assigned.
Cap-178, Step k stereoisomer 1 (130 mg): LC-MS: Anal. Calcd. for [M+Na]+ C18H25NNaO5 358.16; found 358.16; 1H NMR (500 MHz, CDCl3) δ ppm 7.28-7.38 (5H, m), 5.94 (1H, q, J=6.71 Hz), 5.12 (1H, d, J=9.16 Hz), 4.55 (1H, t, J=9.00 Hz), 3.72-3.81 (1H, m), 3.67 (3H, s), 3.60-3.70 (2H, m), 1.98-2.08 (1H, m), 1.59 (3H, d, J=6.71 Hz), 1.38-1.47 (2H, m), 1.30 (2H, t, J=5.34 Hz), 0.93 (3H, d, J=6.41 Hz).
Cap-178, Stereoisomer 1
To a solution of Cap-178, Step k stereoisomer 1 ((S)-2-(methoxycarbonylamino)-2-((2S,4R)-2-methyltetrahydro-2H-pyran-4-yl)acetic acid) (150 mg, 0.447 mmol) in 10 mL of EtOH was added Pd/C (20 mg, 0.188 mmol) and the mixture was hydrogenated on Parr shaker at 40 psi overnight. The mixture was then filtered and the filtrate was concentrated to afford Cap-178, stereoisomer 1 (100 mg) as a sticky white solid. LC-MS: Anal. Calcd. for [M+H]+ C10H18NO5 232.12; found 232.1; 1H NMR (500 MHz, CDCl3) δ ppm 5.14-5.27 (1H, m), 4.51 (1H, t, J=8.39 Hz), 3.90-4.07 (1H, m), 3.60-3.83 (5H, m), 2.06-2.27 (1H, m), 1.45-1.77 (4H, m), 1.21 (3H, d, J=6.41 Hz).
Cap-179 (Enantiomer-1 and Enantiomer-2)




Cap-179, Step a




2,6-Dimethyl-4H-pyran-4-one (10 g, 81 mmol) was dissolved in ethanol (125 mL) and Pd/C (1 g, 0.94 mmol) was added. The mixture was hydrogenated in a Parr shaker under H2 (0.325 g, 161 mmol) (70 psi) at room temperature for 12 hrs. The catalyst was filtered through a pad of CELITE® and washed with ethanol. The filtrate was concentrated in vacuum and the residue was purified via BIOTAGE® (2% to 25% EtOAc/Hex; 160 g column). Two fractions of clear oils were isolated. The first eluting one corresponded to (2R,6S)-2,6-dimethyldihydro-2H-pyran-4(3H)-one (1.8 g) while the second one corresponded to Cap-179, Step a (1.8 g).
(2R,6S)-2,6-Dimethyldihydro-2H-pyran-4(3H)-one data: 1H NMR (500 MHz, CDCl3) δ ppm 3.69 (2H, ddd, J=11.29, 5.95, 2.29 Hz), 2.24-2.36 (2H, m), 2.08-2.23 (2H, m), 1.18-1.34 (6H, m); 13C NMR (126 MHz, CDCl3) δ ppm 206.96 (1C, br. s.), 72.69 (2C, s), 48.70 (2C, s), 21.72 (2C, s).
Cap-179, Step a data: 1H NMR (500 MHz, CDCl3) δ ppm 3.69-3.78 (1H, m), 3.36-3.47 (2H, m), 2.10 (1H, br. s.), 1.88 (2H, dd, J=12.05, 4.73 Hz), 1.19 (6H, d, J=6.10 Hz), 1.10 (2H, q, J=10.70 Hz); 13C NMR (126 MHz, CDCl3) δ ppm 71.44 (2C, s), 67.92 (1C, s), 42.59 (2C, s), 21.71 (2C, s).
Cap-179, Step b




DEAD (2.311 mL, 14.59 mmol) was added drop wise to a solution of Cap-179, Step a (0.38 g, 2.92 mmol), 4-nitrobenzoic acid (2.195 g, 13.14 mmol) and Ph3P (3.83 g, 14.59 mmol) in benzene (25 mL). Heat evolution was detected and the resulting amber solution was stirred at ambient temperature for 6 h. Solvent was removed under reduced pressure and the residue was purified via BIOTAGE® (0 to 15% EtOAc/Hex; 80 g column). A white solid corresponding to Cap-179, Step b (0.77 g) was isolated. LC-MS: Anal. Calcd. for [M]+ C14H17NO5: 279.11; found 279.12. 1H NMR (500 MHz, CDCl3) δ ppm 8.27-8.32 (2H, m), 8.20-8.24 (2H, m), 5.45 (1H, quin, J=2.82 Hz), 3.92 (2H, dqd, J=11.90, 6.10, 6.10, 6.10, 1.53 Hz), 1.91 (2H, dd, J=14.80, 2.29 Hz), 1.57 (3H, dt, J=14.65, 3.05 Hz), 1.22 (6H, d, J=6.10 Hz).
Cap-179, Step c




A solution LiOH (0.330 g, 13.8 mmol) in water (8 mL) was added to a solution of Cap-179, Step b (0.77 g, 2.76 mmol) in THF (30 mL) and the resulting mixture was stirred at ambient temperature for 16 h. THF was removed under reduced pressure and the aqueous layer was diluted with more water (20 mL) and extracted with EtOAc (3×15 mL). The combined organic layers were dried (MgSO4), filtered and concentrated under vacuum. An oily residue with a white solid was recovered. The mixture was triturated with hexanes and the solid was filtered off to yield a clear oil corresponding to Cap-179, Step c (0.34 g). 1H NMR (500 MHz, CDCl3) δ ppm 4.21 (1H, quin, J=2.82 Hz), 3.87-3.95 (2H, m), 1.72 (1H, br. s.), 1.63 (2H, dd, J=14.34, 2.14 Hz), 1.39-1.47 (2H, m), 1.17 (6H, d, J=6.41 Hz).
Cap-179, Step d




p-Tosyl chloride (3.98 g, 20.89 mmol) was added to a solution of Cap-179, Step c (1.36 g, 10.5 mmol) and Pyridine (3.38 mL, 41.8 mmol) in CH2Cl2 (150 mL) at room temperature and stirred for 24 h and then concentrated to a yellow oil. The remaining residue was added to pyridine (20 mL) and water (30 mL) and the resulting mixture was stirred at ambient temperature for 11⁄2 h. The mixture was extracted with Et2O (75 mL) and the separated organic layer was the washed thoroughly with 1 N aq. HCl (4×50 mL). The organic layer was then dried (MgSO4), filtered and concentrated. A white solid corresponding to Cap-179, Step d (2.2 g) was isolated. LC-MS: Anal. Calcd. for [2M+H]+ C28H41O8S2: 569.22; found 569.3. 1H NMR (400 MHz, CDCl3) δ ppm 7.80 (2H, d, J=8.28 Hz), 7.35 (2H, d, J=8.03 Hz), 4.89 (1H, quin, J=2.82 Hz), 3.77-3.88 (2H, m), 2.46 (3H, s), 1.77 (2H, dd, J=14.93, 2.89 Hz), 1.36 (2H, ddd, J=14.31, 11.54, 2.76 Hz), 1.13 (6H, d, J=6.27 Hz).
Cap-179, Step e




LiHMDS (4.30 mL, 4.30 mmol) was added to a solution of Cap-179, Step d (1.02 g, 3.59 mmol) and benzyl 2-(diphenylmethyleneamino)acetate (1.181 g, 3.59 mmol) in toluene (25 mL) at room temperature in a sealed microwave vial and the resulting mixture was then stirred for 5 h at 100° C. under microwave radiation. The reaction was quenched with water (10 mL), extracted with EtOAc, washed with water, dried over MgSO4, filtrated, and concentrated in vacuum. The residue was purified via BIOTAGE® (0% to 6% EtOAc/Hex; 80 g column) and a yellow oil corresponding to Cap-179, Step e (1.2 g) was isolated. Anal. Calcd. for [2M+Na]+ C58H62N2NaO6: 905.45; found 905.42. 1H NMR (400 MHz, CDCl3) δ ppm 7.64-7.70 (4H, m), 7.29-7.44 (29H, m), 7.06 (4H, dd, J=7.65, 1.63 Hz), 5.18 (2H, d, J=2.01 Hz), 3.89 (2H, d, J=6.53 Hz), 3.79-3.87 (1H, m), 3.46 (5H, dquind, J=11.26, 5.87, 5.87, 5.87, 5.87, 1.88 Hz), 2.47 (2H, s), 2.35-2.46 (2H, m), 1.78 (1 H, dd, J=14.81, 3.01 Hz), 1.62-1.65 (1H, m), 1.61 (2H, s), 1.36-1.43 (3H, m), 1.19 (7H, d, J=6.27 Hz), 1.14 (11H, dd, J=6.15, 2.89 Hz), 0.86-0.96 (3H, m).
Cap-179, Step f (Enantiomer-1 and Enantiomer-2)




Cap-179, Step e (2.08 g, 4.71 mmol) was dissolved in THF (100 mL) and treated with 2 N HCl (9.42 mL, 18.84 mmol). The resulting clear solution was stirred at ambient temperature for 4 h and then THF was removed under reduced pressure. The remaining aqueous layer was extracted with hexanes (3×20 ml) and after diluting with H2O (20 mL), the aqueous phase was basified with 1 N NaOH to pH=10 and extracted with EtOAc (3×10 mL). The combined organic layers were dried (MgSO4), filtered and concentrated under vacuum. The resulting residue was taken up in CH2Cl2 (100 mL) and charged with DIEA (2.468 mL, 14.13 mmol) and methyl chloroformate (0.401 mL, 5.18 mmol). The resulting solution was stirred at ambient temperature for 2 h. The reaction mixture was quenched with water (10 mL) and the organic layer was removed under reduced pressure. The aqueous layer was then extracted with EtOAc (3×10 mL) and the combined organic layers were dried (MgSO4), filtered and concentrated. The residue was purified via BIOTAGE® (10% EtOAc/Hex; 25 g column). A clear colorless oil corresponding to Cap-179, Step f (1.05 g) was recovered. LC-MS: Anal. Calcd. for [M+H]+ C18H26NO5: 336.18; found 336.3. 1H NMR (500 MHz, CDCl3) δ ppm 7.32-7.40 (5H, m), 5.26 (1H, d, J=8.24 Hz), 5.13-5.24 (2H, m), 4.36 (1H, dd, J=8.85, 4.88 Hz), 3.68 (3H, s), 3.32-3.46 (2H, m), 2.02-2.14 (1H, m), 1.52 (1H, d, J=12.82 Hz), 1.32 (1H, d, J=12.51 Hz), 1.11-1.18 (6H, m), 0.89-1.07 (2H, m).
A chiral SFC method was developed to separate the racemic mixture by using 12% methanol as the modifier on a CHIRALPAK® AD-H column (30×250 mm, 5 nm) (Temp=35° C., Pressure=150 bar, Wavelength=210 nm, Flow rate=70 mL/min for 8 min, Solvent A=CO2, Solvent B=MeOH). The two separated isomers, Cap-179 Step f (Enantiomer-1) (first eluting) and Cap-179 Step f (Enantiomer-2) (second eluting) exhibited the same analytical data as the corresponding mixture (see above).
Cap-179 (Enantiomer-1 and Enantiomer-2)
Cap-179 Step f (Enantiomer-1) (0.35 g, 1.044 mmol) was dissolved in MeOH (50 mL) in a Parr bottle and charged with Pd/C (0.111 g, 1.044 mmol). The suspension was then placed in a Parr shaker and the mixture was flushed with N2 (3×), placed under 40 psi of H2 (2.104 mg, 1.044 mmol) and shaken at room temperature for 2 h. The catalyst was filtered off through a pad of CELITE® and the solvent was removed under reduced pressure, to yield an amber solid corresponding to Cap-179 Enantiomer-1 (0.25 g). 1H NMR (500 MHz, DMSO-d6) δ ppm 12.74 (4H, br. s.), 7.35 (4H, d, J=6.10 Hz), 3.85 (4H, br. s.), 3.53 (3H, s), 3.35 (2H, ddd, J=15.95, 9.99, 6.10 Hz), 1.97 (1H, br. s.), 1.48 (2H, t, J=13.28 Hz), 1.06 (6H, d, J=6.10 Hz), 0.82-1.00 (2H, m).
Cap-179 Enantiomer-2 was prepared similarly: 1H NMR (500 MHz, DMSO-d6) δ ppm 12.50 (1H, br. s.), 7.31 (1H, br. s.), 3.84 (1H, t, J=7.32 Hz), 3.53 (3H, s), 3.29-3.41 (2H, m), 1.99 (1H, s), 1.48 (2H, t, J=14.34 Hz), 1.06 (6H, d, J=6.10 Hz), 0.95 (1H, q, J=12.21 Hz), 0.87 (1H, q, J=11.80 Hz). [Note: the minor variation in the 1H NMR profile of the enantiomers is likely a result of a difference in sample concentration.]
Cap-180 (Racemic Mixture)




Cap-180, Step a




p-Tosyl-Cl (4.39 g, 23.0 mmol) was added to a solution of Cap-179, Step a (1.50 g, 11.5 mmol) and pyridine (3.73 mL, 46.1 mmol) in CH2Cl2 (50 mL) at room temperature and stirred for 2 days. The reaction was diluted with CH2Cl2, washed with water, then 1 N HCl. The organic layer was dried (MgSO4) and concentrated to a yellow oil which was purified via BIOTAGE® (5% to 20% EtOAc/Hex; 40 g column). A clear oil that solidified under vacuum and corresponding to Cap-180, Step a (2.89 g) was isolated. LC-MS: Anal. Calcd. for [2M+Na]+ C28H40NaO8S2: 591.21; found 591.3. 1H NMR (500 MHz, CDCl3) δ ppm 7.80 (2H, d, J=8.24 Hz), 7.35 (2H, d, J=7.93 Hz), 4.59 (1H, tt, J=11.37, 4.96 Hz), 3.36-3.46 (2H, m), 2.46 (3H, s), 1.91 (2H, dd, J=12.05, 5.04 Hz), 1.37 (2H, dt, J=12.67, 11.52 Hz), 1.19 (6H, d, J=6.10 Hz).
Cap-180, Step b




LiHMDS 1N (7.09 mL, 7.09 mmol) was added to a solution of Cap-180, Step a (1.68 g, 5.91 mmol) and ethyl 2-(diphenylmethyleneamino)acetate (1.579 g, 5.91 mmol) in toluene (30 mL) at room temperature and the resulting mixture was then stirred for 16 h at 85° C. The reaction was quenched with water (50 mL), extracted with EtOAc, washed with water, dried over MgSO4, filtrated, and concentrated in vacuo. The residue was purified via BIOTAGE® (0% to 15% EtOAc/Hex; 40 g column). A clear yellowish oil corresponding to Cap-180, Step b (racemic mixture; 0.64 g) was isolated. LC-MS: Anal. Calcd. for [M+H]+ C24H30NO3: 380.22; found 380.03. 1H NMR (400 MHz, CDCl3) δ ppm 7.64-7.70 (2H, m), 7.45-7.51 (3H, m), 7.38-7.44 (1H, m), 7.31-7.37 (2H, m), 7.13-7.19 (2H, m), 4.39 (1H, d, J=10.54 Hz), 4.16-4.26 (2H, m), 3.29-3.39 (1H, m), 2.93-3.03 (1H, m), 2.70 (1H, m, J=9.41, 4.14 Hz), 1.42-1.49 (2H, m), 1.31-1.37 (1H, m), 1.29 (4H, t, J=7.15 Hz), 1.04 (6H, dd, J=7.78, 6.27 Hz).
Cap-180, Step c




Cap-180, Step b (0.36 g, 0.949 mmol) was dissolved in THF (10 mL) and treated with 2 N HCl (1.897 mL, 3.79 mmol). The resulting clear solution was stirred at ambient temperature for 20 h and THF was removed under reduced pressure. The remaining aqueous layer was extracted with hexanes (3×20 mL) and after diluting with H2O (20 mL), the aqueous phase was basified with 1 N NaOH to pH=10 and extracted with EtOAc (3×10 mL). The combined organic layers were dried (MgSO4), filtered and concentrated under vacuum. The resulting residue was taken up in CH2Cl2 (10.00 mL) and charged with DIEA (0.497 mL, 2.85 mmol) and methyl chloroformate (0.081 mL, 1.044 mmol). The resulting solution was stirred at ambient temperature for 2 h and the reaction mixture was quenched with water (10 mL) and the organic layer was removed under reduced pressure. Aqueous layer was extracted with EtOAc (3×10 mL) and the combined organic layers were dried (MgSO4), filtered and concentrated. An amber oil corresponding to Cap-180, Step c (0.21 g) was recovered and it was used without further purification. LC-MS: Anal. Calcd. for [M+H]+ C13H24NO5: 273.17; found 274.06. 1H NMR (400 MHz, CDCl3) δ ppm 5.20 (1H, d, J=8.03 Hz), 4.59 (1H, t, J=10.16 Hz), 4.11-4.27 (3H, m), 3.69-3.82 (2H, m), 3.64 (3H, s), 1.95-2.07 (1H, m), 1.63 (1H, d, J=13.80 Hz), 1.41 (2H, dd, J=8.03, 4.02 Hz), 1.31-1.37 (1H, m), 1.26 (3H, t, J=7.15 Hz), 1.16 (1H, d, J=6.27 Hz), 1.12 (6H, dd, J=6.15, 3.89 Hz).
Cap-180 (Racemic Mixture)
Cap-180, Step c (0.32 g, 1.2 mmol) was dissolved in THF (10 mL) and charged with LiOH (0.056 g, 2.342 mmol) in water (3.33 mL) at 0° C. The resulting solution was stirred at rt for 2 h. THF was removed under reduced pressure and the remaining residue was diluted with water (15 mL) and washed with Et2O (2×10 mL). The aqueous layer was then acidified with 1N HCl to pH  ̃2 and extracted with EtOAc (3×15 mL). The combined organic layers were dried (MgSO4), filtered and concentrated under vacuum to yield Cap-180 (racemic mixture) (0.2 g) as a white foam. LC-MS: Anal. Calcd. for [M+H]+ C11H20NO5: 246.13; found 246.00. 1H NMR (400 MHz, CDCl3) δ ppm 5.14 (1H, d, J=9.03 Hz), 4.65 (1H, t, J=9.91 Hz), 3.63-3.89 (5H, m), 1.99-2.13 (1H, m), 1.56-1.73 (2H, m), 1.48-1.55 (1H, m), 1.35-1.48 (1H, m), 1.27 (1H, br. s.), 1.17 (6H, d, J=6.02 Hz).
Cap-185 (Enantiomer-1 and Enantiomer-2)




Cap-185, Step a




To a mixture of furan (1.075 mL, 14.69 mmol) and zinc (1.585 g, 24.24 mmol) in 1 mL of THF was added 1,1,3,3-tetrabromopropan-2-one (8.23 g, 22.03 mmol) and triethyl borate (5.25 mL, 30.8 mmol) in 4 mL of THF dropwise during 1 hour in dark. The resulting mixture was stirred at room temperature in dark for 17 hours. The resulting dark brown mixture was cooled to −15° C., and 6 mL of water was added. The mixture was warmed to 0° C. and stirred at this temperature for 30 min. The mixture was then filtered and washed with ether. The filtrate was diluted with water and extracted with ether (3×). The combined organic layers were dried with MgSO4 and concentrated to afford dark brown oil. The dark brown oil was dissolved in 6 mL of MeOH and the solution was added dropwise to a mixture of zinc (4.99 g, 76 mmol), copper (I) chloride (0.756 g, 7.64 mmol) and ammonium chloride (5.4 g, 101 mmol) in 20 mL of MeOH. The reaction temperature was maintained below 15° C. during addition. The mixture was then stirred at room temperature for 20 hours, filtered, and the filtrate was diluted with water and extracted with CH2Cl2 (3×). The combined organic layers were dried with MgSO4 and concentrated. The crude product was purified by flash chromatography (silica gel, 0-14% EtOAc/Hex) to afford Cap-185, Step a as a white solid (1.0 g) as a white solid, which turned yellow soon. 1H NMR (500 MHz, CDCl3) δ ppm 6.24 (2H, s), 5.01 (2H, d, J=4.88 Hz), 2.73 (2H, dd, J=16.94, 5.04 Hz), 2.31 (2H, d, J=16.79 Hz).
Cap-185, Step b




To a solution of Cap-185, Step a (240 mg, 1.933 mmol) in 2 mL of THF at −78° C. was added L-selectride (3.87 mL, 3.87 mmol) (1 M in THF) dropwise over 100 min. The resulting mixture was stirred at −78° C. for 1 hour and then at room temperature overnight. The mixture was then cooled to 0° C., 4 mL of 20% NaOH aqueous solution was added, followed by 2 mL of H2O2 (30% water solution) dropwise. The resulting mixture was stirred for 1 hour and then neutralized with 6N HCl ( ̃5 mL). The aqueous layer was saturated with NaCl and extracted with CH2Cl2 (3×). The combined organic layers were dried with MgSO4 and concentrated. The crude product was purified by flash chromatography (silica gel, 0-40% EtOAc/Hex) to afford Cap-185, Step b (180 mg) as clear oil. 1H NMR (400 MHz, CDCl3) δ ppm 6.49 (2H, s), 4.76 (2H, d, J=4.27 Hz), 3.99 (1H, t, J=5.77 Hz), 2.29 (2H, ddd, J=15.18, 5.65, 4.02 Hz), 1.70-1.78 (2H, m).
Cap-185, Step c




p-Tosyl-Cl (544 mg, 2.85 mmol) was added to a solution of Cap-185, Step b (180 mg, 1.427 mmol) and pyridine (0.462 mL, 5.71 mmol) in 5 mL of CH2Cl2 (5 mL) and the mixture was stirred at room temperature for 2 days. The reaction was diluted with CH2Cl2 and washed with 1 N aq. HCl. The aqueous layer was extracted with CH2Cl2 (2×). The combined organic layers were dried with MgSO4 and concentrated. The crude product was purified by flash chromatography (silica gel, 0-15% EtOAc/Hex) to afford Cap-185, Step c (210 mg) as a white solid. 1H NMR (500 MHz, CDCl3) δ ppm 7.73 (2H, d, J=8.24 Hz), 7.32 (2H, d, J=8.24 Hz), 6.25 (2H, s), 4.76 (1H, t, J=5.65 Hz), 4.64 (2H, d, J=3.66 Hz), 2.44 (3H, s), 2.18 (2H, td, J=10.07, 5.49 Hz), 1.71 (2H, d, J=15.56 Hz).
Cap-185, Step d




A microwave tube was charged with benzyl 2-(diphenylmethyleneamino)acetate (1.5 g, 4.57 mmol) and Cap-185, Step c (1.28 g, 4.57 mmol) in 5 mL of toluene. The tube was sealed and LiHMDS (5.5 mL, 5.5 mmol) (1 N in toluene) was added dropwise under N2. The resulting dark brown solution was heated at 100° C. in microwave for 5 hours. To the mixture was then added water and EtOAc. The layers were separated and the water phase was extracted with EtOAc (2×). The combined organic layers were concentrated to afford Cap-185, Step d as a racemic mixture of. The crude mixture was submitted to the next step without purification or separation. LC-MS: Anal. Calcd. for [M+H]+ C29H28NO3 438.21; found 438.4.
Cap-185, Step e




To a solution of the racemic mixture of Cap-185, Step d in 30 mL of THF was added HCl (20 mL) (2 N aq.). The resulting mixture was stirred at room temperature for 2 hours. After the reaction was done as judged by TLC, the two layers were separated. The aqueous layer was washed with EtOAc, neutralized with sat. NaHCO3 aq. solution and then extracted with EtOAc (3×). The combined organic layers were dried with MgSO4 and concentrated to afford Cap-185, Step e. LC-MS: Anal. Calcd. for [M+H]+ C16H20NO3 274.14; found 274.12.
Cap-185, Step f




A solution of the crude Cap-185, Step e, DiPEA (1.24 mL, 7.1 mmol) and methyl chloroformate (0.55 mL, 7.1 mmol) in 5 mL of CH2Cl2 was stirred at room temperature for 1 hour. The mixture was then diluted with CH2Cl2 and washed with water. The organic layer was dried with Na2SO4 and concentrated. The crude product was purified by flash chromatography (silica gel, 0-40% EtOAc/Hex) to afford 700 mg of the racemic mixture. The mixture was then separated by chiral HPLC (CHIRALPAK® AD-H column, 30×250 mm, 5 um) eluting with 88% CO2-12% EtOH at 70 mL/min to afford 240 mg of Enantiomer-1 and 310 mg of Enantiomer-2 of Cap-1, Step f as white solids. Enantiomer-1: LC-MS: Anal. Calcd. for [M+H]+ C18H22NO5 332.15; found 332.3. 1H NMR (500 MHz, CDCl3) δ ppm 7.30-7.40 (5H, m), 6.03-6.16 (2H, m), 5.09-5.26 (3H, m), 4.65-4.74 (2H, m), 4.33 (1H, dd, J=9.16, 4.88 Hz), 3.67 (3H, s), 2.27-2.38 (1H, m), 1.61-1.69 (1H, m), 1.45-1.56 (1H, m), 1.34 (1H, dd, J=13.43, 5.19 Hz), 1.07 (1H, dd, J=13.12, 5.19 Hz). Enantiomer-2: LC-MS: Anal. Calcd. for [M+H]+ C18H22NO5 332.15; found 332.06.
Cap-185 (Enantiomer-1 and Enantiomer-2)
To a hydrogenation bottle containing a solution Cap-185, Step f (Enantiomer-2) (300 mg, 0.905 mmol) in 10 mL of MeOH was added Pd/C (15 mg, 0.141 mmol) under a cover of nitrogen. The mixture was hydrogenated on a Parr shaker at 40 psi for 3 hours. The mixture was then filtered and the filtrate was concentrated to afford Cap-185 (Enantiomer-2) (200 mg) as a white solid. LC-MS: Anal. Calcd. for [M+H]+ C11H18NO5 244.12; found 244.2. 1H NMR (500 MHz, CDCl3) δ ppm 5.33 (1H, br. s.), 4.46 (2H, d), 4.28 (1H, br. s.), 3.68 (3H, s), 2.35 (1H, br. s.), 1.91-2.03 (2H, m), 1.56-1.80 (4H, m), 1.36-1.55 (2H, m). [Note: Cap-185 (Enantiomer-1) can be obtained in a similar fashion.]
Cap-186




To a solution of the ester Cap-185, Step f (Enantiomer-2) (150 mg, 0.453 mmol) in 4 mL of MeOH was added NaOH (4 mL of 1 N in water, 4.00 mmol). The resulting mixture was stirred at room temperature for 3 hours. The methanol was then removed under vacuum, and the residue was neutralized with 1 N HCl solution and extracted with EtOAc (3×). The combined organic layers were dried with MgSO4 and concentrated to afford Cap-186 that was contaminated with some benzyl alcohol (sticky white solid; 115 mg). LC-MS: Anal. Calcd. for [M+H]+ C11H16NO5 242.10; found 242.1. 1H NMR (500 MHz, CDCl3) δ ppm 6.10-6.19 (2H, m), 5.36 (1H, d, J=8.85 Hz), 4.75-4.84 (2H, m), 4.28 (1H, dd, J=8.55, 4.58 Hz), 3.68 (3H, s), 2.33-2.45 (1H, m), 1.60-1.72 (2H, m), 1.30-1.48 (2H, m).
Cap-187




Cap-187, Step a




To a solution of Cap-178, Step e (2.2 g, 18.94 mmol), PPh3 (24.84 g, 95 mmol) and 4-nitrobenzoic acid (14.24 g, 85 mmol) in 30 mL of benzene was added DEAD (42.9 mL, 95 mmol) dropwise. The resulting light orange solution was stirred at room temperature overnight. The solvent was then removed under vacuum and the residue was purified by flash chromatography (silica gel, 0-15% EtOAc/Hex) to afford Cap-187, Step a (2.3 g) as a white solid. 1H NMR (500 MHz, CDCl3) δ ppm 8.27-8.34 (2H, m), 8.20-8.26 (2H, m), 5.45 (1H, t, J=2.90 Hz), 3.83-3.96 (3H, m), 1.90-2.03 (2H, m), 1.80-1.88 (1H, m), 1.61-1.70 (1H, m), 1.21 (3H, d, J=6.10 Hz).
Cap-187, Step b




To a solution of Cap-187, Step a (2.3 g, 8.67 mmol) in 10 mL of MeOH was added sodium methoxide (2.372 mL, 8.67 mmol) (25% in Methanol). The resulting mixture was stirred at room temperature for 3 hours. Water was added, and the mixture was extracted with EtOAc (5×). The combined organic layers were dried with MgSO4 and concentrated. The crude product was purified by flash chromatography (silica gel, 0-15% EtOAc/Hex, then 15-50% EtOAc/Hex) to afford Cap-187, Step b (0.85 g) as clear oil. 1H NMR (500 MHz, CDCl3) δ ppm 4.19-4.23 (1H, m), 3.82-3.91 (2H, m), 3.73-3.79 (1H, m), 1.79-1.88 (1H, m), 1.62-1.68 (1H, m), 1.46-1.58 (2H, m), 1.14 (3H, d, J=6.10 Hz).
Cap-187
The individual enantiomers of Cap-187 were synthesized from Cap-187, Step b according to the procedure described for Cap-178. LC-MS: Anal. Calcd. for [M+H]+ C10H18NO5 232.12; found 232.1. 1H NMR (400 MHz, CDCl3) δ ppm 5.26 (1H, d, J=7.78 Hz), 4.32-4.43 (1H, m), 4.07 (1H, dd, J=11.54, 3.51 Hz), 3.72 (3H, s), 3.39-3.50 (2H, m), 2.08-2.23 (1H, m), 1.54-1.68 (1H, m), 1.38-1.52 (1H, m), 1.11-1.32 (5H, m).
Cap-188 (Four Stereoisomers)




Cap-188, Step a




To a solution of 2,2-dimethyldihydro-2H-pyran-4(3H)-one (2 g, 15.60 mmol) in 50 mL of MeOH was slowly added sodium borohydride (0.649 g, 17.16 mmol). The resulting mixture was stirred at room temperature for 3 hours. To the mixture was then added 1 N HCl aqueous solution until it crosses into acidic pH range and then extracted with EtOAc (3×). The combined organic layers were dried with MgSO4 and concentrated to afford Cap-188, Step a (1.9 g) as clear oil. The product was used in the next step without purification. 1H NMR (400 MHz, CDCl3) δ ppm 3.91-4.02 (1H, m), 3.79-3.86 (1H, m), 3.63 (1H, td, J=12.05, 2.51 Hz), 1.82-1.93 (2H, m), 1.40-1.53 (1H, m), 1.29-1.38 (1H, m), 1.27 (3H, s), 1.20 (3H, s).
Cap-188.1 and Cap-188.2, Step b




p-Tosyl-Cl (5.56 g, 29.2 mmol) was added to a solution of Cap-188, Step a (1.9 g, 14.59 mmol) and pyridine (4.72 mL, 58.4 mmol) in 100 mL of CH2Cl2. The resulting mixture was stirred at room temperature for 3 days. To the reaction was added 10 mL of water, and the mixture was stirred at room temperature for an additional hour. The two layers were separated and the organic phase was washed with water and 1 N HCl aqueous solution. The organic phase was dried with MgSO4 and concentrated to afford the mixture of two enantiomers as a light yellow solid. The mixture was then separated by chiral HPLC (CHIRALPAK® AD column, 21×250 mm, 10 um) eluting with 92% 0.1% diethylamine/Heptane-8% EtOH at 15 mL/min to afford Cap-188.1, Step b (1.0 g) and Cap-188.2, Step b (1.0 g). The absolute stereochemistry of the two enantiomers was not assigned. Cap-188.1, Step b: LC-MS: Anal. Calcd. for [2M+Na]+ C28H40NaO8S2 591.21; found 591.3. 1H NMR (500 MHz, CDCl3) δ ppm 7.79 (2H, d, J=8.24 Hz), 7.34 (2H, d, J=8.24 Hz), 4.72-4.81 (1H, m), 3.78 (1H, dt, J=12.44, 4.16 Hz), 3.53-3.61 (1H, m), 2.45 (3H, s), 1.75-1.86 (2H, m), 1.61-1.71 (1H, m), 1.52-1.60 (1H, m), 1.22 (3H, s), 1.14 (3H, s). Cap-188.2, Step b: LC-MS: Anal. Calcd. for [2M+Na]+ C28H40NaO8S2 591.21; found 591.3.
Cap-188
The four stereoisomers of Cap-188 could be synthesized from Cap-188.1, Step b and Cap-188.2, Step b, according to the procedure described for the preparation of Cap-178. Cap-188 (Steroisomer-1): LC-MS: Anal. Calcd. for [M+Na]+ C11H19NNaO5 268.12; found 268.23. 1H NMR (500 MHz, CDCl3) δ ppm 5.32 (1H, d, J=8.55 Hz), 4.26-4.35 (1H, m), 3.57-3.82 (5H, m), 2.11-2.34 (1H, m), 1.25-1.58 (4H, m), 1.21 (6H, d, J=6.10 Hz). Cap-188 (Stereoisomer-2): LC-MS: Anal. Calcd. for [M+H]+ C11H20NO5 246.13; found 246.1. 1H NMR (500 MHz, CDCl3) δ ppm 5.25 (1H, d, J=8.55 Hz), 4.33 (1H, dd, J=8.39, 5.04 Hz), 3.80 (1H, dd, J=11.90, 3.97 Hz), 3.62-3.76 (4H, m), 2.20-2.32 (1H, m), 1.52-1.63 (1H, m), 1.27-1.49 (3H, m), 1.22 (6H, d, J=14.04 Hz).
Cap-189




Cap-189, Step a




To a solution of phenylmagnesium bromide (113 mL, 340 mmol) (3 M in ether) in 100 mL of ether was added dropwise exo-2,3-epoxynorbornane (25 g, 227 mmol) in 50 mL of ether. After the initial exotherm, the mixture was heated to reflux overnight. The reaction was then cooled to room temperature and quenched carefully with water ( ̃10 mL). The mixture was diluted with ether and washed with a 3 N HCl aqueous solution ( ̃160 mL). The aqueous layer was extracted with ether (2×) and the combined organic layers were dried with MgSO4 and concentrated. The crude product was purified by flash chromatography (silica gel, 0-18% EtOAc/Hex) to afford Cap-189, Step a (11 g). 1H NMR (400 MHz, CDCl3) δ ppm 6.03-6.11 (2H, m), 3.76 (1H, d, J=11.29 Hz), 2.72-2.81 (2H, m), 1.98 (1H, d, J=11.29 Hz), 1.67-1.76 (2H, m), 0.90-0.97 (2H, m).
Cap-189, Step b




To a solution of oxalyl chloride (59.9 mL, 120 mmol) in 200 mL of CH2Cl2 at −78° C. was added DMSO (17.01 mL, 240 mmol) in 100 mL of CH2Cl2. The mixture was stirred for 10 min, and Cap-189, Step a (11 g, 100 mmol) in 150 mL of CH2Cl2 was added followed by Et3N (72.4 mL, 519 mmol) in 30 mL of CH2Cl2. The mixture was stirred at −78° C. for 30 min and then warmed to room temperature. Water (150 mL) was added and the mixture was stirred at room temperature for 30 mins. The two layers were then separated, and the aqueous layer was extracted with CH2Cl2 (2×). The organic layers were combined, dried with MgSO4 and concentrated. The crude product was purified by flash chromatography (silica gel, 0-5% EtOAc/Hex) to afford Cap-189, Step b (5.3 g) as a light yellow oil. 1H NMR (500 MHz, CDCl3) δ ppm 6.50-6.55 (2H, m), 2.78-2.84 (2H, m), 1.92-1.99 (2H, m), 1.17-1.23 (2H, m).
Cap-189, Step c




A mixture of Cap-189, Step b (5.3 g, 49.0 mmol), p-toluenesulfonic acid monohydrate (1.492 g, 7.84 mmol) and ethylene glycol (4.10 mL, 73.5 mmol) in 100 mL of benzene was refluxed for 4 hours and then stirred at room temperature overnight. The reaction was partitioned between Et2O and aqueous sat. NaHCO3 solution and the two layers were separated. The organic layer was washed with brine, dried with MgSO4 and concentrated. The crude product was purified by flash chromatography (silica gel, 0-6% EtOAc/Hex) to afford Cap-189, Step c (5.2 g) as a clear oil. 1H NMR (400 MHz, CDCl3) δ ppm 6.20 (2H, t, J=2.13 Hz), 3.90-3.97 (2H, m), 3.81-3.89 (2H, m), 2.54 (2H, m), 1.89-1.99 (2H, m), 0.95-1.03 (2H, m).
Cap-189, Step d




A solution of Cap-189, Step c (5.2 g, 34.2 mmol) in 60 mL of MeOH and 50 mL of CH2Cl2 was cooled to −78° C. and treated with ozone gas until a light blue color was apparent. The reaction was then bubbled with N2 to remove the excess ozone gas (blue color disappeared) and sodium borohydride (1.939 g, 51.3 mmol) was added into the reaction. The reaction was then warmed to 0° C. Acetone was added into the mixture to quench the excess sodium borohydride. The mixture was concentrated and the residue was purified by flash chromatography (silica gel, 100% EtOAc) to afford Cap-189, Step d (5.0 g) as a clear oil. 1H NMR (400 MHz, CDCl3) δ ppm 3.99-4.09 (4H, m), 3.68 (4H, m), 2.17-2.29 (2H, m), 1.92-2.10 (2H, m), 1.77-1.88 (2H, m), 1.57-1.70 (2H, m).
Cap-189, Step e




To a solution of Cap-189, Step d (1 g, 5.31 mmol) in 20 mL of CH2Cl2 was added silver oxide (3.8 g), p-Ts-Cl (1.215 g, 6.38 mmol) and KI (0.176 g, 1.063 mmol). The resulting solution was stirred at room temperature for 3 days. The mixture was then filtered and the filtrate was concentrated. The crude product was purified by flash chromatography (silica gel, 60% EtOAc/Hex) to afford Cap-189, Step e (0.79 g) as clear oil. LC-MS: Anal. Calcd. for [M+Na]+ C16H22NaO6S 365.10; found 365.22. 1H NMR (400 MHz, CDCl3) δ ppm 7.80 (2H, d, J=8.28 Hz), 7.36 (2H, d, J=8.03 Hz), 4.11-4.17 (1H, m), 3.85-4.06 (5H, m), 3.64-3.71 (1H, m), 3.55-3.63 (1H, m), 2.47 (3H, s), 2.32-2.43 (1H, m), 2.15-2.27 (1H, m), 1.70-1.89 (2H, m), 1.52-1.66 (1H, m), 1.35-1.47 (1H, m).
Cap-189, Step f




To a solution of Cap-189, Step e (2.2 g, 6.43 mmol) in 40 mL of MeOH was added potassium carbonate (1.776 g, 12.85 mmol). The resulting mixture was stirred at room temperature overnight. The mixture was then diluted with water and EtOAc. The two layers were separated. The aqueous layer was extracted with EtOAc (2×). The combined organic layers were washed with brine, dried with MgSO4 and concentrated. The crude product was purified by flash chromatography (silica gel, 0-15% EtOAc/Hex) to afford Cap-189, Step f (0.89 g, 5.23 mmol, 81%) as clear oil. 1H NMR (400 MHz, CDCl3) δ ppm 3.89-4.02 (6H, m), 3.58 (2H, dd, J=10.79, 2.51 Hz), 1.69-1.89 (6H, m).
Cap-189, Step g




To the solution of Cap-189, Step f (890 mg, 5.23 mmol) in 15 mL of THF was added HCl (15 mL, 45.0 mmol) (3 M aqueous). The resulting mixture was stirred at room temperature overnight. The mixture was then diluted with ether and the two layers were separated. The aqueous phase was extracted with ether (2×) and the combined organic layers were dried with MgSO4 and concentrated to afford Cap-189, Step g (0.95 g, containing some residual solvents). The product was used in the next step without purification. 1H NMR (500 MHz, CDCl3) δ ppm 3.95-4.00 (2H, m), 3.85 (2H, d, J=10.68 Hz), 2.21-2.28 (2H, m), 1.99-2.04 (2H, m), 1.90-1.96 (2H, m).
Cap-189, Step h (Enantiomer-1 and Enantiomer-2)




To a solution of (+/−)-benzyloxycarbonyl-α-phosphonoglycine trimethyl ester (1733 mg, 5.23 mmol) in 6 mL of THF at −20° C. was added 1,1,3,3-tetramethylguanidine (0.723 mL, 5.75 mmol). The resultant light yellow mixture was stirred at −20° C. for 1 hour, and Cap-189, Step g (660 mg, 5.23 mmol) in 3 mL of THF was added and mixture was then stirred at room temperature for 3 days. The reaction mixture was then diluted with EtOAc, washed with a 0.1 N HCl aq. solution. The aqueous layer was extracted with EtOAc (2×) and the combined organic layers were dried with MgSO4 and concentrated. The crude product was purified by flash chromatography (silica gel, 0-4% EtOAc/CH2Cl2) to afford 960 mg of the racemic mixture. The mixture was separated by chiral HPLC (CHIRALPAK® AD column, 21×250 mm, 10 um) eluting with 90% 0.1% diethylamine/Heptane-10% EtOH at 15 mL/min to afford Cap-189, Step h (Enantiomer-1; 300 mg) and Cap-189, Step h (Enantiomer-2; 310 mg) as white solids. Cap-189, Step h (Enantiomer-1): LC-MS: Anal. Calcd. for [M+H]+ C18H22NO5 332.15; found 332.2. 1H NMR (500 MHz, CDCl3) δ ppm 7.29-7.41 (5H, m), 6.00 (1H, br. s.), 5.13 (2H, s), 3.63-3.87 (8H, m), 2.84 (1H, br. s.), 1.84-2.02 (2H, m), 1.63-1.84 (2H, m). Cap-189, Step h (Enantiomer-2): LC-MS: Anal. Calcd. for [M+H]+ C18H22NO5 332.15; found 332.2.
Cap-189, Step i




N2 was bubbled through a solution of Cap-189, Step h (Enantiomer-2; 290 mg, 0.875 mmol) in 10 mL of MeOH in a 500 mL hydrogenation bottle for 30 mins To the solution was added (S,S)-Me-BPE-Rh(9.74 mg, 0.018 mmol), and the mixture was then hydrogenated at 60 psi for 6 days. The mixture was concentrated, and chiral analytical HPLC (CHIRALPAK® OJ column) indicated that there were a small amount of remaining starting material and one major product. The residue was then separated by chiral HPLC (CHIRALPAK® OJ column, 21×250 mm, 10 um) eluting with 70% 0.1% diethylamine/Heptane-30% EtOH at 15 mL/min to afford Cap-189, Step i, (150 mg) as clear oil. LC-MS: Anal. Calcd. for [M+H]+ C18H24NO5 334.17; found 334.39. 1H NMR (500 MHz, CDCl3) δ ppm 7.28-7.41 (5H, m), 5.12-5.18 (1H, m), 5.09 (2H, s), 4.05 (1H, t, J=10.07 Hz), 3.75 (3H, s), 3.60-3.72 (2 H, m), 3.41-3.50 (2H, m), 2.10 (1H, br. s.), 1.72-1.99 (6H, m).
Cap-189, Step j




To a solution of Cap-189, Step i (150 mg, 0.450 mmol) in 10 mL of MeOH in a hydrogenation bottle were added dimethyl dicarbonate (0.072 mL, 0.675 mmol) and 10% Pd/C (23.94 mg, 0.022 mmol) under a cover of nitrogen cover. The mixture was then hydrogenated on Parr-shaker at 45 psi overnight. The mixture was filtered and the filtrate was concentrated to afford Cap-189, Step j (110 mg) as a clear oil. LC-MS: Anal. Calcd. for [M+H]+ C12H20NO5 258.13; found 258.19. 1H NMR (500 MHz, CDCl3) δ ppm 5.08 (1H, d, J=9.16 Hz), 4.03 (1H, t, J=10.07 Hz), 3.75 (3H, s), 3.60-3.72 (5H, m), 3.46 (2H, t, J=10.38 Hz), 2.11 (1H, br. s.), 1.72-1.99 (6H, m).
Cap-189
To a mixture of Cap-189, Step j (110 mg, 0.428 mmol) in 2 mL of THF and 1 mL of water was added LiOH (0.641 mL, 1.283 mmol) (2 N aq.). The resulting mixture was stirred at room temperature overnight. The mixture was neutralized with a 1 N HCl aq. solution and extracted with EtOAc (3×). The combined organic layers were dried with MgSO4 and concentrated to afford Cap-189 (100 mg) as a white solid. LC-MS: Anal. Calcd. for [M+Na]+ C11H17NNaO5 266.10; found 266.21. 1H NMR (500 MHz, CDCl3) δ ppm 5.10 (1H, d, J=9.16 Hz), 4.02 (1H, t, J=10.07 Hz), 3.62-3.78 (5H, m), 3.49 (2H, d, J=10.68 Hz), 2.07-2.22 (2H, m), 1.72-1.98 (6H, m).
Cap-190 (Diastereomeric Mixture)




Cap-190, Step a




To a mixture of cyclopent-3-enol (2.93 g, 34.8 mmol) and imidazole (5.22 g, 77 mmol) in 30 mL of DMF at 0° C. was added t-butyldimethylchlorosilane (6.30 g, 41.8 mmol). The resulting colorless mixture was stirred at room temperature overnight. Hexanes and water were then added to the mixture and the two layers were separated. The aqueous layer was extracted with EtOAc (2×) and the combined organic layers were washed with brine, dried with MgSO4 and concentrated. The crude product was purified by flash chromatography (silica gel, 2% EtOAc/Hex) to afford Cap-190, Step a (6.3 g) as a clear oil. 1H NMR (500 MHz, CDCl3) δ ppm 5.65 (2H, s), 4.49-4.56 (1H, m), 2.56 (2H, dd, J=15.26, 7.02 Hz), 2.27 (2H, dd, J=15.26, 3.36 Hz), 0.88 (9H, s), 0.06 (6H, s).
Cap-190, Step b




To a solution of Cap-190, Step a (2.3 g, 11.59 mmol) in 40 mL of CH2Cl2 at 0° C. was added m-CPBA (5.60 g, 16.23 mmol) in 5 portions. The reaction mixture was stirred at room temperature overnight. Hexanes and water were then added to the mixture and the two layers were separated. The organic layer was washed with 50 mL aq. 10% NaHSO3 and brine, dried with MgSO4 and concentrated. The crude product was purified by flash chromatography (silica gel, 3%-6% EtOAc/Hex) to afford Cap-190, Step b (1.42 g) and its trans diastereomer (0.53 g) as clear oils. Cap-190, Step b (cis): 1H NMR (400 MHz, CDCl3) δ ppm 4.39-4.47 (1H, m), 3.47 (2H, s), 2.01-2.10 (2H, m), 1.93-2.00 (2H, m), 0.88 (9H, s), 0.04 (6H, s). Cap-190, Step b (trans): 1H NMR (400 MHz, CDCl3) δ ppm 4.04-4.14 (1H, m), 3.47 (2H, s), 2.41 (2H, dd, J=14.05, 7.28 Hz), 1.61 (2H, dd, J=14.18, 6.90 Hz), 0.87 (9H, s), 0.03 (6H, s).
Cap-190, Step c




To a solution of (S)-1,2′-methylenedipyrrolidine (0.831 g, 5.39 mmol) in 15 mL of benzene at 0° C. was added dropwise n-butyllithium (4.90 mL, 4.90 mmol) (1 M in hexane). The solution turned bright yellow. The mixture was stirred at 0° C. for 30 min. Cap-190, Step b (cis-isomer; 0.7 g, 3.27 mmol) in 10 mL of benzene was then added and the resulting mixture was stirred at 0° C. for 3 hours. EtOAc and sat. NH4Cl aq. solution were added into the mixture, and the two layers were separated. The organic layer was washed with water and brine, dried with MgSO4 and concentrated. The crude product was purified by flash chromatography (silica gel, 15% EtOAc/Hex) to afford Cap-190, Step c (400 mg) as a light yellow oil. 1H NMR (500 MHz, CDCl3) δ ppm 5.84-5.98 (2H, m), 4.53-4.69 (2H, m), 2.63-2.73 (1H, m), 1.51 (1H, dt, J=13.73, 4.43 Hz), 0.89 (9H, s), 0.08 (6H, s).
Cap-190, Step d




To a solution of Cap-190, Step c (400 mg, 1.866 mmol), MeI (1.866 mL, 3.73 mmol) (2 M in t-butyl methyl ether) in 5 mL of THF at 0° C. was added NaH (112 mg, 2.80 mmol) (60% in mineral oil). The resulting mixture was allowed to warm up to room temperature and stirred at room temperature overnight. The reaction was then quenched with water and extracted with EtOAc (3×). The combined organic layers were washed with brine, dried with MgSO4 and concentrated. The crude product was purified by flash chromatography (silica gel, 5% EtOAc/Hex) to afford Cap-190, Step d (370 mg) as light yellow oil. 1H NMR (500 MHz, CDCl3) δ ppm 5.92-5.96 (1H, m), 5.87-5.91 (1H, m), 4.64-4.69 (1H, m), 4.23-4.28 (1H, m), 3.32 (3H, s), 2.62-2.69 (1H, m), 1.54 (1H, dt, J=13.12, 5.49 Hz), 0.89 (9H, s), 0.07 (5H, d, J=1.83 Hz).
Cap-190, Step e




To a solution of Cap-190, Step d (400 mg, 1.751 mmol) in 10 mL of EtOAc in a hydrogenation bottle was added platinum(IV) oxide (50 mg, 0.220 mmol). The resulting mixture was hydrogenated at 50 psi on Parr shaker for 2 hours. The mixture was then filtered through CELITE®, and the filtrate was concentrated to afford Cap-190, Step e (400 mg) as a clear oil. LC-MS: Anal. Calcd. for [M+H]+ C12H27O2Si 231.18; found 231.3. 1H NMR (500 MHz, CDCl3) δ ppm 4.10-4.17 (1H, m), 3.65-3.74 (1H, m), 3.27 (3H, s), 1.43-1.80 (6H, m), 0.90 (9H, s), 0.09 (6H, s).
Cap-190, Step f




To a solution of Cap-190, Step e (400 mg, 1.736 mmol) in 5 mL of THF was added TBAF (3.65 mL, 3.65 mmol) (1 N in THF). The color of the mixture turned brown after several min., and it was stirred at room temperature overnight. The volatile component was removed under vacuum, and the residue was purified by flash chromatography (silica gel, 0-25% EtOAc/Hex) to afford Cap-190, Step f (105 mg) as light yellow oil. 1H NMR (500 MHz, CDCl3) δ ppm 4.25 (1H, br. s.), 3.84-3.92 (1H, m), 3.29 (3H, s), 1.67-2.02 (6H, m).
Cap-190
Cap-190 was then synthesized from Cap-190, Step f according to the procedure described for Cap-182. LC-MS: Anal. Calcd. for [M+Na]+ C10H17NNaO5 254.10; found 254.3. 1H NMR (500 MHz, CDCl3) δ ppm 5.25 (1H, d, J=8.55 Hz), 4.27-4.41 (1H, m), 3.81-3.90 (1H, m), 3.69 (3H, s), 3.26 (3H, s), 2.46-2.58 (1H, m), 1.76-1.99 (3H, m), 1.64-1.73 (1H, m), 1.40-1.58 (1H, m), 1.22-1.38 (1H, m).
Cap-191 (Enantiomer-1)




Cap-191, Step a




To a solution of diisopropylamine (3 ml, 21.05 mmol) in THF (3 ml) at −78° C. under nitrogen was added n-butyl lithium (2.5 M in hexanes; 8.5 ml, 21.25 mmol). The reaction was stirred at −78° C. for 10 min then brought up to 0° C. for 25 min. The reaction was cooled down again to −78° C., methyl tetrahydro-2H-pyran-4-carboxylate (3 g, 20.81 mmol) in THF (3 ml) was added. The reaction was stirred at −78° C. for 15 min then brought up to 0° C. for 30 min. The reaction was cooled down to −78° C., methyl iodide (1.301 ml, 20.81 mmol) was added. After the addition, the cold bath was removed and the reaction was allowed to slowly warm up to  ̃25° C. and stirred for 22 h. Ethyl acetate and aqueous HCl (0.1N) were added, and the organic layer was separated and washed with brine and dried (MgSO4), filtered, and concentrated in vacuo. The residue was loaded on a Thomson's silica gel cartridge eluting with 10% ethyl acetate/hexanes to afford a light yellow oil (2.83 g). 1H NMR (400 MHz, DMSO-d6) δ ppm 3.73-3.66 (m, 2H), 3.66 (s, 3H), 3.40-3.30 (m, 2H), 1.95-1.93 (dm, 1H), 1.92-1.90 (dm, 1H), 1.43 (ddd, J=13.74, 9.72, 3.89, 2H), 1.18 (s, 3H).
Cap-191, Step b




To a solution of Cap-191, Step a (3 g, 18.96 mmol) in toluene (190 ml) at −78° C. under nitrogen was added diisobutylaluminum hydride (1.5M in toluene; 26.5 ml, 39.8 mmol) dropwise. The reaction was continued to stir at −78° C. for 1.5 h., and the bath was removed and was stirred for 18 h. The reaction was quenched with MeOH (20 mL). HCl (1M, 150 mL) was added and the mixture was extracted with EtOAc (4×40 mL). The combined organic phases were washed with brine, dried (MgSO4), filtered, and concentrated in vacuo. The residue was purified with flash chromatography (silica gel; 40% ethyl acetate/hexanes) to afford a colorless oil (1.36 g). 1H NMR (400 MHz, CDCl3) δ ppm 3.77 (dt, J=11.73, 4.55, 2H), 3.69-3.60 (m, 2H), 3.42 (s, 2H), 1.71-1.40 (bs, 1H) 1.59 (ddd, J=13.74, 9.72, 4.39, 2H), 1.35-1.31 (m, 1H), 1.31-1.27 (m, 1H), 1.06 (s, 3H).
Cap-191, Step c




To a solution of DMSO (5.9 ml, 83 mmol) in CH2Cl2 (85 ml) at −78° C. under nitrogen was added oxalyl chloride (3.8 ml, 43.4 mmol) and stirred for 40 min. A solution of Cap-191, Step b (4.25 g, 32.6 mmol) in CH2Cl2 (42.5 ml) was then added. The reaction was continued to be stirred at −78° C. under nitrogen for 2 h. The reaction was quenched with cold 20% K2HPO4 (aq) (10 mL) and water. The mixture was stirred at  ̃25° C. for 15 min, diluted with diethyl ether (50 mL) and the layers were separated. The aqueous layer was extracted with diethyl ether (2×50 mL). The combined organic layers were washed with brine, dried (MgSO4), filtered, and concentrated in vacuo. The residue was taken up in CH2Cl2 (4 mL) and purified with flash chromatography (silica gel, eluting with CH2Cl2) to afford a colorless oil (2.1 g). 1H NMR (400 MHz, CDCl3) δ ppm 9.49 (s. 1H), 3.80 (dt, J=11.98, 4.67, 2H), 3.53 (ddd, J=12.05, 9.41, 2.89, 2H), 1.98 (ddd, J=4.71, 3.20, 1.38, 1H), 1.94 (ddd, J=4.71, 3.20, 1.38, 1H), 1.53 (ddd, J=13.87, 9.60, 4.14, 2H), 1.12 (s, 3H).
Cap-191, Step d




To a solution of Cap-191c (2.5 g, 19.51 mmol) in CHCl3 (20 ml) under nitrogen at  ̃25° C. was added (R)-2-amino-2-phenylethanol (2.94 g, 21.46 mmol) and stirred for 5 h. The reaction was cooled to 0° C., trimethylsilyl cyanide (3.8 ml, 30.4 mmol) was added dropwise. The cold bath was removed and the reaction was allowed to stir at  ̃25° C. under nitrogen for 15.5 h. The reaction was treated with 3N HCl (20 mL) and water (20 mL), and the product was extracted with CHCl3 (3×50 mL). The combined organic layers were dried (NaSO4), filtered, and concentrated in vacuo. The residue was purified with flash chromatography (silica gel; 40% ethyl acetate/hexanes) to afford two diastereomers: Cap-191, Step d1 (diastereomer 1) as a colorless oil which solidified into a white solid upon standing (3 g). 1H NMR (400 MHz, DMSO-d6) δ ppm 7.42-7.26 (m, 5H), 5.21 (t, J=5.77, 1H), 3.87 (dd, J=8.53, 4.52, 1H), 3.61-3.53 (m, 1H), 3.53-3.37 (m, 5H), 3.10 (d, J=13.05, 1H), 2.65 (d, J=13.05, 1H), 1.64-1.55 (m, 1H), 1.55-1.46 (m, 1H), 1.46-1.39 (m, 1H), 1.31-1.23 (m, 1H), 1.11 (s, 3H). LC-MS: Anal. Calcd. for [M+H]+ C16H23N2O2: 275.18; found 275.20. Cap-191, Step d2 (diastereomer 2) as a light yellow oil (0.5 g). 1H NMR (400 MHz, DMSO-d6) δ ppm 7.44-7.21 (m, 5H), 4.82 (t, J=5.40, 1H), 3.82-3.73 (m, 1H), 3.73-3.61 (m, 3H), 3.61-3.37 (m, 5H), 2.71 (dd, J=9.29, 4.77, 1H), 1.72-1.55 (m, 2H), 1.48-1.37 (m, 1H), 1.35-1.25 (m, 1H), 1.10 (s, 3H). LC-MS: Anal. Calcd. for [M+H]+ C16H23N2O2: 275.18; found 275.20.
Cap-191, Step e




To a solution of Cap-191, Step d2 (diastereomer 2) (0.4472 g, 1.630 mmol) in CH2Cl2 (11 ml) and MeOH (5.50 ml) at 0° C. under nitrogen was added lead tetraacetate (1.445 g, 3.26 mmol). The reaction was stirred for 1.5 h, the cold bath was removed and stirring was continued for 20 h. The reaction was treated with a phosphate buffer (pH=7; 6 mL) and stirred for 45 min. The reaction was filtered over CELITE®, washed with CH2Cl2 and the layers were separated. The aqueous layer was extracted with CH2Cl2 (3×25 mL), and the combined organic layers was washed with brine, dried (MgSO4), filtered and concentrated in vacuo. The residue was purified with flash chromatography (silica gel; 15% ethyl acetate/hexanes) to afford the imine intermediate as a colorless oil (181.2 mg). 1H NMR (400 MHz, DMSO-d6) δ ppm 8.55 (d, J=1.00, 1H), 7.89-7.81 (m, 2H), 7.61-7.46 (m, 3H), 4.80 (d, J=1.00, 1H), 3.74 (tt, J=11.80, 4.02, 2H), 3.62-3.46 (m, 2H), 1.79-1.62 (m, 2H), 1.46-1.30 (m, 2H), 1.15 (s, 3H).
The imine intermediate was taken up in 6N HCl (10 mL) and heated at 90° C. for 10 days. The reaction was removed from the heat, allowed to cool to room temperature and extracted with ethyl acetate (3×25 mL). The aqueous layer was concentrated in vacuo to afford an off-white solid. The solid was taken up in MeOH and loaded on a pre-conditioned MCX (6 g) cartridge, washed with MeOH followed by elution with 2N NH3/MeOH solution and concentrated in vacuo to afford an off-white solid (79.8 mg). 1H NMR (400 MHz, DMSO-d6) δ ppm 14.33-13.51 (bs, 1H), 8.30 (bs, 3H), 3.82-3.75 (m, 1H), 3.70 (dt, J=11.80, 4.02, 2H), 3.58-3.43 (m, 2H), 1.76-1.60 (m, 2H), 1.47-1.36 (m, 1H), 1.36-1.27 (m, 1H), 1.08 (s, 3H). LC-MS: Anal. Calcd. for [M+H]+ C8H16NO3: 174.11; found 174.19.
Cap-191 (Enantiomer-1)
To a solution of Cap-191, Step e (0.0669 g, 0.386 mmol) and sodium carbonate (0.020 g, 0.193 mmol) in sodium hydroxide (1M aq.; 0.4 ml, 0.40 mmol) at 0° C. was added methyl chloroformate (0.035 ml, 0.453 mmol) dropwise. The reaction was removed from the cold bath and allowed to stir at  ̃25° C. for 3 h. The reaction was washed with diethyl ether (3×20 mL). The aqueous layer was acidified with 12 N HCl (pH  ̃1-2), and extracted with ethyl acetate (2×20 mL). The combined organic layers were dried (MgSO4), filtered, and concentrated in vacuo to afford Cap-191 as a colorless film (66.8 mg). 1H NMR (400 MHz, DMSO-d6) δ ppm 13.10-12.37 (bs, 1H), 7.37 (d, J=9.04, 1H), 4.02 (d, J=9.29, 1H), 3.72-3.57 (m, 2H), 3.56 (s, 3H), 3.54-3.44 (m, 2H), 1.65 (ddd, J=13.61, 9.72, 4.27, 1H), 1.53 (ddd, J=13.68, 9.66, 4.27, 1H), 1.41-1.31 (m, 1H), 1.31-1.22 (m, 1H), 1.00 (s, 3H). LC-MS: Anal. Calcd. for [M+Na]+ C10H17NO5Na: 254.10; found 254.11.
Cap-192 (Enantiomer-2)




Cap-192 (Enantiomer-2) was prepared from Cap-191, Step d1 according to the procedure described for the preparation of its enantiomer Cap-191.
Cap-193




Cap-193, Step a




To a solution of methyl 2-(benzyloxycarbonylamino)-2-(dimethoxyphosphoryl)acetate (1.45 g, 4.2 mmol) in DCM was added DBU (0.70 ml, 4.7 mmol). The reaction mixture was stirred for 10 min, followed by addition of a solution of 1,3-dimethoxypropan-2-one (0.5 g, 4.2 mmol) in DCM. The reaction mixture was stirred at room temperature for 18 hrs. The reaction mixture was charged to an 80 g silica gel cartridge which was eluted with an 18 min gradient of 0-70% EtOAc in hexane to afford Cap-193, Step a (0.8 g) as a thick oil. 1H NMR (400 MHz, MeOD) ppm 7.23-7.43 (5H, m), 4.99-5.18 (2H, m), 4.16 (2H, s), 4.06 (2 H, s), 3.66-3.78 (3H, s), 3.26 (3H, s), 3.23 (3H, s). LC-MS: Anal. Calcd. For [M+Na]+ C16H21NNaO6: 346.14; found: 346.12.
Cap-193, Step b




A reaction mixture of ester Cap-193, Step a (0.5 g) and (+)-1,2-bis((2S,5S)-2,5-diethylphospholano)benzene(cyclooctadiene)rhodium (I) tetrafluoroborate (0.1 g) in MeOH was stirred under 55 psi of H2 for 18 hrs. The reaction mixture was concentrated to dryness. The residue was charged to a 25 g silica gel cartridge and eluted with an 18 min gradient of 0-80% EtOAc in hexane to afford Cap-193, Step b (0.49 g) as a clear oil. LC-MS: Anal. Calcd. For [M+Na]+ C16H23NNaO6: 348.15; found: 348.19.
Cap-193, Step c




A reaction mixture of Cap-193, Step b (0.16 g), dimethyl dicarbonate (0.13 g) and 10% Pd/C (0.026 g) in EtOAc was stirred under H2 at room temperature for 2 hrs. The reaction mixture was filtered and concentrated to yield the methyl carbamate Cap-193, Step c. LC-MS: Anal. Calcd. For [M+Na]+ C10H19NNaO6: 272.12; found: 272.07.
Cap-193
To a solution of ester Cap-193, Step c in THF (1 mL) and MeOH (0.25 mL) was added 1 N NaOH (1 mL). The reaction mixture was stirred at room temperature for 2 hrs. The reaction mixture was concentrated and diluted with EtOAc and 1 N HCl. The aqueous phase was extracted with EtOAc, and the combined organic phase was washed with sat. NaCl, dried over anhydrous Na2SO4, filtered and concentrated to yield Cap-193 (0.082 g). 1H NMR (400 MHz, CDCl3) 5.99 (1H, d, J=8.56 Hz), 4.57 (1H, dd, J=8.56, 3.27 Hz), 3.67 (3H, s), 3.49 (2H, d, J=4.28 Hz), 3.45-3.44 (2H, m), 3.26-3.35 (6H, m). LC-MS: Anal. Calcd. For [M+Na]+ C9H17NNaO6: 258.11; found: 258.13.
Cap-194




Piperidine (1.0 mL, 10 mmol) was added to a solution of (S)-2-(9H-fluoren-9-yl)methoxy)carbonylamino)-4-methoxybutanoic acid (0.355 g, 1 mmol) in DMF (3 mL), and the mixture was stirred at rt for 3 h. The volatiles were removed and the residue was partitioned between sat. NaHCO3 (aq.) (5 mL) and EtOAc (5 mL). The aqueous layer was further washed with EtOAc and Et2O. To the aqueous solution was added Na2CO3 (212 mg, 2.0 mmol) followed by methyl chloroformate (0.16 mL, 2.0 mmol) and the reaction mixture was stirred at rt for 16 h. The reaction mixture was acidified with 1 N HCl (aq.) until pH<7 and then extracted with EtOAc (2×10 mL). The combined organic layers were dried (Na2SO4), filtered and concentrated. The residue was purified by flash silica chromatography (EtOAc/hexanes, gradient from 20% to 70%) to yield (S)-4-methoxy-2-(methoxycarbonylamino)butanoic acid (Cap-194) (91.5 mg) as viscous colorless oil. LC-MS retention time=0.61 min; m/z 214 [M+Na]+. (Column: PHENOMENEX® Luna 3.0×50 mm S10. Solvent A=90% Water: 10% Methanol: 0.1% TFA. Solvent B=10% Water: 90% Methanol: 0.1% TFA. Flow Rate=4 mL/min. Start % B=0. Final % B=100. Gradient Time=3 min. Wavelength=220). 1H NMR (400 MHz, chloroform-d) δ ppm 7.41 (br. s., 1H), 5.74-6.02 (m, 1H), 4.32-4.56 (m, 1H), 3.70 (s, 3H), 3.54 (t, J=5.0 Hz, 2H), 3.34 (s, 3H), 1.99-2.23 (m, 2H).
EXAMPLES
Purity assessment and low resolution mass analysis were conducted on a Shimadzu LC system coupled with Waters Micromass ZQ MS system. It should be noted that retention times may vary slightly between machines. Unless noted otherwise, the LC conditions employed in determining the retention time (Rt) were:
Condition OL1
Column=XTERRA C18 S7 (4.6×30 mm)
Start % B=0
Final % B=100
Gradient time=3 min
Stop time=4 min
Flow Rate=4 mL/min
Wavelength=220 nm
Solvent A=0.1% TFA in 10% methanol/90% water
Solvent B=0.1% TFA in 90% methanol/10% water
Condition OL2
Column=XTERRA C18 S7 (4.6×50 mm)
Start % B=0
Final % B=100
Gradient time=3 min
Stop time=4 min
Flow Rate=4 mL/min
Wavelength=220 nm
Solvent A=0.1% TFA in 10% methanol/90% water
Solvent B=0.1% TFA in 90% methanol/10% water
Condition OL3
Column=XTERRA C18 S7 (3.0×50 mm)
Start % B=0
Final % B=100
Gradient time=3 min
Stop time=4 min
Flow Rate=4 mL/min
Wavelength=220 nm
Solvent A=0.1% TFA in 10% methanol/90% water
Solvent B=0.1% TFA in 90% methanol/10% water
Cond.-OL4
Column=XTERRA 5 u (4.6×50 mm)
Start % B=0
Final % B=100
Gradient time=2 min
Stop time=3 min
Flow Rate=4 mL/min
Wavelength=220 nm
Solvent A=0.2% H3PO4 in 10% methanol/90% H2O
Solvent B=0.2% H3PO4 in 90% methanol/10% H2O
Cond.-MS-W1
Column=XTERRA C18 S7 (3.0×50 mm)
Start % B=0
Final % B=100
Gradient time=2 min
Stop time=3 min
Flow Rate=5 mL/min
Wavelength=220 nm
Solvent A=0.1% TFA in 10% methanol/90% H2O
Solvent B=0.1% TFA in 90% methanol/10% H2O
Cond.-MS-W6
Column=YMC-Pack Pro C-18 S3 (6.0×150 mm)
Start % B=50
Final % B=100
Gradient time=15 min
Stop time=16 min
Flow Rate=15 mL/min
Wavelength=220 nm
Solvent A=0.1% TFA in 10% methanol/90% H2O
Solvent B=0.1% TFA in 90% methanol/10% H2O
Cond.-D1
Column=XTERRA C18 S7 (3.0×50 mm)
Start % B=0
Final % B=100
Gradient time=3 min
Stop time=4 min
Flow Rate=4 mL/min
Wavelength=220 nm
Solvent A=0.1% TFA in 10% methanol/90% H2O
Solvent B=0.1% TFA in 90% methanol/10% H2O
Cond.-D2
Column=Phenomenex-Luna C18 S10 (4.6×50 mm)
Start % B=0
Final % B=100
Gradient time=3 min
Stop time=4 min
Flow Rate=4 mL/min
Wavelength=220 nm
Solvent A=0.1% TFA in 10% methanol/90% H2O
Solvent B=0.1% TFA in 90% methanol/10% H2O
Cond.-D3
Column=Phenomenex Luna C18 S7 (3.0×50 mm)
Start % B=0
Final % B=100
Gradient time=3 min
Stop time=4 min
Flow Rate=4 mL/min
Wavelength=220 nm
Solvent A=0.1% TFA in 10% methanol/90% H2O
Solvent B=0.1% TFA in 90% methanol/10% H2O
Cond.-M3
Column=XTERRA C18 3.0×50 mm S7
Start % B=0
Final % B=40
Gradient time=2 min
Stop time=3 min
Flow Rate=5 mL/min
Wavelength=220 nm
Solvent A=0.1% TFA in 10% methanol/90% H2O
Solvent B=0.1% TFA in 90% methanol/10% H2O
Cond-CB1
Column=Primesphere C18-HC 4.6×30 mm
Start % B=0
Final % B=100
Gradient Time=2 min
Flow Rate=4 mL/min
Wavelength=220
Solvent A=10% CH3CN-90% H2O-5 mM NH4OAc
Solvent B=90% CH3CN-10% H2O-5 mM NH4Oac
Cond.-JG1
Column=XTERRA 3.0×50 mm S7
Start % B=0
Final % B=100
Gradient time=3 min
Stop time=4 min
Flow Rate=4 mL/min
Wavelength=220 nm
Solvent A=0.1% TFA in 10% methanol/90% H2O
Solvent B=0.1% TFA in 90% methanol/10% H2O
Cond.-JG2
Column=XTERRA 3.0×50 mm S7
Start % B=0
Final % B=100
Gradient time=4 min
Stop time=5 min
Flow Rate=4 mL/min
Wavelength=220 nm
Solvent A=0.1% TFA in 10% methanol/90% H2O
Solvent B=0.1% TFA in 90% methanol/10% H2O
Cond.-JG3
Column=Phenomenex-Luna 3.0×50 mm S10
Start % B=0
Final % B=100
Gradient time=3 min
Stop time=4 min
Flow Rate=4 mL/min
Wavelength=220 nm
Solvent A=0.2% H3PO4 in 10% methanol/90% H2O
Solvent B=0.2% H3PO4 in 90% methanol/10% H2O
Cond.-JG4
Column=Phenomenex-Luna 3.0×50 mm S10
Start % B=0
Final % B=100
Gradient Time=4 min
Flow Rate=4 mL/min
Wavelength=220
Solvent A=10% methanol-90% H2O-10 mm Ammonium Acetate
Solvent B=90% methanol-10% H2O-10 mm Ammonium Acetate
Condition IV
Column=XTERRA 3.0×50 mm S7
Start % B=0
Final % B=100
Gradient time=2 min
Stop time=3 min
Flow Rate=5 mL/min
Wavelength=220 nm
Solvent A=0.1% TFA in 10% methanol/90% H2O
Solvent B=0.1% TFA in 90% methanol/10% H2O
Cond-RK1
Column=XTerra MS C18-HC 4.6×50 mm, 5 um
Start % B=10
Final % B=100
Gradient Time=2 min
Flow Rate=4 mL/min
Wavelength=220 nm
Solvent A=H2O-10 mM NH4OAc
Solvent B=CH3CN-10 mM NH4Oac
Cond.-J1
Column=Phenomenex-Luna 4.6×50 mm S10
Start % B=0
Final % B=100
Gradient time=2 min
Stop time=3 min
Flow Rate=4 mL/min
Wavelength=220 nm
Solvent A=0.1% TFA in 10% methanol/90% H2O
Solvent B=0.1% TFA in 90% methanol/10% H2O
Cond.-J2
Column=XTERRA 4.6×50 mm S5
Start % B=0
Final % B=100
Gradient time=2 min
Stop time=3 min
Flow Rate=4 mL/min
Wavelength=220 nm
Solvent A=0.1% TFA in 10% methanol/90% H2O
Solvent B=0.1% TFA in 90% methanol/10% H2O
Example OL-1




Example OL-1a




Ethyl malonyl chloride (2.5 mL, 19.5 mmol) was added slowly to a solution of benzoin (3.77 g, 17.8 mmol), pyridine (1.44 mL, 17.8 mmol) and dimethylaminopyridine (100 mg) in dichloromethane (30 mL) and kept at 10° C. in an ice-water bath for 30 min then allowed to warm to ambient temperature for 2 h. The solvent was removed in vacuo followed by addition of acetic acid (60 mL) and ammonium chloride (6.25 g, 81.15 mmol). The resulting mixture was heated to reflux temperature for 2 h, diluted with water and extracted with dichloromethane to yield an oil that was purified by flash chromatography, eluting with ethyl acetate/hexanes (10:90) to give Example OL-1a (2.93 g, 54% yield). 1H NMR (CDCl3, 500 MHz): δ 7.64 (m, 2H), 7.58 (m, 2H), 7.29-7.38 (m, 6H), 4.24 (q, J=7.1 Hz, 2H), 3.93 (s, 2H), 1.29 (t, J=7.1 Hz, 3H). LC/MS (Cond. OL1): Rt=1.85 min; Anal. Calc. for [M+H]+ C19H18NO3: 308.12; found: 308.
Example OL-1b




Example OL-1a (0.35 g, 1.14 mmol) was added to cold fuming nitric acid (25 mL/g) keeping the temperature below 0° C. at all times. The yellow solution was stirred at 0° C. for 30 min then allowed to warm to ambient temperature, where it stirred for 1 h. The mixture was then poured onto ice and the aqueous suspension was neutralized with 5N sodium hydroxide and extracted with ethyl acetate. The organic layer was dried (MgSO4), filtered and concentrated, to give Example OL-1b as a yellow solid (0.4 g, 88% yield) which was used without further purification. 1H NMR (DMSO-d6, 500 MHz): δ 8.26 (dd, J=9.1, 2.2 Hz, 4H), 7.82 (d, J=8.8 Hz, 2 H), 7.75 (d, J=8.8 Hz, 2H), 4.27 (q, J=7.1, 2H), 3.98 (s, 2H), 1.32 (t, J=7.1 Hz, 3H). LC/MS (Cond. OL2): Rt=2.04 min; Anal. Calc. for [M+H]+ C19H16N3O7: 398.09; found: 398.
Example OL-1c




A catalytic amount of 20% palladium hydroxide on carbon (100 mg) in methanol (2 mL) was added to Example OL-1b (0.15 g, 0.38 mmol) in ethyl acetate/methanol (30:15 mL). The system was then placed under 1 atm of hydrogen gas (balloon) and stirred at ambient temperature overnight. The suspension was filtered through a pad of Celite and concentrated in vacuo. The product was purified by flash chromatography, eluting first with ethyl acetate/hexanes (50:50), then ethyl acetate and finally methanol/ethyl acetate (5:95) to give Example OL-1c (85 mg (67% yield) as an off-white solid. 1H NMR (DMSO-d6, 500 MHz): δ 7.22 (d, J=8.5 Hz, 2H), 7.17 (d, J=8.5 Hz, 2H), 6.57 (d, J=8.5 Hz, 2H), 6.53 (d, J=8.5 Hz, 2H), 5.43 (bs, 2H), 5.23 (bs, 2H), 4.15 (q, J=7.2, 2H), 3.96 (s, 2H), 1.21 (t, J=7.2 Hz, 3H). LC/MS (Cond. OL2): Rt=0.91 min; Anal. Calc. for [M+H]+ C19H20N3O3: 338.14; found: 338.
Example OL-1d




2-Ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (EEDQ, 0.13 g, 0.54 mmol) was added in one portion to a stirred suspension of Example OL-1c (0.08 g, 0.24 mmol) and N-benzyloxycarbonyl-L-alanine (0.12 g, 0.52 mmol) in anhydrous dichloromethane (3 mL). The mixture was stirred at ambient temperature for 15 h before the solvent was removed in vacuo and purified by reverse phase preparative HPLC to afford Example OL-1d as a white solid (0.13 g, 75% yield). 1H NMR (DMSO-d6, 500 MHz): δ 10.19 (s, 1H), 10.11 (s, 1H), 7.68 (d, J=8.55 Hz, 2H), 7.63 (dd, J=11.1, 8.1 Hz, 4H), 7.51 (d, J=8.55 Hz, 2H), 7.47 (d, J=8.55 Hz, 2H), 7.35 (m, 6H), 7.31 (m, 2H), 7.25 (bs, 1H), 7.18 (bs, 1H), 5.02 (m, 4H), 4.18 (m, 4H), 4.06 (s, 2H), 1.29 (d, J=7.32 Hz, 6H), 1.22 (t, J=7.17 Hz, 3H). LC/MS (Cond. OL3): Rt=1.80 min; Anal. Calc. for [M+H]+ C41H42N5O9: 748.29; found: 748.
Example OL-1
A solution of lithium hydroxide (3.6 mg, 0.15 mmol) in water (2 mL) was added to a solution of Example OL-1d (75 mg, 0.094 mmol) in tetrahydrofuran (2 mL) and the mixture was stirred at ambient temperature for 3 h. The solvent was removed in vacuo and the remaining aqueous solution was extracted with ethyl acetate (2×5 mL). The combined organic layers were washed with sat. aqueous sodium bicarbonate and all the aqueous layers were combined, acidified to pH=4 and extracted with ethyl acetate. The organic layers were dried (MgSO4), filtered and concentrated. The residue was recrystallized from dichloromethane/diethyl ether to afford Example OL-1 (32 mg, 40% yield) as a white solid. 1H NMR (DMSO-d6, 500 MHz): δ 13.02 (b.s, 1H), 10.17 (s, 1H), 10.09 (s, 1H), 7.66 (d, J=8.55 Hz, 2H), 7.60 (m, 4H), 7.49 (d, J=8.55 Hz, 2H), 7.45 (d, J=8.55 Hz, 2H), 7.34 (m, 6H), 7.29 (m, 2H), 7.25 (bs, 1H), 7.18 (bs, 1H), 5.00 (m, 4H), 4.17 (t, J=7.32, 2H), 3.93 (s, 2H), 1.27 (t, J=7.02 Hz, 6H). LC/MS (Cond. OL1): Rt=1.72 min; Anal. Calc. for [M+H]+ C39H38N5O9: 720.26; found: 720.
Example OL-2




Prepared from Example OL-1c and Carbobenzyloxy-L-Proline, according to the procedure described for Example OL-1d. This afforded Example OL-2 (0.14 g, 95% yield) as an off-white solid. 1H NMR (DMSO-d6, 500 MHz): δ 10.26 (s, 1H), 10.18 (d, J=6.1 Hz, 1H), 7.66 (m, 4H), 7.51 (m, 4H), 7.37 (d, J=3.66 Hz, 4H), 7.32 (dd, J=8.4, 4.1 Hz, 1H), 7.23 (m, 2H), 7.18 (t, J=7.2 Hz, 1H), 7.12 (m, 2H), 5.08 (m, 4H), 4.94 (d, J=13.2 Hz, 2H), 4.37 (m, 2H), 4.17 (q, J=7.2 Hz, 2H), 4.08 (d, J=3.7 Hz, 2H), 3.51 (m, 2H), 3.45 (m, 2H), 2.25 (m, 2H), 1.91 (m, 6H), 1.23 (t, J=7.0 Hz, 3H). LC/MS (Cond. OL3): Rt=1.83 min; Anal. Calc. for [M+H]+ C45H46N5O9: 800.32; found: 800.
Example OL-3




Prepared from Example OL-2 according to the procedure described for Example OL-1. This gave Example OL-3 as an off-white solid (45 mg, 62% yield).
1H NMR (DMSO-d6, 500 MHz): δ 10.26 (s, 1H), 10.18 (d, J=6.1 Hz, 1H), 7.66 (m, 4H), 7.51 (m, 4H), 7.37 (d, J=3.66 Hz, 4H), 7.32 (dd, J=8.4, 4.1 Hz, 1H), 7.23 (m, 2H), 7.18 (t, J=7.2 Hz, 1H), 7.12 (m, 2H), 5.08 (m, 4H), 4.94 (d, J=13.2 Hz, 2H), 4.37 (m, 2H), 4.97 (d, J=3.7 Hz, 2H), 3.51 (m, 2H), 3.45 (m, 2H), 2.25 (m, 2H), 1.91 (m, 6H). LC/MS (Cond. OL3): Rt=1.72 min; Anal. Calc. for [M+H]+ C43H42N5O9: 772.29; found: 772.
Example OL-4




Example OL-4a




Acetyl chloride (2 mL, 28.3 mmol) was added slowly to a solution of benzoin (5.47 g, 25.58 mmol), pyridine (2.1 mL, 25.8 mmol) and N,N′-dimethylaminopyridine (100 mg, catalytic) in dichloromethane (50 mL) at 10° C. The mixture was stirred at 10° C. for 0.5 h and at ambient temperature for 2 h. The solvent was then removed under reduced pressure and a mixture of ammonium acetate (9.7 g, 126 mmol) and glacial acetic acid (100 mL) was added to the residue. The resulting solution was then stirred at reflux temperature for 2 h, diluted with water and extracted with dichloromethane. The organic layer was washed with brine, dried (MgSO4), filtered and concentrated. The yellow oil was purified by flash chromatography, eluting with ethyl acetate/hexanes (10:90) to afford Example OL-4a (5.65 g, 93% yield). 1H NMR (CDCl3, 500 MHz): δ 7.64 (d, J=7.0 Hz, 2H), 7.58 (d, J=7.0 Hz, 2H), 7.29-7.38 (m, 6H), 2.55 (s, 3H). LC/MS (Cond. OL1): Rt=1.96 min; Anal. Calc. for [M+H]+ C16H14NO: 236.1; found: 236.
Example OL-4b




Prepared from Example OL-4a, according to the procedure described for Example OL-1b. This afforded Example OL-4b (1.1 g, 80% yield) as a yellow solid.
1H NMR (CDCl3, 500 MHz): δ 8.31 (m, 4H), 7.87 (d, J=8.1 Hz, 2H), 7.82 (d, J=9.2 Hz, 2H), 2.58 (s, 3H). LC/MS (Cond. OL2): Rt=2.10 min; Anal. Calc. for [M+H]+ C16H12N3O5: 326.07; found: 326.
Example OL-4c




Prepared from Example OL-4b, according to the procedure described for Example OL-1c. This afforded Example OL-4c (0.22 g, 68% yield) as an off-white solid. 1H NMR (CDCl3, 500 MHz): δ 7.23 (d, J=8.3 Hz, 2H), 7.15 (d, J=8.3 Hz, 2H), 6.57 (d, J=8.3 Hz, 2H), 6.54 (d, J=8.3 Hz, 2H), 5.28 (bs, 4H), 2.40 (s, 3H). LC/MS (Cond. OL1): Rt=0.81 min; Anal. Calc. for [M+H]+ C16H16N3O: 266.12; found: 266.
Example OL-4
Prepared from Example OL-4c, according to the procedure described for Example OL-1d. This afforded Example OL-4 (0.12 g, 75% yield) as an off-white solid. 1H NMR (CDCl3, 500 MHz): δ 10.19 (s, 1H), 10.11 (s, 1H), 7.68 (d, J=8.55 Hz, 2H), 7.63 (dd, J=11.1, 8.1 Hz, 4H), 7.51 (d, J=8.55 Hz, 2H), 7.47 (d, J=8.55 Hz, 2H), 7.36 (m, 6H), 7.32 (m, 2H), 7.25 (bs, 1H), 7.18 (bs, 1H), 5.03 (m, 4H), 4.20 (m, 2H), 2.49 (s, 3H), 1.30 (d, J=7.02 Hz, 6H). LC/MS (Cond. OL1): Rt=1.84 min; Anal. Calc. for [M+H]+ C38H38N5O7: 676.27; found: 676.
Example OL-5




Prepared from Example OL-4c and Carbobenzyloxy-L-Proline, according to the procedure described for Example OL-1d. This afforded Example OL-5 (0.11 g, 63% yield) as an off-white solid. 1H NMR (DMSO-d6, 500 MHz): δ 10.24 (s, 1H), 10.16 (d, J=6.1 Hz, 1H), 7.63 (m, 4H), 7.49 (m, 4H), 7.37 (d, J=3.66 Hz, 4H), 7.32 (m, 1H), 7.23 (d, J=7.0 Hz, 2H), 7.18 (m, 1H), 7.12 (m, 2H), 5.08 (m, 3H), 4.95 (d, J=13.2 Hz, 1H), 4.39 (dd, J=7.9, 3.9 Hz, 1H), 4.35 (dd, J=8.1, 2.9 Hz, 1H), 3.52 (m, 2H), 3.45 (m, 2H), 2.25 (m, 2H), 1.90 (m, 6H). LC/MS (Cond. 1): Rt=1.87 min; Anal. Calc. for [M+H]+ C42H42N5O7: 728.3; found: 728.
Example OL-6




Example OL-6a




N-bromosuccinamide (0.76 g, 4.25 mmol) and benzoyl peroxide (0.17 g, 0.7 mmol) were added in one portion to a solution of 2-methyl-4,5-diphenyloxazole (1 g, 4.25 mmol) in carbon tetrachloride (5 mL). The mixture was heated to reflux temperature for 6 h, the resulting succinimide was filtered-off and the solvent was removed in vacuo. The remaining residue was purified by flash chromatography, eluting with ethyl acetate/hexanes (5:95) to give Example OL-6a (0.95 g, 72% yield) as a brown solid. 1H NMR (CDCl3, 500 MHz): δ 7.79 (m, 2H), 7.75 (m, 2H), 7.50-7.62 (m, 6H), 4.38 (s, 2H). LC/MS (Cond. OL1): Rt=1.93 min; Anal. Calc. for [M+H]+ C16H13BrNO: 314.1; found: 314.
Example OL-6b




OL-6a (0.018 g, 0.57 mmol) and dimethylamine hydrochloride (93 mg, 1.14 mmol) were added to a suspension of cesium carbonate (1 g, 2.87 mmol) in acetone (15 mL). The mixture was stirred at ambient temperature for 5 h and the solvent was removed in vacuo. The residue was partitioned between water and dichloromethane, and the organic layer was separated, dried (MgSO4), filtered and concentrated. The desired product was purified by flash chromatography, eluting with ethyl acetate/hexanes (60:40) to give Example OL-6b (0.13 g, 83% yield) as an off-white solid. 1H NMR (CDCl3, 500 MHz): δ 7.65 (d, J=7.1 Hz, 2H), 7.60 (d, J=7.1 Hz, 2H), 7.31-7.35 (m, 6H), 3.72 (s, 2H), 2.41 (s, 6H). LC/MS (Cond. OL3): Rt=1.34 min; Anal. Calc. for [M+H]+ C18H19N2O: 279.14; found: 279.
Example OL-6b




Prepared from Example OL-6a according to the procedure described for Example OL-1b. This afforded Example OL-6b (0.15 g, 87% yield) as a yellow solid.
1H NMR (DMSO-d6, 500 MHz): δ 8.13 (d, J=8.0, 2H), 7.94 (d, J=8.0 Hz, 2H), 7.58 (d, J=8.0 Hz, 2H), 7.29 (d, J=8.0 Hz, 2H), 3.82 (s, 2H), 2.48 (s, 6H). LC/MS (Cond. OL1): Rt=1.33 min; Anal. Calc. for [M+H]+ C18H17N4O5: 369.11; found: 369.
Example OL-6c




Prepared from Example OL-6b according to the procedure described for Example OL-1c. This afforded Example OL-6c (40 mg, 32% yield) as an off-white solid. 1H NMR (CDCl3, 500 MHz): δ 7.43 (d, J=8.5, 2H), 7.38 (d, J=8.5 Hz, 2 H), 6.65 (d, J=8.5 Hz, 2H), 6.62 (d, J=8.5 Hz, 2H), 3.66 (s, 2H), 2.38 (s, 6H). LC/MS (Cond. 1): Rt=0.15 min; Anal. Calc. for [M+H]+ C18H21N4O: 309.16; found: 309.
Example OL-6
Prepared from Example OL-6c and (S)-1-(2-phenylacetyl)pyrrolidine-2-carboxylic acid according to the procedure described for Example OL-1d. This afforded Example OL-6 (75 mg, 89% yield). 1H NMR (DMSO-d6, 500 MHz): δ 10.25 (s, 1H), 10.16 (s, 1H), 7.71 (d, J=8.85 Hz, 2H), 7.66 (d, J=8.85 Hz, 2H), 7.53 (m, 4H), 7.25 (m, 10H), 4.64 (s, 2H), 4.45 (dd, J=8.4 Hz, 3.8 Hz, 2H), 3.70 (d, J=3.36 Hz, 4H), 3.63 (m, 4H), 2.94 (s, 6H), 2.16 (m, 2H), 2.01 (m, 2H), 1.90 (m, 4H). LC/MS (Cond. OL3): Rt=2.09 min; Anal. Calc. for [M+H]+ C44H46N6O5: 739.35; found (M+NH4): 777. Anal. Calc. for [M−H]− C44H47N6O5: 737.35; found: 737.
Example MS-1




Example MS-1a




2-Amino-1-(4-bromo-phenyl)-ethanone hydrochloride salt (2.5 g, 10.0 mmol) was added portionwise to a cold (0° C.) solution of 4-nitrobenzoyl chloride (1.85 g, 10.0 mmol) and pyridine (2.4 mL, 30.0 mmol) in methylene chloride (100 mL). Upon completion of the addition, the mixture was allowed to warm up to rt where it stirred for 2 h before it was diluted with more methylene chloride and poured into 1N HCl. The organic phase was separated and concentrated down to yield Example MS-1a (3.6 g, 99%) as a white solid. 1H NMR (DMSO-d6, 500 MHz) δ 9.25 (t, 1H, J=5.5 Hz), 8.37 (d, 2H, J=8.8 Hz), 8.13 (d, 2H, J=8.8 Hz), 7.99 (d, 2H, J=8.4 Hz).); Rt=1.35 min (Cond.-MS-W1).
Example MS-1b




Neat phosphorous oxychloride (40 mL) was added to Example MS-1a (3.1 g, 8.56 mmol) and the mixture was heated at 80° C. for 16 h. Upon cooling, the reaction mixture was carefully poured into ice water and stirred vigorously to afford a yellow solid after filtration. The solid was taken up in dichloromethane and neutralized with 10N NaOH. The organic phase was separated and evaporated to yield a solid which was triturated with methanol to furnish Example MS-1b (1.2 g, 41%) as a yellow solid. 1H NMR (DMSO-d6, 500 MHz) δ 8.36 (d, 2H, J=9.2 Hz), 8.29 (d, 2H, J=9.2 Hz), 8.00 (s, 1H), 7.82 (d, 2H, J=8.6 Hz), 7.71 (d, 2H, J=8.6 Hz); 13C NMR (DMSO-d6, 125 MHz) δ 158.5, 151.0, 148.1, 132.0, 131.8, 127.0, 126.2, 126.0, 125.6, 124.4, 122.1. Rt=1.87 min (Cond.-MS-W1); LCMS: Anal. Calc. for [M+H]+ C15H10BrN2O3: 344.99; found: not obsd. LRMS: Anal. Calc. for [M+H]+ C15H10BrN2O3: 344.99, 346.99; found: 345.15, 347.15.
Example MS-1c




Benzophenone imine (585 μL, 3.5 mmol, 1.2 eq.) was added to a mixture of Example MS-1b (1.0 g, 2.9 mmol, 1.0 eq.), cesium carbonate (1.32 g, 4.0 mmol, 1.4 eq.), Pd2 dba3 (53 mg, 0.058 mmol, 0.02 eq.), and (R)-(+)-2,2′-bis(diphenylphosphino)-1,1′-binaphthalene (BINAP, 72 mg, 0.116 mmol, 0.04 equiv) in dioxane (10 mL) under an argon atmosphere. The reaction vessel was sealed and heated at 80° C. overnight. The mixture was cooled to ambient temperature and filtered through Celite, washing the filter pad with ether. The filtrate was concentrated in vacuo to yield the crude imine (1.3 g) as a brown solid. A portion of the crude imine (1.0 g) was hydrolyzed with 1N HCl (5 mL) in THF (15 mL) for 20 min, and the resulting aniline was isolated by basifying with 10N NaOH and extractive workup with dichloromethane (3×). The crude aniline was then acylated with N-phenacetyl-L-proline (450 mg, 3.0 mmol) following the procedure outlined for Example OL-1d. Flash chromatography on silica gel (gradient elution with 0% methanol in dichloromethane followed by 5% methanol in dichloromethane) afforded MS-1c (800 mg, 66%) as a yellow solid. 1H NMR (DMSO-d6, 500 MHz) δ 10.2 (s, 1H), 8.39 (d, 2H, J=7.3 Hz), 8.32 (d, 2H, J=7.3 Hz), 7.88 (s, 1H), 7.84 (d, 2H, J=8.9 Hz), 7.75 (d, 2H, J=8.9 Hz), 4.42 (m, 1H), 3.51-3.64 (m, 2H), 2.15 (m, 1H), 2.01 (s, 3H), 1.93 (m, 3H); 13C NMR (DMSO-d6, 125 MHz) 170.9, 168.4, 157.9, 152.1, 148.0, 139.8, 132.1, 126.8, 125.0, 124.4, 124.0, 121.6, 119.4, 59.8, 47.6, 29.6, 24.3, 22.1. LC (Cond.-MS-W1): Rt=1.55 min; LC/MS: Anal. Calcd. for [M+H]+ C22H21N4O5: 421.15; found 421.16. HRMS: Anal. Calc. for [M+H]+ C22H21N4O5: 421.1512; found: 421.1501.
Example MS-1d




Example MS-1c (800 mg, 1.90 mmol) was subjected to catalytic hydrogenation using 10% palladium on carbon (400 mg) in methanol (40 mL) under 1 atm of hydrogen for 16 h. The reaction was filtered through Celite and concentrated to afford Example MS-1d (658 mg, 82%) as a light tan solid. 1H NMR (DMSO-d6, 500 MHz) δ 10.1 (s, 1H), 7.73 (d, 2H, J=8.5 Hz), 7.70 (s, 2H), 7.55 (s, 1H), 6.66 (d, 2H, J=8.5 Hz), 5.73 (br s, 2H), 4.40 (m, 1H), 3.50-3.62 (m, 2H), 2.13 (m, 1H), 2.00 (s, 3H), 1.91 (m, 3H); 13C NMR (DMSO-d6, 125 MHz) 170.8, 168.4, 161.0, 151.0, 149.0, 138.7, 127.3, 124.0, 122.6, 119.4, 113.5, 59.8, 47.6, 29.6, 24.3, 22.1. LRMS: Anal. Calcd. for [M+H]+ C22H23N4O3: 391.18; found 391.2. HRMS: Anal. Calc. for [M+H]+ C22H23N4O3: 391.1770; found: 391.1760.
Example MS-1
Prepared from Example MS-1d with N-phenacetyl-L-proline according to the procedure described for Example OL-1d. This afforded Example MS-1 (26.6 mg, 34%) as a yellow solid. 1H NMR (MeOH-d4, 500 MHz) δ 7.86 (d, 2H, J=8.9 Hz), 7.65 (d, 2H, J=8.9 Hz), 7.58 (m, 4H), 7.43 (s, 1H), 7.31 (m, 5H), 4.55 (m, 2H), 3.97 (s, 2H), 3.80, (m, 2H), 3.61-3.77 (m, 4H), 2.23 (m, 2H), 2.15 (s, 3H), 2.02 (m, 2H). LC (Cond.-MS-W6: Rt=11.00 min; 95% homogeneity index; LRMS: Anal. Calc. for [M+H]+ C35H36N5O5: 606.27; found: 606.3. HRMS: Anal. Calc. for [M+H]+ C35H36N5O5: 606.2716; found: 606.2738.
Example MS-2




Prepared from Example MS-1d and (2S,4R)-1-(benzyloxycarbonyl)-4-tert-butoxypyrrolidine-2-carboxylic acid according to the procedure described for Example OL-1d. This afforded Example MS-2 (23.1 mg, 26%) as an off-white solid.
1H NMR (6:1 MeOH-d4/CDCl3, 500 MHz) δ 7.99 (m, 2H), 7.64-7.75 (m, 5H), 7.49 (s, 1H), 7.30-7.36 (m, 2H), 7.20 (m, 2H), 7.08 (m, 2H), 5.15 (m, 2H), 4.45-4.54 (m, 2H), 3.79 (m, 2H), 3.61 (m, 2H), 3.42 (m, 2H), 2.27 (m, 3H), 2.17 (m, 2H), 2.13 (s, 3H), 1.22 (s, 9H). LC (Cond.-MS-W6): Rt=13.83 min, 95% homogeneity index; LRMS: Anal. Calc. for [M+H]+ C39H44N5O7: 694.33; found: 694.3. HRMS: Anal. Calc. for [M+H]+ C39H44N5O7: 694.3240; found: 694.3264.
Example MS-3




Prepared from Example MS-1d and (2S,4R)-1-(benzyloxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid according to the procedure described for Example OL-1d. This afforded Example MS-3 (29.8 mg, 37%) as a yellow solid. 1H NMR (MeOH-d4, 500 MHz) δ 7.99 (d, 2H, J=8.9 Hz), 7.63-7.72 (m, 7H), 7.53 (s, 1H), 7.21 (d, 2H, J=7.0 Hz), 7.09 (d, 2H, J=7.0 Hz), 5.15 (m, 2H), 4.55 (m, 2 H), 4.48 (m, 2H), 3.71 (m, 2H), 3.63 (m, 3H), 2.31 (m, 2H), 2.13 (s, 3H), 2.09 (m, 2H). LC (Cond.-MS-W6): Rt=10.03 min; LRMS: Anal. Calc. for [M+H]+ C35H36N5O7: 638.26; found: 638.3. HRMS: Anal. Calc. for [M+H]+ C35H36N5O7: 638.2615; found: 638.2628.
Example MS-4




Prepared from Example MS-1d and (RS)-1-(benzyloxycarbonyl)pyrrolidine-3-carboxylic acid according to the procedure described for Example OL-1d. This afforded Example MS-4 as a mixture of diastereomers (25.6 mg, 32%) and as a yellow solid. 1H NMR (MeOH-d4, 500 MHz) δ 7.99 (d, 2H, J=8.9 Hz), 7.67-7.75 (m, 6H), 7.51 (s, 1H), 7.37 (m, 5H), 5.13 (s, 2H), 4.53 (m, 1H), 3.61-3.72 (m, 5H), 3.45, (m, 1H), 3.21 (m, 1H), 2.17-2.31 (m, 3H), 2.13 (s, 3H), 2.05 (m, 3H). LC (Cond.-MS-W6): Rt=13.33 min; LRMS: Anal. Calc. for [M+H]+ C35H36N5O6: 622.26; found: 622.2. HRMS: Anal. Calc. for [M+H]+ C35H36N5O6: 622.2666; found: 622.2500.
Example MS-5




Prepared from Example MS-1d and (RS)-5-oxo-1-(2-(thiophen-2-yl)ethyl)pyrrolidine-3-carboxylic acid according to the procedure described for Example OL-1d. This afforded Example MS-5 as a mixture of diastereomers (50.0 mg, 64%) and as a greenish-yellow solid. 1H NMR (MeOH-d4, 500 MHz) δ 7.98 (d, 2H, J=8.9 Hz), 7.72 (d, 2H, J=8.9 Hz), 7.67 (m, 3H), 7.45 (s, 1H), 7.18 (m, 1H), 6.88 (m, 3H), 4.54 (m, 1H), 3.71 (m, 1H), 3.54-3.62 (m, 5H), 3.09 (m, 2H), 2.73 (d, 1H, J=6.7 Hz), 2.66 (d, 1H, J=9.8 Hz), 2.26 (m, 2H), 2.13 (s, 3H), 2.02 (m, 3H). LC (Cond.-MS-W6): Rt=11.30 min; 95% homogeneity index; LRMS: Anal. Calc. for [M+H]+ C33H34N5O5S: 612.22; found: 612.2. HRMS: Anal. Calc. for [M+H]+ C33H34N5O5S: 612.2280; found: 612.2280.
Example MS-6




Prepared from Example MS-1b according to the five step sequence described for Example MS-1 (using N-acetyl-L-proline first instead of N-phenacetyl-L-proline). This afforded Example MS-6 (43.3 mg, 12.3% overall yield) as a white solid. 1H NMR (DMSO-d6, 500 MHz) δ 10.24 (s, 1H), 10.17 (s, 1H), 8.01 (d, 2H, J=8.5 Hz), 7.69-7.78 (m, 7H), 7.18-7.32 (m, 5H), 5.75 (s, 2H), 4.44 (m, 2H), 3.71, (s, 1 H), 3.53-3.66 (m, 3H), 2.16 (m, 2H), 2.01 (s, 3H), 1.92 (m, 6H). LC (Cond.-MS-W6): Rt=11.29 min, 95% homogeneity index; LRMS: Anal. Calc. for [M+H]+ C35H36N5O5: 606.27; found: 606.3. HRMS: Anal. Calc. for [M+H]+ C35H36N5O5: 606.2717; found: 606.2721.
Example MS-7




Example MS-7a




Prepared from Example MS-1d and (S)-1-(tert-butoxycarbonyl)-2,5-dihydro-1H-pyrrole-2-carboxylic acid according to the procedure described for Example OL-1d. This afforded Example MS-7a (315 mg, 66%) as a light tan solid. 1H NMR (DMSO-d6, 500 MHz) δ 10.37 (s, 1H), 10.14 (s, 1H), 8.04 (m, 2H), 7.70-7.78 (m, 6H), 6.08 (m, 1H), 5.86 (m, 1H), 4.99 (m, 1H), 4.41 (m, 1H), 4.10-4.19 (m, 2H), 3.53-3.60 (m, 3H), 2.14 (s, 3H), 1.92 (m, 3H), 1.30 (s, 9H). LC (Cond.-MS-W6): Rt=10.94 min; or LC/MS (Cond.-MS-W1): Rt=1.55 min; Anal. Calc. for [M+H]+ C32H36N5O6: 586.27; found: 586.21. HRMS: Anal. Calc. for [M+H]+ C32H36N5O6: 586.2665; found: 586.2674.
Example MS-7b




A cold (0° C.) solution of 4N HCl in dioxane (10 mL) was added to Example MS-7a (300 mg, 0.512 mmol) dissolved in dioxane (5 mL). The mixture was stirred rapidly at 0° C. for 0.5 h before it was allowed to warm up to room temperature. After 1 h at room temperature, the mixture was concentrated down in vacuo to afford Example MS-7b (303 mg, 100+%) as a pale, yellow solid. 1H NMR (MeOH-d4, 400 MHz) δ 8.05-7.99 (m, 2H), 7.77-7.65 (series of m, 6H), 7.52 and 7.49 (2s, 1H), 6.14-6.06 (m, 2H), 5.22 (br s, 1H), 4.59-4.56 and 4.53-4.50 (2m, 1H), 4.31-4.26 (m, 1H), 4.19-4.15 (m, 1H), 3.73-3.68 (m, 1H), 3.65-3.59 (m, 1H), 2.29-2.26 (m, 1H), 2.11 and 1.99 (2s, 3H), 2.10-2.00 (m, 3H). LC/MS (Cond.-D1): Rt=1.61 min; Anal. Calc. for [M+H]+ C22H28N5O4: 486.21; found: 486.27. HRMS: Anal. Calc. for [M+H]+ C27H28N5O4: 486.2141; found: 486.2125.
Example MS-7
Prepared from Example MS-7b and thiophene-2-carboxylic acid according to the procedure described for Example D-57. This afforded Example MS-7 (32.6 mg, 57%) as a tan solid. 1H NMR (MeOH-d4, 500 MHz) δ 8.04-8.02 (m, 2H), 7.79-7.67 (series of m, 8H), 7.54-7.52 (m, 1H), 7.22-7.20 (m, 1H), 6.22-6.20 (m, 1H), 6.01-6.00 (m, 1H), 5.51 (br s, 1H), 4.73-4.40 (m, 1H), 4.59-4.53 (2m, 1H), 3.74-3.70 (m, 1H), 3.66-3.62 (m, 2H), 2.31-2.27 (m, 1H), 2.13 and 2.01 (2s, 3H), 2.12-2.03 (m, 3H). LC/MS (Cond.-D1): Rt=2.04 min; Anal. Calc. for [M+H]+ C32H30N5O5S: 596.20; found: 596.14. HRMS: Anal. Calc. for [M+H]+ C32H30N5O5S: 596.1968; found: 596.1963.
Example D-1




Prepared from Example MS-7b and 2-(thiophen-2-yl)acetic acid according to the procedure described for Example D-57. This afforded Example D-1 (35.4 mg, 61%) as a tannish-orange solid. 1H NMR (MeOH-d4, 500 MHz) δ 8.03-7.88 (2m, 2H), 7.76-7.67 (series of m, 3H), 7.61 (s, 3H), 7.52, 7.51 and 7.45 (3s, 1H), 7.30-7.25 (m, 1H), 7.02-6.90 (3m, 2H), 6.15-6.12 (m, 1H), 5.93-5.90 (2m, 1H), 5.33-5.28 (2m, 1H), 4.60-4.39 (m, 3H), 4.08-3.98 (m, 2H), 3.74-3.71 (m, 1H), 3.65-3.63 (m, 1H), 2.30-2.26 (m, 1H), 2.15, 2.14 and 2.01 (3s, 3H), 2.13-2.03 (m, 3H). LC/MS (Cond.-D1): Rt=2.08 min; Anal. Calc. for [M+H]+ C33H32N5O5S: 610.21; found: 610.17. HRMS: Anal. Calc. for [M+H]+ C33H32N5O5S: 610.2124; found: 610.2126.
Example D-2




Prepared from Example MS-7b and 2-ethylbenzoic acid according to the procedure described for Example D-57. This afforded Example D-2 (36.3 mg, 61%) as a pale, yellow solid. 1H NMR (MeOH-d4, 500 MHz) δ 8.07-7.68 (series of m, 7H), 7.56-7.49 (m, 2H), 7.42-7.37 (m, 2H), 7.31-7.23 (m, 2H), 6.22-5.85 (4m, 2H), 5.48-5.47 (m, 1H), 4.57-4.53 (m, 2H), 4.22-4.19 (m, 1H), 4.04-4.01 (m, 1H), 3.74-3.72 (m, 1H), 3.65-3.60 (m, 1H), 2.83-2.79 (m, 1H), 2.72-2.67 (m, 1H), 2.30-2.27 (m, 1H), 2.14, 2.13 and 2.01 (3s, 3H), 2.10-2.02 (m, 3H), 1.26-1.19 (m, 3H). LC/MS (Cond.-D1): Rt=2.22 min; Anal. Calc. for [M+H]+ C36H36N5O5: 618.27; found: 618.22. HRMS: Anal. Calc. for [M+H]+ C36H36N5O5: 618.2717; found: 618.2746.
Example D-3




Prepared from Example MS-7b and isoxazole-5-carboxylic acid according to the procedure described for Example D-57. This afforded Example D-3 (28.3 mg, 51%) as a tan solid. 1H NMR (MeOH-d4, 500 MHz) δ 8.57-8.47 (2m, 1H), 8.05-7.98 (m, 2H), 7.79-7.64 (2m, 7H), 7.54-7.51 (m, 1H), 7.08 and 7.00 (2s, 1H), 6.22-6.20 (m, 1H), 6.05-6.00 (2m, 1H), 5.90-5.50 (2m, 1H), 4.59-4.53 (m, 2H), 3.73-3.70 (m, 1H), 3.65-3.63 (m, 1H), 2.31-2.26 (m, 1H), 2.14 and 2.01 (2s, 3H), 2.13-2.02 (m, 3H). LC/MS (Cond.-D1): Rt=1.88 min; Anal. Calc. for [M+H]+ C3H29N6O6: 581.21; found: 581.16. HRMS: Anal. Calc. for [M+H]+ C31H29N6O6: 581.2149; found: 581.2171.
Example D-4




Example D-4a




Sulfuric acid (10 mL) was cooled to 0° C. and 2,5-diphenyloxazole (12 g, 54 mmol) was added in two portions. To this orange suspension was added dropwise a 1:1 solution of HNO3/H2SO4 concentrated acids over 10 min. The reaction was stirred for 2.5 h at 0° C. and poured onto chopped ice and filtered. The product was washed with water and diethyl ether and dried to afford Example D-4a (5 g, 30%) as a bright, yellow solid. The cold filtrate was extracted with EtOAc (300 mL) and the organic extract was decanted into a clean flask. Hexanes (60 mL) was then added and the mixture was allowed to stand idle at rt for 16 h to afford a second crop of Example D-4a (7 g, 42%). 1H NMR (DMSO-d6, 300 MHz) δ 8.40 (d, J=3.3 Hz, 4H), 8.36 (m, 2H), 8.29 (s, 1H), 8.18 (d, J=8.8 Hz, 2H). LC/MS (Cond.-D2): Rt=2.87 min; Anal. Calc. for [M+H]+ C15H9N3O5: 312.05; found: 312.13.
Example D-4b




A suspension of Example D-4a (9.83 g, 31.6 mmol) in methanol (100 mL) and ethyl acetate (100 mL) was subjected to balloon hydrogenation over 20% Pd(OH)2/C (1.0 g) for 6 h at ambient temperature before it was suction-filtered through Celite and concentrated down in vacuo to yield the crude product as a reddish solid. The solid was dissolved in hot methanol and the solution was cooled to ambient temperature and the precipitate which formed on cooling was suctioned-filtered to furnish crop 1 of Example D-4b (1.70 g, 21%) as a brick-colored solid. The filtrate was concentrated in vacuo and this residue was dissolved again in a minimal amount of hot methanol to afford crop 2 of Example D-4b (2.90 g, 37%) as a reddish-brown solid after cooling to rt and suction-filtration. This filtrate was concentrated down in vacuo and the residue was subjected to flash chromatography on silica gel (gradient elution first with 50% ethyl acetate in hexanes followed by 75% ethyl acetate in hexanes and finally 100% ethyl acetate) to yield crop 3 of Example D-4b (2.3 g, 29%) as an orange solid after concentration of the eluant to 1⁄4 volume and suction-filtration of the precipitate. 1HNMR (DMSO-d6+D2O, 300 MHz) δ 7.72 (d, J=8.4 Hz, 2H), 7.54 (d, J=8.4 Hz, 2H), 7.40 (s, 1H), 6.83 (d, J=8.05 Hz, 2H), 6.69 (d, J=8.05 Hz, 2H). LC/MS (Cond.-D3): Rt=1.17 min; Anal. Calc. for [M+H]+ C15H13N3O: 252.11; found: 252.05.
Example D-4c




To a mixture of Example D-4b (3.0 g, 11.94 mmol) and Boc-L-proline (5.27 g, 24.47 mmol) in dichloromethane (120 ml) was added EEDQ (6.20 g, 25.07 mmol). The mixture was stirred at 25° C. for 2 h before additional Boc-L-proline (2.64 g) and EEDQ (3.1 g) were added. After stirring for an additional 1.5 h at rt, most of the solvent was removed in vacuo and the residue was loaded onto a silica gel column and was eluted with 50% ethyl acetate in hexanes) to afford Example D-4c as an orange solid (6.2 g, 80%). 1H NMR (400 MHz, DMSO-d6) δ 10.28 (s, 1H), 10.17 (s, 1H), 8.04-8.02 (m, 2H), 7.79-7.68 (m, 7H), 4.28-4.19 (m, 2H), 3.46-3.32 (m, 4H), 2.25-2.17 (m, 2H), 1.95-1.80 (2m, 6H), 1.41 and 1.27 (2s, 18H); LC/MS (Cond. D2): Rt=2.95 min; Anal. Calc. for [M+H]+ C35H44N5O2: 646.63; found: 646.51. HRMS: Anal. Calc. for [M+H]+ C35H44N5O2: 646.3241; found: 646.3254.
Example D-4d




To a cold (0° C.) solution of Example D-4c (6.2 g, 9.60 mmol) in methanol (5 mL) was added 4N HCl in dioxane (30 ml). The reaction mixture was allowed to warm up to 25° C. where it stirred for 4 h before it was diluted with ether (100 ml) and filtered. The precipitate was washed with ether (2×100 ml) and dried under high vacuum to afford Example D-4d as an orange solid (4.91 g, 98%). 1H NMR (400 MHz, DMSO-d6) δ 10.39-10.38 and 9.64-9.62 (2m, 2H), 8.09 (s, 1H), 7.93-7.02 (series of m, 8H), 4.78-4.75 and 4.48-4.45 (2m, 2H), 3.34-3.28 (m, 2H), 3.23-3.18 (m, 2H), 2.40-2.30 (m, 2H), 2.10-1.80 (2m, 6H); LC/MS (Cond.-D2): Rt=1.64 min; Anal. Calc. for [M+H]+ C25H28N5O3: 446.22; found: 446.50. HRMS: Anal. Calc. for [M+H]+ C25H28N5O3: 446.2192; found: 446.2207.
Example D-4
Prepared from Example D-4d and (RS)-2-(dimethylamino)-2-(2-fluorophenyl)acetic acid (i.e. Cap-38) according to the procedure described for Example D-57. This afforded Example D-4 (51.3 mg, 66%) as a pale, yellow solid.
1H NMR (400 MHz, DMSO-d6) δ 10.53-10.26 (m, 3H), 8.07-8.02 (m, 2H), 7.82-7.62 (3m, 8H), 7.51-7.40 (m, 4H), 5.81-5.79 and 5.74-5.73 (2m, 2H), 4.60-4.55 and 4.50-4.47 (2m, 2H), 4.03-3.93 (m, 1H), 3.80-3.73 (m, 1H), 3.17-3.12 (m, 1H), 3.01-2.95 (m, 1H), 2.85-2.78 (m, 1H), 2.54 and 2.50 (2s, 12H), 2.31-2.11 (m, 2H), 2.06-1.75 (3m, 5H); LC/MS (Cond.-D1): Rt=1.84 min; Anal. Calc. for [M+H]+ C45H48F2N2O5: 804.37; found: 804.36. HRMS: Anal. Calc. for [M+H]+ C45H48F2N2O5: 804.3685; found: 804.3721.
Examples D-5 to D-33




Examples D-5 to D-33 were prepared from Example D-4d and 2.0 eq. of the appropriate, commercially-available or synthesized carboxylic acid according to the procedure described for Example D-57. Purification of the final targets was accomplished using a Shimadzu reverse phase preparative HPLC instrument (solvent systems: H2O/MeOH/TFA or H2O/ACN/TFA) and the final products were isolated as TFA salts. The coupling partner (ROH) obtained from commercial sources unless otherwise noted.
















Rt (LC-Cond.); %



Coupling

homogeneity index;


Example
Protocol
R
MS data







D-5 
HATU, DIPEA, DMF



   two diastereomers
1.86 and 1.93 min (Cond.-D1); LCMS: Anal. Calc. for [M + H]+ C45H46F4N7O5: 840.35; found: 840.39. HRMS: Anal. Calc. for [M + H]+ C45H46F4N7O5: 840.3497; found: 840.3502.


 


D-6 
HATU, DIPEA, DMF



   predominantly one diastereomer contaminated with D-5
1.92 min (Cond.-D1); LCMS: Anal. Calc. for [M + H]+ C45H46F4N7O5: 840.35; found: 840.40. HRMS: Anal. Calc. for [M + H]+ C45H46F4N7O5: 840.3497; found: 840.3491.


 


D-7 
HATU, DIPEA, DMF



   predominantly one diastereomer different from D-5 and D-6
1.98 min (Cond.-D1); LCMS: Anal. Calc. for [M + H]+ C45H46F4N7O5: 840.38; found: 840.40. HRMS: Anal. Calc. for [M + H]+ C45H46F4N7O5: 840.3497; found: 840.3480.


 


D-8 
HATU, DIPEA, DMF




2.51 min (Cond.-D2); LCMS: Anal. Calc. for [M + H]+ C51H60N9O5: 878.47; found: 878.72. HRMS: Anal. Calc. for [M + H]+ C51H60N9O5: 878.4717; found: 878.4718.


 


D-9 
HATU, DIPEA, DMF




3.43 min (Cond.-D2); LCMS: Anal. Calc. for [M + H]+ C49H48F4N9O7: 950.36; found: 950.81. HRMS: Anal. Calc. for [M + H]+ C49H48F4N9O7: 950.3613; found: 950.3582.


 


D-10
HATU, DIPEA, DMF




2.36 min (Cond.-D2); LCMS: Anal. Calc. for [M + H]+ C35H34N7O7S2: 728.20; found: 728.40. HRMS: Anal. Calc. for [M + H]+ C35H34N7O7S2: 728.1961; found: 728.1926.


 


D-11
HATU, DIPEA, DMF




1.82 min (Cond.-D2); LCMS: Anal. Calc. for [M + H]+ C37H41N9O7: 722.31; found: 722.51. HRMS: Anal. Calc. for [M + H]+ C37H41N9O7: 722.3051; found: 722.3056.


 


D-12
HATU, DIPEA, DMF




2.50 min (Cond.-D2); LCMS: Anal. Calc. for [M + H]+ C43H47N7O11: 836.33; found: 836.56. HRMS: Anal. Calc. for [M + H]+ C43H47N7O11: 836.3255; found: 836.3248.


 


D-13
HATU, DIPEA, DMF




1.87 min (Cond.-D2); LCMS: Anal. Calc. for [M + H]+ C43H41N9O7: 794.31; found: 794.50. HRMS: Anal. Calc. for [M + H]+ C43H41N9O7: 794.3051; found: 794.3060.


 


D-14
HATU, DIPEA, DMF




1.92 min (Cond.-D2); LCMS: Anal. Calc. for [M − H]− C39H36N7O7: 714.27; found: 714.35. HRMS: Anal. Calc. for [M − H]− C39H36N7O7: 714.2676; found: 714.2681.


 


D-15
HATU, DIPEA, DMF




2.41 min (Cond.-D2); LCMS: Anal. Calc. for [M + H]+ C49H51N7O9: 880.37; found: 880.62. HRMS: Anal. Calc. for [M + H]+ C49H51N7O9: 880.3670; found: 880.3632.


 


D-16
HATU, DIPEA, DMF




1.95 min (Cond.-D2); LCMS: Anal. Calc. for [M + H]+ C43H41N9O7: 794.31; found: 794.50. HRMS: Anal. Calc. for [M + H]+ C43H41N9O7: 794.3051; found: 794.3082.


 


D-17
HATU, DIPEA, DMF




1.86 min (Cond.-D2); LCMS: Anal. Calc. for [M + H]+ C43H41N9O7: 794.31; found: 794.50. HRMS: Anal. Calc. for [M + H]+ C43H41N9O7: 794.3051; found: 794.3066.


 


D-18
HATU, DIPEA, DMF




2.63 min (Cond.-D2, S5 instead); LCMS: Anal. Calc. for [M + H]+ C47H51N7O9: 856.37; found: 856.32. HRMS: Anal. Calc. for [M + H]+ C47H51N7O9: 856.3670; found: 856.3699.


 


D-19
HATU, DIPEA, DMF




2.35 min (Cond.-D2); LCMS: Anal. Calc. for [M + H]+ C47H52Cl2N7O7: 896.33; found: 896.46. HRMS: Anal. Calc. for [M + H]+ C47H52Cl2N7O7: 896.3305; found: 896.3318.


 


D-20
HATU, DIPEA, DMF




2.68 min (Cond.-D1); LCMS: Anal. Calc. for [M + H]+ C35H40N5O5: 610.30; found: 610.56. HRMS: Anal. Calc. for [M + H]+ C35H40N5O5: 610.3029; found: 610.3048


 


D-21
HATU, DIPEA, DMF



   stereochemical composition undetermined
2.56 min (Cond.-D2); LCMS: Anal. Calc. for [M + H]+ C51H58N7O5: 848.45; found: 848.54. HRMS: Anal. Calc. for [M + H]+ C51H58N7O5: 848.4499; found: 848.4464.


 


D-22
HATU, DIPEA, DMF



   mixture of diasteromers stereochemical composition undetermined
2.66 and 2.84 min (Cond.-D2); LCMS: Anal. Calc. for [M + H]+ C51H70N7O5: 860.54; found: 860.61. HRMS: Anal. Calc. for [M + H]+ C51H70N7O5: 860.5438; found: 860.5468.


 


D-23
HATU, DIPEA, DMF



   stereochemical composition undetermined
2.79 min (Cond.-D2); LCMS: Anal. Calc. for [M + H]+ C51H54N7O7: 876.41; found: 876.45. HRMS: Anal. Calc. for [M − H]− C51H52N7O7: 874.3928; found: 874.3950.


 


D-24
HATU, DIPEA, DMF



   stereochemical composition undetermined
2.13 min (Cond.-D2); LCMS: Anal. Calc. for [M + H]+ C37H43N7O7: 696.31; found: 696.37. HRMS: Anal. Calc. for [M + H]+ C37H43N7O7: 696.3146; found: 696.3160.


 


D-25
HATU, DIPEA, DMF



   stereochemical composition undetermined
2.41 min [Cond.-D2); LCMS: Anal. Calc. for [M + H]+ C41H51N7O7: 752.38; found: 752.42. HRMS: Anal. Calc. for [M + H]+ C41H51N7O7: 752.3772; found: 752.3766.


 


D-26
HATU, DIPEA, DMF




3.57 min (Cond.-D2); LRMS: Anal. Calc. for [M + H]+ C51H46Cl4N7O7: 1010.78; found: 1010.69.


 


D-27
HATU, DIPEA, DMF




3.01 min (Cond.-D2); LCMS: Anal. Calc. for [M + H]+ C45H58N7O9: 840.43; found: 840.70. HRMS: Anal. Calc. for [M − H]− C45H56N7O9: 838.4140; found: 838.4142


 


D-28
HATU, DIPEA, DMF




2.99 min (Cond.-D2); LCMS: Anal. Calc. for [M + H]+ C45H58N7O9: 840.43; found: 840.46. HRMS: Anal. Calc. for [M − H]− C45H56N7O9: 838.4140; found: 838.4148.


 


D-29
HATU, DIPEA, DMF



   stereochemical composition undetermined
3.07 min (Cond.-D2); LCMS: Anal. Calc. for [M + H]+ C47H62N7O9: 868.46; found: 868.50. HRMS: Anal. Calc. for [M − H]− C47H60N7O9: 866.4453; found: 866.4488.


 


D-30
HATU, DIPEA, DMF



   stereochemical composition undetermined
3.16 min (Cond.-D2); LCMS: Anal. Calc. for [M + H]+ C47H62N7O9: 868.46; found: 868.56. HRMS: Anal. Calc. for [M − H]− C47H60N7O9: 866.4453; found: 866.4460.


 


D-31
HATU, DIPEA, DMF



   stereochemical composition undetermined
3.06 min (Cond.-D2); LCMS: Anal. Calc. for [M + H]+ C47H58N7O9: 864.43; found: 864.72. HRMS: Anal. Calc. for [M + H]+ C47H58N7O9: 864.4296; found: 864.4313.


 


D-32
HATU, DIPEA, DMF



   stereochemical composition undetermined
3.44 min (Cond.-D2); LCMS: Anal. Calc. for [M + H]+ C59H70N7O9: 1020.52; found: 1020.77. HRMS: Anal. Calc. for [M − H]− C59H68N7O9: 1018.5079; found: 1018.5067.


 


D-33
HATU, DIPEA, DMF



   mixture of diasteromers stereochemical composition undetermined
3.39 and 3.54 min (Cond.-D2); LCMS: Anal. Calc. for [M + H]+ C59H70N7O9: 1020.52; found: 1020.82. HRMS: Anal. Calc. for [M − H]− C59H68N7O9: 1018.5079; found: 1018.5059.









Examples D-34 to D-37




Examples D-34 to D-37 were prepared from their respective Boc-protected (D-27, D-28, D-29/D-30 and D-32/D-33) analogs according to the procedure described for Example MS-7b. The final targets were isolated as HCl salts.
















Rt (LC-Cond.); %



Reaction

homogeneity


Example
Protocol
R1 and R2
index; MS data







D-34
4N HCl in dioxane




1.86 min (Cond.- D2); LCMS: Anal. Calc. for [M + H]+ C35H42N7O5: 640.32; found: 640.57. HRMS: Anal. Calc. for [M + H]+ C35H42N7O5: 640.3247; found: 640.3261


 


D-35
4N HCl in dioxane




1.83 min (Cond.- D2); LCMS: Anal. Calc. for [M + H]+ C35H42N7O5: 640.32; found: 640.26. HRMS: Anal. Calc. for [M + H]+ C35H42N7O5: 640.3247; found: 640.3242


 


D-36
4N HCl in dioxane



   stereochemical composition undetermined
1.87 min (Cond.- D2); LCMS: Anal. Calc. for [M + H]+ C37H46N7O5: 668.36; found: 668.29. HRMS: Anal. Calc. for [M + H]+ C37H46N7O5: 668.3560; found: 668.3530.


 


D-37
4N HCl in dioxane



   stereochemical composition undetermined
2.26 min (Cond.- D2); LCMS: Anal. Calc. for [M + H]+ C49H54N7O5: 820.42; found: 820.31. HRMS: Anal. Calc. for [M + H]+ C49H54N7O5: 820.4186; found: 820.4174.









Examples D-38 to D-41




Examples D-38 to D-41 were prepared from their respective deprotected analogs [shown above, D-34, D-35, D-31 (see comment below), and D-36] and Cap-1 according to the procedure described for the preparation of Example D-57. Purification of the final targets was accomplished using a Shimadzu reverse phase preparative HPLC instrument (solvent systems: H2O/MeOH/TFA or H2O/ACN/TFA) and the final products were isolated as TFA salts. Note: Example D-40 was prepared from D-31 and Cap-1 through its respective deprotected analog (which was not characterized and carried forward directly) according to the procedure described for the preparation of Example D-57. Purification of Example D-40 was accomplished using a Shimadzu reverse phase preparative HPLC instrument (solvent systems: H2O/MeOH/TFA or H2O/ACN/TFA) and the final product was isolated as a TFA salt.
















Rt (LC-Cond.); %



Coupling

homogeneity index;


Example
Protocol
R1 and R2 
MS data







D-38
HATU, DIPEA, DMF




2.21 min (Cond.- D2); LCMS: Anal. Calc. for [M + H]+ C55H64N9O7: 962.49; found: not obsd. HRMS: Anal. Calc. for [M + H]+ C55H64N9O7: 962.4929; found: 962.4929.


 


D-39
HATU, DIPEA, DMF




2.26 min (Cond.- D2); LCMS: Anal. Calc. for [M + H]+ C55H64N9O7: 962.49; found: 962.34. HRMS: Anal. Calc. for [M + H]+ C55H64N9O7: 962.4929; found: 962.4957.


 


D-40
HATU, DIPEA, DMF



   stereochemical composition undetermined
2.28 min (Cond- D2); LCMS: Anal. Calc. for [M + H]+ C57H64N9O7: 986.49; found: 986.78. HRMS: Anal. Calc. for [M + H]+ C57H64N6O7: 986.4929; found: 986.4930.


 


D-41
HATU, DIPEA, DMF



   stereochemical composition undetermined
2.18 min (Cond.- D2); LCMS: Anal. Calc. for [M + H]+ C57H68N9O7: 990.52; found: 990.48. HRMS: Anal. Calc. for [M+H]+ C57H68N9O7: 990.5242; found: 990.5234.









Example OL-7




Example OL-7a




Prepared from 2,5-diphenyl imidazole according to the procedure described for Example OL-1b. This afforded Example OL-7a (1.0 g, 71% yield) as a yellow solid. 1H NMR (DMSO-d6, 500 MHz) δ 13.07 (s, 1H), 8.25 (m, 4H), 8.03 (s, 1H), 7.73 (m, 4H). LC/MS (Cond. OL2): Rt=1.34 min; Anal. Calc. for [M+H]+ C15H11N4O4: 311.07; found: 311.
Example OL-7b




Prepared from Example OL-7a according to the procedure described for Example OL-1c. This afforded Example OL-7b as an off-white solid (0.44 g, 85% yield). 1H NMR (DMSO-d6, 500 MHz) δ 12.36 (bs, 1H), 7.96 (bs, 1H), 7.54 (d, J=8.5 Hz, 4H), 6.93 (d, J=8.5 Hz, 4H), 5.49 (bs, 4H). LC/MS (Cond. OL1): Rt=0.16 min; Anal. Calc. for [M+H]+ C15H15N4: 251.12; found: 251.
Example OL-7
Prepared from Example OL-7b and Carbobenzyloxy-L-Proline, according to the procedure described for Example OL-1d. This afforded the TFA salt of Example OL-7 (0.15 g, 67% yield) as an off-white solid. 1H NMR (DMSO-d6, 500 MHz) δ10.28 (s, 2H), 9.26 (s, 1H), 7.69 (m, 4H), 7.42 (m, 4H), 7.37 (m, 4H), 7.32 (m, 1H), 7.21 (d, J=7.3 Hz, 2H), 7.18 (m, 1H), 7.11 (m, 2H), 5.09 (m, 3H), 4.94 (d, J=13.2 Hz, 1H), 4.39 (dd, J=8.4, 3.9 Hz, 1H), 4.35 (dd, J=8.4, 3.2 Hz, 1H), 3.48 (m, 4H), 2.25 (m, 2H), 1.89 (m, 6H). LC/MS (Cond. OL1): Rt=1.54 min; Anal. Calc. for [M+H]+ C41H41N6O6: 713.30; found: 713.
Example OL-8




Prepared from Example OL-7b and L-Cbz-Alanine according to the procedure described for Example OL-1d. This afforded the TFA salt of Example OL-8 (0.13 g, 75% yield) as an off-white solid. 1H NMR (DMSO-d6, 500 MHz) δ 10.21 (s, 2H), 9.15 (s, 1H), 7.69 (d, J=8.55 Hz, 4H), 7.65 (d, J=7.02 Hz, 2H), 7.41 (d, J=8.55 Hz, 4H), 7.36 (m, 6H), 7.32 (m, 2H), 7.25 (bs, 1H), 7.18 (bs, 1H), 5.03 (m, 4H), 4.19 (m, 2H), 1.30 (d, J=7.02 Hz, 6H). LC/MS (Cond. OL3): Rt=Rt=1.52 min; Anal. Calc. for [M+H]+ C37H37N6O6: 661.27; found: 661.
Example OL-9




Prepared from Example OL-7b and (S)-2-(2-phenylacetamido)propanoic acid according to the procedure described for Example OL-1d. This afforded the TFA salt of Example OL-9 (0.16 g, 78% yield) as an off-white solid. 1H NMR (DMSO-d6, 500 MHz) δ 10.23 (s, 2H), 9.17 (s, 1H), 8.45 (d, J=7.02 Hz, 2H), 7.67 (d, J=8.55 Hz, 4H), 7.39 (d, J=8.55 Hz, 4H), 7.27 (m, 9H), 7.21 (m, 3H), 4.40 (m, 2H), 3.49 (s, 4H), 1.31 (d, J=7.02 Hz, 6H). LC/MS (Cond. OL3): Rt=1.42 min; Anal. Calc. for [M+H]+ C37H37N6O4: 629.28; found: 629.
Example OL-10




Prepared from Example OL-7b and (S)-1-(2-phenylacetyl)pyrrolidine-2-carboxylic acid according to the procedure described for Example OL-1d. This afforded the TFA salt of Example OL-10 (45 mg, 77% yield) as an off-white solid.
1H NMR (DMSO-d6, 500 MHz) δ 10.22 and 10.41 (2s, 2H), 9.26 (s, 1H), 7.68 (d, J=8.85 Hz, 4H), 7.40 (m, 4H), 7.30 (m, 4H), 7.20 (m, 7H), 4.44 and 4.66 (2dd, J=8.4, 3.8 Hz, 4H), 3.70 (m, 4H), 3.60 (m, 4H), 2.16 (m, 2H), 2.01 (m, 2H), 1.90 (m, 4H). LC/MS (Cond. OL2): Rt=1.61 min; Anal. Calc. for [M+H]+ C41H41N6O4: 681.31; found: 681.
Example OL-11




Prepared from Example OL-7b and (2S,4R)-4-hydroxy-1-(2-phenylacetyl)pyrrolidine-2-carboxylic acid according to the procedure described for Example OL-1d. This afforded the TFA salt of Example OL-11 (42 mg, 37% yield) as an off-white solid. 1H NMR (DMSO-d6, 500 MHz) δ 10.25 and 10.41 (2s, 2H), 9.13 (s, 1H), 7.65 (d, J=8.7 Hz, 4H), 7.36 (d, J=8.7 Hz, 4H), 7.24 (m, 10H), 5.18 (bs, 2H), 4.48 (t, J=7.8 Hz, 2H), 4.38 (m, 2H), 3.65 (m, 6H), 3.50 (m, 4H), 2.09 (m, 2H), 1.95 (m, 2H). LC/MS (Cond. OL1): Rt=1.31 min; Anal. Calc. for [M+H]+ C41H41N6O6: 713.30; found: 713.
Example D-42




Example D-42a




4,5-Diphenyl-2-methylthiazole (5.0 g, 19.9 mmol) was added in two portions to cold (0° C.), fuming nitric acid (50 mL). The mixture was stirred at 0° C. for 1 h before it was allowed to warm to ambient temperature where it stirred for 6 h. The mixture was then poured into crushed ice/water and stirred for 1 h before the precipitate was suction-filtered to afford Example D-42a (5.36 g, 79%) as a bright, yellow solid which was used directly in the next reaction. 1H NMR (DMSO-d6, 400 MHz) δ 8.25 (d, J=8.8 Hz, 2H), 8.21 (d, J=8.8 Hz, 2H), 7.69 (d, J=8.8 Hz, 2H), 7.62 (d, J=8.8 Hz, 2H), 2.78 (s, 3H). LC/MS (Cond.-D1): Rt=2.31 min; Anal. Calc. for [M+H]+ C16H13N3O4S: 342.06; found: 342.05. HRMS: Anal. Calc. for [M+H]+ C16H13N3O4S: 342.0549; found: 342.0547.
Example D-42b




A suspension of 20% palladium hydroxide on carbon (0.20 g) in anhydrous methanol (1 mL) was added to a solution of Example D-42a (0.50 g, 1.46 mmol) in anhydrous methanol (20 mL). The mixture was subjected to balloon hydrogenation for 4 h at ambient temperature before it was suction-filtered through Celite and concentrated in vacuo to afford Example D-42b (0.365 g, 89%) as a pale, yellow solid. 1H NMR (MeOD-d4, 400 MHz) δ 7.15 (d, J=8.8 Hz, 2H), 6.97 (d, J=8.8 Hz, 2H), 6.61-6.58 (m, 4H), 2.62 (s, 3H). LC/MS (Cond.-D1): Rt=0.85 min; Anal. Calc. for [M+H]+ C16H15N3S: 282.11; found: 282.07. HRMS: Anal. Calc. for [M+H]+ C16H15N3S: 282.1065; found: 282.1056.
Example D-42
Example D-42 was prepared from Example D-42b and 1.0 eq. of N—Ac-L-proline and 1.0 eq. of N—PhAc-L-proline according to the procedure for Example OL-1d. This afforded D-42 (84.2 mg, 37%) as a mixture of regioisomers as well as Example D-43 (36.4 mg, 18%) and Example D-44 (43.9 mg, 17%) as colorless oils (vide infra).
For Example D-42: 1H NMR (MeOH-d4, 400 MHz) δ 7.53-7.48 (m, 4H), 7.37-7.33 (m, 2H), 7.28-7.19 (2m, 7H), 4.60-4.46 (series of m, 2H), 3.75 (s, 2H), 3.71-3.61 (2m, 4H), 2.70 (s, 3H), 2.30-2.23 (m, 2H), 2.09 and 1.96 (2s, 3H), 2.08-1.92 (m, 6H). LC/MS (Cond.-D1): Rt=2.10 min; Anal. Calc. for [M+H]+ C36H38N5O4S: 636.26; found: 636.17. HRMS: Anal. Calc. for [M+H]+ C36H38N5O4S: 636.2645; found: 636.2622.
Example D-43 and Example D-44




For Example D-43: 1H NMR (MeOD-d4, 400 MHz) δ 7.53-7.49 (m, 4H), 7.38-7.33 (m, 2H), 7.25-7.20 (m, 2H), 4.55-4.45 (series of m, 2H), 3.72-3.66 (m, 2H), 3.62-3.57 (m, 2H), 2.70 (s, 3H), 2.30-2.23 (m, 2H), 2.09 and 1.97 (2s, 6H), 2.08-2.00 (m, 6H). LC/MS (Cond.-D1): Rt=1.78 min; Anal. Calc. for [M+H]+ C30H34N5O4S: 560.23; found: 560.15. HRMS: Anal. Calc. for [M+H]+ C30H34N5O4S: 560.2332; found: 560.2334.
For Example D-44: 1H NMR (MeOD-d4, 400 MHz) δ 7.52-7.47 (m, 4H), 7.35-7.33 (m, 2H), 7.28-7.18 (2m, 12H), 4.60-4.50 (series of m, 2H), 3.75 (s, 4H), 3.71-3.57 (series of m, 4H), 2.70 (2s, 3H), 2.25-2.20 (m, 2H), 2.10-1.95 (series of m, 6H). LC/MS (Cond.-D1): Rt=2.34 min; Anal. Calc. for [M+H]+ C42H42N5O4S: 712.30; found: 712.19. HRMS: Anal. Calc. for [M+H]+ C42H42N5O4S: 712.2958; found: 712.2951.
Example D-45




Example D-45a




p-Azidophenacyl bromide (1.0 g, 4.2 mmol) was added in one portion to a stirred solution of p-aminobenzthioamide (0.64 g, 4.2 mmol) in absolute ethanol (10 mL). The mixture was heated to reflux for 2 h before it was cooled to ambient temperature, diluted with ether and chilled for 16 h at −20° C. before it was suction-filtered to afford Example D-45a (1.38 g, 88%) as a mustard-colored solid. A portion of the residue was used to characterize the compound. The bulk of the material was taken up in ethyl acetate and washed with saturated sodium bicarbonate solution and brine, dried over Na2SO4 and concentrated. The free base was directly used in the next step. 1H NMR (MeOD-d4, 500 MHz) δ 8.19 (d, J=8.6 Hz, 2H), 8.06 (d, J=8.9 Hz, 2H), 7.88 (s, 1H), 7.48 (d, J=8.8 Hz, 2H), 7.17 (d, J=8.9 Hz, 2H); LC/MS (Cond.-D1): Rt=2.06 min; Anal. Calc. for [M+H]+ C15H12N5S: 294.08; found: 294.10. HRMS: Anal. Calc. for [M+H]+ C15H12N5S: 294.0814; found: 294.0812.
Example D-45b




Prepared from Example D-45a and N-acetyl-L-proline according to the procedure described for Example OL-1d. There was isolated Example D-45a (440 mg mg, 82%) as a yellowish-tan solid. 1H NMR (MeOD-d4, 400 MHz) δ 8.03-8.00 (m, 2H), 7.98-7.95 (2m, 2H), 7.74-7.68 (m, 3H), 7.13-7.11 (m, 2H), 4.59-4.56 and 4.54-4.50 (2m, 1H), 3.74-3.68 (m, 1H), 3.65-3.59 (m, 1H), 2.31-2.25 (m, 1H), 2.11 and 1.99 (2s, 3H), 2.09-1.96 (m, 3H). LC/MS (Cond.-D1): Rt=2.50 min; Anal. Calc. for [M+H]+ C22H21N6O2S: 433.14; found: 433.15. HRMS: Anal. Calc. for [M+H]+ C22H21N6O2S: 433.14467 found: 433.1464.
Example D-45c




Example D-45b (640.1 mg, 1.48 mmol) was hydrogenated at ambient temperature under 1 atm of hydrogen for 2 h in methanol (20 mL) using 20% palladium hydroxide on carbon (300 mg) to afford Example D-45c (586.1 mg, 97%) as an orange foam which was used directly. 1H NMR (MeOD-d4, 400 MHz) δ 10.41 and 10.22 (2s, 1H), 7.97-7.93 (m, 2H), 7.77-7.68 (series of m, 5H), 6.63 (d, J=8.6 Hz, 1H), 5.37 (v br s, 2H), 4.55-4.41 (2m, 1H), 3.64-3.50 (2m, 2H), 2.35-2.10 (2m, 1H), 2.01 and 1.86 (2s, 3H), 1.96-1.87 (m, 3H). LC/MS (Cond.-D1): Rt=1.51 min; Anal. Calc. for [M+H]+ C22H23N4O2S: 407.15; found: 407.13. HRMS: Anal. Calc. for [M+H]+ C22H23N4O2S: 407.1542; found: 407.1539.
Example D-45
Prepared from Example D-45c and N-phenacetyl-L-proline according to the procedure described for Example OL-1d. This afforded Example D-45 (17.9 mg, 39%) as an off-white solid. 1H NMR (DMSO-d6, 400 MHz) δ 10.42, 10.35, 10.23 and 10.13 (4s, 2H), 8.04-7.96 (m, 5H), 7.78-7.68 (m, 4H), 7.33-7.19 (m, 5H), 4.69-4.41 (3m, 2H), 3.71 (s, 2H), 3.68-3.43 (series of m, 4H), 2.40-2.14 (2m, 2H), 2.01-1.86 (2s, 3H), 2.00-1.89 (m, 6H). LC/MS (Cond.-D1): Rt=2.26 min; Anal. Calc. for [M+H]+ C35H36N5O4S: 622.25; found: 622.29. HRMS: Anal. Calc. for [M+H]+ C35H36N5O4S: 622.2488; found: 622.2483.
Example D-46




Prepared from Example D-45c and 5-oxo-1-(2-(thiophen-2-yl)ethyl)pyrrolidine-3-carboxylic acid according to the procedure described for Example OL-1d. This afforded Example D-46 (14.3 mg, 31%) as an off-white solid.
1H NMR (DMSO-d6, 400 MHz) δ 10.43 and 10.24 (2s, 2H), 8.02-7.96 (m, 5H), 7.79-7.69 (m, 4H), 7.36-7.34 (m, 1H), 6.96-6.92 (m, 2H), 4.55-4.53 and 4.44-4.41 (2m, 1H), 3.63-3.55 (m, 2H), 3.50-3.43 (m, 4H), 3.03-3.00 (m, 2H), 2.53 (s, 1H), 2.40-2.10 (2m, 1H), 2.01-1.86 (2s, 3H), 1.94-1.90 (m, 3H). LC/MS (Cond.-D1): Rt=2.29 min; Anal. Calc. for [M+H]+ C33H34N5O4S2: 628.21; found: 628.13. HRMS: Anal. Calc. for [M+H]+ C33H34N5O4S2: 628.2052; found: 628.2076.
Example D-47




Example D-47a




Prepared from Example D-45c and (S)-1-(tert-butoxycarbonyl)-2,5-dihydro-1H-pyrrole-2-carboxylic acid according to the procedure described for Example OL-1d. This afforded Example D-47a (554 mg, 76%) as a pale, yellow solid. 1H NMR (DMSO-d6, 500 MHz) δ 10.41, 10.22 and 10.20 (3s, 2H), 8.01-7.96 (m, 5H), 7.78-7.70 (m, 4H), 6.08-6.04 (m, 1H), 5.88-5.85 (m, 1H), 5.02-4.97 (m, 1H), 4.55-4.41 (2m, 1H), 4.23-4.14 (m, 1H), 4.10-4.06 (m, 1H), 3.63-3.59 (m, 1H), 3.56-3.51 (m, 1H), 2.18-2.14 (m, 1H), 2.01 and 1.86 (2s, 3H), 1.99-1.91 (m, 3H), 1.43 and 1.31 (2s, 9H). LC/MS (Cond.-D1): Rt=2.27 min; Anal. Calc. for [M+H]+ C32H36N5O5S: 602.24; found: 602.28. HRMS: Anal. Calc. for [M+H]+ C32H36N5O5S: 602.2437; found: 602.2458.
Example D-47b




Example D-47a (0.50 g, 0.828 mmol) was subjected to acidic hydrolysis with 4N HCl in dioxane (20 mL) for 3 h before it was concentrated down in vacuo to yield Example D-47b (0.50 g, 113+%) as a yellow solid which was used directly. 1H NMR (MeOH-d4, 400 MHz) δ 7.99-7.93 (m, 4H), 7.73-7.65 (m, 5H), 6.13-6.09 (m, 2H), 5.22-5.21 (m, 1H), 4.60-4.50 (2m, 1H), 4.30-4.25 (m, 1H), 4.18-4.14 (m, 1H), 3.73-3.68 (m, 1H), 3.65-3.59 (m, 1H), 2.50-2.25 (2m, 1H), 2.11 and 1.99 (2s, 3H), 2.09-2.00 (m, 3H). LC/MS (Cond.-D1): Rt=1.72 min; Anal. Calc. for [M+H]+ C22H28N5O3S: 502.19; found: 502.15 HRMS: Anal. Calc. for [M+H]+ C22H28N5O3S: 502.1913; found: 502.1918.
Example D-47
Prepared from Example D-47b and thiophene-2-carboxylic acid according to the procedure described for Example D-57. This afforded Example D-47 (15.1 mg, 27%) as an off-white solid. 1H NMR (DMSO-d4, 400 MHz) δ 10.42, 10.34 and 10.23 (3s, 2H), 8.03-7.97 (m, 5H), 7.87-7.86 (m, 1H), 7.77-7.70 (m, 5H), 7.24-7.22 (m, 1H), 6.20-6.18 (m, 1H), 6.03-6.01 (m, 1H), 5.70-5.40 (2m, 1H), 4.80-4.75 (m, 1H), 4.69-4.65 (m, 1H), 4.55-4.41 (2m, 1H), 3.63-3.50 (2m, 2H), 2.31-2.13 (2m, 1H), 2.01 and 1.86 (2s, 3H), 1.99-1.87 (m, 3H). LC/MS (Cond.-D1): Rt=2.11 min; Anal. Calc. for [M+H]+ C32H30N5O4S2: 612.17; found: 612.12. HRMS: Anal. Calc. for [M+H]+ C32H30N5O4S2: 612.1739; found: 612.1716.
Example D-48




Prepared from Example D-47b and 2-(thiophen-2-yl)acetic acid according to the procedure described for Example D-57. This afforded Example D-48 (23.9 mg, 41%) as a light, yellow solid. 1H NMR (DMSO-d6, 400 MHz) δ 10.46, 10.42, 10.24 and 10.23 (4s, 2H), 8.05-7.94 (m, 5H), 7.78-7.68 (2m, 4H), 7.40-7.36 (2m, 1H), 6.99-6.89 (series of m, 2H), 6.14-6.12 (m, 1H), 6.03-5.92 (2m, 1H), 5.43-5.41 and 5.17-5.16 (2m, 1H), 4.55-4.42 (m, 1H), 4.46 (s, 2H), 4.00-3.98 (m, 1H), 3.64-3.51 (m, 2H), 2.36-2.10 (2m, 2H), 2.01 and 1.86 (2s, 3H), 1.97-1.90 (m, 3H). LC/MS (Cond.-D1): Rt=2.17 min; Anal. Calc. for [M+H]+ C33H32N5O4S2: 626.19; found: 626.12. HRMS: Anal. Calc. for [M+H]+ C33H32N5O4S2: 626.1896; found: 626.1891.
Example D-49




Prepared from Example D-47b and 2-phenylacetic acid according to the procedure described for Example D-57. This afforded Example D-49 (24.0 mg, 42%) as an off-white solid. 1H NMR (DMSO-d6, 400 MHz) δ 10.46, 10.42, 10.24 and 10.23 (4s, 2H), 8.05-7.96 (m, 5H), 7.79-7.68 (2m, 4H), 7.34-7.19 (m, 5H), 6.14-6.10 (m, 1H), 6.02-5.92 (2m, 1H), 5.41-5.39 and 5.16-5.15 (2m, 1H), 4.55-4.52 and 4.44-4.41 (2m, 2H), 3.74 (s, 2H), 3.64-3.51 (2m, 3H), 2.36-2.30 and 2.20-2.10 (2m, 1H), 2.01 and 1.86 (2s, 3H), 1.95-1.90 (m, 3H). LC/MS (Cond.-D1): Rt=2.21 min; Anal. Calc. for [M+H]+ C35H34N5O4S: 620.23; found: 620.17. HRMS: Anal. Calc. for [M+H]+ C35H34N5O4S: 620.2332; found: 620.2355.
Example D-50




Prepared from Example D-47b and isoxazole-5-carboxylic acid according to the procedure described for Example D-57. This afforded Example D-50 (21.4 mg, 39%) as an off-white solid. 1H NMR (DMSO-d6, 400 MHz) δ 10.48, 10.42, 10.39 and 10.23 (4s, 2H), 8.83 and 8.69 (2m, 1H), 8.03-7.95 (m, 5H), 7.78-7.56 (series of m, 4H), 7.20-7.19 and 7.04-7.03 (2m, 1H), 6.20-6.18 (m, 1H), 6.07-6.02 (m, 1H), 5.80-5.76 and 5.41-5.39 (2m, 1H), 4.78-4.41 (series of m, 3H), 3.63-3.50 (2m, 2H), 2.35-2.13 (2m, 1H), 2.01 and 1.86 (2s, 3H), 1.99-1.87 (m, 3H). LC/MS (Cond.-D1): Rt=1.98 min; Anal. Calc. for [M+H]+ C31H29N6O5S: 597.19; found: 597.13. HRMS: Anal. Calc. for [M+H]+ C31H29N6O5S: 597.1920; found: 597.1936.
Example D-51




Prepared from Example D-47b and (R)-tetrahydrofuran-2-carboxylic acid according to the procedure described for Example D-57. This afforded Example D-51 (27.1 mg, 49%) as an off-white solid. 1H NMR (DMSO-d6, 400 MHz) δ 10.42, 10.39 and 10.24 (3s, 2H), 8.03-7.97 (m, 5H), 7.79-7.74 (m, 2H), 7.70-7.68 (m, 2H), 6.12-6.10 (m, 1H), 5.99-5.91 (2m, 1H), 5.53-5.51 and 5.15-5.14 (2m, 1H), 4.62-4.20 (series of m, 4H), 3.85-3.70 (m, 2H), 3.64-3.51 (2m, 2H), 2.35-2.05 (2m, 2H), 2.01 and 1.86 (2s, 3H), 2.00-1.83 (m, 6H). LC/MS (Cond.-D1): Rt=1.99 min; Anal. Calc. for [M+H]+ C32H34N5O5S: 600.23; found: 600.17. HRMS: Anal. Calc. for [M+H]+ C32H34N5O5S: 600.2281; found: 600.2286.
Example D-52




Prepared from Example D-47b and (S)-tetrahydrofuran-2-carboxylic acid according to the procedure described for Example D-57. This afforded Example D-52 (12.4 mg, 22%) as an off-white solid. 1H NMR (DMSO-d6, 400 MHz) δ 10.42, 10.25 and 10.24 (3s, 2H), 8.02-7.96 (m, 5H), 7.79-7.74 (m, 2H), 7.71-7.69 (m, 2 H), 6.12-6.10 (m, 1H), 5.96-5.92 (m, 1H), 5.42-5.40 and 5.17-5.15 (2m, 1H), 4.66-4.64 (m, 1H), 4.58-4.36 (series of m, 3H), 3.83-3.76 (m, 2H), 3.66-3.50 (2m, 2H), 2.35-2.05 (2m, 2H), 2.01 and 1.86 (2s, 3H), 1.96-1.83 (m, 6H). LC/MS (Cond.-D1): Rt=2.01 min; Anal. Calc. for [M+H]+ C32H34N5O5S: 600.23; found: 600.15. HRMS: Anal. Calc. for [M+H]+ C32H34N5O5S: 600.2281; found: 600.2305.
Example D-53




Prepared from Example D-47b and benzoic acid according to the procedure described for Example D-57. This afforded Example D-53 (16.8 mg, 30%) as a light, yellow solid. 1H NMR (DMSO-d6, 400 MHz) δ 10.42, 10.33, 10.23 and 9.96 (4s, 2H), 8.03-7.90 (m, 5H), 7.79-7.73 (m, 4H), 7.63-7.61 (m, 1H), 7.51-7.48 (m, 2H), 7.43-7.34 (2m, 2H), 6.18-5.88 (series of m, 2H), 5.42-5.40 and 5.22 (2m, 1H), 4.55-4.41 (series of m, 2H), 4.21-4.14 (m, 1H), 3.64-3.50 (2m, 2H), 2.35-2.15 (2m, 1H), 2.01 and 1.86 (2s, 3H), 1.96-1.88 (m, 3H). LC/MS (Cond.-D1): Rt=2.12 min; Anal. Calc. for [M+H]+ C34H32N5O4S: 606.22; found: 606.15. HRMS: Anal. Calc. for [M+H]+ C34H32N5O4S: 606.2175; found: 606.2188.
Example OL-12




Example OL-12a




p-Nitroaniline (1.5 g, 10.86 mmol) and p-nitrobenzoyl chloride (2.05 g, 11.08 mmol) were mixed in tetrahydrofuran (30 mL) and stirred at ambient temperature overnight. A brown solid crashed out, which was filtered and washed with tetrahydrofuran to give Example OL-12a (2.40 g, 77% yield) which was used without further purification. 1H NMR (DMSO-d6, 500 MHz) δ 11.10 (s, 1H), 8.40 (d, J=9.1, 2H), 8.30 (d, J=9.1 Hz, 2H), 8.21 (d, J=9.1 Hz, 2H), 8.06 (d, J=9.1 Hz, 2H). LC/MS (Cond. OL1): Rt=1.57 min; Anal. Calc. for [M+H]+ C13H10N3O5: 288.05; found: 288.
Example OL-12b




Phosphorous pentachloride (0.32 g, 1.53 mmol) was added to a solution of Example OL-12a (0.4 g, 1.39 mmol) in benzene (15 mL). The mixture was heated to reflux temperature for 4 h., concentrated under reduced pressure and the residue was taken up in tetrahydrofuran (5 mL). The solution was then transferred via-canula into a solution of hydrazine (0.44 mL, 13.9 mmol) in tetrahydrofuran (10 mL) at 0° C. The mixture was stirred at ambient temperature for 1 h., poured into water and extracted with ethyl acetate (2×). The combined organic layers were washed with brine, dried (Na2SO4), filtered and concentrated under reduced pressure to give Example OL-12b (0.38 g, 92% yield) as a yellow solid which was used without further purification. 1H NMR (DMSO-d6, 500 MHz) δ 8.85 (bs, 1H), 8.19 (d, J=9.1, 2H), 8.07 (d, J=9.1 Hz, 2H), 7.73 (d, J=9.1 Hz, 2H), 7.35 (bs, 2H), 6.59 (d, J=9.1 Hz, 2H). LC/MS (Cond. OL2): Rt=1.05 min; Anal. Calc. for [M+H]+ C13H12N5O4: 302.08; found: 302.
Example OL-12c




Carbonyldiimidazole (0.1 g, 0.65 mmol) was added to a solution of Example OL-12b (0.16 g, 0.54 mmol) in tetrahydrofuran (5 mL), and allowed to stir at ambient temperature until the disappearance of the starting material, as judged by TLC. The mixture was then concentrated under reduced pressure, and the residue was re-dissolved in ethyl acetate, washed with 0.1 N HCl, water and brine, dried (MgSO4), filtered and concentrated. The remaining residue was purified by flash chromatography, eluting with ethyl acetate/hexanes (50:50) and the obtained oil was dissolved in dichloromethane and triturated with hexanes, to give Example OL-12c (0.11 g, 62% yield) as a yellowish solid. 1H NMR (DMSO-d6, 500 MHz) δ 12.81 (bs, 1H), 8.33 (d, J=8.8, 2H), 8.22 (d, J=8.8 Hz, 2H), 7.59 (d, J=8.8 Hz, 2H), 7.57 (d, J=8.8 Hz, 2H). LC/MS (Cond. OL2): Rt=1.34 min; Anal. Calc. for [M+H]+ C14H10N5O5: 328.06; found: 328.
Example OL-12d




Prepared from Example OL-12c according to the procedure described for Example OL-1c. This afforded Example OL-12d (73 mg, 63% yield) as an off-white solid. 1H NMR (DMSO-d6, 500 MHz) δ 11.65 (s, 1H), 6.95 (d, J=8.5, 2H), 6.82 (d, J=8.5 Hz, 2H), 6.56 (d, J=8.5 Hz, 2H), 6.42 (d, J=8.5 Hz, 2H), 5.43 (bs, 2 H), 5.34 (bs, 2H). LC/MS (Cond. OL1): Rt=0.21 min; Anal. Calc. for [M+H]+ C14H14N5O: 268.11; found: 268.
Example OL-12
Prepared from Example OL-12d and L-Cbz-Alanine, according to the procedure described for Example OL-1d. This afforded Example OL-12 (60 mg, 65% yield) as an off-white solid. 1H NMR (DMSO-d6, 500 MHz) δ 12.01 (s, 1H), 10.14 (d, J=12.8, 2H), 7.62 (m, 4H), 7.54 (d, J=8.7 Hz, 2H), 7.31 (m, 10H), 7.18 (dd, J=11.9, 8.9 Hz, 4H), 5.00 (m, 4H), 4.15 (m, 2H), 1.28 (d, J=7.3 Hz, 3H), 1.24 (d, J=7.3 Hz, 3H). LC/MS (Cond. OL2): Rt=1.85 min; Anal. Calc. for [M+H]+ C36H36N7O7: 678.26; found: 678.
Example OL-13




Prepared from Example OL-12d and Carbobenzyloxy-L-Proline, according to the procedure described for Example OL-1d. This afforded Example OL-13 (71 mg, 72% yield). 1H NMR (DMSO-d6, 500 MHz) δ 12.07 (s, 1H), 10.23 (d, J=3.66 Hz, 1H), 10.19 (d, J=5.12 Hz, 1H), 7.66 (m, 2H), 7.54 (m, 2H), 7.35 (m, 4H), 7.21 (m, 8H), 7.09 (d, J=7.3 Hz, 1H), 7.04 (d, J=6.9 Hz, 1H), 5.07 (m, 3H), 4.90 (m, 1H), 4.35 (m, 2H), 3.47 (m, 4H), 2.22 (m, 2H), 1.89 (m, 6H). LC/MS (Cond. OL2): Rt=1.68 min; Anal. Calc. for [M+H]+ C40H40N7O7: 730.29; found: 730.
Example OL-14




Example OL-14a




p-Toluenesulfonic acid (25 mg, catalytic) was added to a mixture of 4-Nitro phenyl-N-(4-nitro-phenyl)-hydrazonamide (160 mg, 053 mmol) and N,N′-dimethylformamide dimethylacetal (92 μL, 069 mmol) in benzene (10 mL). The suspension was stirred at reflux temperature under Dean-Stark conditions with a yellow solid forming after 1 h. The solvent was removed under reduced pressure and the residue was taken up in ethyl acetate, washed with 0.1 N HCl and brine, dried (MgSO4), filtered and concentrated. The residue was purified by flash chromatography, eluting with dichloromethane and methanol/dichloromethane (10:90), to give Example OL-14a (0.11 g, 67% yield) as a yellow solid. 1H NMR (DMSO-d6, 500 MHz) δ 9.11 (s, 1H), 8.37 (d, J=8.8, 2H), 8.26 (d, J=8.8 Hz, 2 H), 7.72 (d, J=8.8 Hz, 2H), 7.69 (d, J=8.8 Hz, 2H). LC/MS (Cond. OL2): Rt=1.20 min; Anal. Calc. for [M+Na]+ C14H9N5NaO4: 334.06; found: 334.
Example OL-14b




Prepared from Example OL-14a according to the procedure described for Example OL-1c. This afforded Example OL-14b (60 mg, 75% yield) as an off-white solid. 1H NMR (DMSO-d6, 500 MHz) δ 8.49 (s, 1H), 7.07 (d, J=8.5, 2H), 6.94 (d, J=8.8 Hz, 2H), 6.59 (d, J=8.8 Hz, 2H), 6.47 (d, J=8.5 Hz, 2H), 5.46 (s, 2H), 5.43 (s, 2H). LC/MS (Cond. OL2): Rt=0.18 min; Anal. Calc. for [M+H]+ C14H14N5: 252.12; found: 252.
Example OL-14
Prepared from Example OL-14b and Carbobenzyloxy-L-Proline according to the procedure described for Example OL-1d. This afforded the TFA salt of Example OL-14 (46 mg, 75% yield) as an off-white solid. 1H NMR (DMSO-d6, 500 MHz) δ 10.31 (m, 1H), 10.22 (d, J=7.2 Hz, 1H), 8.82 d, J=3.0 Hz, 1H), 7.70 (m, 2H), 7.60 (m, 2H), 7.32 (t, J=4.3 Hz, 4H), 7.31 (m, 4H), 7.18 (m, 3H), 7.10 (d, J=7.3 Hz, 1H), 7.05 (t, J=7.0 Hz, 1H), 5.08 (m, 3H), 4.92 (m, 1H), 4.35 (m, 2H), 3.45 (m, 5H), 2.34 (m, 2H), 1.88 (m, 6H). LC/MS (Cond. OL1): Rt=1.56 min; Anal. Calc. for [M+H]+ C40H40N7O6: 714.30; found: 714.
Example OL-15




Prepared from Example OL-14b and (S)-1-(2-phenylacetyl)pyrrolidine-2-carboxylic acid according to the procedure described for Example OL-1d. This afforded the TFA salt of Example OL-15 (46 mg, 63% yield) as an off-white solid. 1H NMR (DMSO-d6, 500 MHz) δ 10.25 and 10.43 (2s, 1H), 10.17 and 10.35 (2s, 1H), 8.82 (s, 1H), 7.69 (d, J=8.8 Hz, 2H), 7.59 (d, J=8.8 Hz, 2H), 7.24 (m, 14H), 4.42 (m, 2H), 3.69 (d, J=4.4 Hz, 4H), 3.59 (m, 4H), 3.40 (m, 1H), 2.14 (m, 2H), 1.95 (m, 6H). LC/MS (Cond. OL1): Rt=1.50 min; Anal. Calc. for [M+H]+ C40H40N7O4: 682.31; found: 682.
Example OL-16




Prepared from Example OL-14b and L-Cbz-Alanine according to the procedure described for Example OL-1d. This afforded the TFA salt of Example OL-16 (40 mg, 45% yield) as an off-white solid. 1H NMR (DMSO-d6, 500 MHz) δ 10.68 (s, 1H), 10.59 (s, 1H), 9.22 (d, J=2.1, 1H), 8.15 (d, J=8.5, 2H), 8.08 (m, 1H), 8.04 (d, J=8.8 Hz, 2H), 7.76 (m, 13H), 7.64 (m, 1H), 7.53 (m, 1H), 5.45 (m, 4H), 4.62 (m, 2H), 1.73 (d, J=7.3 Hz, 3H), 1.71 (d, J=7.3 Hz, 3H). LC/MS (Cond. OL2): Rt=1.65 min; Anal. Calc. for [M+H]+ C36H36N7O6: 662.26; found: 662.
Example OL-17




Prepared from Example OL-14b and (2S,4R)-4-hydroxy-1-(2-phenylacetyl)pyrrolidine-2-carboxylic acid according to the procedure described for Example OL-1d. This aforded the TFA salt of Example OL-17 (52 mg, 52% yield) as an off-white solid. 1H NMR (DMSO-d6, 500 MHz) δ 10.28 and 10.47 (2s, 1H), 10.19 and 10.39 (2s, 1H), 8.77 (s, 1H), 7.69 (d, J=8.5 Hz, 2H), 7.58 (d, J=8.5 Hz, 2H), 7.25 (m, 14H), 5.14 (bs, 2H), 4.48 (q, J=7.8 Hz, 2H), 4.38 (m, 2H), 3.67 (m, 6H), 3.49 (m, 4H), 2.10 (m, 2H), 1.95 (m, 2H). LC/MS (Cond. OL2): Rt=1.37 min; Anal. Calc. for [M+H]+ C40H40N7O6: 714.30; found: 714.
Example MS-8




Prepared from commercially available 4,4′-(1,3,4-oxadiazole-2,5-diyl)dianiline and (S)-1-(benzyloxycarbonyl)pyrrolidine-2-carboxylic acid (i.e. N—CBz-L-proline) according to the procedure described for Example OL-1d. This afforded Example MS-8 (16.1 mg, 11%) as a colorless film. 1H NMR (CDCl3, 500 MHz) δ 9.67 (br s, 2H), 8.02 (m, 2H), 7.81 (m, 4H), 7.55 (m, 4H), 7.20-7.36 (series of m, 8H), 5.16-5.25 (m, 4H), 4.50 (br s, 2H), 3.63 (br s, 2H), 3.52 (br s, 2H), 2.32 (m, 2H), 1.97-2.12 (m, 6H). LC/MS (Cond.-MS-W1): Rt=1.82 min; Anal. Calc. for [M+H]+ C40H39N6O7: 715.28; found: 715.41.
Example MS-9




Prepared from commercially available 4,4′-(1,3,4-oxadiazole-2,5-diyl)dianiline and (S)-1-(2-phenylacetyl)pyrrolidine-2-carboxylic acid (i.e. N-phenacetyl-L-proline) according to the procedure described for Example OL-1d. This afforded Example MS-9 (22.7 mg, 17%) as a colorless film. 1H NMR (CDCl3, 500 MHz) δ 9.91 (s, 2H), 7.72-7.70 (m, 4H), 7.50-7.48 (m, 4H), 7.33-7.25 (m, 10H), 4.84 (br s, 4H), 4.63 (s, 2H), 3.77 (s, 2H), 3.61-3.59 (m, 2H), 2.24-2.23 (m, 4H), 1.98 (br s, 4H); LC/MS (Cond. MS-W1): Rt=1.78 min; Anal. Calc. for [M+H]+ C40H39N6O5: 683.30; found: 683.44.
Example D-54, Example D-55, and Example D-56







Examples D-54, D-55 and D-56 were prepared from commercially available 4,4′-(1,3,4-oxadiazole-2,5-diyl)dianiline and 1.0 eq. of phenylacetic acid and 1.0 eq. acetic acid according to the procedure described for Example OL-1d. There was isolated a statistical mixture of products (Example D-54, Example D-55 and Example D-56) which were purified by preparative HPLC on a C18-reverse phase column (MeOH/H2O/TFA) to give all three components separately.
For Example D-54 (84.2 mg, 35%), off-white solid. 1H NMR (MeOH-d4, 400 MHz) δ 7.90-7.80 and 7.71-7.68 (2m, 4H), 7.68-7.62 and 7.57-7.54 (2m, 4H), 7.28-7.27 (m, 3H), 7.22-7.16 (m, 2H), 4.54-4.51 (m, 2H), 3.77 (2s, 2H), 3.75-3.56 (m, 4H), 2.40-2.30 and 2.22-2.06 (m, 2H), 2.13 and 1.97 (2s, 3H), 2.00-1.90 (m, 6H). LC/MS (Cond.-D1): Rt=2.18 min; Anal. Calc. for [M+H]+ C34H35N6O5: 607.26; found: 607.23. HRMS: Anal. Calc. for [M+H]+ C34H35N6O5: 607.2669; found: 607.2669.
For Example D-55 (36.4 mg, 17%), off-white solid. 1H NMR (MeOH-d4, 400 MHz) δ 7.98-7.94 and 7.85-7.83 (2m, 4H), 7.78-7.72 and 7.67-7.65 (2m, 4H), 4.60-4.53 (m, 2H), 3.75-3.68 (m, 2H), 3.65-3.60 (m, 2H), 2.50-2.40 and 2.32-2.23 (2m, 2H), 2.13, 2.12 and 1.99 (3s, 6H), 2.10-1.97 (m, 6H). LC/MS (Cond.-D1): Rt=1.79 min; Anal. Calc. for [M+H]+ C28H30N6O5: 531.24; found: 531.37. HRMS: Anal. Calc. for [M+H]+ C28H30N6O5: 531.2356; found: 531.2338.
For Example D-56 (43.9 mg, 16%), off-white solid. 1H NMR (MeOH-d4, 400 MHz) δ 7.97-7.92 and 7.74-7.72 (2m, 4H), 7.72-7.68 and 7.58-7.56 (2m, 4H), 7.29-7.28 (m, 6H), 7.24-7.19 (m, 4H), 4.52-4.49 (m, 2H), 3.80 and 3.79 (2s, 4H), 3.76-3.72 (m, 2H), 3.67-3.64 (m, 2H), 2.15-2.05 (m, 4H), 1.98-1.90 (m, 4H). LC/MS (Cond.-D1): Rt=2.42 min; Anal. Calc. for [M+H]+ C40H39N6O5: 683.30; found: 683.26. HRMS: Anal. Calc. for [M+H]+ C40H39N6O5: 683.2982; found: 683.2993. Note: Example MS-9 is the same as Example D-56, however, these were prepared differently.
Example D-57




Example D-57a




Prepared from commercially available 4,4′-(1,3,4-oxadiazole-2,5-diyl)dianiline and (S)-1-(tert-butoxycarbonyl)pyrrolidine-2-carboxylic acid according to the procedure described for Example OL-1d. This afforded Example D-57a (2.85 g, 89%) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 10.38 and 10.37 (2s, 2H), 8.08 (d, J=8.8 Hz, 4H), 7.87-7.84 (m, 4H), 4.31 and 4.22 (2m, 2H), 3.47-3.41 (m, 2H), 3.39-3.35 (m, 2H), 2.24-2.18 (m, 2H), 1.94-1.81 (2m, 6H), 1.41 and 1.27 (2s, 18H); LC/MS (Cond. D1): Rt=2.42 min; Anal. Calc. for [M+H]+ C34H43N6O7: 647.32; found: 647.28. HRMS: Anal. Calc. for [M−H]− C34H41N6O7: 645.3037; found: 645.3016.
Example D-57b




A cold (0° C.) solution of 4N HCl in dioxane (20 mL) was added to Example D-57a (2.50 g, 3.86 mmol). The mixture was stirred rapidly at 0° C. for 1 h before it was allowed to warm up to room temperature. After 1 h at room temperature, the mixture was concentrated down in vacuo to afford Example D-57b (1.74 g, 86%) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 11.38 (s, 2H), 10.01-10.00 (m, 2H), 8.74-8.72 (m, 2H), 8.12 (d, J=8.8 Hz, 4H), 7.91 (d, J=8.8 Hz, 4H), 4.49-4.46 (m, 2H), 3.31-3.25 (m, 4H), 2.49-2.43 (m, 2H), 2.03-1.92 (m, 6H); LC/MS (Cond.-D1): Rt=1.27 min; Anal. Calc. for [M+H]+ C24H29N6O3: 447.21; found: 447.22. HRMS: Anal. Calc. for [M+H]+ C24H29N6O3: 447.2145; found: 447.2120.
Example D-57
HATU (10.3 mg, 0.103 mmol) was added in one portion to a stirred solution of Example D-57b (42 mg, 0.094 mmol), diisopropylethylamine (97 mg, 0.753 mmol) and 2-cyclopropylacetic acid (10.4 mg, 0.103 mmol; 1.0 eq. of each acid was used for the unsymmetrical cases) in anhydrous dimethylformamide (1 mL) at ambient temperature. The mixture was stirred for 4 h before it was diluted with methanol (1 mL) and purified by preparatory HPLC on C18— reverse phase to afford Example D-57 as a trifluoroacetic acid salt. The salt was taken up in methanol (2.0 mL) and free-based using a UCT CHQAX12M6 anion exchange cartridge to afford Example D-57 (35.8 mg, 61%, free base) as an off-white solid. 1H NMR (MeOH-d4, 400 MHz) δ 7.99-7.94 and 7.79-7.77 (2m, 4H), 7.77-7.72 and 7.65-7.63 (2m, 4H), 4.61-4.57 (m, 2H), 3.71-3.58 (2m, 4H), 2.42-233 (m, 4H), 2.29-1.95 (3m, 8H), 1.09-1.02 (m, 2H), 0.55-0.47 (m, 4H), 0.23-0.15 (m, 4H). LC/MS (Cond.-D1): Rt=2.26 min; Anal. Calc. for [M+H]+ C34H39N6O5: 611.30; found: 611.25. HRMS: Anal. Calc. for [M+H]+ C34H39N6O5: 611.2982; found: 611.2971.
Example D-58




Prepared from Example D-57b and cyclopropanecarboxylic acid according to the procedure described for Example D-57. This afforded Example D-58 (34.0 mg, 61%) as an off-white solid. 1H NMR (DMSO-d6, 400 MHz) δ 10.50 and 10.39 (2s, 2H), 8.10-8.05 (m, 4H), 7.87-7.82 (m, 4H), 4.78-4.75 and 4.47-4.43 (2m, 2H), 3.82-3.70 (2m, 4H), 2.25-1.80 (series of m, 10H), 0.77-0.64 (m, 8H). LC/MS (Cond.-D1): Rt=2.06 min; Anal. Calc. for [M+H]+ C32H35N6O5: 583.27; found: 583.38. HRMS: Anal. Calc. for [M+H]+ C32H35N6O5: 583.2669; found: 583.2656.
Example D-59




Prepared from Example D-57b and cyclobutanecarboxylic acid according to the procedure described for Example D-57. This afforded Example D-59 (21.0 mg, 36%) as an off-white solid. 1H NMR (MeOH-d4, 400 MHz) δ 8.05-8.00 and 7.89-7.87 (2m, 4H), 7.81-7.76 and 7.71-7.69 (2m, 4H), 4.56-4.53 (m, 2H), 3.65-3.51 (2m, 4H), 3.46-3.39 (m, 2H), 2.35-1.94 (series of m, 18H), 1.90-1.80 (m, 2H). LC/MS (Cond.-D1): Rt=2.33 min; Anal. Calc. for [M+H]+ C34H39N6O5: 611.30; found: 611.40. HRMS: Anal. Calc. for [M+H]+ C34H39N6O5: 611.2982; found: 611.2997.
Example D-60




Prepared from Example D-57b and (S)-tetrahydrofuran-2-carboxylic acid according to the procedure described for Example D-57. This afforded Example D-60 (35.2 mg, 57%) as an off-white solid. 1H NMR (MeOH-d4, 400 MHz) δ 7.97-7.93 and 7.80-7.78 (2m, 4H), 7.74-7.71 and 7.64-7.61 (2m, 4H), 4.72-4.66 (m, 2H), 4.59-4.55 and 4.48-4.43 (2m, 2H), 3.97-3.92 (m, 2H), 3.88-3.82 (m, 2H), 3.79-3.72 (m, 2H), 3.69-3.62 (m, 2H), 2.33-2.21 (m, 4H), 2.18-2.08 (m, 4H), 2.05-1.80 (m, 8H). LC/MS (Cond.-D1): Rt=1.95 min; Anal. Calc. for [M+H]+ C34H39N6O7: 643.29; found: 643.37. HRMS: Anal. Calc. for [M+H]+ C34H39N6O7: 643.2880; found: 643.2825.
Example D-61 and Example D-62




Prepared from Example D-57b and 1.0 eq of 2-(thiophen-2-yl)acetic acid and 1.0 eq. of acetic acid according to the procedure described for Example D-57. This afforded Example D-61 (14.9 mg, 11%) as an off-white solid and Example D-62 (39.8 mg, 34%) also as an off-white solid. Example D-55 was also isolated from the mixture (see above for its characterization data).
For Example D-61: 1H NMR (DMSO-d6, 400 MHz) δ 10.61 and 10.41 (2s, 2H), 8.10-8.06 (m, 4H), 7.87-7.82 (m, 4H), 7.39-7.37 (2m, 2H), 6.97-6.80 (m, 4H), 4.70-4.65 and 4.49-4.46 (2m, 2H), 3.95 (br s, 4H), 3.73-3.62 (2m, 4H), 2.35-2.15 (2m, 2H), 2.07-1.90 (2m, 6H). LC/MS (Cond.-D1): Rt=2.29 min; Anal. Calc. for [M+H]+ C36H35N6O5S2: 695.21; found: 695.19. HRMS: Anal. Calc. for [M+H]+ C36H35N6O5S2: 695.2110; found: 695.2109.
For Example D-62: 1H NMR (DMSO-d6, 400 MHz) δ 10.59, 10.53, 10.41 and 10.35 (4s, 2H), 8.11-8.06 (m, 4H), 7.87-7.83 (m, 4H), 7.39-7.34 (m, 1H), 6.97-6.86 (m, 2H), 4.73-4.54 and 4.49-4.41 (2m, 2H), 3.95 (s, 2H), 3.71-3.51 (series of m, 4H), 2.37-2.10 (2m, 2H), 2.01 and 1.86 (2s, 3H), 2.00-1.90 (m, 6H). LC/MS (Cond.-D1): Rt=2.09 min; Anal. Calc. for [M+H]+ C32H33N6O5S: 613.22; found: 613.20. HRMS: Anal. Calc. for [M+H]+ C32H33N6O5S: 613.2233; found: 613.2223.
Example D-63 and Example D-64




Prepared from Example D-57b and 1.0 eq. of 2-(pyridin-3-yl)acetic acid and 1.0 eq. of acetic acid according to the procedure described for Example D-57. This afforded Example D-63 (19.4 mg, 15%) as an off-white solid and Example D-64 (38.4 mg, 33%) also as an off-white solid. Example D-55 was also isolated from the mixture (see above for its characterization data).
For Example D-63: 1H NMR (MeOH-d4, 400 MHz) δ 8.48-8.47 (m, 2H), 8.40-8.35 (m, 2H), 8.01-7.96 and 7.80-7.77 (2m, 6H), 7.75-7.70 and 7.59-7.57 (2m, 4H), 7.40-7.30 (2m, 2H), 4.77-4.55 and 4.54-4.51 (2m, 2H), 3.87 (s, 4H), 3.80-3.71 (m, 4H), 2.21-2.12 (m, 4H), 2.05-1.95 (m, 4H). LC/MS (Cond.-D1): Rt=1.58 min; Anal. Calc. for [M+H]+ C38H37N8O5: 685.29; found: 685.40. HRMS: Anal. Calc. for [M+H]+ C38H37N8O5: 685.2887; found: 685.2888.
For Example D-64: 1H NMR (MeOH-d4, 400 MHz) δ 8.47 (m, 1H), 8.39-8.38 (m, 1H), 7.97-7.89 and 7.80-7.67 (2m, 5H), 7.61-7.58 (m, 4H), 7.39-7.36 (m, 1H), 4.58-4.51 (m, 2H), 3.87 (s, 2H), 3.80-3.58 (2m, 4H), 2.26-2.17 (m, 2H), 2.13 and 1.98 (2s, 3H), 2.04-1.95 (m, 6H). LC/MS (Cond.-D1): Rt=1.68 min; Anal. Calc. for [M+H]+ C33H34N7O5: 608.26; found: 608.23. HRMS: Anal. Calc. for [M+H]+ C33H34N7O5: 608.2622; found: 608.2605.
Example OL-18




Example OL-18a




Pd(PPh3)2Cl2 (10 mg, 0.013 mmol), copper (I) iodide (5 mg, 0.026 mmol), potassium carbonate (0.36 g, 2.26 mmol) and nBu3N (31 μL, 0.131 mmol) were added to a suspension of p-nitro-iodobenzene (0.32 g, 1.31 mmol) and p-nitrophenyl-acetylene (0.25 g, 1.7 mmol) in a mixture of water (10 mL) and dimethylformamide (10 mL). The mixture was stirred at ambient temperature for 3 h and then it was extracted with diethyl ether. The combined organic layers were washed with brine, dried (MgSO4), filtered and concentrated to give Example OL-18a (0.23 g, 98% yield) as a brown solid, which was used without further pufirication. 1H NMR (DMSO-d6, 500 MHz) δ 8.31 (d, J=8.8 Hz, 4H), 7.91 (d, J=8.8 Hz, 4H). LC/MS (Cond. OL1): Rt=1.79 min; Anal. Calc. for [M+H]+ C14H9N2O4: 269.05; found: 179.
Example OL-18b




Example OL-18a (50 mg, 0.28 mmol) and sodium azide (22 mg, 0.34 mmol) were dissolved in dimethylformamide (2 mL) and heated under microwave conditions at 220° C., for 30 min. The brown solution was evaporated and the residue was taken up in ethyl acetate, washed with brine, dried (MgSO4), filtered and concentrated to afford Example OL-18b (85 mg, 98% yield) as a brown solid that was used without further purification. 1H NMR (DMSO-d6, 500 MHz) δ 15.85 (bs, 1H), 8.31 (d, J=8.8 Hz, 4H), 7.79 (d, J=8.8 Hz, 4H). LC/MS (Cond. OL1): Rt=1.63 min; Anal. Calc. for [M+H]+ C14H10N5O4: 312.07; found: 312.
Example OL-18c




Prepared from Example OL-18b according to the procedure described for Example OL-1c. This afforded Example OL-18c (82 mg, 51% yield) as an off-white solid. 1H NMR (DMSO-d6, 500 MHz) δ 14.98 (bs, 1H), 7.15 (d, J=8.2 Hz, 4H), 6.57 (d, J=8.2 Hz, 4H), 5.21 (bs, 4H). LC/MS (Cond. OL2): Rt=0.18 min; Anal. Calc. for [M+H]+ C14H14N5: 252.12; found: 252.
Example OL-18
Prepared from Example OL-18c and L-Cbz-Alanine according to the procedure described for Example OL-1d. This afforded Example OL-18 (37 mg, 56% yield) as an off-white solid. 1H NMR (DMSO-d6, 500 MHz) δ 10.13 (s, 2H), 7.64 (m, 6H), 7.43 (d, J=8.8 Hz, 2H), 7.36 (m, 7H), 7.31 (m, 2H), 7.25 (bs, 1H), 7.18 (bs, 1H), 5.03 (m, 4H), 4.30 (dq, J=7.0 Hz, 2H), 1.30 (d, J=7.0 Hz, 6H), LC/MS (Cond. OL2): Rt=5.48 min; Anal. Calc. for [M+H]+ C36H36N7O6: 662.26; found: 662.
Example OL-19




Prepared from Example OL-18c and Carbobenzyloxy-L-Proline according to the procedure described for Example OL-1d. This afforded the TFA salt of Example OL-19 (41 mg, 57% yield) as an off-white solid. 1H NMR (DMSO-d6, 500 MHz) δ 10.18 (s, 2H), 7.64 (m, 4H), 7.43 (m, 4H), 7.37 (d, J=3.6 Hz, 4H), 7.32 (m, 1H), 7.22 (d, J=7.3 Hz, 2H), 7.18 (t, J=7.3 Hz, 1H), 7.12 (q, J=7.0 Hz, 2H), 5.09 (m, 3H), 4.94 (d, J=13.1, 1H), 4.37 (m, 2H), 3.51 (m, 2H), 3.44 (m, 2H), 2.25 (m, 2H), 1.90 (m, 6H). LC/MS (Cond. OL2): Rt=5.96 min; Anal. Calc. for [M+H]+ C40H40N7O6: 714.30; found: 714.
Example OL-20




Prepared from Example OL-18c and (S)-1-(2-phenylacetyl)pyrrolidine-2-carboxylic acid according to the procedure described for Example OL-1d. This gave the TFA salt of Example OL-20 (25 mg, 31% yield) as an off-white solid. 1H NMR (DMSO-d6, 500 MHz) δ 10.12 and 10.23 (2s, 2H), 7.62 (d, J=8.8 Hz, 4H), 7.41 (d, J=8.5 Hz, 4H), 7.24 (m, 10H), 4.44 and 4.65 (2dd, J=8.5, 3.4, 2H), 3.71 (m, 4 H), 3.62 (m, 5H), 2.15 (m, 2H), 2.01 (m, 2H), 1.90 (m, 4H). LC/MS (Cond. OL2): Rt=6.00 min; Anal. Calc. for [M+H]+ C40H40N7O4: 682.31; found: 682.
Example OL-21




Prepared from Example OL-18c and (2S,4R)-4-hydroxy-1-(2-phenylacetyl)pyrrolidine-2-carboxylic acid according to the procedure described for Example OL-1d. This afforded the TFA salt of Example OL-21 (29 mg, 34% yield) as an off-white solid. 1H NMR (DMSO-d6, 500 MHz) δ 10.17 and 10.39 (2s, 2H), 7.69 (d, J=8.5 Hz, 4H), 7.48 (d, J=8.5 Hz, 4H), 7.24 (m, 12H), 5.12 (bs, 2H), 4.50 (q, J=7.8 Hz, 2H), 4.39 (m, 2H), 3.68 (m, 6H), 3.51 (m, 4H), 2.11 (m, 2H), 1.96 (m, 2H). LC/MS (Cond. OL2): Rt=5.05 min; Anal. Calc. for [M+H]+ C40H40N7O6: 714.30; found: 714.
Example OL-22




Example OL-22a




n-Butyl lithium (21.1 mL, 30.6 mmol) was added dropwise to a solution of thiophene (1.2 mL, 15 mmol) and tetramethylethylenediamine (4.62 mL, 30.6 mmol) in hexanes (20 mL) at 0° C. The mixture was heated to reflux temperature for 30 min and cooled down to 0° C. and trimethyltin chloride (1M in hexanes, 31.7 mL) was added slowly. The reaction mixture was then stirred at ambient temperature overnight, followed by addition of saturated aqueous ammonium chloride and separation of both phases. The organic layer was washed twice with sat. aq. copper (II) sulfate, dried (MgSO4), filtered and concentrated to afford a brown solid. The solid was recrystallized from hexanes to afford Example OL-22a (0.33 g, 81% yield) as a white solid. 1H NMR (CDCl3, 500 MHz) δ 7.36 (s, 2H), 0.36 (m, 18H).
Example OL-22b




Example OL-22a (0.24 g, 0.59 mmol), p-nitrobromobenzene (0.13 g, 0.65 mmol) and Pd(PPh3)Cl2 (21 mg, 0.03 mmol) were combined in tetrahydrofuran (10 mL) and heated to reflux temperature for 6 h. The resulting suspension was diluted with hexanes, cooled to ambient temperature and filtered. A red solid was collected and washed with hexanes to afford Example OL-22b (0.17 g, 88% yield) which was used without further purification. 1H NMR (DMSO-d6, 500 MHz) δ 8.30 (d, J=8.8 Hz, 4H), 8.02 (d, J=8.8 Hz, 4H), 7.94 (s, 2H).
Example OL-22c




Prepared from Example OL-22b according to the procedure described for Example OL-1c. This afforded Example OL-22c (53 mg, 38% yield) as an off-white solid. 1H NMR (DMSO-d6, 500 MHz) δ 7.29 (d, J=8.2 Hz, 4H), 7.09 (s, 2H), 6.57 (d, J=8.2 Hz, 4H), 5.28 (s, 4H). LC/MS (Cond. OL2): Rt=0.83 min; Anal. Calc. for [M+H]+ C16H15N2S: 267.09; found: 267.
Example OL-22
Prepared from Example OL-22c and (S)-1-(2-phenylacetyl)pyrrolidine-2-carboxylic acid according to the procedure described for Example OL-1d. This gave Example OL-22 (15 mg, 15% yield) as an off-white solid. 1H NMR (DMSO-d6, 500 MHz) δ 10.11 and 10.39 (2s, 2H), 7.62 (m, 8H), 7.42 (s, 2H), 7.24 (m, 10H), 4.44 and 4.65 (2dd, J=8.1, 3.5, 2H), 3.70 (m, 4H), 3.61 (m, 4H), 2.16 (m, 2H), 2.01 (m, 2H), 1.91 (m, 4H). LC/MS (Cond. OL2): Rt=2.00 min; Anal. Calc. for [M+H]+ C42H41N4O4S: 697.28; found: 697.
Example OL-23




Prepared from Example OL-22c and Carbobenzyloxy-L-Proline according to the procedure described for Example OL-1d. This afforded Example OL-23 (23 mg, 27% yield) as an off-white solid. 1H NMR (DMSO-d6, 500 MHz) δ 10.17 (d, J=4.5 Hz, 2H), 7.65 (m, 8H), 7.45 (t, J=4.5 Hz, 2H), 7.38 (d, J=4.3 Hz, 4H), 7.33 (m, 1H), 7.25 (d, J=7.3 Hz, 2H), 7.19 (d, J=7.3 Hz, 1H), 7.15 (d, J=7.3 Hz, 2H), 5.09 (m, 3H), 4.96 (d, J=12.8, 1H), 4.39 (dd, J=8.4, 3.2 Hz, 1H), 4.35 (dd, J=8.2, 3.0 Hz, 1H), 3.53 (m, 2H), 3.46 (m, 2H), 2.28 (m, 1H), 2.22 (m, 1H), 1.90 (m, 6H). LC/MS (Cond. OL2): Rt=2.09 min; Anal. Calc. for [M+H]+ C42H40N4NaO6S: 751.26; found: 751.
Example OL-24




Prepared from Example OL-22c and L-Acetyl-proline according to the procedure described for Example OL-1d. This afforded Example OL-24 (51 mg, 92% yield) as an off-white solid. 1H NMR (DMSO-d6, 500 MHz) δ 10.08 and 10.27 (2s, 2H), 7.64 (m, 8H), 7.43 and 7.44 (2s, 2H), 4.38 and 4.51 (2dd, J=8.6, 3.1 Hz, 2H), 3.51 (m, 4H), 2.15 (m, 2H), 1.92 (m, 4H), 1.83 (m, 2H), 1.85 and 2.00 (2m, 6H). LC/MS (Cond. OL1): Rt=1.59 min; Anal. Calc. for [M+H]+ C30H33N4O4S: 545.21; found: 545.
Example OL-25




Example OL-25a




Prepared from 2,5-bis(3-nitrophenyl)thiophene according to the procedure described for Example OL-22c. This afforded Example OL-25a (81 mg, 66% yield) as an off-white solid. 1H NMR (DMSO-d6, 500 MHz) δ 7.31 (s, 2H), 7.31 (s, 2H), 7.05 (t, J=7.8 Hz, 2H), 6.83 (m, 4H), 6.51 (dd, J=7.8, 1.3 Hz, 2H), 5.22 (s, 4H). LC/MS (Cond. OL2): Rt=1.04 min; Anal. Calc. for [M+H]+ C16H15N2S: 267.09; found: 267.
Example OL-25
Prepared from Example OL-25a and (S)-1-(2-phenylacetyl)pyrrolidine-2-carboxylic acid according to the procedure described for Example OL-1d. This afforded Example OL-25 (41 mg, 51% yield) as an off-white solid. 1H NMR (DMSO-d6, 500 MHz) δ10.12 and 10.33 (2s, 2H), 8.05 (s, 2H), 7.15-7.55 (m, 18H), 4.45 and 4.65 (2dd, J=8.2, 3.4, 2H), 3.72 (m, 4H), 3.68 (m, 2H), 3.60 (m, 2H), 2.16 (m, 2H), 2.03 (m, 2H), 1.93 (m, 4H). LC/MS (Cond. OL2): Rt=2.26 min; Anal. Calc. for [M+H]+ C42H41N4O4S: 697.28; found: 697.
Example OL-26




Example OL-26a




Prepared from 3,5-diphenyl-1H-pyrazole according to the procedure described for Example OL-1b. This gave Example OL-25a (3.51 g, 98% yield) as a yellow solid. 1H NMR (DMSO-d6, 500 MHz) δ 13.07 (s, 1H), 8.25 (bs, 4H), 8.03 (s, 1H), 7.73 (d, J=7.0 Hz, 4H). LC/MS (Cond. OL2): Rt=1.48 min; Anal. Calc. for [M+H]+ C15H11N4O4: 311.07; found: 311.
Example OL-26b




Prepared from Example OL-26a according to the procedure described for Example OL-1c. This gave Example OL-26b (0.78 g, 97% yield) as an off-white solid. 1H NMR (DMSO-d6, 500 MHz) δ 11.71 (bs, 1H), 7.52 (s, 1H), 7.11 (m, 4H), 6.48 (m, 4H), 5.17 (bs, 2H), 4.94 (bs, 2H). LC/MS (Cond. OL2): Rt=0.87 min; Anal. Calc. for [M+H]+ C15H15N4: 251.12; found: 251.
Example OL-26
Prepared from Example OL-26b and Carbobenzyloxy-L-Proline according to the procedure described for Example OL-1d. This gave the TFA salt of Example OL-26 (73 mg, 73% yield) as an off-white solid. 1H NMR (DMSO-d6, 500 MHz) δ 10.16 (d, J=2.93 Hz, 2H), 7.78 (m, 4H), 7.67 (m, 4H), 7.38 (m, 4H), 7.34 (m, 1H), 7.24 (d, J=6.9 Hz, 2H), 7.12 (m, 4H), 5.09 (m, 3H), 4.96 (d, J=12.8, 1H), 4.39 (m, 2H), 3.49 (m, 4H), 2.27 (m, 2H), 1.93 (m, 6H). LC/MS (Cond. OL1): Rt=1.82 min; Anal. Calc. for [M+H]+ C41H41N6O6: 713.30; found: 713.
Example OL-27




Prepared from Example OL-26b and (S)-1-(2-phenylacetyl)pyrrolidine-2-carboxylic acid according to the procedure described for Example OL-1d. This gave the TFA salt of Example OL-27 (61 mg, 64% yield) as an off-white solid. 1H NMR (DMSO-d6, 500 MHz) δ 10.09 and 10.32 (2s, 2H), 7.75 (d, J=8.8 Hz, 4H), 7.65 (d, J=8.8 Hz, 4H), 7.26 (m, 12H), 4.45 (dd, J=8.2, 3.5 Hz, 2H), 3.72 (s, 4H), 3.61 (m, 4H), 2.15 (m, 2H), 1.92 (m, 6H). LC/MS (Cond. OL): Rt=1.71 min; Anal. Calc. for [M+H]+ C41H41N6O4: 681.31; found: 681.
Example OL-28




Prepared from Example OL-26b and (2S,4R)-4-hydroxy-1-(2-phenylacetyl)pyrrolidine-2-carboxylic acid according to the procedure described for Example OL-1d. This gave the TFA salt of Example OL-28 (69 mg, 69% yield) as an off-white solid. 1H NMR (DMSO-d6, 500 MHz) δ 10.12 and 10.37 (2s, 2H), 7.75 (d, J=8.5 Hz, 4H), 7.65 (d, J=8.5 Hz, 4H), 7.25 (m, 10H), 7.03 and 7.05 (2s, 1H), 5.26 (bs, 2H), 4.51 and 4.74 (2t, J=7.8 Hz, 2H), 4.32 and 4.40 (2m, 2H), 3.69 (m, 4H), 3.15 (m, 4H), 2.15 (m, 2H), 1.97 (m, 2H). LC/MS (Cond. OL1): Rt=1.47 min; Anal. Calc. for [M+H]+ C41H41N6O6: 713.30; found: 713.
Example OL-29




Prepared from Example OL-26b and L-Acetyl-proline according to the procedure described for Example OL-1d. This gave the TFA salt of Example OL-29 (63 mg, 60% yield) as an off-white solid. 1H NMR (DMSO-d6, 500 MHz) δ 10.46 and 10.66 (2s, 2H), 8.18 and 8.19 (2d, J=8.8 Hz, 4H), 8.08 and 8.10 (2d, J=8.8 Hz, 4H), 7.47 and 7.48 (2s, 1H), 4.84 and 4.95 (2dd, J=8.5, 3.7 Hz, 2H), 4.03 (m, 2H), 3.96 (m, 1H), 3.88 (m, 1H), 2.57 (m, 2H), 2.35 (m, 4H), 2.28 and 2.41 (2m, 6H), 2.26 (m, 2H). LC/MS (Cond. OL3): Rt=1.24 min; Anal. Calc. for [M+H]+ C29H33N6O4: 529.25; found: 529.
Example OL-30




Example OL-30a




Prepared from Example OL-26b and L-Acetyl-proline and (S)-1-(tert-butoxycarbonyl)-2,5-dihydro-1H-pyrrole-2-carboxylic acid according to the procedure described for Example OL-1d. This gave Example OL-30a (51 mg, 66% yield) as an off-white solid. 1H NMR (DMSO-d6, 500 MHz) δ 10.24 and 10.44 (2s, 2H), 9.19 (bs, 1H), 7.68 (m, 4H), 7.41 (m, 4H), 6.10 (dd, J=6.3, 1.7 Hz, 2H), 5.88 and 5.94 (2m, 2H), 5.09 and 5.27 (2dd, J=4.7, 2.3 Hz, 2H), 4.37 (m, 3H), 4.15 (m, 1H), 1.41 and 1.27 (2s, 18H). LC/MS (Cond. OL1): Rt=1.02 min; Anal. Calc. for [M+H]+ C35H41N6O6: 641.30; found: 641.
Example OL-30b




Prepared from Example OL-30a according to the procedure described for Example D-47d. This afforded Example OL-30b (0.11 mg, 80% yield) as a brown solid. 1H NMR (DMSO-d6, 500 MHz) δ 10.24 and 10.44 (2s, 2H), 9.19 (bs, 1H), 7.68 (m, 4H), 7.41 (m, 4H), 6.10 (dd, J=6.3, 1.7 Hz, 2H), 5.88 and 5.94 (2m, 2H), 5.09 and 5.27 (2dd, J=4.7, 2.3 Hz, 2H), 4.37 (m, 3H), 4.15 (m, 1H), 3.30 (bs, 2H). LC/MS (Cond. OL1): Rt=0.84 min; Anal. Calc. for [M+H]+ C25H25N6O2: 441.20; found: 441.
Example OL-30
Acetyl chloride (27 μL, 0.51 g, 0.375 mmol) was added slowly to a solution of OL-30b (75 mg, 0.17 mmol) and triethylamine (71 μL, 0.51 mmol) in anhydrous methylene chloride (3 mL). The mixture was stirred at ambient temperature for 0.5 h and poured into water. The aqueous layer was extracted with ethyl acetate and the combined layers were dried (MgSO4), filtered and concentrated. The remaining residue was purified by preparative HPLC on a C18-reverse phase column (MeOH/H2O/TFA) to afford the TFA salt of Example OL-30 (51 mg, 66% yield) as an off-white solid. 1H NMR (DMSO-d6, 500 MHz) δ 10.24 and 10.44 (2s, 2H), 9.19 (bs, 1H), 7.68 (m, 4H), 7.41 (m, 4H), 6.10 (dd, J=6.3, 1.7 Hz, 2H), 5.88 and 5.94 (2m, 2H), 5.09 and 5.27 (2dd, J=4.7, 2.3 Hz, 2H), 4.37 (m, 3H), 4.15 (m, 1H), 1.88 and 2.03 (2s, 6H). LC/MS (Cond. OL1): Rt=1.45 min; Anal. Calc. for [M+H]+ C29H29N6O4: 525.23; found: 525.
Example OL-31




Example OL-31a




Prepared from Example OL-26b and (S)-1-(tert-butoxycarbonyl)pyrrolidine-2-carboxylic acid according to the procedure described for Example OL-1d. This gave Example OL-31a (0.43 g, 73%) as an off-white solid. 1H NMR (DMSO-d6, 500 MHz) δ 10.16 (d, J=2.93 Hz, 2H), 8.08 (m, 4H), 7.67 (m, 4H), 7.34 (m, 1H), 4.39 (m, 2H), 3.49 (m, 4H), 2.27 (m, 2H), 1.93 (m, 6H), 1.41 and 1.27 (2s, 18H). LC/MS (Cond. OL3): Rt=1.49 min; Anal. Calc. for [M+H]+ C35H45N6O6: 645.33; found: 645.
Example OL-31b




Trifluoroacetic acid (2 mL) was added to a solution of OL-31a (0.43 g, 0.67 mmol) in anhydrous methylene chloride (20 mL) and the resulting solution was stirred at ambient temperature for 2 h. The solvent and excess trifluoroacetic acid were removed under reduced pressure and the resulting brown solid was free-based using UCT MCX cartridges (2.0 g) and methanol, to give Example OL-31b (026 g, 87%) as a brown solid. 1H NMR (DMSO-d6, 500 MHz) δ 10.16 (sz, 2H), 8.08 (m, 4H), 7.67 (m, 4H), 7.34 (m, 1H), 4.39 (m, 2H), 3.49 (m, 4H), 2.50 (bs, 2H), 2.24 (m, 2H), 1.95 (m, 6H). LC/MS (Cond. OL3): Rt=0.77 min; Anal. Calc. for [M+H]+ C25H29N6O2: 445.23; found: 445.
Example OL-31
Prepared from Example OL-31b and isobutyryl chloride according to the procedure described for Example OL-30. This gave the TFA salt of Example OL-31 (43 mg, 63% yield) as an off-white solid. 1H NMR (DMSO-d6, 500 MHz) δ 10.17 and 10.35 (2s, 2H), 9.23 (bs, 1H), 7.68 (d, J=8.5 Hz, 4H), 7.40 (m, 4H), 4.40 and 4.58 (2dd, J=8.5, 3.9 Hz, 2H), 3.61 (m, 3H), 3.46 (m, 1H), 2.73 (qq, J=6.7 Hz, 2 H), 2.14 (m, 2H), 2.01 (m, 2H), 1.88 (m, 4H), 1.02 (d, J=6.7 Hz, 6H), 1.00 (d, J=6.7 Hz, 6H). LC/MS (Cond. OL1): Rt=2.27 min; Anal. Calc. for [M+H]+ C33H41N6O4: 585.31; found: 585.
Example OL-32




Prepared from Example OL-31b and propionyl chloride according to the procedure described for Example OL-30. This gave the TFA salt of Example OL-32 (33 mg, 44% yield) as an off-white solid. 1H NMR (DMSO-d6, 500 MHz) δ 10.17 and 10.34 (2s, 2H), 9.22 (bs, 1H), 7.68 (d, J=8.5 Hz, 4H), 7.40 (m, 4H), 4.41/4.52 (dd, J=8.3, 3.8 Hz, 2H), 3.54 (m, 4H), 2.31 (q, J=7.5 Hz, 4H), 2.13 (m, 2H), 2.00 (m, 2H), 1.91 (m, 4H), 0.98 (t, J=7.5 Hz, 6H). LC/MS (Cond. OL1): Rt=1.99 min; Anal. Calc. for [M+H]+ C31H37N6O4: 557.28; found: 557.
Example OL-33




Prepared from Example OL-31b and cyclobutanecarbonyl chloride according to the procedure described for Example OL-30. This gave the TFA salt of Example OL-33 (47 mg, 57% yield) as an off-white solid. 1H NMR (DMSO-d6, 500 MHz) δ 10.20 and 10.30 (2s, 2H), 7.69 (d, J=8.5 Hz, 4H), 7.40 (m, 4H), 4.40 and 4.45 (2dd, J=8.4, 3.8 Hz, 2H), 3.45 (m, 5H), 3.31 (q, J=8.5 Hz, 2H), 2.11 (m, 9H), 1.91 (m, 8H), 1.74 (m, 2H). LC/MS (Cond. OL1): Rt=2.44 min; Anal. Calc. for [M+H]+ C35H41N6O4: 609.31; found: 609.
Example OL-34




Prepared from Example OL-31b and isonicotinoyl chloride according to the procedure described for Example OL-30. This gave the TFA salt of Example OL-34 (36 mg, 41% yield) as an off-white solid. 1H NMR (DMSO-d6, 500 MHz) δ 9.97 and 10.35 (2s, 2H), 9.28 (bs, 1H), 8.72 (m, 3H), 8.56 (m, 1H), 7.73 (d, J=8.5 Hz, 3H), 7.52 (d, J=5.5 Hz, 3H), 7.41 (m, 4H), 7.35 (m, 2H), 4.40 and 4.61 (2dd, J=8.1, 4.7 Hz, 2H), 3.65 (m, 1H), 3.51 (m, 3H), 2.30 (m, 2H), 1.97 (m, 4H), 1.88 (m, 2H). LC/MS (Cond. OL1): Rt=1.50 min; Anal. Calc. for [M+H]+ C37H35N8O4: 655.27; found: 655.
Example OL-35




Prepared from Example OL-31b and cyclopropanecarbonyl chloride according to the procedure described for Example OL-30. This gave the TFA salt of Example OL-35 (29 mg, 37% yield) as an off-white solid. 1H NMR (DMSO-d6, 500 MHz) δ 10.19 and 10.33 (2s, 2H), 9.19 (bs, 1H), 7.67 (m, 4H), 7.39 (m, 4H), 4.42 and 4.73 (2dd, J=8.4, 3.8 Hz, 2H), 3.78 (m, 3H), 3.72 (m, 2H), 2.18 (m, 1H), 2.06 (m, 2H), 1.95 (m, 3H), 1.83 (m, 2H), 0.73 (m, 8H). LC/MS (Cond. OL1): Rt=2.08 min; Anal. Calc. for [M+H]+ C33H37N6O4: 581.28; found: 581.
Example OL-36




Prepared from Example OL-31b according to the procedure described for Example OL-30 using a 1:1 mixture of the corresponding acid chlorides. This gave the TFA salt of Example OL-36 (25 mg, 30% yield) as an off-white solid. 1H NMR (DMSO-d6, 500 MHz) δ 10.06 and 10.21 (2s, 1H), 10.02 and 10.21 (2s, 2H), 7.77 (m, 4H), 7.66 (m, 4H), 7.25 (m, 5H), 7.04 (m, 1H), 4.46 and 4.67 (2dd, J=8.5, 3.7, 1H), 4.42 and 4.52 (2dd, J=8.5, 3.4, 1H), 3.73 (s, 2H), 3.66 (m, 1H), 3.61 (m, 2H), 3.53 (m, 1H), 3.43 (m, 1H), 2.15 (m, H H), 1.99 (m, 2H), 1.91 (m, 3H), 1.87 and 2.01 (2s, 3H). LC/MS (Cond. OL3): Rt=2.67 min; Anal. Calc. for [M+H]+ C35H37N6O4: 605.28; found: 605.
Example OL-37




Prepared from Example OL-30b and cyclopropanecarbonyl chloride according to the procedure described for Example OL-30. This afforded the TFA salt of Example OL-37 (44 mg, 56% yield) as an off-white solid. 1H NMR (DMSO-d6, 500 MHz) δ 10.27 and 10.40 (2s, 2H), 9.20 (bs, 1H), 7.67 (m, 4H), 7.40 (m, 4H), 6.14 (m, 2H), 5.90 and 5.98 (2m, 2H), 5.13 and 5.46 (2m, 2H), 4.53 (m, 3H), 4.22 (m, 1H), 2.49 (m, 1H), 1.83 (m, 1H), 0.76 (m, 7H). LC/MS (Cond. OL3): Rt=1.18 min; Anal. Calc. for [M+H]+ C33H33N6O4: 577.25; found: 577.
Example OL-38




Prepared from Example OL-30b and cyclobutanecarbonyl chloride according to the procedure described for Example OL-30. This gave the TFA salt of Example OL-38 (52 mg, 63% yield) as an off-white solid. 1H NMR (DMSO-d6, 500 MHz) δ 10.29 and 10.39 (2s, 2H), 9.20 (bs, 1H), 7.68 (d, J=8.8 Hz, 4H), 7.41 (m, 4H), 6.09 (m, 2H), 5.89 and 5.91 (2dd, J=6.3, 1.9, 2H), 5.11 and 5.19 (2dd, J=4.6, 2.1 Hz, 2H), 4.24 (m, 4H), 3.34 (tt, J=8.2 Hz, 2H), 2.14 (m, 8H), 1.94 (m, 2H), 1.77 (m, 2H). LC/MS (Cond. OL3): Rt=1.34 min; Anal. Calc. for [M+H]+ C35H37N6O4: 605.28; found: 605.
Example OL-39




Prepared from Example OL-30b and 2-cyclopentylacetyl chloride according to the procedure described for Example OL-30. This afforded the TFA salt of Example OL-39 (26 mg, 29% yield) as an off-white solid. 1H NMR (DMSO-d6, 500 MHz) δ 10.26 and 10.41 (2s, 2H), 9.18 (bs, 1H), 7.67 (d, J=8.8 Hz, 4H), 7.41 (m, 4H), 6.09 (dd, J=6.4, 2.0 Hz, 2H), 5.89 (dd, J=6.4, 2.0, 1H), 5.10 (m, 1H), 4.35 (m, 3H), 2.34 (m, 4H), 2.16 (m, 4H), 1.54 (m, 8H), 1.14 (m, 4H). LC/MS (Cond. OL3): Rt=1.64 min; Anal. Calc. for [M+H]+ C39H45N6O4: 661.34; found: 661.
Example OL-40




Et3N (64 μL, 0.46 mmol) was added to a suspension of Example OL-31b, 3-chloroisoquinoline-1-carboxylic acid (Cap 145) (49 mg, 0.235 mmol), HOBT (32 mg, 0.235 mmol) and EDCI (45 mg, 0.235 mmol) in DMF (3 mL) and the resulting solution was stirred at ambient temperature overnight. The reaction mixture was concentrated under vacuo and the remaining residue was purified by reverse phase preparative HPLC (solvent system: H2O, MeOH/TFA) and the TFA salt of Example OL-40 was isolated as a white solid (43 mg, 45% yield). 1H NMR (500 MHz, DMSO-d6) δ ppm 10.44 and 9.64 (2s, 2H) 8.30 (d, J=8.55 Hz, 2H) 8.12-8.23 (m, 2H) 8.06 (t, J=9.31 Hz, 2H) 7.91 (t, J=7.48 Hz, 2H) 7.67-7.87 (m, 8H) 7.56 (d, J=8.24 Hz, 1H) 6.99-7.13 (m, 2H) 4.79 and 4.45 (m, 2H) 3.82 (br. s., 1H) 3.30-3.42 (m, 2H) 3.17-3.29 (m, 2H) 2.29-2.45 (m, 2H) 1.81-2.12 (m, 6H). LCMS (cond. OL3): Rt=1.87 min Anal. Calcd. for [M+H]+: C45H37Cl2N8O4 822.23; Found: 822.96; HRMS: Anal. Calcd. for: C45H37Cl2N8O4 (M+H)+ 823.2315; Found: 823.2319.
Examples OL-41 to OL-42




Examples OL-41 to OL-42 were prepared from Example OL-31b and 2.0 eq. of the appropriate, commercially-available or synthesized carboxylic acids according to the procedure described for the preparation of Example OL-40. Purification of the final targets was accomplished using a Shimadzu reverse phase preparative HPLC instrument (solvent systems: H2O/MeOH/TFA or H2O/ACN/TFA) and the final products were isolated as TFA salts.












Example
RCOOH
Conditions







OL-41




LCMS: Anal.Calcd. for (M + H)+: C47H41Cl2N8O6 883.25; Found: 683.43 HRMS: Anal. Calcd. for (M − H)+ C47H39Cl2N8O6: 881.2370; Found: 881.2401 Rt = 2.17 min (Cond. OL3)


 


OL-42




LCMS: Anal.Calcd. for (M + H)+: C45H47N8O6 795.36; Found: 795.78 HRMS: Anal. Calcd. for (M + H)+ C45H47N8O6: 765.3619; Found: 795.3604 Rt = 1.80 min (Cond. OL3)









Example OL-43




Example OL-43a




To a mixture of Example OL-26b (0.6 g, 2.4 mmol) and Boc-L-alanine (0.95 g, 5.04 mmol) in dichloromethane (75 ml) was added EEDQ (1.30 g, 5.28 mmol). The mixture was stirred at ambient temperature for 16 h. The solvent was removed in vacuo and the residue was triturated hexanes. The resulting brown solid was filtered and dried under vacuo. Example OL-43a (1.15 g, 81% yield) was used without further purification. 1H NMR (500 MHz, DMSO-d6) δ ppm 9.83-10.18 (m, 2H) 7.55-7.87 (m, 8H) 7.09 (br. s., 2H) 7.03 (s, 1H) 4.12 (qd, J=6.92, 6.71 Hz, 2H) 1.38 (s, 18H) 1.27 (d, J=7.02 Hz, 6H). LC/MS (Cond. OL1): Rt=1.94 min; Anal. Calc. for [M+H]+ C31H41N6O6: 593.31; found: 593.
Example OL-43b




To a solution of Example OL-43a (1.15 g, 1.94 mmol) in dichloromethane (50 mL) was added 4N HCl in dioxane (10 ml). The reaction mixture was stirred at ambient temperature for 4 h before it was concentrated under vacuo. The residue was triturated with ether (100 ml), filtered and dried in vacuo to afford Example OL-43b as an orange solid (0.97 g, quant.) which was used without further purification. 1H NMR (500 MHz, DMSO-d6) δ ppm 10.92 (s, 2H) 8.35 (d, J=4.58 Hz, 6H) 7.81 (d, 4H) 7.72 (d, J=8.55 Hz, 4H) 7.08 (s, 1H) 4.04-4.15 (m, 2H) 3.55 (s, 1H) 1.48 (d, J=7.02 Hz, 6H). LC/MS (Cond. OL1): Rt=0.95 min; Anal. Calc. for [M+H]+ C21H25N6O2: 393.20; found: 393.08.
Example OL-43
DIEA (63 μL, 0.38 mmol) was added to a suspension of Example OL-43b (50 mg, 0.1 mmol), S-mandelic acid (30.4 mg, 0.2 mmol), HOBT (27 mg, 0.2 mmol) and EDCI (38 mg, 0.2 mmol) in DMF (3 mL) and the resulting solution was stirred at ambient temperature overnight. The reaction mixture was concentrated under vacuo and the remaining residue was purified by reverse phase preparative HPLC (solvent system: H2O, MeOH/TFA) and the TFA salt of Example OL-43 was isolated as a yellowish solid (42 mg, 54% yield) 1H NMR (500 MHz, DMSO-d6) δ ppm 10.13 (br. s., 2H) 8.10 (d, J=7.63 Hz, 2H) 7.76 (d, J=8.24 Hz, 4H) 7.65 (d, J=8.55 Hz, 4H) 7.42 (d, J=7.63 Hz, 4H) 7.33 (t, J=7.48 Hz, 4H) 7.24-7.29 (m, 2H) 7.05 (s, 1H) 4.97 (s, 2H) 4.44-4.53 (m, 2H) 1.33 (d, J=7.02 Hz, 6H). LCMS (cond. OL3): Rt=1.81 min Anal. Calcd. for [M+H]+ C37H37N6O6: 661.27; Found: 661.22; HRMS: Anal. Calcd. for: C37H35N6O6 (M−H)+659.2618; Found: 659.2642.
Examples OL-44 to OL-48




Examples OL-44 to OL-48 were prepared from Example OL-43b and 2.0 eq. of the appropriate, commercially-available or synthesized carboxylic acids according to the procedure described for the preparation of Example OL-43. Purification of the final targets was accomplished using a Shimadzu reverse phase preparative HPLC instrument (solvent systems: H2O/MeOH/TFA or H2O/ACN/TFA) and the final products were isolated as TFA salts.















Example
RCOOH
Conditions









OL-44




LCMS: Anal. Calcd. for (M + H)+: C37H37N6O6 661.27; Found: 661.22; HRMS: Anal. Calcd. for (M + H)+ C37H37N6O6: 661.2775; Found: 661.2755 Rt = 1.75 min (Cond. OL3)



 



OL-45




LCMS: Anal. Calcd. for (M + H)+: C39H41N6O6 689.31; Found: 689.26; HRMS: Anal. Calcd. for (M + H)+ C39H41N6O6: 689.3088; Found: 689.3084 Rt = 1.95 min (Cond. OL3)



 



OL-46




LCMS: Anal. Calcd. for (M + H)+: C39H41N6O6 689.31; Found: 689.39; HRMS: Anal. Calcd. for (M − H)− C39H39N6O6: 687.2931; Found: 687.2947 Rt = 1.85 min (Cond. OL3)



 



OL-47




LCMS: Anal. Calcd. for (M + H)+: C43H35Cl2N6O4 769.21; Found: 769.14 HRMS: Anal. Calcd. for (M + H)+ C43H35Cl2N6O4: 769.2097; Found: 769.2096 Rt = 2.17 min (Cond. OL3)



 



OL-48




LCMS: Anal. Calcd. for (M + H)+: C41H33Cl2N8O4 771.20; Found: 771.15 HRMS: Anal. Calcd. for (M + H)+ C41H33Cl2N8O4: 771.2002; Found: 771.1977 Rt = 2.19 min (Cond. OL3)










Example OL-49




To a mixture of Example OL-31b (62 mg, 0.25 mmol) and (2S,4R)-1-(benzyloxycarbonyl)-4-tert-butoxypyrrolidine-2-carboxylic acid (0.175 g, 0.54 mmol) in dichloromethane (5 ml) was added EEDQ (0.141 g, 0.57 mmol). The mixture was stirred at ambient temperature for 16 h. The solvent was removed in vacuo and the residue purified by flash chromatography eluting with 30% to 50% EtOAc/hexanes, obtaining Example OL-49 as an off-white solid (0.126 g, 60%). 1H NMR (500 MHz, DMSO-d6) δ ppm 13.19 (br. s., 1H) 10.24 (d, J=2.44 Hz, 1H) 10.16 (d, J=8.85 Hz, 1H) 7.59-7.85 (m, 8H) 7.30-7.43 (m, 5H) 6.98-7.25 (m, 6H) 5.02-5.16 (m, 3H) 4.96 (d, J=13.12 Hz, 1H) 4.33-4.53 (m, 4H) 3.65 (td, J=10.91, 5.34 Hz, 2H) 2.00-2.24 (m, 4H) 1.17 (s, 9H) 1.15 (s, 9H). LC/MS (Cond. OL1): Rt=2.25 min; Anal. Calc. for [M+H]+ C49H56N6Os: 857.42; found: 857.38.
Examples OL-50 to OL-53




Examples OL-50 to OL-53 were prepared from Example JR-D-1d and 2.0 eq. of the appropriate, commercially-available or synthesized carboxylic acids according to the procedure described for the preparation of Example JR-D-1. Purification of the final targets was accomplished using a Shimadzu reverse phase preparative HPLC instrument (solvent systems: H2O/MeOH/TFA or H2O/ACN/TFA) and the final products were isolated as TFA salts. The coupling partner (ROH) was obtained from commercial sources unless otherwise noted.












Example
RCOOH
Conditions







OL-50




LCMS: Anal. Calcd. for (M + H)+: C37H32F2N7O5 692.24; Found: 692.20; HRMS: Anal. Calcd. for (M + H)+ C37H32F2N7O5: 692.2433; Found: 692.2402; Rt = 1.83 min (Cond. OL3)


 


OL-51




LCMS: Anal. Calcd. for (M + H)+: C45H49N7O5 768.39; Found: 768.35; HRMS: Anal. Calcd. for (M + H)+ C45H49N7O5: 768.3873; Found: 768.3889; Rt = 1.43 min (Cond. OL3)


 


OL-52




LCMS: Anal. Calcd. for (M + H)+: C47H40Cl2N7O7 884.24; Found: 884.42; HRMS: Anal. Calcd. for (M − H)− C47H38Cl2N7O7: 882.2210; Found: 882.2207; Rt = 1.85 min (Cond. OL3)


 


OL-53




LCMS: Anal. Calcd. for (M + H)+: C45H46N7O7 796.34; Found: 796.75; HRMS: Anal. Calcd. for (M + H)+ C45H46N7O7: 796.3459; Found: 796.3481; Rt = 2.17 min (Cond. OL3)









Examples OL-54 to OL-57




Examples OL-54 to OL-57 were prepared following the procedures for the preparation of Examples OL-43 to OL-48 but using Example JR-D-1d as starting material. The following final products were prepared using the appropriate, commercially-available or synthesized carboxylic acids according to the procedure described for the preparation of Example OL-43. Purification of the final targets was accomplished using a Shimadzu reverse phase preparative HPLC instrument (solvent systems: H2O/MeOH/TFA or H2O/ACN/TFA).















Example
RCOOH
Conditions









OL-54




LCMS: Anal. Calcd. for (M + H)+: C37H36N5O7 662.26; Found: 662.70; HRMS: Anal. Calcd. for (M + H)+ C37H36N5O7: 662.2615; Found: 662.2616; Rt = 1.90 min (Cond. OL3)



 



OL-55




LCMS: Anal. Calcd. for (M + H)+: C37H36N5O7 662.26; Found: 662.70; HRMS: Anal. Calcd. for (M + H)+ C37H36N5O7: 662.2615; Found: 662.2616; Rt = 1.85 min (Cond. OL3)



 



OL-56




LCMS: Anal. Calcd. for (M + H)+: C39H40N5O7 690.29; Found: 690.07; HRMS: Anal. Calcd. for (M + H)+ C39H40N5O7: 690.2928; Found: 690.2939; Rt = 2.00 min (Cond. OL3)



 



OL-57




LCMS: Anal. Calcd. for (M + H)+: C39H40N5O7 690.29; Found: 690.48; HRMS: Anal. Calcd. for (M + H)+ C39H40N5O7: 690.2928; Found: 690.2897; Rt = 1.97 min (Cond. OL3)










Examples OL-58 to OL-60




Examples OL-58 to OL-60 were prepared following the procedures for the preparation of Examples OL-50 to OL-53 replacing Boc-(L)-proline for (2S,4R)-1-(tert-butoxycarbonyl)-4-methoxypyrrolidine-2-carboxylic acid as starting material. The following final products were prepared using the appropriate, commercially-available or synthesized carboxylic acids according to the procedure described for the preparation of Example OL-43. Purification of the final targets was accomplished using a Shimadzu reverse phase preparative HPLC instrument (solvent systems: H2O/MeOH/TFA or H2O/ACN/TFA) and Example OL-59 was isolated as a TFA salt.















Example
RCOOH
Conditions









OL-58




LCMS: Anal. Calcd. for (M + H)+: C43H44N5O9 774.31; Found: 774.31; HRMS: Anal. Calcd. for (M + H)+ C43H44N5O9: 774.3139; Found: 774.3101; Rt = 1.77 min (Cond. OL3)



 



OL-59




LCMS: Anal. Calcd. for (M + H)+: C47H54N7O7 828.41; Found: 828.47; HRMS: Anal. Calcd. for (M + H)+ C47H54N7O7: 828.4085; Found: 828.4075; Rt = 1.34 min (Cond. OL3)



 



OL-60




LCMS: Anal. Calcd. for (M + H)+: C47H50N7O9 856.37; Found: 856.42; HRMS: Anal. Calcd. for (M + H)+ C47H50N7O9: 856.3670; Found: 856.3649; Rt = 1.83 min (Cond. OL3)










Example OL-61




Example OL61-a




Prepared from Example MS-1b and 1-Boc-Proline according to the procedure described for Example MS-1c. This afforded Example OL61-a (530 mg) as a yellow solid. 1H NMR (500 MHz, DMSO-d6) δ ppm 10.21 (1H, bs), 8.36-8.42 (2H, m), 8.28-8.33 (2H, m), 7.81-7.91 (3H, m), 7.73-7.79 (2H, m), 4.17-4.30 (1H, m), 3.39-3.46 (1H, m), 3.33-3.38 (1H, m), 2.13-2.26 (1H, m), 1.75-1.97 (3H, m), 1.25-1.44 (9H, m). LC (Cond.-OL4): Rt=2.14 min; LRMS: Anal. Calc. for [M+H]+ C25H27N4O6: 479.19; found: Molecule does not ionize well.
Example OL61-b




A cold (0° C.) solution of 4N HCl in dioxane (5 mL) was added to Example OL-61a (478 mg, 1.88 mmol) dissolved in CH2Cl2 (30 mL). The mixture was stirred rapidly at 0° C. for 0.5 h before it was allowed to warm up to room temperature. After 15 h at room temperature, the mixture was triturated with Et2O, filtered and concentrated in vacuo to afford the HCl salt of Example OL-61b (780 mg, 97%) as an orange solid 1H NMR (500 MHz, DMSO-d6) δ ppm 10.88 (1H, br. s.), 8.38-8.43 (2H, m), 8.31-8.35 (2H, m), 7.87-7.96 (3H, m), 7.79 (2H, d, J=8.9 Hz), 4.56 (1H, t, J=5.6 Hz), 4.31-4.41 (1H, m), 3.49 (2H, q, J=5.2 Hz), 3.39-3.44 (3H, m), 2.36-2.45 (1H, m), 1.91-2.05 (3H, m). LC (Cond.-OL4): Rt=1.56 min; LRMS: Anal. Calc. for [M+H]+ C20H19N4O4: 379.14; found: Molecule does not ionize well.
Example OL61-c




Prepared from Example OL-61b and Cap-15, according to the procedure described for Example D-57. This afforded Example OL61-c (597 mg) as a yellow solid. 1H NMR (500 MHz, DMSO-d6) δ ppm 9.75-10.60 (1H, m), 8.36-8.44 (2H, m), 8.27-8.35 (2H, m), 8.04-8.12 (1H, m), 7.90 (2H, dd, J=6.6, 1.4 Hz), 7.81-7.87 (2H, m), 7.55-7.77 (2H, m), 7.17-7.39 (1H, m), 4.42-4.83 (1H, m), 3.87-4.08 (3H, m), 3.18-3.27 (1H, m), 2.29-2.45 (1H, m), 2.00-2.10 (1H, m), 1.84-1.97 (2H, m). LC (Cond.-OL1): Rt=2.01 min; LRMS: Anal. Calc. for [M]+ C31H24ClN5O6: 597.14; found: 597.78.
Example OL61-d




Prepared from Example OL-61c according to the procedure described for Example MS1-d. This afforded Example OL61-d (568 mg) as an off-white solid. LC (Cond.-J1): Rt=2.14 min; LRMS: Anal. Calc. for [M+H]+ C31H27ClN5O4: 568.18; found: 568.53. HRMS: Anal. Calc. for [M+H]+ C31H27ClN5O4: 568.11752; found: 568.1754.
Example OL61
Prepared from Example OL61-d, L-Boc Proline and Cap 1, according to the procedure described for Example MS-7. This afforded Example OL61 (15 mg) as a pale yellow solid. 1H NMR (500 MHz, DMSO-d6) δ ppm 10.53 (2H, br. s.), 10.27 (1H, br. s.), 7.99-8.13 (4H, m), 7.69-7.88 (10H, m), 7.54-7.64 (7H, m), 7.35 (1H, d, J=7.9 Hz), 7.14-7.24 (1H, m), 5.54 (1H, d, J=8.5 Hz), 4.77 (1H, dd, J=8.5, 4.6 Hz), 4.42-4.52 (1H, m), 3.94 (1H, br. s.), 3.87-3.91 (1H, m), 3.71-3.84 (1H, m), 3.27-3.36 (1H, m), 3.18-3.26 (2H, m), 2.95 (3H, d, J=3.7 Hz), 2.45 (3H, d, J=4.3 Hz), 2.35-2.42 (1H, m), 2.15-2.23 (1H, m), 1.84-2.07 (8H, m). LC (Cond.-IV): Rt=2.14 min; LRMS: Anal. Calc. for [M+H]+ C46H44N7O6: 826.32; found: 826.78. HRMS: Anal. Calc. for [M+H]+ C46H44N7O6: 826.3120; found: 826.3116.
Example CB-1




Example CB-1a




A solution of Di-t-butyl dicarbonate (1.35 g, 6.2 mmol) in CH3CN (2 mL) was added slowly to a suspension of 4-dimethylaminopyridine (24.4 mg, 0.2 mmol) and (1S,3S,55)-tert-butyl 3-carbamoyl-2-azabicyclo[3.1.0]hexane-2-carboxylate (425 mg, 2 mmol) in CH3CN (8 mL). The resulting mixture was stirred at ambient temperature for 5 h. The solvent was removed under reduced pressure and the residue was taken up un EtOAc (10 mL) and washed with water (2×10 mL) and brine (10 ml), dried (MgSO4), filtered and concentrated. The residue was purified by flash chromatography, eluting with EtOAc/hexanes (10 to 60%), to give Example CB-1a as a clear oil (2.46 g, 65% yield). 1HNMR (CDCl3, 400 MHz) (mixture of rotamers) δ 5.38 (2 dd, J=11.7, 3.6 Hz, 1H), 3.56 (m, 1H), 2.71 (m, 1H), 2.04 (m, 1H), 1.53 (m, 27H); 1.07 and 0.92 (2m, 1H); 0.71 and 0.63 (2m, 1H); LC/MS (Cond. CB1): Rt=2.31 min; Anal. Calc. for [M+H]+ C21H35N2O7: 427.24; found: 427.
Example CB-1b




A 0.5M aqueous solution of NaOH (0.5 mL, 0.25 mmol) was added to a solution of CB-1a (100 mg, 0.23 mmol) in THF (1.5 mL) and the resulting mixture was stirred at ambient temperature for 16 h. The mixture was concentrated under reduced pressure to remove and the remaining aqueous phase was diluted with water (1 mL) and EtOAc (1 mL). The organic phase was discarded and the remaining aqueous phase was acidified with 1N HCl to pH=3 and extracted with EtOAc (3×2 mL). The organic layers were combined, dried (MgSO4), filtered and concentrated to give Example CB-1b as a clear oil (52.2 mg, quantitative). 1H NMR (CDCl3, 400 MHz) (mixture of rotamers) δ 4.65 (m, 1H), 3.56 (m, 1H), 2.56 (m, 1H), 2.39 (m, 1H), 1.55 (m, 9H); 0.75-0.89 (m, 1H); LCMS (Cond. CB1) Rt=1.33 min, Anal. Calc. for [M+H]+ C11H15NO4; 228.12; found: 228.
Example CB-1c




EEDQ (178 mg, 0.72 mmol) and CB-1b (143 mg, 0.63 mmol) were added to a suspension of JR-D-1b (75.3 mg, 0.3 mmol) in dry CH2Cl2 (5 mL). The reaction mixture was stirred at room temperature for 16 hours. Solvents were removed in vacuo and the crude mixture was purified on a reverse phase preparative C-18 column. CB-1c was isolated as a white solid (188 mg, 93% yield). LCMS (Cond. CB1)Rt=2.00 min, Anal. Calc. for C37H44N5O7; [M+H]+670.32; found: 670.
Example CB-1
TFA (1 mL) was added to a solution of CB-1c (100 mg, 0.15 mmol) in CH2Cl2 and the resulting mixture was stirred at ambient temperature for 2 h. Volatiles were removed under reduced pressure and the remaining residue was taken up in DMF (4mL) and charged with Cap 130 (58 mg, 0.3 mmol), HATU (34.8 mg, 0.3 mmol) and DIEA (0.156 mL, 0.90 mmol). The resulting mixture was stirred at ambient temperature for 16 h. and purified by reverse phase preparative HPLC (solvent system: H2O/MeOH/TFA or H2O/CH3CN/TFA) and Example CB1 was obtained as a white TFA salt solid (19.2 mg, 31% yield; 1HNMR (CDCl3, 400 MHz) (mixture of rotamers) δ 10.36, 10.25 and 10.13 (3 s, 2H), 8.63 and 8.55 (2d, J=8.1 Hz, 1H), 8.04 (m, 1H); 7.81-7.69 (m, 6H), 7.49-7.30 (m, 9H), 6.01 and 5.92 (2d, J=6.1, 2 H); 4.57 (m, 2H); 3.71-3.43 (m, 5H), 2.55 (m 2H), 1.83 (m, 8H), 1.62 (m, 2H), 1.17 (m, 1H), 0.92-0.70 (m, 2H), 0.42 (m, 1H); LCMS (Cond. CB1)Rt=1.68 min, Anal. Calc. for C47H45N7O7; [M+H]+819.34; found: 819.
Examples CB-2 to CB-10




Examples CB-2 to CB-10 were prepared from Example CB-1c and 2.0 eq. of the appropriate, commercially-available or synthesized carboxylic acids according to the procedure described for the preparation of Example CB-1. Purification of the final targets was accomplished using a Shimadzu reverse phase preparative HPLC instrument (solvent systems: H2O/MeOH/TFA or H2O/ACN/TFA) and the final products were isolated as TFA salts. The coupling partner (ROH) was obtained from commercial sources unless otherwise noted.












Example
ROH
Analysis







CB-2




LCMS: Anal. Calcd. For [M + H]+: C47H38N7O5 780.29; Found: 780. Rt = 1.86 min Cond. CB1


 


CB-3




LCMS: Anal. Calcd. For [M + H]+: C47H36Cl2N7O5 848.22; Found: 848. Rt = 2.23 min Cond. CB1


 


CB-4




LCMS: Anal. Calcd. For [M + H]+: C49H40Cl2N7O7 908.24; Found: 908.2 Rt = 2.35 min Cond. CB1


 


CB-5




LCMS: Anal. Calcd. For [M + H]+: C43H40N5O7 738.29; Found: 738. Rt = 1.81 min Cond. CB1


 


CB-6




LCMS: Anal. Calcd. For [M + H]+: C43H40N5O7 738.29; Found: 738. Rt = 1.79 min Cond. CB1


 


CB-7




LCMS: Anal. Calcd. For [M + H]+: C37H40N5O7 666.29; Found: 666. Rt = 1.53 min Cond. CB1


 


CB-8




LCMS: Anal. Calcd. For [M + H]+: C45H44N5O7 766.32; Found: 766. Rt = 1.98 min Cond. CB1


 


CB-9




LCMS: Anal. Calcd. For [M + H]+: C47H50N7O5 792.39; Found: 792. Rt = 2.17 min Cond. CB1


 


CB-10




LCMS: Anal. Calcd. For [M + H]+: C45H44N5O7 766.32; Found: 766. Rt = 2.01 min Cond. CB1









Example JG-1




Example JG-1a




A mixture of conc. HNO3 (8 mL) and conc. H2SO4 (20 mL) was added with stirring to a solution of 2,5-diphenyloxazole (20 g, 0.09 mol) in 20 mL conc. H2SO4 cooled to 0° C. in an ice/water bath. After addition the mixture was allowed to stir at 0° C. for 2 hours and then poured over crushed ice. The precipitated solid was filtered off, washed with water, and crystallized from ethanol to afford JG-1a as a yellow solid (17.02 g, 0.055 mol, 61% yield). 1H NMR (DMSO-d6, 300 MHz) δ 8.40 (d, J=3.3 Hz, 4H), 8.36 (m, 2H), 8.29 (s, 1H), 8.18 (d, J=8.8 Hz, 2H); LCMS (Cond. JG1): Rt=2.41, Anal. Calc. for C15H10N3O5[M+H]+312.06; found: 312.
Example JG-1b




JG-1a (9 g, 0.029 mol) was suspended in 110 mL of a 1:1 mixture of ethyl acetate/methanol. The suspension was placed under a hydrogen atmosphere (1 atm) in the presence of 1 g of 20% palladium hydroxide on carbon and stirred for 4 hours. HPLC indicates reaction completion. Reaction diluted with 50 mL of methanol and filtered through a bed of celite. The filter cake was washed with 100 mL methanol. The filtrate was concentrated under reduced pressure and the residual solid was crystallized from methanol to afford JG-1b as light brown needles (5.2 g, 71% yield). 1H NMR (DMSO-d6+D2O, 300 MHz) δ 7.72 (d, J=8.4 Hz, 2H), 7.54 (d, J=8.4 Hz, 2H), 7.40 (s, 1H), 6.83 (d, 8.05 Hz, 2H), 6.69 (d, 8.05 Hz, 2H); LCMS (Cond. JG1)Rt=0.87 min, Anal. Calc. for C15H14N3O; [M+H]+ 252.11; found: 252.
Example JG-1
EEDQ (0.085 g, 0.35 mmol) and carbobenzyloxy-L-Proline (0.082 g, 0.33 mmol) were added to a suspension of JG-1b (0.038 g, 0.15 mmol) in 2 mL dry CH2Cl2. The reaction stirred at room temperature for 16 hours. Solvents were removed in vacuo and the crude mixture was purified on a reverse phase preparative C-18 column. JG-1 was isolated as a white solid (0.015 g, 26% yield). 1HNMR (DMSO-d6, 300 MHz) δ 10.22 (1s, 1H) 10.07 (1s, 1H), 7.66-7.83, (2m, 2H), 7.55 (dd, J=8.9 Hz×2, 2H), 7.49-7.51 (m, 2H), 7.31-7.38 (m, 7H), 7.08-7.21 (2m, 5H), 5.04-5.11 (m, 4H), 4.36 (m, 2H), 4.03-4.09 (m, 2H), 3.46 (m, 2H), 2.25 (m, 2H), 1.88-1.94 (m, 6H); LCMS (Cond. JG1)Rt=2.66 min, Anal. Calc. for C41H40N5O2; [M+H]+ 714.29; found: 714.
Examples JG-2 to JG-6




Examples JG-2 to JG-6 were prepared from Example JG-1b and 2.0 eq. of the appropriate, commercially-available or synthesized carboxylic acids according to the procedure described for the preparation of Example JG-1. Purification of the final targets was accomplished using a Shimadzu reverse phase preparative HPLC instrument (solvent systems: H2O/MeOH/TFA or H2O/ACN/TFA. The coupling partner (ROH) was obtained from commercial sources unless otherwise noted.














JG-2




LCMS: Anal. Calcd. for: C41H39N5O7 713.8; Found: 714 (M + H)+. Rt = 1.09 min Cond. JG1


 


JG-3




LCMS: Anal. Calcd. for: C41H39N5O5 681.8; Found: 682 (M + H)+. Rt = 2.55 min Cond. JG1


 


JG-4




LCMS: Anal. Calcd. for: C41H43N5O7 717.83; Found: 718 (M + H)+. Rt = 2.53 min Cond. JG1


 


JG-5




LCMS: Anal. Calcd. for: C41H43N5O7 717.83; Found: 718 (M + H)+. Rt = 2.49 min Cond. JG1


 


JG-6




LCMS: Anal. Calcd. for: C4H43N5O5 709.85; Found: 710 (M + H)+. Rt = 2.83 min Cond. JG1









Example JG-7




Example JG-7a




EEDQ (2.14 g, 8.6 mmol) and tBoc-L-Proline (1.77 g, 8.3 mmol) were added to a suspension of JG-1b (0.9 g, 3.6 mmol) in 14 mL dry CH2Cl2. The reaction stirred at room temperature for 4 hours. The solution volume was reduced to 3 mL under reduced pressure and pentane was added to the resulting concentrate in order to precipitate solid. Solid was collected by vacuum filtration and dried under vacuum to yield JG-7a as a tan solid, 1.21 g (52% yield). 1H NMR (DMSO-d6, 300 MHz) δ 10.26 (s, 1H), 10.17 (s, 1H), 8.02 (m, 2H), 7.65-7.80 (m, 7H), 4.22 (m, 2H), 2.21 (m, 2H), 1.89 (m, 6H), 1.40+1.27 (2s, 18H); LCMS (Cond. JG1)Rt=2.61 min, Anal. Calc. for C35H44N5O2; [M+H]+646.3; found: 646.
Example JG-7b




To a solution of JG-7a (0.6 g, 0.90 mmol) in 2 mL CH2Cl2 was added 8 mL of a 1:1 solution of trifluoroacetic acid and CH2Cl2. After stirring at room temperature for 4 hours, solvents were removed in vacuo leaving a red oil. Pentane was added to the residue and once again placed under vacuum to remove solvent. Residual oil was pumped dry and JG-7b is obtained as a crunchy brown solid (0.68 g) which is of sufficient purity for use in subsequent reactions. 1H NMR (DMSO-d6, 500 MHz) δ 10.86 (s, 1H), 10.77 (s, 1H), 9.48 (br s, 2H), 8.08 (t, J=7.9 Hz×2, 2H), 7.73-7.84 (m, 7H) 4.16-4.38 (m, 2H), 4.31 (m, 4H), 2.40 (m, 2H), 2.05-1.93 (m, 6H); LCMS (Cond. JG1)Rt=2.61 min, Anal. Calc. for C25H28N5O3; [M+H]+446.5; found: 446.
Example JG-7
Triethylamine (0.125 mL, 0.9 mmol) and cyclopropanecarbonyl chloride (0.034 mL, 0.4 mmol) were added to a solution of 0.1 g JG-7b in 1 mL dry CH2Cl2. The mixture was stirred at 25° C. for 1 hour and monitored by HPLC. The reaction was diluted with 5 mL CH2Cl2 and washed with water, and brine. The organic layer was dried over MgSO4 and evaporated to dryness. Crude material was purified on a reverse phase preparative C-18 column. JG-7 was isolated as a yellow solid (0.017 g, 20% yield). 1H NMR (DMSO-d6, 300 MHz) δ 10.29 (s, 1H), 10.17 (s, 1H), 8.00 (m, 2H), 7.68-7.90 (m, 7H), 4.74-4.44 (m, 2H), 2.21 (m, 2H), 3.48-3.79 (2m, 4H), 2.16 (m, 2H) 1.84-2.05 (3m, 8H) 0.66-0.76 (m, 8H); LCMS (Cond. JG2)Rt=2.75 min, Anal. Calc. for C33H36N5O5; [M+H]+582.6; found: 582.
Examples JG-8 to JG-10




Examples JG-8 to JG-10 were prepared from Example JG-7b and 2.0 eq. of the appropriate, commercially-available or synthesized carboxylic acids according to the procedure described for the preparation of Example JG-7. Purification of the final targets was accomplished using a Shimadzu reverse phase preparative HPLC instrument (solvent systems: H2O/MeOH/TFA or H2O/ACN/TFA. The coupling partner (ROH) was obtained from commercial sources unless otherwise noted.














JG-8




LCMS: Anal. Calcd. for: C31H35N5O5 557.6; Found: 558 (M + H)+. Rt = 2.65 min Cond. JG2


 


JG-9




LCMS: Anal. Calcd. for: C35H39N5O5 609.7; Found: 610 (M + H)+. Rt = 3.04 min Cond. JG2


 


JG-10




LCMS: Anal. Calcd. for: C37H33N7O5 655.7; Found: 656 (M + H)+. Rt = 2.12 min Cond. JG2


 


JG-11




LCMS: Anal. Calcd. for: C29H31N5O5 529.6; Found: 530 (M + H)+. Rt = 2.03 min Cond. JG1









The following examples were synthesized by parallel synthesis performing each step in 21 mL scintillation vials without purification until the third and final step.
Example JG-12




EEDQ (0.061 g, 0.25 mmol) and Fmoc-Val-OH (0.084 g, 0.25 mmol) were added to a solution of JG-1b (0.025 g, 0.099 mmol) in 3 mL dry CH2Cl2 in a 21 mL scintillation vial. The reaction stirred at room temperature for 18 hours. Piperidine (0.25 mL) was added to the vial and the mixture was stirred at room temperature for an additional 6 hours. Solvents were removed in vacuo and the resulting residue was re-dissolved in 3 ml dry CH2Cl2. Triethylamine (0.050 mL, 0.30 mmol) and phenacetyl chloride (0.039 mL, 0.30 mmol) were added to the vial and stirred at room temperature for 2 hours. Solvents were removed in vacuo and the crude mixture was purified on a reverse phase preparative C-18 column. JG-12 was isolated as a white solid (0.0038 g, 5.6% yield). LCMS (Cond. JG1)Rt=2.76 min, Anal. Calc. for C41H45N5O5; [M+H]+ 686.8; found: 686.
Examples JG-13 to JG-18




Examples JG-13 to JG-18 were prepared from Example JG-1b and 2.0 eq. of the appropriate, commercially-available or synthesized carboxylic acids according to the procedure described for the preparation of Example JG-12. Purification of the final targets was accomplished using a Shimadzu reverse phase preparative HPLC instrument (solvent systems: H2O/MeOH/TFA or H2O/ACN/TFA. The coupling partner (ROH) was obtained from commercial sources unless otherwise noted.














JG-13




LCMS: Anal. Calcd. for: C41H43N5O5S2 749.9; Found: 750.2 (M + H)+. Rt = 2.71 min Cond. JG1


 


JG-14




LCMS: Anal. Calcd. for: C39H39N5O5S2 721.9; Found: 722 (M + H)+. Rt = 2.65 min Cond. JG1


 


JG-15




LCMS: Anal. Calcd. for: C41H43N5O7 717.83; Found: 718 (M + H)+. Rt = 3.89 min Cond. JG3


 


JG-16




LCMS: Anal. Calcd. for: C45H51N5O7 773.9; Found: 775 (M + H)+. Rt = 3.15 min Cond. JG3


 


JG-17




LCMS: Anal. Calcd. for: C43H47N5O5 713.88; Found: 714 (M + H)+. Rt = 3.02 min Cond. JG1


 


JG-18




LCMS: Anal. Calcd. for: C39H35N5O5 653.74; Found: 654 (M + H)+. Rt = 2.66 min Cond. JG1









Example JG-19




HATU (48 mg, 0.128 mmol)) was added in one portion to a stirred solution of JG-7b (30 mg, 0.058 mmol), diisopropylethylamine (0.045 ml, 0.350 mmol) and (S)-(+)-methoxyphenyl acetic acid (21 mg, 0.128 mmol) in anhydrous dimethylformamide (1.5 mL) at room temperature. The mixture was stirred for 16 h. Solvents were removed in vacuo and residue was purified by preparatory HPLC on C18— reverse phase to afford JG-19 as a yellow solid, 12.8 mg (30% yield). LRMS: Anal. Calc. for [M+H]+ C43H44N5O2 742.8; found 742.5.
Examples JG-20 to JG-30




Examples JG-20 to JG-30 were prepared from Example JG-7b and 2.0 eq. of the appropriate, commercially-available or synthesized carboxylic acids according to the procedure described for the preparation of Example JG-19. Purification of the final targets was accomplished using a Shimadzu reverse phase preparative HPLC instrument (solvent systems: H2O/MeOH/TFA or H2O/ACN/TFA. The coupling partner (ROH) was obtained from commercial sources unless otherwise noted.














JG-20




LCMS: Anal. Calcd. for: C41H39N5O7 713.8; Found: 714.2 (M + H)+. Rt = 2.02 min Cond. JG1


 


JG-21




HRMS: Anal. Calcd. for: C45H44N5O9 798.3139; Found: 798.3173 (M + H)+.


 


JG-22




LCMS: Anal. Calcd. for: C43H43N5O7 741.8; Found: 742.3 (M + H)+. Rt = 2.60 min Cond. JG1


 


JG-23




LCMS: Anal. Calcd. for: C41H39N5O7 713.8; Found: 714.2 (M + H)+. Rt = 1.99 min Cond. JG1


 


JG-24




HRMS: Anal. Calcd. for: C45H44N5O9 798.3139; Found: 798.3114 (M + H)+.


 


JG-25




LCMS: Anal. Calcd. for: C43H43N5O7 741.9; Found: 742.4 (M + H)+. Rt = 2.37 min Cond. JG1


 


JG-26




LCMS: Anal. Calcd. for: C41H37Cl2N5O7 782.6; Found: 783.3 (M + H)+. Rt = 2.42 min Cond. JG1


 


JG-27




LCMS: Anal. Calcd. for: C41H35N5O7 741.9; Found: 710.2 (M + H)+. Rt = 2.90 min Cond. JG1


 


JG-28




LCMS: Anal. Calcd. for: C43H35N5O7 733.8; Found: 734.2 (M + H)+. Rt = 2.95 min Cond. JG1


 


JG-29




LCMS: Anal. Calcd. for: C41H33N7O5S2 767.9; Found: 768.3 (M + H)+. Rt = 2.45 min Cond. JG4


 


JG-30




LCMS: Anal. Calcd. for: C41H33N7O7 735.7; Found: 736.2 (M + H)+. Rt = 1.82 min Cond. JG4









Example JG-31




HATU (45 mg, 0.119 mmol)) was added in one portion to a stirred solution of OL-31b (30 mg, 0.054 mmol), diisopropylethylamine (0.060 ml, 0.324 mmol) and benzoyl formic acid (18 mg, 0.119 mmol) in anhydrous dimethylformamide (1.5 mL) at room temperature. The mixture was stirred for 16 h. Solvents were removed in vacuo and residue was purified by preparatory HPLC on C18— reverse phase to afford JG-31 as a trifluoroacetic acid salt, 11.3 mg (25% yield). 1H NMR (500 MHz, DMSO-d6) δ ppm 10.40 (2H, br. s.), 8.06 (1H, s), 8.05 (2H, d, J=1.2 Hz), 7.87-7.94 (1H, m), 7.76-7.85 (4H, m), 7.70-7.75 (3H, m), 7.63-7.69 (4H, m), 7.53 (1H, t, J=7.8 Hz), 7.36 (1H, d, J=8.5 Hz), 7.09 (1H, s), 4.58-4.71 (2H, m), 3.69 (2H, br. s.), 3.35-3.55 (4H, m), 2.28-2.48 (2H, m), 1.87-1.98 (6H, m); LCMS (Cond. JG4)Rt=2.20 min, Anal. Calc. for [M+H]+ C41H37N6O6:709.8; found 709.3.
Examples JG-32 to JG-41




Examples JG-32 to JG-41 were prepared from Example OL31b and 2.0 eq. of the appropriate, commercially-available or synthesized carboxylic acids according to the procedure described for the preparation of Example JG-31. Purification of the final targets was accomplished using a Shimadzu reverse phase preparative HPLC instrument (solvent systems: H2O/MeOH/TFA or H2O/ACN/TFA) and the final products were isolated as the TFA salts. The coupling partner (ROH) was obtained from commercial sources unless otherwise noted.














JG-32




LCMS: Anal. Calcd. for: C41H39N5O7 712.8; Found: 713.2 (M + H)+. Rt = 1.84 min Cond. JG1


 


JG-33




LCMS: Anal. Calcd. for: C41H39N5O7 712.8; Found: 713.3 (M + H)+. Rt = 1.86 min Cond. JG1


 


JG-34




HRMS: Anal. Calcd. for: C45H45N6O8 797.3294; Found: 797.3286 (M + H)+.


 


JG-35




HRMS: Anal. Calcd. for: C45H45N6O8 797.3294; Found: 797.3276 (M + H)+.


 


JG-36




LCMS: Anal. Calcd. for: C41H38Cl2N6O6 781.7; Found: 782.4 (M + H)+. Rt = 1.97 min Cond. JG4


 


JG-37




LCMS: Anal. Calcd. for: C43H44N6O6 740.8; Found: 741.2 (M + H)+. Rt = 1.94 min Cond. JG4


 


JG-38




LCMS: Anal. Calcd. for: C43H44N6O6 740.8; Found: 741.3 (M + H)+. Rt = 1.96 min Cond. JG4


 


JG-39




LCMS: Anal. Calcd. for: C43H44N6O6 740.8; Found: 741.2 (M + H)+. Rt = 2.11 min Cond. JG4


 


JG-40




LCMS: Anal. Calcd. for: C43H36N6O6 732.8; Found: 733.5 (M + H)+. Rt = 2.09 min Cond. JG4


 


JG-41




LCMS: Anal. Calcd. for: C41H34N8O4S2 766.9; Found: 767.8 (M + H)+. Rt = 2.25 min Cond. JG4









Example JG-42




Prepared according to the procedure described for Example JG-31. This afforded Example JG-42 as a trifluoroacetic acid salt, 8.7 mg (29% yield). 1H NMR (300 MHz, DMSO-d6) δ ppm 10.53 (2H, s), 9.27 (1H, br. s.), 8.03 (2H, d, J=7.3 Hz), 7.89 (1H, d, J=7.3 Hz), 7.70-7.81 (5H, m), 7.63 (4H, t, J=7.5 Hz), 7.35-7.56 (6H, m), 7.23-7.34 (1H, m), 4.64 (2H, d, J=4.0 Hz), 3.68 (2H, br. s.), 3.33-3.55 (4H, m), 2.21-2.43 (2H, m), 1.81-2.11 (6H, m); LCMS (Cond. JG3)Rt=2.76 min.: Anal. Calc. for [M+H]+ C41H37N6O6:709.8; found 709.4.
Examples JG-43 to JG-52




Examples JG-43 to JG-52 were prepared from Example JG-31 and 2.0 eq. of the appropriate, commercially-available or synthesized carboxylic acids according to the procedure described for the preparation of Example JG-42. Purification of the final targets was accomplished using a Shimadzu reverse phase preparative HPLC instrument (solvent systems: H2O/MeOH/TFA or H2O/ACN/TFA) and the final products were isolated as TFA salts. The coupling partner (ROH) was obtained from commercial sources unless otherwise noted.














JG-43




LCMS: Anal. Calcd. for: C41H40N6O6 712.8; Found: 713.3 (M + H)+. Rt = 2.45 min Cond. JG3


 


JG-44




LCMS: Anal. Calcd. for: C41H40N6O6 712.8; Found: 713.4 (M + H)+. Rt = 2.49 min Cond. JG3


 


JG-45




LCMS: Anal. Calcd. for: C43H44N6O6 740.8; Found: 741.5 (M + H)+. Rt = 2.69 min Cond. JG3


 


JG-46




LCMS: Anal. Calcd. for: C43H44N6O6 740.8; Found: 741.4 (M + H)+. Rt = 2.95 min Cond. JG3


 


JG-47




LCMS: Anal. Calcd. for: C43H44N6O6 740.8; Found: 741.4 (M + H)+. Rt = 2.84 min Cond. JG3


 


JG-48




LCMS: Anal. Calcd. for: C45H38N8O4 754.8; Found: 755.5 (M + H)+. Rt = 1.98 min Cond. JG4


 


JG-49




LCMS: Anal. Calcd. for: C45H36Cl2N8O4 823.7; Found: 824.9 (M + H)+. Rt = 2.39 min Cond. JG3


 


JG-50




LCMS: Anal. Calcd. for: C47H40Cl2N8O6 883.8; Found: 884.5 (M + H)+. Rt = 3.36 min Cond. JG3


 


JG-51




LCMS: Anal. Calcd. for: C43H36N6O6 732.8; Found: 733.4 (M + H)+. Rt = 2.81 min Cond. JG3


 


JG-52




LCMS: Anal. Calcd. for: C43H36N6O6 732.8; Found: 733.4 (M + H)+. Rt = 2.67 min Cond. JG3









Example JG-53




Example JG-53a




Sec-butyllithium (107 mL, 150 mmol) was added drop-wise to a solution of furan (4.4 mL, 60 mmol) and tetramethylethylenediamine (22.60 mL, 150 mmol) in 150 mL hexanes at 0° C. After 1 hour, the reaction mixture was warmed to room temperature and stirred for four hours. The mixture was cooled to 0° C. and trimethyltin chloride (32.3 g, 162 mmol) in 50 mL hexanes was added drop-wise. The mixture was warmed to room temperature and stirred overnight (17 hours). Saturated ammonium chloride (150 mL) was added and the layers separated. Organic phase was washed with aqueous copper sulfate, dried over anhydrous sodium sulfate and concentrated under reduced pressure to give Example JG-53a as a orange oil. The material was used for the next step without further purification. 1H NMR (500 MHz, DMSO-d6) ppm 6.65 (s, 2H), 0.30 (s, 18H).
Example JG-53b




Example JG-53a (2.00 g, 5.10 mmol) was added to a suspension of Pd(PPh3)2Cl2 (0.033 g, 0.180 mmol), and 4-nitrobenzene (2.60 g, 10.5 mmol) in 75 mL THF and heated at reflux temperature for 20 hours. Upon cooling, an orange solid precipitated. The suspension was diluted with 100 mL hexanes and the solid was collected by vacuum filtration. The collected solid was washed three times with hexanes and dried. Example JG-53b was isolated as an orange solid (1.28 g, 81%).
1H NMR (DMSO-d6, 300 MHz) δ ppm 8.33 (4H, d, J=8.4 Hz), 8.15 (4H, d, J=8.8 Hz), 7.56 (2H, s); LRMS, Anal. Calc. for C16H10N2O5 [M+H]+311.20; found: 311.
Example JG-53c




Example JG-53b (1.20 g. 3.90 mmol) was suspended in 200 mL of a 1:1 mixture of ethyl acetate/methanol. The suspension was placed under a hydrogen atmosphere (1 atm) in the presence of 0.10 g of 20% palladium hydroxide on carbon and stirred for 4 hours. HPLC indicated the reaction was completed, so the mixture was diluted with 50 mL of methanol and filtered through a bed of celite. The filter cake was washed with 100 mL methanol and the filtrate was concentrated under reduced pressure and the residual solid corresponding to Example JG-53c was collected as light brown needles (0.75 g, 77% yield). 1H NMR (DMSO-d6, 300 MHz) δ 7.37 (m, 8H), 6.94 (s, 2H); LRMS Anal. Calc. for C16H14N2O [M+H]+251.20; found: 251.
Example JG-53d




EEDQ (1.47 g, 5.96 mmol) and Boc-L-Proline (1.28 g, 5.96 mmol) were added to a suspension of Example JG-53c (0.71 g, 2.84 mmol) in 15 mL dry CH2Cl2. The reaction stirred at room temperature for 16 hours. The reaction was concentrated to 5 mL in vacuo. Pentane was added to precipitate a white solid, which was collected by vacuum filtration. Example JG-53d was isolated as a white solid (1.42 g, 77% yield). The material was used for the next step without further purification. LRMS: Anal. Calc. for C36H44N4O7; [M+H]+645.50; found: 645.
Example JG-53e




4.0M HCl in dioxane (2.20 mL, 8.68 mmol) was added to a suspension of Example JG-53d (1.40, 2.17 mmol) in 4.0 mL of dioxane and stirred for 4 hours. The volatile component was removed in vacuo and the HCl salt of Example JG-53e was isolated as a tan solid (1.12 g, 98% yield). Material was used for next steps without further purification. 1H NMR (DMSO-d6, 300 MHz 6 ppm 10.99 (2H, s), 9.88 (2H, br. s.), 8.69 (2H, br. s.), 7.77-7.85 (4H, m), 7.67-7.76 (4H, m), 7.00 (2H, s), 4.39 (2H, d, J=6.6 Hz), 3.27 (4H, br. s.), 2.35-2.47 (2H, m), 1.86-2.06 (6H, m) LRMS Anal. Calcd. for [M+H]+ C26H28N4O3: 445.22; found 445.
Example JG-53




HATU (30.0 mg, 0.086 mmol) was added to a mixture of Example JG-53e (20.0 mg, 0.039 mmol), (R)-2-phenylpropanoic acid (18.0 mg, 0.078 mmol) and DIEA (41 μL, 0.23 mmol) in DMF (1.5 mL), and the mixture was stirred for 3 h. The volatile component was removed in vacuo and the residue was purified by reverse phase HPLC (MeOH/H2O/TFA) to afford the Example JG-53 as an off-white solid (10.1 mg) 1H NMR (DMSO-d6, 500 MHz) δ ppm 10.14 (2H, s), 7.73-7.83 (4H, m), 7.66-7.73 (4H, m), 7.29-7.39 (7H, m), 7.26 (3H, d, J=6.7 Hz), 6.97 (2H, s), 4.41 (2H, dd, J=8.2, 3.7 Hz), 4.01 (2H, d, J=6.7 Hz), 3.80 (2H, br. s.), 3.22 (2H, d, J=9.8 Hz), 2.03 (4H, br. s.), 1.89 (3H, br. s.), 1.77 (2H, br. s.), 1.31 (6H, d, J=6.7 Hz). LRMS: Anal. Calcd. for [M+H]+ C44H45N4O5: 709.33; found: 709. HRMS: Anal. Calcd. for [M+H]+ C44H45N4O5: 709.3388; found 709.3390.
Example JG-54 to JG-70




Examples 54-70 were prepared from intermediate Example JG-53c or Example JG-53e and appropriate acids by employing EEDQ or HATU coupling conditions and a reverse phase HPLC (H2O/MeOH/TFA) purification system.














JG-54




LRMS: Anal. Calcd. For (M + H)+ C42H40N4O7: 712.81 found: 713.13


 


JG-55




LRMS: Anal. Calcd. For (M + H)+ C30H32N4O5: 528.61 found: 529.13


 


JG-56




LRMS: Anal. Calcd. For (M + H)+ C40H40N4O7: 712.81 found: 713.72 HRMS: Anal. Calcd. For (M + H)+ C40H41N4O7: 713.2975 found: 713.3010


 


JG-57




LRMS: Anal. Calcd. For (M + H)+ C42H40N4O7: 712.81 found: 713.72 HRMS: Anal. Calcd. For (M + H)+ C42H41N4O7: 713.2975 found: 713.2836


 


JG-58




LRMS: Anal. Calcd. For (M + H)+ C44H44N4O7: 740.86 found: 741.20 HRMS: Anal. Calcd. For (M + H)+ C44H45N4O7: 741.3131 found: 741.3710


 


JG-59




LRMS: Anal. Calcd. For (M + H)+ C44H44N4O7: 740.32 found: 741.43 HRMS: Anal. Calcd. For (M + H)+ C44H45N4O7: 741.3288 found: 741.3269


 


JG-60




LRMS: Anal. Calcd. For (M + H)+ C48H40Cl2N6O7: 883.80 found: 883.74 HRMS: Anal. Calcd. For (M + H)+ C48H41Cl2N6O7: 883.2413 found: 883.2426


 


JG-61




LRMS: Anal. Calcd. For (M + H)+ C46H36Cl2N6O5: 823.74 found: 823.69 HRMS: Anal. Calcd. For (M + H)+ C46H37Cl2N6O5: 823.2202 found: 823.2224


 


JG-62




LRMS: Anal. Calcd. For (M + H)+ C46H38N6O5: 754.85 found: 755.72 HRMS: Anal. Calcd. For (M + H)+ C46H39N6O5: 755.2982 found: 755.2985


 


JG-63




LRMS: Anal. Calcd. For (M + H)+ C46H40N6O5: 766.95 found: 767.82 HRMS: Anal. Calcd. For (M + H)+ C46H41N6O5: 767.3921 found: 767.3953









Example JG-64




HATU (65.0 mg, 0.14 mmol) was added to a mixture of Example JG-53a (40.0 mg, 0.07 mmol), R-(−)-Mandelic acid (11.8 mg, 0.07 mmol, Cap-151 (18.4 mg, 0.07 mmol), and DIEA (82 μL, 0.42 mmol) in DMF (1.5 mL), and the mixture was stirred for 3 h. The volatile component was removed in vacuo and the residue was purified with a reverse phase HPLC (MeOH/H2O/TFA) to afford Example JG-64 as an off-white solid (6.7 mg) LRMS: Anal. Calcd. for [M+H]+ C45H41ClN5O2: 798.33; found: 798. HRMS: Anal. Calcd. for [M+H]+ C45H41ClN5O2: 798.2594; found 798.2547. The symmetrical analogs were also separated and they were described previously.














JG-65




LRMS: Anal.  Calcd. for  (M + H)+ C47H45ClN6O6: 825.37 found: 825.77 HRMS: Anal.  Calcd. for  (M + H)+ C47H46ClN6O6: 825.3167 found: 825.3002


 


JG-66




LRMS: Anal.  Calcd. for (M + H)+ C44H45ClN5O6: 739.88 found: 740.43 HRMS: Anal.  Calcd. for  (M + H)+ C44H46ClN5O6: 740.3448 found: 740.7561


 


JG-67




LRMS: Anal.  Calcd. for (M + H)+ C47H43ClN6O7: 839.36 found: 839.81 HRMS: Anal.  Calcd. for  (M + H)+ C47H44ClN6O7: 839.2960 found: 839.2930


 


JG-68




LRMS: Anal.  Calcd. for (M + H)+ C45H40ClN5O7: 798.30 found: 798.76 HRMS: Anal.  Calcd. for  (M + H)+ C45H41ClN5O7: 798.2694 found: 798.2671


 


JG-69




LRMS: Anal.  Calcd. for (M + H)+ C46H44N4O9: 796.88 found: 797.53 HRMS: Anal.  Calcd. for  (M + H)+ C46H45N4O9: 797.3186 found: 797.3220


 


JG-70




LRMS: Anal.  Calcd. for (M + H)+ C46H44N4O9: 796.88 found: 797.00 HRMS: Anal.  Calcd. for  (M + H)+ C46H45N4O9: 797.3186 found: 797.3148









Example FY-1




Example FY-1a




Prepared according to the procedure described for Example OL-1c from 1-methyl-3,5-bis(4-nitrophenyl)-1H-pyrazole, which was obtained from commercially available 1-methyl-3,5-diphenyl-1H-pyrazole according to the procedure described for Example JR-D-1a. This afforded Example FY-1a (0.2831 g, 99% yield) as an off-white solid. 1H NMR (500 MHz, DMSO-d6) δ ppm 7.45 (2H, d, J=8.9 Hz), 7.18 (2H, d, J=8.5 Hz), 6.65 (2H, d, J=8.5 Hz), 6.57 (2H, d, J=8.5 Hz), 6.42 (1H, s), 5.24 (4H, br. s.), 3.72-3.79 (3H, m); LC/MS (Cond. IV): Rt=0.197 min; Anal. Calc. for [M+H]+ C16H17N4: 265.15; found: 265.31.
Example FY-1




Prepared according to the procedure described for Example OL-1d. This afforded Example FY-1 (0.0872 g, 83% yield) as a white powder. 1H NMR (500 MHz, <DMSO>) δ ppm 9.88-10.47 (2H, m), 7.42-7.91 (8H, m), 7.08-7.39 (10 H, m), 6.67-6.92 (1H, m), 4.31-4.80 (2H, m), 3.23-3.99 (11H, m), 1.71-2.43 (8H, m). LC/MS (Cond. 1V): Rt=1.683 min; Anal. Calc. for [M+H]+ C42H43N6O4: 695.34; found: 695.40.
Example FY-2




Prepared according to the procedure described for Example OL-1d. This afforded Example FY-2 (0.0547 g, 67% yield) as a white powder. 1H NMR (500 MHz, <DMSO>) δ ppm 9.92-10.38 (2H, m), 7.70-7.84 (4H, m), 7.59-7.67 (2H, m), 7.46-7.57 (2H, m), 6.74-6.84 (1H, m), 4.32-4.61 (2H, m), 3.82-3.93 (3H, m), 3.32-3.72 (4H, m), 1.70-2.40 (14H, m); LC/MS (Cond. 1V): Rt=1.28 min; Anal. Calc. for [M+H]+ C30H35N6O4: 543.27; found: 543.42.
Example FY-3




Prepared according to the procedure described for Example OL-1d. This afforded Example FY-3 (0.0996 g, 20% yield) as a white powder 1H NMR (500 MHz, <DMSO>) δ ppm 10.19-10.28 (1H, m), 10.09 (1H, d, J=9.2 Hz), 7.00-7.93 (18H, m), 6.80 (1H, t, J=6.4 Hz), 5.03-5.17 (3H, m), 4.91-5.02 (1H, m), 4.26-4.47 (2H, m), 3.77-3.93 (3H, m), 3.33-3.63 (4H, m), 2.12-2.39 (2H, m), 1.77-2.05 (6H, m); LC/MS (Cond. 1V): Rt=1.77 min; Anal. Calc. for [M+H]+ C42H43N6O6: 727.33; found: 727.36.
Example FY-4




Prepared according to the procedure described for Example OL-1d. This afforded Example FY-4 (0.0185 g, 14% yield) as a white powder. 1H NMR (500 MHz, <DMSO>) δ ppm 9.89-10.39 (2H, m), 7.44-7.83 (8H, m), 6.68-6.85 (1H, m), 4.34-4.82 (2H, m), 3.86 (3H, s), 3.65-3.83 (3H, m), 3.37-3.58 (1H, m), 1.44-2.41 (10H, m), 0.56-0.85 (8H, m); LC/MS (Cond. 1V): Rt=1.43 min; Anal. Calc. for [M+H]+ C34H39N6O4: 595.31; found: 595.36.
Example FY-5




Example FY-5a




To a stirred solution of Example JG-1b (0.2 g, 0.796 mmol) and charcoal (0.01 g, 0.05 wt %) in EtOAc (8 mL) at ambient temperature was added diphosgene (0.205 g, 1.035 mmol). The reaction was heated to reflux for two hours and concentrated in vacuo to give Example FY-5a (0.241 g, 100%) as a green powder. 1H NMR (500 MHz, DMSO-d6) δ ppm 7.95-8.17 (2H, m), 7.57-7.93 (4H, m), 7.37-7.51 (1H, m), 7.22-7.35 (2H, m).
Example FY-5b




To a stirred solution of (R)-3-Aminopyrrolidine (1.2 g, 11.61 mmol) in MeOH (10 mL) at −5° C. was added 1N HCl (11.6 mL, 11.61 mmol) followed by di-t-butyldicarbonate (2.79 g, 12.78 mmol) in MeOH (10 mL). Two hours later, it was concentrated in vacuo. To the residue was added 1N HCl (2.32 mL) and the aqueous mixture was washed with methylene chloride (10 mL). The aqueous layer was basified by addition of potassium carbonate (1.93 g, 13.96 mmol) and then extracted with methylene chloride (30 mL×2). The combined extracts were concentrated in vacuo to give Example FY-5b (1.91 g, 88%) as colorless oil. 1H NMR (500 MHz, DMSO-d6) δ ppm 3.36-3.45 (1H, m), 3.27-3.36 (2H, m), 3.13-3.25 (1H, m), 2.87 (1H, dd, J=10.5, 4.7 Hz), 1.77-1.95 (1H, m), 1.63 (2H, br. s.), 1.47-1.59 (1H, m), 1.40 (9H, s).
Example FY-5c




To a stirred solution of Example FY-5a (0.04 g, 0.139 mmol) in CH2Cl2 (1 mL) at ambient temperature was added Example FY-5b (0.059 g, 0.316 mmol) in CH2Cl2 (1 mL). After one hour, the mixture was filtered and concentrated in vacuo to give Example FY-5c (0.02 g, 22%) as white solid. 1H NMR (500 MHz, DMSO-d6) δ ppm 8.71 (1H, br. s.), 8.58 (1H, br. s.), 7.94 (2H, d, J=8.5 Hz), 7.69 (2H, d, J=8.5 Hz), 7.61 (1H, s), 7.57 (2H, d, J=8.5 Hz), 7.52 (2H, d, J=8.5 Hz), 6.61 (1H, br. s.), 6.55 (1H, br. s.), 4.18 (2H, br. s.), 3.49 (2H, br. s.), 3.34 (4H, br. s.), 3.13 (2H, br. s.), 2.07 (2H, br. s.), 1.81 (2H, br. s.), 1.43 (18H, s); LC/MS (Cond. 1V): Rt=1.90 min; Anal. Calc. for [M+H]+ C35H46N7O7: 676.35; found: 676.52.
Example FY-5d




To Example FY-5c (0.178 g, 0.2631 mmol) was added 4N HCl/dioxane (15 ml) and stirred for three hours at ambient temperature. The reaction mixture was concentrated in vacuo to give Example FY-5d (0.1901 g, 100%) as yellow solid. 1H NMR (500 MHz, DMSO-d6) δ ppm 9.26 (1H, s), 9.13-9.22 (1H, m), 9.11 (1H, s), 9.04 (1H, br. s.), 7.90-7.97 (2H, m), 7.70 (2H, d, J=8.5 Hz), 7.58-7.63 (3H, m), 7.52-7.57 (2H, m), 7.02 (1H, d, J=6.1 Hz), 6.96 (1H, d, J=5.8 Hz), 4.30 (2H, br. s.), 3.39 (2H, dd, J=4.6, 2.4 Hz), 3.28-3.35 (2H, m), 3.17-3.28 (2H, m), 3.00-3.12 (2H, m), 2.15-2.26 (2H, m), 1.86 (2H, dd, J=13.1, 6.4 Hz); LC/MS (Cond. 1V): Rt=1.03 min; Anal. Calc. for [M+H]+ C25H30N7O3: 476.24; found: 476.64.
Example FY-5
To a stirred solution of Example FY-5d (0.025 g, 0.0046 mmol) in DMF (1 mL) at ambient temperature was added Hunig's base (0.048 mL, 0.0276 mmol), (R)-mandelic acid (0.021 g, 0.0138 mmol), and HATU (0.0536 g, 0.0138) sequentially. The reaction was allowed to stir overnight at which point methanol (1 ml) was added and the reaction was loaded directly onto preparative HPLC. Purification via preparative HPLC provided Example FY-5 (0.0057 g, 17%) as a yellow wax. 1H NMR (500 MHz, DMSO-d6) δ ppm 8.47-8.76 (2H, m), 7.93 (2H, d, J=8.5 Hz), 7.68 (2H, d, J=7.9 Hz), 7.18-7.62 (15H, m), 6.34-6.68 (2H, m), 5.12-5.34 (2H, m), 4.04-4.29 (2H, m), 3.42-3.92 (6H, m), 3.36 (1H, d, J=15.3 Hz), 3.18-3.27 (1H, m), 2.94-3.06 (2H, m), 2.05 (2H, br. s.), 1.85 (1H, br. s.), 1.69 (1H, br. s.); LC/MS (Cond. 1V): Rt=1.61 min; Anal. Calc. for [M+H]+ C41H42N7O7: 744.32; found: 744.51.
Example FY-6




Prepared according to the procedure described for Example FY-5. This afforded Example FY-6 (0.0057 g, 17% yield) as a yellow powder. 1H NMR (500 MHz, DMSO-d6) δ ppm 8.69 (1H, d, J=7.3 Hz), 8.57 (1H, d, J=7.6 Hz), 7.88-7.99 (2H, m), 7.64-7.74 (2H, m), 7.19-7.64 (15H, m), 6.37-6.68 (2H, m), 5.17-5.34 (2H, m), 4.17 (4H, br. s.), 3.69 (2H, d, J=4.9 Hz), 3.43-3.59 (2H, m), 3.29-3.43 (2H, m), 3.14-3.26 (2H, m), 2.10 (1H, d, J=2.4 Hz), 1.97 (1H, br. s.), 1.78 (2H, br. s.); LC/MS (Cond. 1V): Rt=1.647 min; Anal. Calc. for [M+H]+ C41H42N7O7: 744.32; found: 744.50.
Example FY-7




Prepared according to the procedure described for Example FY-5. This afforded Example FY-7 (0.0090 g, 26% yield) as a yellow powder. 1H NMR (500 MHz, DMSO-d6) δ ppm 8.27-8.75 (2H, m), 7.87-7.97 (2H, m), 7.63-7.72 (2H, m), 7.22-7.63 (13H, m), 6.96-7.11 (2H, m), 6.43-6.57 (1H, m), 6.11-6.25 (1H, m), 4.03 (4H, ddd, J=12.4, 6.1, 6.0 Hz), 3.77-3.86 (1H, m), 3.65-3.75 (1H, m), 3.55-3.63 (1H, m), 3.47-3.55 (1H, m), 3.36-3.46 (1H, m), 3.28 (1H, d, J=11.6 Hz), 2.91 (1H, d, J=4.9 Hz), 2.63-2.74 (1H, m), 1.92-2.04 (1H, m), 1.63-1.83 (1H, m), 1.46-1.63 (8H, m); LC/MS (Cond. 1V): Rt=1.733 min; Anal. Calc. for [M+H]+ C43H46N7O7: 772.35; found: 772.56.
Example FY-8




Prepared according to the procedure described for Example FY-5. This afforded Example FY-8 (0.0146 g, 40% yield) as a yellow powder. 1H NMR (500 MHz, DMSO-d6) δ ppm 8.91-9.17 (1H, m), 8.61-8.83 (1H, m), 7.94 (2H, d, J=8.9 Hz), 7.69 (2H, d, J=8.5 Hz), 7.34-7.63 (15H, m), 6.85-7.07 (1H, m), 6.41-6.66 (1H, m), 5.32-5.57 (2H, m), 4.22-4.36 (1H, m), 3.97-4.15 (2H, m), 3.76-3.89 (1H, m), 3.45-3.64 (3 H, m), 3.33-3.44 (1H, m), 3.05 (1H, d, J=7.9 Hz), 2.95 (6H, br. s.), 2.72-2.83 (1H, m), 2.43 (6H, br. s.), 2.00-2.19 (2H, m), 1.93 (1H, br. s.), 1.70 (1H, td, J=7.8, 3.7 Hz); LC/MS (Cond. 1):Rt=1.318 min; Anal. Calc. for [M+H]+ C45H52N9O5: 798.41; found: 798.66.
Example FY-9




Example FY-9a




Prepared according to the procedure described for Example FY-5c, using pyrazolidine as a starting material. This afforded Example FY-9a (0.0453 g, 26% yield) as a yellow powder. 1H NMR (500 MHz, DMSO-d6) δ ppm 8.96-9.25 (2H, m), 7.93 (2H, d, J=8.9 Hz), 7.52-7.87 (9H, m), 3.41 (4H, d, J=2.4 Hz), 2.84 (4H, d, J=4.9 Hz), 1.91-2.13 (4H, m); LC/MS (Cond. 1V): Rt=1.278 min; Anal. Calc. for [M+H]+ C23H26N7O3: 448.21; found: 448.42.
Example FY-9b




To a stirred solution of (R)-2-(dimethylamino)-2-phenylacetic acid (0.0944 g, 0.438 mmol) (Cap 1) in CH2Cl2 (2 mL) was slowly added 2M oxalyl chloride (284 uL, 0.569 mmol) and one drop of DMF at 0° C. After two hours, the reaction was concentrated in vacuo to give Example FY-9b (0.241 g, 100%) as a light brown wax which was used in the next step without further characterization or purification.
Example FY-9




Prepared according to the procedure described for Example OL-34. This afforded Example FY-9 (0.002, 12% yield) as a yellow wax. 1H NMR (500 MHz, DMSO-d6) δ ppm 9.67-9.90 (2H, m), 8.06 (2H, d, J=8.9 Hz), 7.89 (2H, d, J=8.9 Hz), 7.10-7.87 (15H, m), 5.46-5.76 (2H, m), 3.71-4.24 (4H, m), 3.12-3.37 (2H, m), 3.03 (6H, d, J=3.1 Hz), 2.44 (6H, d, J=3.7 Hz), 1.83-2.23 (2H, m), 1.71 (4H, br. s.); LC/MS (Cond. 1V): Rt=1.198 min; Anal. Calc. for [M+H]+ C43H47N9O5: 770.38; found: 770.62.
Examples RK-1 to RK-42




Examples RK-1 to RK-42 were prepared from Example CB-1c and 2.0 eq. of the appropriate, commercially-available or synthesized carboxylic acids according to the procedure described for the preparation of Example CB-1. Purification of the final targets was accomplished using a Shimadzu reverse phase preparative HPLC instrument (solvent systems: H2O/MeOH/TFA or H2O/ACN/TFA) and the final products were isolated as TFA salts. The coupling partner (RCOOH) was obtained from commercial sources unless otherwise noted.












Example
RCOOH
Analysis







RK-1 




LCMS: Anal. Calcd. For [M + H]+: C40H39N6O7 715.29; Found: 715.28. Rt = 1.41 min Cond. RK1


 


RK-2 




LCMS: Anal. Calcd. For [M + H]+: C40H35N6O9 743.25; Found: 743.41. Rt = 1.61 min Cond. RK1


 


RK-3 




LCMS: Anal. Calcd. For [M + H]+: C40H39N6O5 683.30; Found: 683.28. Rt = 1.43 min Cond. RK1


 


RK-4 




LCMS: Anal. Calcd. For [M + H]+: C42H43N6O7 743.32; Found: 743.31. Rt = 1.81 min Cond. RK1


 


RK-5 




LCMS: Anal. Calcd. For [M + H]+: C42H43N6O7 743.32; Found: 743.32. Rt = 1.85 min Cond. RK1


 


RK-6 




LCMS: Anal. Calcd. For [M + H]+: C40H39N6O7 715.29; Found: 715.26. Rt = 1.26 min Cond. RK1


 


RK-7 




LCMS: Anal. Calcd. For [M + H]+: C40H39N6O7 715.29; Found: 715.28. Rt = 1.31 min Cond. RK1


 


RK-8 




LCMS: Anal. Calcd. For [M + H]+: C42H43N6O7 743.32; Found: 743.32. Rt = 1.37 min Cond. RK1


 


RK-9 




LCMS: Anal. Calcd. For [M + H]+: C42H43N6O5 711.33; Found: 711.32. Rt = 1.54 min Cond. RK1


 


RK-10




LCMS: Anal. Calcd. For [M + H]+: C44H36N8O5 757.29; Found: 757.33. Rt = 1.28 min Cond. RK1


 


RK-11




LCMS: Anal. Calcd. For [M + H]+: C42H43N6O7 743.32; Found: 743.33. Rt = 1.33 min Cond. RK1


 


RK-12




LCMS: Anal. Calcd. For [M + H]+: C36H31Cl2N8O5 725.18; Found: 727.17. Rt = 1.25 min Cond. RK1


 


RK-13




LCMS: Anal. Calcd. For [M + H]+: C36H31N8O5 635.23; Found: 635.22. Rt = 1.14 min Cond. RK1


 


RK-14




LCMS: Anal. Calcd. For [M + H]+: C34H39N6O7 643.29; Found: 643.27. Rt = 1.07 min Cond. RK1


 


RK-15




LCMS: Anal. Calcd. For [M + H]+: C34H39N6O7 643.29; Found: 643.27. Rt = 1.03 min Cond. RK1


 


RK-16




LCMS: Anal. Calcd. For [M + H]+: C40H39N6O7 715.29; Found: 715.27. Rt = 1.21 min Cond. RK1


 


RK-17




LCMS: Anal. Calcd. For [M + H]+: C40H39N6O7 715.29; Found: 715.28. Rt = 1.21 min Cond. RK1


 


RK-18




LCMS: Anal. Calcd. For [M + H]+: C44H35Cl2N8O5 825.21; Found: 825.42. Rt = 1.83 min Cond. RK1


 


RK-19




LCMS: Anal. Calcd. For [M + H]+: C38H39N6O7 691.29; Found: 691.27. Rt = 1.22 min Cond. RK1


 


RK-20




LCMS: Anal. Calcd. For [M + H]+: C32H27Cl2N8O5 673.15; Found: 673.14. Rt = 1.42 min Cond. RK1


 


RK-21




LCMS: Anal. Calcd. For [M + H]+: C30H27N6O7 583.19; Found: 583.17. Rt = 1.13 min Cond. RK1


 


RK-22




LCMS: Anal. Calcd. For [M + H]+: C42H37N8O7 765.28; Found: 765.29. Rt = 1.78 min Cond. RK1


 


RK-23




LCMS: Anal. Calcd. For [M + H]+: C36H35N6O5 631.27; Found: 631.28. Rt = 1.24 min Cond. RK1


 


RK-24




LCMS: Anal. Calcd. For [M + H]+: C36H35N6O7 663.26; Found: 663.24. Rt = 1.17 min Cond. RK1


 


RK-25




LCMS: Anal. Calcd. For [M + H]+: C36H31F2N8O5 693.24; Found: 693.22. Rt = 1.22 min Cond. RK1


 


RK-26




LCMS: Anal. Calcd. For [M + H]+: C48H45N8O7 845.34; Found: 845.31. Rt = 1.36 min Cond. RK1


 


RK-27




LCMS: Anal. Calcd. For [M + H]+: C36H31Cl2N8O5 725.18; Found: 725.17. Rt = 1.23 min Cond. RK1


 


RK-28




LCMS: Anal. Calcd. For [M + H]+: C42H43N6O7 743.32; Found: 743.32. Rt = 1.29 min Cond. RK1


 


RK-29




LCMS: Anal. Calcd. For [M + H]+: C32H27F2N8O5 641.21; Found: 641.19. Rt = 1.31 min Cond. RK1


 


RK-30




LCMS: Anal. Calcd. For [M + H]+: C38H39N6O7 691.29; Found: 691.27. Rt = 1.27 min Cond. RK1


 


RK-31




LCMS: Anal. Calcd. For [M + H]+: C38H39N6O7 691.29; Found: 691.29. Rt = 1.24 min Cond. RK1


 


RK-32




LCMS: Anal. Calcd. For [M + H]+: C46H39Cl2N8O7 885.23; Found: 885.46. Rt = 1.96 min Cond. RK1


 


RK-33




LCMS: Anal. Calcd. For [M + H]+: C42H35Cl2N8O7 833.20; Found: 833.22. Rt = 1.97 min Cond. RK1


 


RK-34




LCMS: Anal. Calcd. For [M + H]+: C30H35N6O7 591.26; Found: 591.24. Rt = 1.05 min Cond. RK1


 


RK-35




LCMS: Anal. Calcd. For [M + H]+: C30H35N6O7 591.26; Found: 591.25. Rt = 1.10 min Cond. RK1


 


RK-36




LCMS: Anal. Calcd. For [M + H]+: C40H31Cl2N8O5 773.18; Found: 773.13. Rt = 1.72 min Cond. RK1


 


RK-37




LCMS: Anal. Calcd. For [M + H]+: C32H27Cl2N8O5 673.15; Found: 673.16. Rt = 1.43 min Cond. RK1


 


RK-38




LCMS: Anal. Calcd. For [M + H]+: C40H45N8O5 717.35; Found: 717.30. Rt = 1.07 min Cond. RK1


 


RK-39




LCMS: Anal. Calcd. For [M + H]+: C44H49N8O5 769.38; Found: 769.33. Rt = 1.01 min Cond. RK1


 


RK-40




LCMS: Anal. Calcd. For [M + H]+: C38H35Cl2N8O7 785.20; Found: 785.19. Rt = 1.39 min Cond. RK1


 


RK-41




LCMS: Anal. Calcd. For [M + H]+: C34H31Cl2N8O7 733.18; Found: 733.19. Rt = 1.43 min Cond. RK1


 


RK-42




LCMS: Anal. Calcd. For [M + H]+: C44H41N8O5 761.32; Found: 761.36. Rt = 1.46 min Cond. RK1









Examples JR-1 to JR-23




Examples JR-1 to JR-23 were prepared from Example D-4d and 2.0 eq. of the appropriate, commercially-available or synthesized carboxylic acid according to the procedure described for Example D-57. Purification of the final targets was accomplished using a Shimadzu reverse phase preparative HPLC instrument (solvent systems: H2O/MeOH/TFA or H2O/ACN/TFA) and the final products were isolated as TFA salts. The coupling partner (ROH) was obtained from commercial sources unless otherwise noted.














Coupling

Rt (LC-Cond.);


Example
Protocol
R
%; MS data







JR-1 
HATU, DIPEA, DMF




LRMS: Anal. Calcd. For [M + H]+: C47H42N7O7 816.31; Found: 816.04.  Rt = 1.50 min Cond. −J2


 


JR-2 
HATU, DIPEA, DMF




LRMS: Anal. Calcd. For [M + H]+: C31H30F6N5O7 698.21; Found: 698.55.  Rt = 1.74 min Cond. −J2


 


JR-3 
HATU, DIPEA, DMF




LRMS: Anal. Calcd. For [M + H]+: C37H40N9O7 722.31; Found: 722.66.  Rt = 1.19 min Cond. −J2


 


JR-4 
HATU, DIPEA, DMF




LRMS: Anal. Calcd. For [M + H]+: C41H42N7O7 744.31; Found: 744.73.  


 


JR-5 
HATU, DIPEA, DMF




LRMS: Anal. Calcd. For [M + H]+: C47H46N7O7 820.35; Found: 820.80.  


 


JR-6 
HATU, DIPEA, DMF




LRMS: Anal. Calcd. For [M + H]+: C37H36N5O7S2 726.21; Found: 726.61.  


 


JR-7 
HATU, DIPEA, DMF




LRMS: Anal. Calcd. For [M + H]+: C39H38N7O7 716.28; Found: 716.31.  Rt = 1.21 min Cond. −J2


 


JR-8 
HATU, DIPEA, DMF




LRMS: Anal. Calcd. For [M + H]+: C47H52Br2N7O5 952.24; Found: 952.14.  Rt = 1.69 min Cond. −J1


 


JR-9 
HATU, DIPEA, DMF




LRMS: Anal. Calcd. For [M + H]+: C43H40N9O7 794.31; Found: 794.35.  Rt = 1.83 min Cond. −J1


 


JR-10
HATU, DIPEA, DMF




LRMS: Anal. Calcd. For [M + H]+: C49H52N9O7 878.40; Found: 878.40.  Rt = 2.09 min Cond. −J1


 


JR-11
HATU, DIPEA, DMF




LRMS: Anal. Calcd. For [M + H]+: C55H48N9O7 946.37; Found: 946.43.  Rt = 2.14 min Cond. −J1


 


JR-12
HATU, DIPEA, DMF




LRMS: Anal. Calcd. For [M + H]+: C39H48N13O5 778.39; Found: 778.41.  Rt = 1.36 min Cond. −J1


 


JR-13
HATU, DIPEA, DMF




LRMS: Anal. Calcd. For [M + H]+: C47H54N7O7 828.41; Found: 828.42.  Rt = 1.67 min Cond. −J1


 


JR-14
HATU, DIPEA, DMF




LRMS: Anal. Calcd. For [M + H]+: C47H54N7O7 828.41; Found: 828.42.  Rt = 1.58 min Cond. −J1


 


JR-15
HATU, DIPEA, DMF




LRMS: Anal. Calcd. For [M + H]+: C43H50N7O7S2 840.32; Found: 840.43.  Rt = 1.61 min Cond. −J1


 


JR-16
HATU, DIPEA, DMF




LRMS: Anal. Calcd. For [M + H]+: C43H50N7O7S2 840.32; Found: 840.42.  Rt = 1.62 min Cond. −J1


 


JR-17
HATU, DIPEA, DMF




LRMS: Anal. Calcd. For [M + H]+: C39H42N7O7S2 784.26; Found: 784.13.  Rt = 1.89 min Cond. −J1


 


JR-18
HATU, DIPEA, DMF




LRMS: Anal. Calcd. For [M + H]+: C49H54N7O9 884.40; Found: 884.25.  Rt = 2.04 min Cond. −J1


 


JR-19
HATU, DIPEA, DMF




LRMS: Anal. Calcd. For [M + H]+: C53H58N7O9 936.43; Found: 936.23.  Rt = 2.22 min Cond. −J1


 


JR-20
HATU, DIPEA, DMF




LRMS: Anal. Calcd. For [M + H]+: C47H46N7O9 852.34; Found: 852.36.  


 


JR-21
HATU, DIPEA, DMF




LRMS: Anal. Calcd. For [M + H]+: C47H46N7O9 852.34; Found: 852.26.  Rt = 1.96 min Cond. −J1


 


JR-22
HATU, DIPEA, DMF




LRMS: Anal. Calcd. For [M + H]+: C47H42N7O11 880.29; Found: 880.21.  









Examples XY-1 to XY-43




Examples XY-1 to XY-44 were prepared from Example D-4d and 2.0 eq. of the appropriate, commercially-available or synthesized carboxylic acid according to the procedure described for Example D-57. Purification of the final targets was accomplished using a Shimadzu reverse phase preparative HPLC instrument (solvent systems: H2O/MeOH/TFA or H2O/ACN/TFA). The coupling partner (ROH) obtained from commercial sources unless otherwise noted.













Example
R








XY-1 






 



XY-2 






 



XY-3 






 



XY-4 






 



XY-5 






 



XY-6 






 



XY-7 






 



XY-8 






 



XY-9 






 



XY-10






 



XY-11






 



XY-12






 



XY-13






 



XY-14






 



XY-15






 



XY-16






 



XY-17






 



XY-18






 



XY-19






 



XY-20






 



XY-21






 



XY-22






 



XY-23






 



XY-24






 



XY-25






 



XY-26






 



XY-27






 



XY-28






 



XY-29






 



XY-30






 



XY-31






 



XY-31






 



XY-33 






 



XY-34 






 



XY-35






 



XY-36






 



XY-37 






 



XY-38






 



XY-39






 



XY-40






 



XY-41






 



XY-42






 



XY-43













Examples XY-44 to XY-58




Examples XY-44 to XY-58 were prepared according to the method described to prepare Example D-4 using L-trans-hydroxyproline and 2.0 eq. of the appropriate, commercially-available or synthesized carboxylic acid according to the procedure described for Example D-57. Purification of the final targets was accomplished using a Shimadzu reverse phase preparative HPLC instrument (solvent systems: H2O/MeOH/TFA or H2O/ACN/TFA). The coupling partner (ROH) obtained from commercial sources unless otherwise noted.













Example
R








XY-44






 



XY-45






 



XY-46






 



XY-47






 



XY-48






 



XY-49






 



XY-50






 



XY-51






 



XY-52






 



XY-53






 



XY-54






 



XY-55






 



XY-56






 



XY-57






 



XY-58













Examples XY-59 to XY-77




Examples XY-59 to XY-77 were prepared according to the method described to prepare Example D-4 using L-trans-t-butoxyproline and 2.0 eq. of the appropriate, commercially-available or synthesized carboxylic acid according to the procedure described for Example D-57. Purification of the final targets was accomplished using a Shimadzu reverse phase preparative HPLC instrument (solvent systems: H2O/MeOH/TFA or H2O/ACN/TFA). The coupling partner (ROH) obtained from commercial sources unless otherwise noted.













Example
R








XY-59






 



XY-60
H


 



XY-61






 



XY-62






 



XY-63






 



XY-64






 



XY-65






 



XY-66






 



XY-67






 



XY-68






 



XY-69






 



XY-70






 



XY-71






 



XY-72






 



XY-73






 



XY-74






 



XY-75






 



XY-76






 



XY-77













Biological Activity
An HCV Replicon assay was utilized in the present disclosure, and was prepared, conducted and validated as described in commonly owned PCT/US2006/022197 and in O'Boyle et al., Antimicrob. Agents Chemother., 49(4):1346-1353 (April 2005). Assay methods incorporating luciferase reporters have also been used as described (Apath.com).
HCV-neo replicon cells and replicon cells containing resistance substitutions in the NS5A region were used to test the currently described family of compounds. The compounds were determined to have differing degrees of reduced inhibitory activity on cells containing mutations vs. the corresponding inhibitory potency against wild-type cells. Thus, the compounds of the present disclosure can be effective in inhibiting the function of the HCV NS5A protein and are understood to be as effective in combinations as previously described in application PCT/US2006/022197 and commonly owned WO 04/014852. It should be understood that the compounds of the present disclosure can inhibit multiple genotypes of HCV. Table 2 shows the EC50 (Effective 50% inhibitory concentration) values of representative compounds of the present disclosure against the HCV 1b genotype. In one embodiment, compounds of the present disclosure are inhibitory versus 1a, 1b, 2a, 2b, 3a, 4a, and 5a genotypes. EC50 ranges against HCV 1b are as follows: A (1-10 μM); B (100-999 nM); C (4.57-99 nM); D (<4.57 nM).










TABLE 2





Example
1b (μM)
Range
Name


















OL-1

A
4,5-bis[4-[[(2S)-1-oxo-2-





[[(phenylmethoxy)carbonyl]amino]propyl]amino]phenyl]-





2-oxazoleacetic acid


OL-1d

A
4,5-bis[4-[[(2S)-1-oxo-2-





[[(phenylmethoxy)carbonyl]amino]propyl]amino]phenyl]-





2-oxazoleacetic acid, ethyl ester


OL-2

A
4,5-bis[4-[[[(2S)-1-[(phenylmethoxy)carbonyl]-2-





pyrrolidinyl]carbonyl]amino]phenyl]-2-oxazoleacetic





acid, ethyl ester


OL-3

A
4,5-bis[4-[[[(2S)-1-[(phenylmethoxy)carbonyl]-2-





pyrrolidinyl]carbonyl]amino]phenyl]-2-oxazoleacetic





acid


OL-4
0.22
B
[(2-methyl-4,5-oxazolediyl)bis[4,1-





phenyleneimino[(1S)-1-methyl-2-oxo-2,1-





ethanediyl]]]bis-carbamic acid, bis(phenylmethyl) ester


OL-5

B
(2S,2′S)-2,2′-[(2-methyl-4,5-oxazolediyl)bis(4,1-





phenyleneiminocarbonyl)]bis-1-pyrrolidinecarboxylic





acid, bis(phenylmethyl) ester


OL-6

A
(2S,2′S)-N,N′-[[2-[(dimethylamino)methyl]-4,5-





oxazolediyl]di-4,1-phenylene]bis[1-(phenylacetyl)-2-





pyrrolidinecarboxamide


MS-1

B
(2S)-1-acetyl-N-(4-(2-(4-((((2S)-1-(phenylacetyl)-2-





pyrrolidinyl)carbonyl)amino)phenyl)-1,3-oxazol-5-





yl)phenyl)-2-pyrrolidinecarboxamide


MS-2

B
benzyl (2S,4R)-2-((4-(5-(4-((((2S)-1-acetyl-2-





pyrrolidinyl)carbonyl)amino)phenyl)-1,3-oxazol-2-





yl)phenyl)carbamoyl)-4-tert-butoxy-1-





pyrrolidinecarboxylate


MS-3

B
benzyl (2S,4R)-2-((4-(5-(4-((((2S)-1-acetyl-2-





pyrrolidinyl)carbonyl)amino)phenyl)-1,3-oxazol-2-





yl)phenyl)carbamoyl)-4-hydroxy-1-





pyrrolidinecarboxylate


MS-4
0.90070
B
benzyl 3-((4-(5-(4-((1-acetyl-L-prolyl)amino)phenyl)-





1,3-oxazol-2-yl)phenyl)carbamoyl)-1-





pyrrolidinecarboxylate


MS-5

B
(2S)-1-acetyl-N-[4-[2-[4-[[[5-oxo-1-[2-(2-





thienyl)ethyl]-3-pyrrolidinyl]carbonyl]amino]phenyl]-





5-oxazolyl]phenyl]-2-pyrrolidinecarboxamide


MS-6
0.1875
B
(2S)-1-acetyl-N-(4-(5-(4-((((2S)-1-(phenylacetyl)-2-





pyrrolidinyl)carbonyl)amino)phenyl)-1,3-oxazol-2-





yl)phenyl)-2-pyrrolidinecarboxamide


MS-7

A
(2S)-N-[4-[5-[4-[[[(2S)-1-acetyl-2-





pyrrolidinyl]carbonyl]amino]phenyl]-2-





oxazolyl]phenyl]-2,5-dihydro-1-(2-thienylcarbonyl)-





1H-pyrrole-2-carboxamide


D-1

A
(2S)-N-[4-[5-[4-[[[(2S)-1-acetyl-2-





pyrrolidinyl]carbonyl]amino]phenyl]-2-





oxazolyl]phenyl]-2,5-dihydro-1-(2-thienylacetyl)-1H-





pyrrole-2-carboxamide


D-2

B
(2S)-N-[4-[5-[4-[[[(2S)-1-acetyl-2-





pyrrolidinyl]carbonyl]amino]phenyl]-2-





oxazolyl]phenyl]-1-(2-ethylbenzoyl)-2,5-dihydro-1H-





pyrrole-2-carboxamide


D-3

A
(2S)-N-[4-[5-[4-[[[(2S)-1-acetyl-2-





pyrrolidinyl]carbonyl]amino]phenyl]-2-





oxazolyl]phenyl]-2,5-dihydro-1-(5-





isoxazolylcarbonyl)-1H-pyrrole-2-carboxamide


D-4

D
(2S,2′S)-N,N′-(2,5-oxazolediyldi-4,1-phenylene)bis[1-





[(dimethylamino)(2-fluorophenyl)acetyl]-2-





pyrrolidinecarboxamide]


D-5

D
(2S,2′S)-N,N′-(2,5-oxazolediyldi-4,1-phenylene)bis[1-





[(2,4-difluorophenyl)(dimethylamino)acetyl]-2-





pyrrolidinecarboxamide]


D-6

D
(2S,2′S)-N,N′-(2,5-oxazolediyldi-4,1-phenylene)bis[1-





[(2,4-difluorophenyl)(dimethylamino)acetyl]-2-





pyrrolidinecarboxamide]


D-7

C
((2S,2′S)-N,N′-(2,5-oxazolediyldi-4,1-phenylene)bis[1-





[(2,4-difluorophenyl)(dimethylamino)acetyl]-2-





pyrrolidinecarboxamide]


D-8

C
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-((4-methyl-1-





piperazinyl)(phenyl)acetyl)-2-pyrrolidinecarboxamide)


D-9
3.33
A
(2S,2′S)-N,N′-(4,4′-(oxazole-2,5-diyl)bis(4,1-





phenylene))bis(1-(2-(5,6-difluoro-3-isopropyl-2-oxo-





2,3-dihydro-1H-benzo[d]imidazol-1-





yl)acetyl)pyrrolidine-2-carboxamide)


D-10

B
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-(hydroxy(1,3-thiazol-2-yl)acetyl)-2-





pyrrolidinecarboxamide)


D-11
2.09
A
(2S,2′S)-N,N′-(4,4′-(oxazole-2,5-diyl)bis(4,1-





phenylene))bis(1-(2-hydroxy-2-(1-methyl-1H-imidazol-





2-yl)acetyl)pyrrolidine-2-carboxamide)


D-12
2.36
A
diethyl 4,4′-(2,2′-(2S,2′S)-2,2′-(4,4′-(oxazole-2,5-





diyl)bis(4,1-





phenylene))bis(azanediyl)bis(oxomethylene)bis(pyrrolidine-





2,1-diyl)bis(1-hydroxy-2-oxoethane-2,1-





diyl))bis(1H-pyrrole-2-carboxylate)


D-13


(2S,2′S)-N,N′-(4,4′-(oxazole-2,5-diyl)bis(4,1-





phenylene))bis(1-(2-hydroxy-2-(imidazo[1,2-a]pyridin-





3-yl)acetyl)pyrrolidine-2-carboxamide)


D-14

B
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-(hydroxy(2-pyridinyl)acetyl)-2-





pyrrolidinecarboxamide)


D-15
6.83
A
(2S,2′S)-N,N′-(4,4′-(oxazole-2,5-diyl)bis(4,1-





phenylene))bis(1-(2-hydroxy-2-(1H-pyrrolo[2,3-





b]pyridin-3-yl)acetyl)pyrrolidine-2-carboxamide)


D-16


(2S,2′S)-N,N′-(4,4′-(oxazole-2,5-diyl)bis(4,1-





phenylene))bis(1-(2-hydroxy-2-(1H-pyrrolo[2,3-





b]pyridin-3-yl)acetyl)pyrrolidine-2-carboxamide)


D-17
6.82
A
(2S,2′S)-N,N′-(4,4′-(oxazole-2,5-diyl)bis(4,1-





phenylene))bis(1-(2-hydroxy-2-(1H-pyrrolo[2,3-





c]pyridin-3-yl)acetyl)pyrrolidine-2-carboxamide)


D-18
5.96
A
(R,S,2S,2′S)-N,N′-(4,4′-(oxazole-2,5-diyl)bis(4,1-





phenylene))bis(1-((2R,3S)-2-benzamido-3-





hydroxybutanoyl)pyrrolidine-2-carboxamide)


D-19

B
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-(2-(4-chlorophenoxy)-3-





(dimethylamino)propanoyl)-2-pyrrolidinecarboxamide)


D-20

B
(2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-





(cyclopropylacetyl)-2-pyrrolidinecarboxamide)


D-21

A
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-((1-benzyl-2-piperidinyl)carbonyl)-2-





pyrrolidinecarboxamide)


D-22

B
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-((1-(cyclohexylmethyl)-2-





piperidinyl)carbonyl)-2-pyrrolidinecarboxamide)


D-23

A
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-((1-benzyl-2-methyl-5-oxo-2-





pyrrolidinyl)carbonyl)-2-pyrrolidinecarboxamide)


D-24
5.14
A
(2S,2′S)-N,N′-(4,4′-(oxazole-2,5-diyl)bis(4,1-





phenylene))bis(1-(2-methyl-5-oxopyrrolidine-2-





carbonyl)pyrrolidine-2-carboxamide)


D-25
5.33
A
(2S,2′S)-N,N′-(4,4′-(oxazole-2,5-diyl)bis(4,1-





phenylene))bis(1-(2,4,4-trimethyl-5-oxopyrrolidine-2-





carbonyl)pyrrolidine-2-carboxamide)


D-26
3.33
A
(S,S,S,2S,2′S)-N,N′-(4,4′-(oxazole-2,5-diyl)bis(4,1-





phenylene))bis(1-((1S,3S,5S)-2-(2,4-dichlorobenzoyl)-





2-azabicyclo[3.1.0]hexane-3-carbonyl)pyrrolidine-2-





carboxamide)


D-27

A
di-tert-butyl (2S,2′S)-2,2′-(1,3-oxazole-2,5-diylbis(4,1-





phenylenecarbamoyl(2S)-2,1-





pyrrolidinediylcarbonyl))di(1-pyrrolidinecarboxylate)


D-28

A
di-tert-butyl (2R,2′R)-2,2′-(1,3-oxazole-2,5-diylbis(4,1-





phenylenecarbamoyl(2S)-2,1-





pyrrolidinediylcarbonyl))di(1-pyrrolidinecarboxylate)


D-29

A
di-tert-butyl 2,2′-(1,3-oxazole-2,5-diylbis(4,1-





phenylenecarbamoyl(2S)-2,1-





pyrrolidinediylcarbonyl))bis(2-methyl-1-





pyrrolidinecarboxylate)


D-30

A
di-tert-butyl 2,2′-(1,3-oxazole-2,5-diylbis(4,1-





phenylenecarbamoyl(2S)-2,1-





pyrrolidinediylcarbonyl))bis(2-methyl-1-





pyrrolidinecarboxylate)


D-31

A
di-tert-butyl (1S,3S,5S,1′S,3′S,5′S)-3,3′-(1,3-oxazole-





2,5-diylbis(4,1-phenylenecarbamoyl(2S)-2,1-





pyrrolidinediylcarbonyl))bis(2-





azabicyclo[3.1.0]hexane-2-carboxylate)


D-32

A
di-tert-butyl 2,2′-(1,3-oxazole-2,5-diylbis(4,1-





phenylenecarbamoyl(2S)-2,1-





pyrrolidinediylcarbonyl))bis(2-benzyl-1-





pyrrolidinecarboxylate)


D-33

A
di-tert-butyl 2,2′-(1,3-oxazole-2,5-diylbis(4,1-





phenylenecarbamoyl(2S)-2,1-





pyrrolidinediylcarbonyl))bis(2-benzyl-1-





pyrrolidinecarboxylate)


D-34

A
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-((2S)-2-pyrrolidinylcarbonyl)-2-





pyrrolidinecarboxamide)


D-35
5.24
A
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-((2R)-2-pyrrolidinylcarbonyl)-2-





pyrrolidinecarboxamide)


D-36

A
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-((2-methyl-2-pyrrolidinyl)carbonyl)-2-





pyrrolidinecarboxamide)


D-37

A
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-((2-benzyl-2-pyrrolidinyl)carbonyl)-2-





pyrrolidinecarboxamide)


D-38
0.11
B
(2S,2′S)-N,N′-(1,3 -oxazole-2,5-diyldi-4,1-





phenylene)bis(1-(((2S)-1-((2R)-2-(dimethylamino)-2-





phenylacetyl)-2-pyrrolidinyl)carbonyl)-2-





pyrrolidinecarboxamide)


D-39

A
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-(((2R)-1-((2R)-2-(dimethylamino)-2-





phenylacetyl)-2-pyrrolidinyl)carbonyl)-2-





pyrrolidinecarboxamide)


D-40

B
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-(((1S,3S,5S)-2-((2R)-2-





(dimethylamino)-2-phenylacetyl)-2-





azabicyclo[3.1.0]hex-3-yl)carbonyl)-2-





pyrrolidinecarboxamide)


D-41

B
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-((1-((2R)-2-(dimethylamino)-2-





phenylacetyl)-2-methyl-2-pyrrolidinyl)carbonyl)-2-





pyrrolidinecarboxamide)


OL-7

C
(2S,2′S)-2,2′-[1H-imidazole-4,5-diylbis(4,1-





phenyleneiminocarbonyl)]bis-1-pyrrolidinecarboxylic





acid, bis(phenylmethyl) ester


OL-8

C
[1H-imidazole-4,5-diylbis[4,1-phenyleneimino[(1S)-1-





methyl-2-oxo-2,1-ethanediyl]]]bis-carbamic acid,





bis(phenylmethyl) ester


OL-9

A
(2S,2′S)-N,N′-(1H-imidazole-4,5-diyldi-4,1-





phenylene)bis(2-((phenylacetyl)amino)propanamide)


OL-10

C
(2S,2′S)-N,N′-(1H-imidazole-4,5-diyldi-4,1-





phenylene)bis(1-(phenylacetyl)-2-





pyrrolidinecarboxamide)


OL-11

B
(2S,4S,2′S,4′S)-N,N′-(1H-imidazole-4,5-diyldi-4,1-





phenylene)bis(4-hydroxy-1-(phenylacetyl)-2-





pyrrolidinecarboxamide)


D-42

A
(2S)-1-acetyl-N-(4-(2-methyl-4-(4-((((2S)-1-





(phenylacetyl)-2-pyrrolidinyl)carbonyl)amino)phenyl)-





1,3-thiazol-5-yl)phenyl)-2-pyrrolidinecarboxamide


D-43

B
(2S,2′S)-N,N′-((2-methyl-1,3-thiazole-4,5-diyl)di-4,1-





phenylene)bis(1-acetyl-2-pyrrolidinecarboxamide)


D-44

C
(2S,2′S)-N,N′-((2-methyl-1,3-thiazole-4,5-diyl)di-4,1-





phenylene)bis(1-(phenylacetyl)-2-





pyrrolidinecarboxamide)


D-45

B
(2S)-1-acetyl-N-(4-(4-(4-((((2S)-1-(phenylacetyl)-2-





pyrrolidinyl)carbonyl)amino)phenyl)-1,3-thiazol-2-





yl)phenyl)-2-pyrrolidinecarboxamide


D-46

A
(2S)-1-acetyl-N-[4-[4-[4-[[[5-oxo-1-[2-(2-





thienyl)ethyl]-3-pyrrolidinyl]carbonyl]amino]phenyl]-





2-thiazolyl]phenyl]-2-pyrrolidinecarboxamide


D-47

A
(2S)-N-[4-[2-[4-[[[(2S)-1-acetyl-2-





pyrrolidinyl]carbonyl]amino]phenyl]-4-





thiazolyl]phenyl]-2,5-dihydro-1-(2-thienylcarbonyl)-





1H-pyrrole-2-carboxamide


D-48

B
(2S)-N-[4-[2-[4-[[[(2S)-1-acetyl-2-





pyrrolidinyl]carbonyl]amino]phenyl]-4-





thiazolyl]phenyl]-2,5-dihydro-1-(2-thienylacetyl)-1H-





pyrrole-2-carboxamide


D-49

A
(2S)-N-[4-[2-[4-[[[(2S)-1-acetyl-2-





pyrrolidinyl]carbonyl]amino]phenyl]-4-





thiazolyl]phenyl]-2,5-dihydro-1-(phenylacetyl)-1H-





pyrrole-2-carboxamide


D-50

B
(2S)-N-[4-[2-[4-[[[(2S)-1-acetyl-2-





pyrrolidinyl]carbonyl]amino]phenyl]-4-





thiazolyl]phenyl]-2,5-dihydro-1-(5-





isoxazolylcarbonyl)-1H-pyrrole-2-carboxamide


D-51
3.43
A
(2S)-N-[4-[2-[4-[[[(2S)-1-acetyl-2-





pyrrolidinyl]carbonyl]amino]phenyl]-4-





thiazolyl]phenyl]-2,5-dihydro-1-[[(2R)-tetrahydro-2-





furanyl]carbonyl]-1H-pyrrole-2-carboxamide


D-52

A
(2S)-N-[4-[2-[4-[[[(2S)-1-acetyl-2-





pyrrolidinyl]carbonyl]amino]phenyl]-4-





thiazolyl]phenyl]-2,5-dihydro-1-[[(2S)-tetrahydro-2-





furanyl]carbonyl]-1H-pyrrole-2-carboxamide


D-53
1.13
A
(2S)-N-[4-[2-[4-[[[(2S)-1-acetyl-2-





pyrrolidinyl]carbonyl]amino]phenyl]-4-





thiazolyl]phenyl]-1-benzoyl-2,5-dihydro-1H-pyrrole-2-





carboxamide


OL-12

A
[(1,5-dihydro-5-oxo-4H-1,2,4-triazole-3,4-diyl)bis[4,1-





phenyleneimino[(1S)-1-methyl-2-oxo-2,1-





ethanediyl]]]bis-carbamic acid, bis(phenylmethyl) ester


OL-13

A
(2S,2′S)-2,2′-[(1,5-dihydro-5-oxo-4H-1,2,4-triazole-





3,4-diyl)bis(4,1-phenyleneiminocarbonyl)]bis-1-





pyrrolidinecarboxylic acid, bis(phenylmethyl) ester,


OL-14

A
(2S,2′S)-2,2′-[4H-1,2,4-triazole-3,4-diylbis(4,1-





phenyleneiminocarbonyl)]bis-1-pyrrolidinecarboxylic





acid, bis(phenylmethyl) ester


OL-15

A
(2S,2′S)-N,N′-(4H-1,2,4-triazole-3,4-diyldi-4,1-





phenylene)bis[1-(phenylacetyl)-2-





pyrrolidinecarboxamide]


OL-16

A
[(1S)-1-methyl-2-oxo-2-[[4-[3-[4-[[(2S)-1-oxo-2-





[[(phenylmethoxy)carbonyl]amino]propyl]amino]phenyl]-





4H-1,2,4-triazol-4-yl]phenyl]amino]ethyl]-carbamic





acid, phenylmethyl ester


OL-17

A
(2S,4R,2′S,4′R)-N,N′-(4H-1,2,4-triazole-3,4-diyldi-4,1-





phenylene)bis[4-hydroxy-1-(phenylacetyl)-2-





pyrrolidinecarboxamide]


MS-8
0.09
C
(2S,2′S)-2,2′-[1,3,4-oxadiazole-2,5-diylbis(4,1-





phenyleneiminocarbonyl)]bis-1-pyrrolidinecarboxylic





acid, bis(phenylmethyl) ester


MS-9
0.15
B
(2S,2′S)-N,N′-(4,4′-(1,3,4-oxadiazole-2,5-diyl)bis(4,1-





phenylene))bis(1-(2-phenylacetyl)pyrrolidine-2-





carboxamide)


D-54
4.76
A
(2S)-1-acetyl-N-[4-[5-[4-[[[(2S)-1-(phenylacetyl)-2-





pyrrolidinyl]carbonyl]amino]phenyl]-1,3,4-oxadiazol-





2-yl]phenyl]-2-pyrrolidinecarboxamide


D-55
10
A
(2S,2′S)-N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-





phenylene)bis[1-acetyl-2-pyrrolidinecarboxamide]


D-56
0.15
B
(2S,2′S)-N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-





phenylene)bis[1-(phenylacetyl)-2-





pyrrolidinecarboxamide]


D-57
1.95
A
(2S,2′S)-N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-





phenylene)bis[1-(cyclopropylacetyl)-2-





pyrrolidinecarboxamide]


D-58
2.21
A
(2S,2′S)-N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-





phenylene)bis[1-(cyclopropylcarbonyl)-2-





pyrrolidinecarboxamide]


D-59
5.45
A
(2S,2′S)-N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-





phenylene)bis[1-(cyclobutylcarbonyl)-2-





pyrrolidinecarboxamide]


D-60
0.65
B
(S,2S,2′S)-N,N′-(4,4′-(1,3,4-oxadiazole-2,5-





diyl)bis(4,1-phenylene))bis(1-((S)-tetrahydrofuran-2-





carbonyl)pyrrolidine-2-carboxamide)


D-61
0.327
B
(2S,2′S)-N,N′-(4,4′-(1,3,4-oxadiazole-2,5-diyl)bis(4,1-





phenylene))bis(1-(2-(thiophen-2-yl)acetyl)pyrrolidine-





2-carboxamide)


D-62
3.467
A
(2S)-1-acetyl-N-[4-[5-[4-[[[(2S)-1-(2-thienylacetyl)-2-





pyrrolidinyl]carbonyl]amino]phenyl]-1,3,4-oxadiazol-





2-yl]phenyl]-2-pyrrolidinecarboxamide


D-63
1.938
A
(2S,2′S)-N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-





phenylene)bis[1-(3-pyridinylacetyl)-2-





pyrrolidinecarboxamide]


D-64
6.57
A
(2S)-1-acetyl-N-[4-[5-[4-[[[(2S)-1-(3-pyridinylacetyl)-





2-pyrrolidinyl]carbonyl]amino]phenyl]-1,3,4-





oxadiazol-2-yl]phenyl]-2-pyrrolidinecarboxamide


OL-18
0.092
C
[(1S)-1-methyl-2-oxo-2-[[4-[4-[4-[[(2S)-1-oxo-2-





[[(phenylmethoxy)carbonyl]amino]propyl]amino]phenyl]-





1H-1,2,3-triazol-5-yl]phenyl]amino]ethyl]-carbamic





acid, phenylmethyl ester


OL-19

C
(2S,2′S)-2,2′-[1H-1,2,3-triazole-4,5-diylbis(4,1-





phenyleneiminocarbonyl)]bis-1-pyrrolidinecarboxylic





acid, bis(phenylmethyl) ester


OL-20

C
(2S,2′S)-N,N′-(1H-1,2,3-triazole-4,5-diyldi-4,1-





phenylene)bis[1-(phenylacetyl)-2-





pyrrolidinecarboxamide]


OL-21

B
(2S,4R,2′S,4′R)-N,N′-(1H-1,2,3-triazole-4,5-diyldi-4,1-





phenylene)bis(4-hydroxy-1-(phenylacetyl)-2-





pyrrolidinecarboxamide)


OL-22

C
(2S,2′S)-N,N′-(2,5-thienediyldi-4,1-phenylene)bis(1-





(phenylacetyl)-2-pyrrolidinecarboxamide)


OL-23

C
(2S,2′S)-2,2′-[2,5-thienediylbis(4,1-





phenyleneiminocarbonyl)]bis-1-pyrrolidinecarboxylic





acid, bis(phenylmethyl) ester


OL-24
0.62
B
(2S,2′S)-N,N′-(2,5-thienediyldi-4,1-phenylene)bis[1-





acetyl-2-pyrrolidinecarboxamide]


OL-25

C
(2S,2′S)-N,N′-(2,5-thienediyldi-3,1-phenylene)bis[1-





(phenylacetyl)-2-pyrrolidinecarboxamide]


OL-26

C
(2S,2′S)-2,2′-[1H-pyrazole-3,5-diylbis(4,1-





phenyleneiminocarbonyl)]bis-1-pyrrolidinecarboxylic





acid, bis(phenylmethyl) ester


OL-27
0.01
C
(2S,2′S)-N,N′-(1H-pyrazole-3,5-diyldi-4,1-





phenylene)bis[1-(phenylacetyl)-2-





pyrrolidinecarboxamide]


OL-28

C
(2S,4R,2′S,4′R)-N,N′-(1H-pyrazole-3,5-diyldi-4,1-





phenylene)bis(4-hydroxy-1-(phenylacetyl)-2-





pyrrolidinecarboxamide)


OL-29
4.55
A
(2S,2′S)-N,N′-(1H-pyrazole-3,5-diyldi-4,1-





phenylene)bis(1-acetyl-2-pyrrolidinecarboxamide)


OL-30

A
(2S,2′S)-N,N′-(1H-pyrazole-3,5-diyldi-4,1-





phenylene)bis(1-acetyl-2,5-dihydro-1H-pyrrole-2-





carboxamide)


OL-31

B
(2S,2′S)-N,N′-(1H-pyrazole-3,5-diyldi-4,1-





phenylene)bis(1-isobutyryl-2-pyrrolidinecarboxamide)


OL-32

A
(2S,2′S)-N,N′-(1H-pyrazole-3,5-diyldi-4,1-





phenylene)bis(1-propionyl-2-pyrrolidinecarboxamide)


OL-33

B
(2S,2′S)-N,N′-(1H-pyrazole-3,5-diyldi-4,1-





phenylene)bis(1-(cyclobutylcarbonyl)-2-





pyrrolidinecarboxamide)


OL-34

A
(2S,2′S)-N,N′-(1H-pyrazole-3,5-diyldi-4,1-





phenylene)bis(1-isonicotinoyl-2-





pyrrolidinecarboxamide)


OL-35
8.25
A
(2S,2′S)-N,N′-(1H-pyrazole-3,5-diyldi-4,1-





phenylene)bis(1-(cyclopropylcarbonyl)-2-





pyrrolidinecarboxamide)


OL-36

B
(2S)-1-acetyl-N-(4-(3-(4-((((2S)-1-(phenylacetyl)-2-





pyrrolidinyl)carbonyl)amino)phenyl)-1H-pyrazol-5-





yl)phenyl)-2-pyrrolidinecarboxamide


OL-37

A
(2S,2′S)-N,N′-(1H-pyrazole-3,5-diyldi-4,1-





phenylene)bis(1-(cyclopropylcarbonyl)-2,5-dihydro-





1H-pyrrole-2-carboxamide)


OL-38
10
A
(2S,2′S)-N,N′-(1H-pyrazole-3,5-diyldi-4,1-





phenylene)bis(1-(cyclobutylcarbonyl)-2,5-dihydro-1H-





pyrrole-2-carboxamide)


OL-39

A
(2S,2′S)-N,N′-(1H-pyrazole-3,5-diyldi-4,1-





phenylene)bis[1-(cyclopentylacetyl)-2,5-dihydro-1H-





pyrrole-2-carboxamide]


OL-40

C
(2S,2′S)-N,N′-(1H-pyrazole-3,5-diyldi-4,1-





phenylene)bis(1-((3-chloro-1-isoquinolinyl)carbonyl)-





2-pyrrolidinecarboxamide)


OL-41

C
(2S,2′S)-N,N′-(1H-pyrazole-3,5-diyldi-4,1-





phenylene)bis(1-((3-chloro-5-methoxy-1-





isoquinolinyl)carbonyl)-2-pyrrolidinecarboxamide)


OL-42

D
N,N′-(1H-pyrazole-3,5-diyldi-4,1-phenylene)bis(1-





((2R)-2-acetamido-2-phenylacetyl)-2-





pyrrolidinecarboxamide)


OL-43

C
(S)-2-((S)-2-hydroxy-2-phenylacetamido)-N-(4-(5-(4-





((R)-2-((S)-2-hydroxy-2-





phenylacetamido)propanamido)phenyl)-1H-pyrazol-3-





yl)phenyl)propanamide


OL-44

D
(S)-2-((R)-2-hydroxy-2-phenylacetamido)-N-(4-(5-(4-





((R)-2-((R)-2-hydroxy-2-





phenylacetamido)propanamido)phenyl)-1H-pyrazol-3-





yl)phenyl)propanamide


OL-45

D
(2S,2′S)-N,N′-(1H-pyrazole-3,5-diylbis(4,1-





phenyleneimino((2S)-1-oxo-1,2-propanediyl)))bis(2-





hydroxy-2-phenylpropanamide)


OL-46

C
(2R,2′R)-N,N′-(1H-pyrazole-3,5-diylbis(4,1-





phenyleneimino((2S)-1-oxo-1,2-propanediyl)))bis(2-





hydroxy-2-phenylpropanamide)


OL-47

C
N,N′-(1H-pyrazole-3,5-diylbis(4,1-





phenyleneimino((2S)-1-oxo-1,2-propanediyl)))bis(3-





chloro-1-naphthamide)


OL-48
0.28
B
N,N′-(1H-pyrazole-3,5-diylbis(4,1-





phenyleneimino((2S)-1-oxo-1,2-propanediyl)))bis(3-





chloro-1-isoquinolinecarboxamide)


OL-49
0.23
B
dibenzyl (2S,4R,2′S,4′R)-2,2′-(1H-pyrazole-3,5-





diylbis(4,1-phenylenecarbamoyl))bis(4-tert-butoxy-1-





pyrrolidinecarboxylate)


OL-50

B
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-((6-fluoro-2-pyridinyl)carbonyl)-2-





pyrrolidinecarboxamide)


OL-51

C
(2S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-





((2R)-2-(dimethylamino)-2-phenylacetyl)-2-





pyrrolidinecarboxamide)


OL-52
0.03
B
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-((3-chloro-5-methoxy-1-





isoquinolinyl)carbonyl)-2-pyrrolidinecarboxamide)


OL-53

D
N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-





((2R)-2-acetamido-2-phenylacetyl)-2-





pyrrolidinecarboxamide)


OL-54

C
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(2-(((2S)-2-hydroxy-2-





phenylacetyl)amino)propanamide)


OL-55

D
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(2-(((2R)-2-hydroxy-2-





phenylacetyl)amino)propanamide)


OL-56

D
((2S,2′S)-N,N′-(1,3-oxazole-2,5-diylbis(4,1-





phenyleneimino((2S)-1-oxo-1,2-propanediyl)))bis(2-





hydroxy-2-phenylpropanamide))


OL-57

C
(2R,2′R)-N,N′-(1,3-oxazole-2,5-diylbis(4,1-





phenyleneimino((2S)-1-oxo-1,2-propanediyl)))bis(2-





hydroxy-2-phenylpropanamide))


OL-58

D
(2S,4S,2′S,4′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-((2R)-2-hydroxy-2-phenylacetyl)-4-





methoxy-2-pyrrolidinecarboxamide)


OL-59

D
(2S,4S,2′S,4′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-((2R)-2-(dimethylamino)-2-





phenylacetyl)-4-methoxy-2-pyrrolidinecarboxamide)


OL-60

C
(2S,4S,2′S,4′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-(acetamido(phenyl)acetyl)-4-methoxy-





2-pyrrolidinecarboxamide)


OL-61

C
(2S)-1-((3-chloro-5-methoxy-1-





isoquinolinyl)carbonyl)-N-(4-(2-(4-((((2S)-1-((2R)-2-





(dimethylamino)-2-phenylacetyl)-2-





pyrrolidinyl)carbonyl)amino)phenyl)-1,3-oxazol-5-





yl)phenyl)-2-pyrrolidinecarboxamide


CB-1
<0.005
C
(1S,3S,5S,1′S,3′S,5′S)-N,N′-(1,3-oxazole-2,5-diyldi-





4,1-phenylene)bis(2-((2R)-2-acetamido-2-





phenylacetyl)-2-azabicyclo[3.1.0]hexane-3-





carboxamide)


CB-2

B
(1S,3S,5S,1′S,3′S,5′S)-N,N′-(1,3-oxazole-2,5-diyldi-





4,1-phenylene)bis(2-(1-isoquinolinylcarbonyl)-2-





azabicyclo[3.1.0]hexane-3-carboxamide)


CB-3
0.38
B
(1S,3S,5S,1′S,3′S,5′S)-N,N′-(1,3-oxazole-2,5-diyldi-





4,1-phenylene)bis(2-((3-chloro-1-





isoquinolinyl)carbonyl)-2-azabicyclo[3.1.0]hexane-3-





carboxamide)


CB-4

B
(1S,3S,5S,1′S,3′S,5′S)-N,N′-(1,3-oxazole-2,5-diyldi-





4,1-phenylene)bis(2-((3-chloro-5-methoxy-1-





isoquinolinyl)carbonyl)-2-azabicyclo[3.1.0]hexane-3-





carboxamide)


CB-5

C
(1S,3S,5S,1′S,3′S,5′S)-N,N′-(1,3-oxazole-2,5-diyldi-





4,1-phenylene)bis(2-((2S)-2-hydroxy-2-phenylacetyl)-





2-azabicyclo[3.1.0]hexane-3-carboxamide)


CB-6

D
(1S,3S,5S,1′S,3′S,5′S)-N,N′-(1,3-oxazole-2,5-diyldi-





4,1-phenylene)bis(2-((2R)-2-hydroxy-2-phenylacetyl)-





2-azabicyclo[3.1.0]hexane-3-carboxamide)


CB-7

B
(1S,3S,5S,1′S,3′S,5′S)-N,N′-(1,3-oxazole-2,5-diyldi-





4,1-phenylene)bis(2-((2R)-tetrahydro-2-





furanylcarbonyl)-2-azabicyclo[3.1.0]hexane-3-





carboxamide)


CB-8
<0.005
D
(1S,3S,5S,1′S,3′S,5′S)-N,N′-(1,3-oxazole-2,5-diyldi-





4,1-phenylene)bis(2-((2S)-2-hydroxy-2-





phenylpropanoyl)-2-azabicyclo[3.1.0]hexane-3-





carboxamide)


CB-9

D
(1S,3S,5S,1′S,3′S,5′S)-N,N′-(1,3-oxazole-2,5-diyldi-





4,1-phenylene)bis(2-((2R)-2-(dimethylamino)-2-





phenylacetyl)-2-azabicyclo[3.1.0]hexane-3-





carboxamide)


CB-10

D
(1S,3S,5S,1′S,3′S,5′S)-N,N′-(1,3-oxazole-2,5-diyldi-





4,1-phenylene)bis(2-((2R)-2-hydroxy-2-





phenylpropanoyl)-2-azabicyclo[3.1.0]hexane-3-





carboxamide)


JG-1

D
dibenzyl (2S,2′S)-2,2′-(1,3-oxazole-2,5-diylbis(4,1-





phenylenecarbamoyl))di(1-pyrrolidinecarboxylate)


JG-2
0.002
D
(2S,4R,2′S,4′R)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(4-hydroxy-1-(phenylacetyl)-2-





pyrrolidinecarboxamide)


JG-3

D
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-(phenylacetyl)-2-





pyrrolidinecarboxamide)


JG-4

B
dibenzyl (1,3-oxazole-2,5-diylbis(4,1-





phenyleneimino((2S)-3-methyl-1-oxo-1,2-





butanediyl)))biscarbamate


JG-5
10
A
dibenzyl (1,3-oxazole-2,5-diylbis(4,1-





phenyleneimino((2R)-3-methyl-1-oxo-1,2-





butanediyl)))biscarbamate


JG-6

B
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-(phenylacetyl)-2-





piperidinecarboxamide)


JG-7

B
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-(cyclopropylcarbonyl)-2-





pyrrolidinecarboxamide)


JG-8

B
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-propionyl-2-pyrrolidinecarboxamide)


JG-9

B
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-(cyclobutylcarbonyl)-2-





pyrrolidinecarboxamide)


JG-10

B
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-isonicotinoyl-2-





pyrrolidinecarboxamide)


JG-11

A
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-acetyl-2-pyrrolidinecarboxamide)


JG-12

C
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(3-methyl-2-





((phenylacetyl)amino)butanamide)


JG-13

B
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(4-(methylsulfanyl)-2-





((phenylacetyl)amino)butanamide)


JG-14

B
(2R,2′R)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(3-(methylsulfanyl)-2-





((phenylacetyl)amino)propanamide)


JG-15

B
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(4-methoxy-2-





((phenylacetyl)amino)butanamide)


JG-16

B
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(3-tert-butoxy-2-





((phenylacetyl)amino)propanamide)


JG-17

B
(2S,2′S)-N,N′-(4,4′-(oxazole-2,5-diyl)bis(4,1-





phenylene))bis(2-(2-phenylacetamido)hexanamide)


JG-18

A
N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-





((phenylacetyl)amino)cyclopropanecarboxamide)


JG-19
0.009
C
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-((2S)-2-methoxy-2-phenylacetyl)-2-





pyrrolidinecarboxamide)


JG-20

C
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-((2S)-2-hydroxy-2-phenylacetyl)-2-





pyrrolidinecarboxamide)


JG-21

D
1,3-oxazole-2,5-diylbis(4,1-phenylenecarbamoyl(2S)-





2,1-pyrrolidinediyl(1S)-2-oxo-1-phenyl-2,1-ethanediyl)





diacetate


JG-22
<0.005
D
(2S)-1-((2S)-2-hydroxy-2-phenylpropanoyl)-N-(4-(2-





(4-((((2S)-1-(2-hydroxy-2-phenylpropanoyl)-2-





pyrrolidinyl)carbonyl)amino)phenyl)-1,3-oxazol-5-





yl)phenyl)-2-pyrrolidinecarboxamide


JG-23

D
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-((2R)-2-hydroxy-2-phenylacetyl)-2-





pyrrolidinecarboxamide)


JG-24

D
1,3-oxazole-2,5-diylbis(4,1-phenylenecarbamoyl(2S)-





2,1-pyrrolidinediyl(1R)-2-oxo-1-phenyl-2,1-ethanediyl)





diacetate


JG-25

C
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-((2R)-2-methoxy-2-phenylacetyl)-2-





pyrrolidinecarboxamide)


JG-26

D
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-((2R)-2-(2-chlorophenyl)-2-





hydroxyacetyl)-2-pyrrolidinecarboxamide)


JG-27

C
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-(oxo(phenyl)acetyl)-2-





pyrrolidinecarboxamide)


JG-28

B
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-(1-benzofuran-2-ylcarbonyl)-2-





pyrrolidinecarboxamide)


JG-29

B
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-(1,3-benzothiazol-2-ylcarbonyl)-2-





pyrrolidinecarboxamide)


JG-30

C
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-(2,1-benzisoxazol-3-ylcarbonyl)-2-





pyrrolidinecarboxamide)


JG-31

C
(2S,2′S)-N,N′-(1H-pyrazole-3,5-diyldi-4,1-





phenylene)bis(1-(oxo(phenyl)acetyl)-2-





pyrrolidinecarboxamide)


JG-32

D
(2S,2′S)-N,N′-(1H-pyrazole-3,5-diyldi-4,1-





phenylene)bis(1-((2R)-2-hydroxy-2-phenylacetyl)-2-





pyrrolidinecarboxamide)


JG-33

C
(2S,2′S)-N,N′-(1H-pyrazole-3,5-diyldi-4,1-





phenylene)bis(1-((2S)-2-hydroxy-2-phenylacetyl)-2-





pyrrolidinecarboxamide)


JG-34

D
1H-pyrazole-3,5-diylbis(4,1-phenylenecarbamoyl(2S)-





2,1-pyrrolidinediyl(1S)-2-oxo-1-phenyl-2,1-ethanediyl)





diacetate


JG-35
<0.005
D
1H-pyrazole-3,5-diylbis(4,1-phenylenecarbamoyl(2S)-





2,1-pyrrolidinediyl(1R)-2-oxo-1-phenyl-2,1-ethanediyl)





diacetate


JG-36

D
(2S,2′S)-N,N′-(1H-pyrazole-3,5-diyldi-4,1-





phenylene)bis(1-((2R)-2-(2-chlorophenyl)-2-





hydroxyacetyl)-2-pyrrolidinecarboxamide)


JG-37

D
(2S,2′S)-N,N′-(1H-pyrazole-3,5-diyldi-4,1-





phenylene)bis(1-((2R)-2-methoxy-2-phenylacetyl)-2-





pyrrolidinecarboxamide)


JG-38

D
(2S,2′S)-N,N′-(1H-pyrazole-3,5-diyldi-4,1-





phenylene)bis(1-((2S)-2-methoxy-2-phenylacetyl)-2-





pyrrolidinecarboxamide)


JG-39
<0.005
D
(2S,2′S)-N,N′-(1H-pyrazole-3,5-diyldi-4,1-





phenylene)bis(1-((2S)-2-hydroxy-2-phenylpropanoyl)-





2-pyrrolidinecarboxamide)


JG-40

B
(2S,2′S)-N,N′-(1H-pyrazole-3,5-diyldi-4,1-





phenylene)bis(1-(1-benzofuran-2-ylcarbonyl)-2-





pyrrolidinecarboxamide)


JG-41

B
(2S,2′S)-N,N′-(1H-pyrazole-3,5-diyldi-4,1-





phenylene)bis(1-(1,3-benzothiazol-2-ylcarbonyl)-2-





pyrrolidinecarboxamide)


JG-42

D
(2S,2′S)-N,N′-(1H-imidazole-4,5-diyldi-4,1-





phenylene)bis(1-(oxo(phenyl)acetyl)-2-





pyrrolidinecarboxamide)


JG-43

D
(2S,2′S)-N,N′-(1H-imidazole-4,5-diyldi-4,1-





phenylene)bis(1-((2R)-2-hydroxy-2-phenylacetyl)-2-





pyrrolidinecarboxamide)


JG-44

B
(2S,2′S)-N,N′-(1H-imidazole-4,5-diyldi-4,1-





phenylene)bis(1-((2S)-2-hydroxy-2-phenylacetyl)-2-





pyrrolidinecarboxamide)


JG-45

C
(2S,2′S)-N,N′-(1H-imidazole-4,5-diyldi-4,1-





phenylene)bis(1-((2S)-2-methoxy-2-phenylacetyl)-2-





pyrrolidinecarboxamide)


JG-46

D
(2S,2′S)-N,N′-(1H-imidazole-4,5-diyldi-4,1-





phenylene)bis(1-((2S)-2-hydroxy-2-phenylpropanoyl)-





2-pyrrolidinecarboxamide)


JG-47

C
(2S,2′S)-N,N′-(1H-imidazole-4,5-diyldi-4,1-





phenylene)bis(1-((2R)-2-hydroxy-2-phenylpropanoyl)-





2-pyrrolidinecarboxamide)


JG-48
2.34
A
(2S,2′S)-N,N′-(1H-imidazole-4,5-diyldi-4,1-





phenylene)bis(1-(1-isoquinolinylcarbonyl)-2-





pyrrolidinecarboxamide)


JG-49

A
(2S,2′S)-N,N′-(1H-imidazole-4,5-diyldi-4,1-





phenylene)bis(1-((3-chloro-1-isoquinolinyl)carbonyl)-





2-pyrrolidinecarboxamide)


JG-50

B
(2S,2′S)-N,N′-(1H-imidazole-4,5-diyldi-4,1-





phenylene)bis(1-((3-chloro-5-methoxy-1-





isoquinolinyl)carbonyl)-2-pyrrolidinecarboxamide)


JG-51

B
(2S,2′S)-N,N′-(1H-imidazole-4,5-diyldi-4,1-





phenylene)bis(1-(1-benzofuran-2-ylcarbonyl)-2-





pyrrolidinecarboxamide)


JG-52

B
(2S,2′S)-N,N′-(1H-imidazole-4,5-diyldi-4,1-





phenylene)bis(1-(1-benzofuran-5-ylcarbonyl)-2-





pyrrolidinecarboxamide)


JG-53

C
(2S,2′S)-N,N′-(2,5-furandiyldi-4,1-phenylene)bis(1-





((2R)-2-phenylpropanoyl)-2-pyrrolidinecarboxamide)


JG-54

B
dibenzyl (2S,2′S)-2,2′-(2,5-furandiylbis(4,1-





phenylenecarbamoyl))di(1-pyrrolidinecarboxylate)


JG-55

B
(2S,2′S)-N,N′-(2,5-furandiyldi-4,1-phenylene)bis(1-





acetyl-2-pyrrolidinecarboxamide)


JG-56
<0.005
D
(2S,2′S)-N,N′-(2,5-furandiyldi-4,1-phenylene)bis(1-





((2R)-2-hydroxy-2-phenylacetyl)-2-





pyrrolidinecarboxamide)


JG-57

B
(2S,2′S)-N,N′-(2,5-furandiyldi-4,1-phenylene)bis(1-





((2R)-2-hydroxy-2-phenylacetyl)-2-





pyrrolidinecarboxamide)


JG-58

C
(2S,2′S)-N,N′-(2,5-furandiyldi-4,1-phenylene)bis(1-





((2R)-2-hydroxy-2-phenylpropanoyl)-2-





pyrrolidinecarboxamide)


JG-59

D
(2S)-1-((2S)-2-hydroxy-2-phenylpropanoyl)-N-(4-(5-





(4-((((2S)-1-(2-hydroxy-2-phenylpropanoyl)-2-





pyrrolidinyl)carbonyl)amino)phenyl)-2-furyl)phenyl)-





2-pyrrolidinecarboxamide


JG-60

A
(2S,2′S)-N,N′-(2,5-furandiyldi-4,1-phenylene)bis(1-((3-





chloro-5-methoxy-1-isoquinolinyl)carbonyl)-2-





pyrrolidinecarboxamide)


JG-61

A
(2S,2′S)-N,N′-(2,5-furandiyldi-4,1-phenylene)bis(1-((3-





chloro-1-isoquinolinyl)carbonyl)-2-





pyrrolidinecarboxamide)


JG-62

B
(2S,2′S)-N,N′-(2,5-furandiyldi-4,1-phenylene)bis(1-(1-





isoquinolinylcarbonyl)-2-pyrrolidinecarboxamide)


JG-63

D
(2S,2′S)-N,N′-(2,5-furandiyldi-4,1-phenylene)bis(1-





((2R)-2-(dimethylamino)-2-phenylacetyl)-2-





pyrrolidinecarboxamide)


JG-64

C
(2S)-1-((3-chloro-5-methoxy-1-





isoquinolinyl)carbonyl)-N-(4-(5-(4-((((2S)-1-((2R)-2-





hydroxy-2-phenylacetyl)-2-





pyrrolidinyl)carbonyl)amino)phenyl)-2-furyl)phenyl)-





2-pyrrolidinecarboxamide


JG-65

D
(2S)-1-((3-chloro-5-methoxy-1-





isoquinolinyl)carbonyl)-N-(4-(5-(4-((((2S)-1-((2R)-2-





(dimethylamino)-2-phenylacetyl)-2-





pyrrolidinyl)carbonyl)amino)phenyl)-2-furyl)phenyl)-





2-pyrrolidinecarboxamide


JG-66

D
(2S)-1-((2R)-2-(dimethylamino)-2-phenylacetyl)-N-(4-





(5-(4-((((2S)-1-((2R)-2-hydroxy-2-phenylacetyl)-2-





pyrrolidinyl)carbonyl)amino)phenyl)-2-furyl)phenyl)-





2-pyrrolidinecarboxamide


JG-67
0.0052
C
(2S)-1-((2R)-2-acetamido-2-phenylacetyl)-N-(4-(5-(4-





((((2S)-1-((3-chloro-5-methoxy-1-





isoquinolinyl)carbonyl)-2-





pyrrolidinyl)carbonyl)amino)phenyl)-2-furyl)phenyl)-





2-pyrrolidinecarboxamide


JG-68

B
(2S)-1-((3-chloro-5-methoxy-1-





isoquinolinyl)carbonyl)-N-(4-(5-(4-((((2S)-1-((2S)-2-





hydroxy-2-phenylacetyl)-2-





pyrrolidinyl)carbonyl)amino)phenyl)-2-furyl)phenyl)-





2-pyrrolidinecarboxamide


JG-69

D
2,5-furandiylbis(4,1-phenylenecarbamoyl(2S)-2,1-





pyrrolidinediyl(1R)-2-oxo-1-phenyl-2,1-ethanediyl)





diacetate


JG-70

B
2,5-furandiylbis(4,1-phenylenecarbamoyl(2S)-2,1-





pyrrolidinediyl(1S)-2-oxo-1-phenyl-2,1-ethanediyl)





diacetate


FY-1

B
(2S,2′S)-N,N′-((1-methyl-1H-pyrazole-3,5-diyl)di-4,1-





phenylene)bis(1-(phenylacetyl)-2-





pyrrolidinecarboxamide)


FY-2

A
(2S,2′S)-N,N′-((1-methyl-1H-pyrazole-3,5-diyl)di-4,1-





phenylene)bis(1-acetyl-2-pyrrolidinecarboxamide)


FY-3

B
dibenzyl (2S,2′S)-2,2′-((1-methyl-1H-pyrazole-3,5-





diyl)bis(4,1-phenylenecarbamoyl))di(1-





pyrrolidinecarboxylate)


FY-4

A
(2S,2′S)-N,N′-((1-methyl-1H-pyrazole-3,5-diyl)di-4,1-





phenylene)bis(1-(cyclopropylcarbonyl)-2-





pyrrolidinecarboxamide)


FY-5

B
N′,N′′′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-





((3R)-1-((2R)-2-hydroxy-2-phenylacetyl)-3-





pyrrolidinyl)urea)


FY-6

B
N′,N′′′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-





((3R)-1-((2S)-2-hydroxy-2-phenylacetyl)-3-





pyrrolidinyl)urea)


FY-7

B
N′,N′′′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-





((3R)-1-(2-hydroxy-2-phenylpropanoyl)-3-





pyrrolidinyl)urea)


FY-8

B
N′,N′′′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-





((3R)-1-((2R)-2-(dimethylamino)-2-phenylacetyl)-3-





pyrrolidinyl)urea)


FY-9

C
N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(2-





((2R)-2-(dimethylamino)-2-phenylacetyl)-1-





pyrazolidinecarboxamide)


RK-1

C
dibenzyl (2S,2′S)-2,2′-(1,3,4-oxadiazole-2,5-





diylbis(4,1-phenylenecarbamoyl))di(1-





pyrrolidinecarboxylate)


RK-2

A
dibenzyl (2S,2′S)-2,2′-(1,3,4-oxadiazole-2,5-





diylbis(4,1-phenylenecarbamoyl))bis(5-oxo-1-





pyrrolidinecarboxylate)


RK-3

B
N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-phenylene)bis(1-





(phenylacetyl)-2-pyrrolidinecarboxamide)


RK-4

B
dibenzyl (2S,2′S)-2,2′-(1,3,4-oxadiazole-2,5-





diylbis(4,1-phenylenecarbamoyl))di(1-





piperidinecarboxylate)


RK-5

A
dibenzyl (2R,2′R)-2,2′-(1,3,4-oxadiazole-2,5-





diylbis(4,1-phenylenecarbamoyl))di(1-





piperidinecarboxylate)


RK-6

B
(2S,2′S)-N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-





phenylene)bis(1-(2-methoxybenzoyl)-2-





pyrrolidinecarboxamide)


RK-7

B
(2S,2′S)-N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-





phenylene)bis(1-(3-methoxybenzoyl)-2-





pyrrolidinecarboxamide)


RK-8
1.85
A
(2S,2′S)-N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-





phenylene)bis(1-(2-ethoxybenzoyl)-2-





pyrrolidinecarboxamide)


RK-9

B
(2S,2′S)-N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-





phenylene)bis(1-(2-ethylbenzoyl)-2-





pyrrolidinecarboxamide)


RK-10

A
(2S,2′S)-N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-





phenylene)bis(1-(2-quinolinylcarbonyl)-2-





pyrrolidinecarboxamide)


RK-11

B
(2S,2′S)-N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-





phenylene)bis(1-(methoxy(phenyl)acetyl)-2-





pyrrolidinecarboxamide)


RK-12
3.96
A
(2S,2′S)-N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-





phenylene)bis(1-((6-chloro-2-pyridinyl)carbonyl)-2-





pyrrolidinecarboxamide)


RK-13

B
(2S,2′S)-N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-





phenylene)bis(1-(2-furoyl)-2-pyrrolidinecarboxamide)


RK-14

B
(2S,2′S)-N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-





phenylene)bis(1-((2S)-tetrahydro-2-furanylcarbonyl)-2-





pyrrolidinecarboxamide)


RK-15

A
(2S,2′S)-N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-





phenylene)bis(1-((2R)-tetrahydro-2-furanylcarbonyl)-2-





pyrrolidinecarboxamide)


RK-16
<0.005
D
(2S,2′S)-N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-





phenylene)bis(1-((2R)-2-hydroxy-2-phenylacetyl)-2-





pyrrolidinecarboxamide)


RK-17

B
(2S,2′S)-N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-





phenylene)bis(1-((2S)-2-hydroxy-2-phenylacetyl)-2-





pyrrolidinecarboxamide)


RK-18

A
(2S,2′S)-N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-





phenylene)bis(1-((3-chloro-1-isoquinolinyl)carbonyl)-





2-pyrrolidinecarboxamide)


RK-19

B
(2S,2′S)-N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-





phenylene)bis(2-





((methoxy(phenyl)acetyl)amino)propanamide)


RK-20

A
N,N′-(1,3,4-oxadiazole-2,5-diylbis(4,1-





phenyleneimino((2S)-1-oxo-1,2-propanediyl)))bis(6-





chloro-2-pyridinecarboxamide)


RK-21

A
N,N′-(1,3,4-oxadiazole-2,5-diylbis(4,1-





phenyleneimino((2S)-1-oxo-1,2-propanediyl)))di(2-





furamide)


RK-22

B
N,N′-(1,3,4-oxadiazole-2,5-diylbis(4,1-





phenyleneimino((2S)-1-oxo-1,2-propanediyl)))bis(4-





methoxy-2-quinolinecarboxamide)


RK-23

B
(2S,2′S)-N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-





phenylene)bis(2-((phenylacetyl)amino)propanamide)


RK-24

B
(2S,2′S)-N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-





phenylene)bis(2-(((2S)-2-hydroxy-2-





phenylacetyl)amino)propanamide)


RK-25

B
(2R,2′R)-N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-





phenylene)bis(1-((6-fluoro-2-pyridinyl)carbonyl)-2-





pyrrolidinecarboxamide)


RK-26

A
(3S,3′S)-N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-





phenylene)bis(1-((4-methoxy-2-quinolinyl)carbonyl)-3-





piperidinecarboxamide)


RK-27

B
(2S,2′S)-N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-





phenylene)bis(1-((4-chloro-2-pyridinyl)carbonyl)-2-





pyrrolidinecarboxamide)


RK-28
0.003
D
(2S,2′S)-N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-





phenylene)bis(1-((2R)-2-hydroxy-2-phenylpropanoyl)-





2-pyrrolidinecarboxamide)


RK-29

A
N,N′-(1,3,4-oxadiazole-2,5-diylbis(4,1-





phenyleneimino((2S)-1-oxo-1,2-propanediyl)))bis(6-





fluoro-2-pyridinecarboxamide)


RK-30

B
(2S,2′S)-N,N′-(1,3,4-oxadiazole-2,5-diylbis(4,1-





phenyleneimino((2S)-1-oxo-1,2-propanediyl)))bis(2-





hydroxy-2-phenylpropanamide)


RK-31

B
(2R,2′R)-N,N′-(1,3,4-oxadiazole-2,5-diylbis(4,1-





phenyleneimino((2S)-1-oxo-1,2-propanediyl)))bis(2-





hydroxy-2-phenylpropanamide)


RK-32

B
(2S,2′S)-N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-





phenylene)bis(1-((3-chloro-5-methoxy-1-





isoquinolinyl)carbonyl)-2-pyrrolidinecarboxamide)


RK-33

B
N,N′-(1,3,4-oxadiazole-2,5-diylbis(4,1-





phenyleneimino((2S)-1-oxo-1,2-propanediyl)))bis(3-





chloro-5-methoxy-1-isoquinolinecarboxamide)


RK-34

A
(2S,2′S)-N,N′-(1,3,4-oxadiazole-2,5-diylbis(4,1-





phenyleneimino((2S)-1-oxo-1,2-





propanediyl)))ditetrahydro-2-furancarboxamide


RK-35

A
(2R,2′R)-N,N′-(1,3,4-oxadiazole-2,5-diylbis(4,1-





phenyleneimino((2S)-1-oxo-1,2-





propanediyl)))ditetrahydro-2-furancarboxamide


RK-36
1.00
A
N,N′-(1,3,4-oxadiazole-2,5-diylbis(4,1-





phenyleneimino((2S)-1-oxo-1,2-propanediyl)))bis(3-





chloro-1-isoquinolinecarboxamide)


RK-37

A
N,N′-(1,3,4-oxadiazole-2,5-diylbis(4,1-





phenyleneimino((2S)-1-oxo-1,2-propanediyl)))bis(4-





chloro-2-pyridinecarboxamide)


RK-38
<0.005
D
(2S,2′S)-N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-





phenylene)bis(2-(((2S)-2-(dimethylamino)-2-





phenylacetyl)amino)propanamide)


RK-39
<0.005
D
(2S,2′S)-N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-





phenylene)bis(1-((2S)-2-(dimethylamino)-2-





phenylacetyl)-2-pyrrolidinecarboxamide)


RK-40

A
(2S,2′S)-N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-





phenylene)bis(1-(2-chloro-6-methoxyisonicotinoyl)-2-





pyrrolidinecarboxamide)


RK-41

A
N,N′-(1,3,4-oxadiazole-2,5-diylbis(4,1-





phenyleneimino((2S)-1-oxo-1,2-propanediyl)))bis(2-





chloro-6-methoxyisonicotinamide)


RK-42

A
(2S,2′S)-N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-





phenylene)bis(1-((1-methyl-1H-indol-3-yl)carbonyl)-2-





pyrrolidinecarboxamide)


JR-1

B
(2S,2′S)-N,N′-(2,5-oxazolediyldi-4,1-phenylene)bis[1-





[2-(1-methyl-1H-indol-3-yl)-1,2-dioxoethyl]-2-





pyrrolidinecarboxamide]


JR-2

B
(2S,2′S)-N,N′-(2,5-oxazolediyldi-4,1-phenylene)bis[1-





(3,3,3-trifluoro-2-hydroxy-1-oxopropyl)-2-





pyrrolidinecarboxamide]


JR-3

B
(2S,2′S)-N,N′-(2,5-oxazolediyldi-4,1-phenylene)bis[1-





[hydroxy(1-methyl-1H-imidazol-5-yl)acetyl]-2-





pyrrolidinecarboxamide]


JR-4

A
(2S,2′S)-N,N′-(2,5-oxazolediyldi-4,1-phenylene)bis[1-





[2-hydroxy-1-oxo-3-(3-pyridinyl)propyl]-2-





pyrrolidinecarboxamide]


JR-5

B
(2S,2′S)-N,N′-(2,5-oxazolediyldi-4,1-phenylene)bis[1-





[2-hydroxy-3-(1H-indol-3-yl)-1-oxopropyl]-2-





pyrrolidinecarboxamide]


JR-6
<0.005
D
(2S,2′S)-N,N′-(2,5-oxazolediyldi-4,1-phenylene)bis[1-





(hydroxy-2-thienylacetyl)-2-pyrrolidinecarboxamide]


JR-7

C
(2S,2′S)-N,N′-(2,5-oxazolediyldi-4,1-phenylene)bis[1-





(hydroxy-3-pyridinylacetyl)-2-pyrrolidinecarboxamide]


JR-8

C
(2S)-N,N′-(4,4′-(oxazole-2,5-diyl)bis(4,1-





phenylene))bis(1-(3-(4-bromophenyl)-2-





(dimethylamino)propanoyl)pyrrolidine-2-carboxamide)


JR-9

B
(2S,2′S)-N,N′-(2,5-oxazolediyldi-4,1-phenylene)bis[1-





[(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)acetyl]-2-





pyrrolidinecarboxamide]


JR-10

A
(2S,2′S)-N,N′-(2,5-oxazolediyldi-4,1-phenylene)bis[1-





[2-(3-ethyl-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-





1-oxopropyl]-2-pyrrolidinecarboxamide]


JR-11

B
(2S,2′S)-N,N′-(2,5-oxazolediyldi-4,1-phenylene)bis[1-





[(2,3-dihydro-2-oxo-1H-benzimidazol-1-





yl)phenylacetyl]-2-pyrrolidinecarboxamide]


JR-12

B
(2S)-N,N′-(4,4′-(oxazole-2,5-diyl)bis(4,1-





phenylene))bis(1-(2-(dimethylamino)-3-(1H-1,2,4-





triazol-1-yl)propanoyl)pyrrolidine-2-carboxamide)


JR-13
0.112
B
(S,S,2S)-N,N′-(4,4′-(oxazole-2,5-diyl)bis(4,1-





phenylene))bis(1-((2S,3S)-2-(dimethylamino)-3-





hydroxy-3-phenylpropanoyl)pyrrolidine-2-





carboxamide)


JR-14

A
(S,R,2S)-N,N′-(4,4′-(oxazole-2,5-diyl)bis(4,1-





phenylene))bis(1-((2S,3R)-2-(dimethylamino)-3-





hydroxy-3-phenylpropanoyl)pyrrolidine-2-





carboxamide)


JR-15

C
(S,S,2S)-N,N′-(4,4′-(oxazole-2,5-diyl)bis(4,1-





phenylene))bis(1-((2S,3S)-2-(dimethylamino)-3-





hydroxy-3-(thiophen-3-yl)propanoyl)pyrrolidine-2-





carboxamide)


JR-16

A
(S,R,2S)-N,N′-(4,4′-(oxazole-2,5-diyl)bis(4,1-





phenylene))bis(1-((2S,3R)-2-(dimethylamino)-3-





hydroxy-3-(thiophen-3-yl)propanoyl)pyrrolidine-2-





carboxamide)


JR-17

A
(2S,2′S)-N,N′-(2,5-oxazolediyldi-4,1-phenylene)bis[1-





[(hexahydro-5-oxopyrrolo[2,1-b]thiazol-3-yl)carbonyl]-





2-pyrrolidinecarboxamide]


JR-18

A
(2S,2′S)-N,N′-(2,5-oxazolediyldi-4,1-phenylene)bis[1-





[2-(octahydro-1,3-dioxo-4,7-methano-2H-isoindol-2-





yl)-1-oxopropyl]-2-pyrrolidinecarboxamide]


JR-19

B
(2S,2′S)-N,N′-(2,5-oxazolediyldi-4,1-phenylene)bis[1-





[2-(1,3,3a,4,7,7a-hexahydro-1,3-dioxo-4,7-methano-





2H-isoindol-2-yl)-3-methyl-1-oxobutyl]-2-





pyrrolidinecarboxamide]


JR-20

A
(2S,2′S)-N,N′-(2,5-oxazolediyldi-4,1-phenylene)bis[1-





[[(4S)-2-oxo-4-phenyl-3-oxazolidinyl]acetyl]-2-





pyrrolidinecarboxamide]


JR-21

A
(2S,2′S)-N,N′-(2,5-oxazolediyldi-4,1-phenylene)bis[1-





[[(4R)-2-oxo-4-phenyl-3-oxazolidinyl]acetyl]-2-





pyrrolidinecarboxamide]


JR-22
1.72
A
(2S,2′S)-N,N′-(2,5-oxazolediyldi-4,1-phenylene)bis[1-





[(2,4-dioxo-5-phenyl-3-oxazolidinyl)acetyl]-2-





pyrrolidinecarboxamide]


XY-1

B
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-(2-thienylcarbonyl)-2-





pyrrolidinecarboxamide)


XY-2

B
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-((1-cyanocyclopropyl)carbonyl)-2-





pyrrolidinecarboxamide)


XY-3
0.321
B
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-((3-methoxyphenyl)acetyl)-2-





pyrrolidinecarboxamide)


XY-4

B
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-(3-pyridinylcarbonyl)-2-





pyrrolidinecarboxamide)


XY-5

A
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-((dimethylamino)acetyl)-2-





pyrrolidinecarboxamide)


XY-6

A
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-(2-pyridinylcarbonyl)-2-





pyrrolidinecarboxamide)


XY-7

B
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-(3,5-difluorobenzoyl)-2-





pyrrolidinecarboxamide)


XY-8

A
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-((2-methoxyethoxy)acetyl)-2-





pyrrolidinecarboxamide)


XY-9

B
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-(2-methylpentanoyl)-2-





pyrrolidinecarboxamide)


XY-10

B
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-(2-fluorobenzoyl)-2-





pyrrolidinecarboxamide)


XY-11

B
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-((5-methoxy-1H-indol-3-yl)acetyl)-2-





pyrrolidinecarboxamide)


XY-12
0.22
B
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-(2-(3-chlorophenoxy)propanoyl)-2-





pyrrolidinecarboxamide)


XY-13
4.54
A
4,4′-(1,3-oxazole-2,5-diylbis(4,1-





phenylenecarbamoyl(2S)-2,1-pyrrolidinediyl))bis(4-





oxobutanoic acid)


XY-14

A
(2S)-1-(1H-imidazol-4-ylacetyl)-N-(4-(2-(4-((((2S)-1-





(1H-imidazol-5-ylacetyl)-2-





pyrrolidinyl)carbonyl)amino)phenyl)-1,3-oxazol-5-





yl)phenyl)-2-pyrrolidinecarboxamide (non-preferred





name)


XY-15

B
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-(cyclohexylcarbonyl)-2-





pyrrolidinecarboxamide)


XY-16

B
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-((2-methylcyclopropyl)carbonyl)-2-





pyrrolidinecarboxamide)


XY-17

B
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-(3-chloro-2,2-dimethylpropanoyl)-2-





pyrrolidinecarboxamide)


XY-18

C
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-(tetrahydro-3-furanylcarbonyl)-2-





pyrrolidinecarboxamide)


XY-19

A
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-(2,2-dimethylpentanoyl)-2-





pyrrolidinecarboxamide)


XY-20
0.062
C
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-((2R)-2-phenylbutanoyl)-2-





pyrrolidinecarboxamide)


XY-21

A
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-((1-methyl-1H-imidazol-2-





yl)carbonyl)-2-pyrrolidinecarboxamide)


XY-22
<0.0045
D
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-((4-fluorophenyl)acetyl)-2-





pyrrolidinecarboxamide)


XY-23

B
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-((1-acetyl-4-piperidinyl)carbonyl)-2-





pyrrolidinecarboxamide)


XY-24

B
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-(cyclopropylacetyl)-2-





pyrrolidinecarboxamide)


XY-25

A
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-((3-chloro-2-thienyl)carbonyl)-2-





pyrrolidinecarboxamide)


XY-26

A
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-((2R)-2-methoxy-2-phenylacetyl)-2-





pyrrolidinecarboxamide)


XY-27

B
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-(4,5-dimethyl-2-furoyl)-2-





pyrrolidinecarboxamide)


XY-28

B
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-((3,5-dimethyl-4-isoxazolyl)carbonyl)-





2-pyrrolidinecarboxamide)


XY-29

B
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-(4-methoxybenzoyl)-2-





pyrrolidinecarboxamide)


XY-30

A
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-((2-methyl-3-pyridinyl)carbonyl)-2-





pyrrolidinecarboxamide)


XY-31
0.054
C
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-(tetrahydro-2-furanylcarbonyl)-2-





pyrrolidinecarboxamide)


XY-32

C
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-((2R)-tetrahydro-2-furanylcarbonyl)-2-





pyrrolidinecarboxamide)


XY-33

A
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-(1H-pyrrol-2-ylcarbonyl)-2-





pyrrolidinecarboxamide)


XY-34

B
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-(2,5-dimethyl-3-furoyl)-2-





pyrrolidinecarboxamide)


XY-35

B
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-((2-methoxyphenyl)acetyl)-2-





pyrrolidinecarboxamide)


XY-36

B
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-(1,3-benzodioxol-5-ylcarbonyl)-2-





pyrrolidinecarboxamide)


XY-37

B
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-(2-furoyl)-2-pyrrolidinecarboxamide)


XY-38

C
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-(3-furoyl)-2-pyrrolidinecarboxamide)


XY-39

B
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-((1-methylcyclopropyl)carbonyl)-2-





pyrrolidinecarboxamide)


XY-40

B
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-((1-methyl-1H-pyrrol-2-yl)acetyl)-2-





pyrrolidinecarboxamide)


XY-41

A
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-(1-piperidinylacetyl)-2-





pyrrolidinecarboxamide)


XY-42

A
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-((1-methyl-1H-imidazol-4-yl)acetyl)-





2-pyrrolidinecarboxamide)


XY-43

A
(2S,2′S)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-(2,5-dimethylbenzoyl)-2-





pyrrolidinecarboxamide)


XY-44

A
(2S,4R,2′S,4′R)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-(cyclopropylacetyl)-4-hydroxy-2-





pyrrolidinecarboxamide)


XY-45

A
(2S,4R,2′S,4′R)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(4-hydroxy-1-(3-pyridinylacetyl)-2-





pyrrolidinecarboxamide)


XY-46

B
(2S,4R,2′S,4′R)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-(cyclobutylcarbonyl)-4-hydroxy-2-





pyrrolidinecarboxamide)


XY-47
0.564
B
(2S,4R,2′S,4′R)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-(2-ethylbenzoyl)-4-hydroxy-2-





pyrrolidinecarboxamide)


XY-48

A
(2S,4R,2′S,4′R)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-(cyclohexylcarbonyl)-4-hydroxy-2-





pyrrolidinecarboxamide)


XY-49

C
(2S,4R,2′S,4′R)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(4-hydroxy-1-(methoxy(phenyl)acetyl)-2-





pyrrolidinecarboxamide)


XY-50

A
(2S,4R,2′S,4′R)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(4-hydroxy-1-((2R)-tetrahydro-2-





furanylcarbonyl)-2-pyrrolidinecarboxamide)


XY-51

B
(2S,4R,2′S,4′R)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(4-hydroxy-1-((3-methylphenyl)acetyl)-





2-pyrrolidinecarboxamide)


XY-52

A
(2S,4R,2′S,4′R)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(4-hydroxy-1-((3-methyl-5-





isoxazolyl)acetyl)-2-pyrrolidinecarboxamide)


XY-53
8.06
A
(2S,4R,2′S,4′R)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-((3,5-dimethyl-4-isoxazolyl)carbonyl)-





4-hydroxy-2-pyrrolidinecarboxamide)


XY-54

A
(2S,4R,2′S,4′R)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(4-hydroxy-1-(2-thienylcarbonyl)-2-





pyrrolidinecarboxamide)


XY-55

B
(2S,4R,2′S,4′R)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(4-hydroxy-1-((3-methoxyphenyl)acetyl)-





2-pyrrolidinecarboxamide)


XY-56

B
(2S,4R,2′S,4′R)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-benzoyl-4-hydroxy-2-





pyrrolidinecarboxamide)


XY-57

A
(2S,4R,2′S,4′R)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-(cyclopropylcarbonyl)-4-hydroxy-2-





pyrrolidinecarboxamide)


XY-58

B
(2S,4R,2′S,4′R)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(4-hydroxy-1-(2-pyridinylacetyl)-2-





pyrrolidinecarboxamide)


XY-59

A
dibenzyl (2S,4R,2′S,4′R)-2,2′-(1,3-oxazole-2,5-





diylbis(4,1-phenylenecarbamoyl))bis(4-tert-butoxy-1-





pyrrolidinecarboxylate)


XY-60

A
(2S,4R,2′S,4′R)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(4-tert-butoxy-2-pyrrolidinecarboxamide)


XY-61

B
(2S,4R,2′S,4′R)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(4-tert-butoxy-1-(cyclopropylacetyl)-2-





pyrrolidinecarboxamide)


XY-62

C
(2S,4R,2′S,4′R)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(4-tert-butoxy-1-(3-pyridinylacetyl)-2-





pyrrolidinecarboxamide)


XY-63

B
(2S,4R,2′S,4′R)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(4-tert-butoxy-1-(2,2-





dimethylpropanoyl)-2-pyrrolidinecarboxamide)


XY-64

A
(2S,4R,2′S,4′R)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(4-tert-butoxy-1-(cyclobutylcarbonyl)-2-





pyrrolidinecarboxamide)


XY-65

A
(2S,4R,2′S,4′R)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(4-tert-butoxy-1-(2-ethylbenzoyl)-2-





pyrrolidinecarboxamide)


XY-66

A
(2S,4R,2′S,4′R)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(4-tert-butoxy-1-(cyclohexylcarbonyl)-2-





pyrrolidinecarboxamide)


XY-67

C
(2S,4R,2′S,4′R)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(4-tert-butoxy-1-





(methoxy(phenyl)acetyl)-2-pyrrolidinecarboxamide)


XY-68

B
(2S,4R,2′S,4′R)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(4-tert-butoxy-1-((2R)-tetrahydro-2-





furanylcarbonyl)-2-pyrrolidinecarboxamide)


XY-69

B
(2S,4R,2′S,4′R)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(4-tert-butoxy-1-((3-





methylphenyl)acetyl)-2-pyrrolidinecarboxamide)


XY-70

C
(2S,4R,2′S,4′R)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(4-tert-butoxy-1-((3-methyl-5-





isoxazolyl)acetyl)-2-pyrrolidinecarboxamide)


XY-71

A
(2S,4R,2′S,4′R)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(4-tert-butoxy-1-((1-methyl-1H-pyrrol-2-





yl)carbonyl)-2-pyrrolidinecarboxamide)


XY-72

B
(2S,4R,2′S,4′R)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(4-tert-butoxy-1-((3,5-dimethyl-4-





isoxazolyl)carbonyl)-2-pyrrolidinecarboxamide)


XY-73

A
(2S,4R,2′S,4′R)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(1-benzoyl-4-tert-butoxy-2-





pyrrolidinecarboxamide)


XY-74

B
(2S,4R,2′S,4′R)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(4-tert-butoxy-1-(cyclopropylcarbonyl)-





2-pyrrolidinecarboxamide)


XY-75

C
(2S,4R,2′S,4′R)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(4-tert-butoxy-1-(2-pyridinylacetyl)-2-





pyrrolidinecarboxamide)


XY-76

A
(2S,4R,2′S,4′R)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(4-tert-butoxy-1-(2-thienylcarbonyl)-2-





pyrrolidinecarboxamide)


XY-77

B
(2S,4R,2′S,4′R)-N,N′-(1,3-oxazole-2,5-diyldi-4,1-





phenylene)bis(4-tert-butoxy-1-((3-





methoxyphenyl)acetyl)-2-pyrrolidinecarboxamide)









The compounds of the present disclosure may inhibit HCV by mechanisms in addition to or other than NS5A inhibition. In one embodiment the compounds of the present disclosure inhibit HCV replicon and in another embodiment the compounds of the present disclosure inhibit NS5A.
It will be evident to one skilled in the art that the present disclosure is not limited to the foregoing illustrative examples, and that it can be embodied in other specific forms without departing from the essential attributes thereof. It is therefore desired that the examples be considered in all respects as illustrative and not restrictive, reference being made to the appended claims, rather than to the foregoing examples, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.

## Claims

1. A compound of Formula (I):




or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein:
Q1, Q2, Q3, Q4, Q5, Q6, Q7, and Q8 are each CRw; wherein each Rw is independently selected from hydrogen, C1-6 alkoxy, C1-4 alkyl, and halo;
L is a five-membered heterocyclyl group selected from the group consisting of





wherein Rx at each occurrence is independently hydrogen, halogen, or C1-4 alkyl optionally substituted by —C(O)OR3 or —NMe2, wherein Ry at each occurrence is independently hydrogen or C1-4 alkyl, and wherein R3 is hydrogen or C1-4 alkyl;
R1 and R2 are independently selected from cycloalkyl, heteroaryl, and heterocyclyl,
wherein any said heteroaryl may optionally be substituted with one or more substituents independently selected from C1-4 alkyl, C1-4 haloalkyl, arylalkyl, heterocyclyl, heterocyclylalkyl, halogen, cyano, nitro, —OR4, —C(O)OR6, —NRaRb, (NRaRb)alkyl, and —OP(O)(OH)(OR5), and
wherein any said cycloalkyl or heterocyclyl may optionally be fused onto an aromatic ring and may optionally be substituted with one or more substituents independently selected from C1-4 alkyl, halogen, aryl, arylalkyl, heteroarylalkyl, fused cyclopropyl, —NRaRb, oxo, —OR4, —C(O)OR6, and —C(O)R7;
R4 is hydrogen, C1-6 alkyl, or benzyl;
R5 is hydrogen or C1-4 alkyl;
R6 at each occurrence is independently C1-6 alkyl, aryl, benzyl, or heteroaryl;
R7 at each occurrence is independently selected from —OR8, C1-6 alkyl, C1-6 haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, and -L1-R11, wherein said aryl and heteroaryl may optionally be substituted by one or more substituents independently selected from C1-4 alkyl, halogen, —OR9, and —NRaRb, and wherein said cycloalkyl and heterocyclyl may optionally be substituted by one or more substituents independently selected from C1-4 alkyl, —C(O)OR10, fused cyclopropyl, cyano, oxo, phenyl, —NRaRb, -L1-R11, C(O)R11, and —C(O)-L1-R11;
R8 is C1-6 alkyl, phenyl optionally substituted with a halogen, arylalkyl, —(C1-3 alkylene)-C(O)OR10, or —(C1-3 alkylene)-O—(C1-3 alkylene);
R9 is hydrogen, C1-6 alkyl, or C1-4 haloalkyl;
R10 is hydrogen, C1-6 alkyl, phenyl, or benzyl;
L1 is C1-2 alkylene optionally substituted by one or two substituents independently selected from C1-4 alkyl, —OR12, —OC(O)R13, —NRaRb, phenyl, and oxo;
R11 is C1-6 alkyl, C1-4 haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, —OR8, or —NRaRb, wherein said aryl or heteroaryl may optionally be substituted by one or more substituents independently selected from C1-4 alkyl, halogen, —OR9, nitro, cyano, and —NRaRb, and wherein said cycloalkyl or heterocyclyl may optionally be substituted by one or more substituents independently selected from C1-4 alkyl, benzyl, phenyl, halogen, —OR9, oxo, fused cyclopropyl, —NRaRb, —C(O)R10, and —C(O)OR10;
R12 is hydrogen, C1-4 alkyl, aryl, or heteroaryl, wherein said aryl or heteroaryl may optionally be substituted by one or more substituents independently selected from C1-4 alkyl, halogen, and —OR9;
R13 is C1-4 alkyl or aryl;
Ra and Rb are independently selected from hydrogen, C1-6 alkyl, cycloalkyl, arylalkyl, heteroaryl, heterocyclyl, —C(O)R14, —C(O)OR15, —C(O)NRcRd, and (NRcRd)alkyl, or alternatively, Ra and Rb, together with the nitrogen atom to which they are attached, form a five- or six-membered ring or bridged bicyclic ring structure, wherein said five- or six-membered ring or bridged bicyclic ring structure optionally may contain one or two additional heteroatoms independently selected from nitrogen, oxygen, and sulfur and may contain one, two, or three substituents independently selected from C1-6 alkyl, C1-4 haloalkyl, aryl, halogen, and —OR9;
Rc and Rd are independently selected from hydrogen, C1-4 alkyl, benzyl, and cycloalkyl;
R14 is C1-4 alkyl, arylalkyl, aryl, or heteroaryl, each optionally substituted by one, two or three substituents independently selected from C1-4 alkyl, halogen, and —OR9; and
R15 is C1-6 alkyl, arylalkyl, or C1-4 haloalkyl.

2. The compound of claim 1, or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are independently selected from the group consisting of:




wherein:
n is 0, 1, 2, or 3;
R16 at each occurrence is independently C1-4 alkyl, —OR4, or oxo;
R17 at each occurrence is independently hydrogen or —C(O)R7, wherein R7 is defined as in claim 1;
R4 is hydrogen or C1-6 alkyl; and
R5 is C1-4 alkyl.

3. The compound of claim 2, or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein R7 at each occurrence is independently selected from the group consisting of —OCH2Ph, —OC(CH3)3, methyl, ethyl, isopropyl, —CH2Ph, cyclopropyl, cyclobutyl, phenyl,

4. The compound of claim 1, further characterized by formula (Ia):




or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein:
Rx is hydrogen, methyl, —CH2C(O)OR3, or —CH2NMe2, wherein R3 is hydrogen or C1-4 alkyl;
R1 and R2 are each




R17 at each occurrence is independently hydrogen or —C(O)R7;
R7 at each occurrence is independently —OR8 or benzyl; and
R8 is C1-4 alkyl or benzyl.

5. The compound of claim 1, further characterized by formula (Ib):




or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein:
Rx is hydrogen or C1-4 alkyl;
R1 and R2 are independently selected from:





wherein:
R16 is hydrogen, OH, or —OR4, wherein R4 is hydrogen or C1-4 alkyl;
R17 at each occurrence is independently hydrogen or —C(O)R7;
R7 at each occurrence is independently selected from —OR8, C1-6 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, heterocyclyl, aryl, heteroaryl, and -L1-R11, wherein said aryl and heteroaryl may optionally be substituted by one, two, or three substituents independently selected from C1-4 alkyl, halogen, —OR9, and —NRaRb, and wherein said cycloalkyl and heterocyclyl may optionally be substituted by one, two, or three substituents independently selected from C1-4 alkyl, —C(O)OR10, fused cyclopropyl, phenyl, oxo, —NRaRb, -L-R11, —C(O)R11, and —C(O)-L1-R11;
R8 is C1-4 alkyl or benzyl;
R9 is hydrogen or C1-4 alkyl;
R10 is C1-4 alkyl, phenyl, or benzyl;
L1 is C1-2 alkylene optionally substituted by one or two substituents independently selected from C1-4 alkyl, —OR12, —OC(O)R13, —NRaRb, phenyl, and oxo;
R11 is C1-4 alkyl, C1-4 haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, or —NRaRb, wherein said aryl or heteroaryl may optionally be substituted by one, two, or three substituents independently selected from C1-4 alkyl, halogen, —OR9, and —NRaRb, and wherein said cycloalkyl or heterocyclyl may optionally be substituted by one, two, or three substituents independently selected from C1-4 alkyl, benzyl, phenyl, halogen, —OR9, oxo, fused cyclopropyl, —NRaRb, —C(O)R10, and —C(O)OR10;
R12 is hydrogen, C1-4 alkyl, aryl, or heteroaryl, wherein said aryl or heteroaryl may optionally be substituted by one or more substituents independently selected from C1-4 alkyl, halogen, and —OR9;
R13 is C1-4 alkyl;
Ra and Rb are independently selected from hydrogen, C1-4 alkyl, —C(O)R14, or alternatively, Ra and Rb, together with the nitrogen atom to which they are attached, form a five- or six-membered ring, wherein said five- or six-membered ring optionally may contain one additional heteroatom selected from nitrogen, oxygen, and sulfur and may contain one, two, or three substituents independently selected from C1-4 alkyl, C1-4 haloalkyl, aryl, halogen, and —OR9;
R14 is C1-4 alkyl; and
R17a is heteroarylalkyl.

6. The compound of claim 5, or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein:
Rx is hydrogen;
R7 is selected from the group consisting of —OCH2Ph, —OC(CH3)3, methyl, ethyl, —CH2Ph, cyclopropyl, cyclobutyl, phenyl,

7. The compound of claim 1, further characterized by Formula (Id):




or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein:
Rx is hydrogen or C1-4 alkyl;
R1 and R2 are each




R16 is hydrogen or —OH;
R17 at each occurrence is independently hydrogen or —C(O)R7;
R7 at each occurrence is independently selected from the group consisting of —OR8, C1-4 alkyl, heteroaryl, and -L-R11, wherein said heteroaryl may optionally be substituted by one, two, or three substituents independently selected from C1-4 alkyl, halogen, and —OR9;
R8 is C1-4 alkyl or benzyl;
R9 is hydrogen or C1-4 alkyl;
L1 is C1-2 alkylene optionally substituted by one or two substituents independently selected from C1-4 alkyl, —OR12, and oxo;
R11 is aryl, C1-4 alkyl, cycloalkyl, aryl, or heteroaryl, wherein said aryl or heteroaryl may optionally be substituted by one, two, or three substituents independently selected from C1-4 alkyl, halogen, and —OR9; and
R12 is hydrogen or C1-4 alkyl.

8. The compound of claim 1, further characterized by Formula (Ie):




or a pharmaceutically acceptable salt thereof, wherein:
Rx and Ry are each independently hydrogen or C1-4 alkyl;
R1 and R2 are each independently selected from




R16 is hydrogen or —OR4, wherein R4 is hydrogen or C1-4 alkyl;
R17 at each occurrence is independently hydrogen or —C(O)R7;
R7 at each occurrence is independently selected from the group consisting of: —OR8, C1-4 alkyl, aryl, C3-6 cycloalkyl, heterocyclyl, heteroaryl, and -L1-R11, wherein said aryl and heteroaryl may optionally be substituted by one, two, or three substituents independently selected from C1-4 alkyl, halogen, —OR9, and —NRaRb, and wherein said cycloalkyl and heterocyclyl may optionally be substituted by one or more substituents independently selected from C1-4 alkyl, —OR9, —NRaRb, and oxo;
R8 is C1-4 alkyl or benzyl;
R9 is hydrogen or C1-4 alkyl;
L1 is C1-2 alkylene optionally substituted by one or two substituents independently selected from C1-4 alkyl, —OR12, —OC(O)R13, —NRaRb, and oxo;
R11 is C1-4 alkyl, cycloalkyl, aryl, or heteroaryl, wherein said aryl or heteroaryl may be optionally substituted by one, two, or three substituents independently selected from C1-4 alkyl, halogen, —OR9, and —NRaRb, and wherein said cycloalkyl or heterocyclyl may optionally be substituted by one or more substituents independently selected from C1-4 alkyl, halogen, —OR9, oxo, and —NRaRb;
R9 is hydrogen, C1-4 alkyl, or C1-4 haloalkyl;
R10 is C1-4 alkyl or benzyl;
R12 is hydrogen or C1-4 alkyl;
R13 is C1-4 alkyl;
Ra and Rb are each independently hydrogen, C1-4 alkyl, or —C(O)R14; and
R14 is C1-4 alkyl.

9. The compound of claim 8, or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein:
Rx is hydrogen;
Ry is hydrogen or C1-4 alkyl; and
R7 at each occurrence is independently selected from the group consisting of —OCH2Ph, —OC(CH3)3, methyl, ethyl, isopropyl, benzyl, cyclopropyl, cyclobutyl,

10. The compound of claim 1, further characterized by Formula (If):




or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein:
Rx is hydrogen or C1-4 alkyl;
R1 and R2 are each




R16 is hydrogen or —OH;
R17 at each occurrence is independently hydrogen or —C(O)R7;
R7 at each occurrence is independently —OR8 or —CH2Ph; and
R8 is C1-4 alkyl or benzyl.

11. The compound of claim 1, further characterized by Formula (Ig):




or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein:
Ry is hydrogen or C1-4 alkyl;
R1 and R2 are each




R17 at each occurrence is independently hydrogen or —C(O)R7; and
R7 at each occurrence is independently —OR8; and
R8 is C1-4 alkyl or benzyl.

12. The compound of claim 1, further characterized by Formula (Ih):




or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein:
Ry is hydrogen or C1-4 alkyl;
R1 and R2 are each




R16 is hydrogen or —OH; and
R17 at each occurrence is independently hydrogen or —C(O)R7;
R7 at each occurrence is independently —OR8 or benzyl; and
R8 is C1-4 alkyl or benzyl.

13. The compound of claim 1, further characterized by
Formula (Ii):





or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein:
Q is S or O;
R1 and R2 are each independently




R17 at each occurrence is independently hydrogen or —C(O)R7; and
R7 at each occurrence is independently selected from the group consisting of —OR8, C1-4 alkyl, and benzyl; and
R8 is C1-4 alkyl or benzyl.

14. The compound of claim 1, further characterized by Formula (Ij):




or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein:
Rx is hydrogen or C1-4 alkyl;
R1 and R2 are each independently




R17 at each occurrence is independently hydrogen or —C(O)R7; and
R7 at each occurrence is independently C1-4 alkyl or benzyl.

15. The compound of claim 1, further characterized by Formula (Ik):




or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein:
Rx is hydrogen or C1-4 alkyl;
R1 and R2 are independently selected from:




R17 at each occurrence is independently hydrogen or —C(O)R7;
R7 at each occurrence is independently C1-6 alkoxy, C1-4 alkyl, phenyl, benzyl, isoxazolyl, tetrahydrofuryl, and thienyl; and
R17a is

16. A compound, or a stereoisomer or a pharmaceutically acceptable salt thereof, selected from the group consisting of:
dibenzyl(2S,2′S)-2,2′-((2-(2-ethoxy-2-oxoethyl)-1,3-oxazole-4,5-diyl)bis(4,1-phenylenecarbamoyl))di(1-pyrrolidinecarboxylate);
(4,5-bis(4-((((2S)-1-((benzyloxy)carbonyl)-2-pyrrolidinyl)carbonyl)amino)phenyl)-1,3-oxazol-2-yl)acetic acid; propanediyl)))biscarbamate;
dibenzyl(2S,2′S)-2,2′-((2-methyl-1,3-oxazole-4,5-diyl)bis(4,1-phenylenecarbamoyl))di(1-pyrrolidinecarboxylate);
(2S,2′S)—N,N′-((2-((dimethylamino)methyl)-1,3-oxazole-4,5-diyl)di-4,1-phenylene)bis(1-(phenylacetyl)-2-pyrrolidinecarboxamide);
(2S)-1-acetyl-N-(4-(2-(4-((((2S)-1-(phenylacetyl)-2-pyrrolidinyl)carbonyl)amino)phenyl)-1,3-oxazol-5-yl)phenyl)-2-pyrrolidinecarboxamide;
benzyl (2S,4R)-2-((4-(5-(4-((((2S)-1-acetyl-2-pyrrolidinyl)carbonyl)amino)phenyl)-1,3-oxazol-2-yl)phenyl)carbamoyl)-4-tert-butoxy-1-pyrrolidinecarboxylate;
benzyl (2S,4R)-2-((4-(5-(4-((((2S)-1-acetyl-2-pyrrolidinyl)carbonyl)amino)phenyl)-1,3-oxazol-2-yl)phenyl)carbamoyl)-4-hydroxy-1-pyrrolidinecarboxylate;
benzyl 3-((4-(5-(4-((1-acetyl-L-prolyl)amino)phenyl)-1,3-oxazol-2-yl)phenyl)carbamoyl)-1-pyrrolidinecarboxylate;
1-acetyl-N-(4-(2-(4-(((5-oxo-1-(2-(2-thienyl)ethyl)-3-pyrrolidinyl)carbonyl)amino)phenyl)-1,3-oxazol-5-yl)phenyl)-L-prolinamide;
(2S)-1-acetyl-N-(4-(5-(4-((((2S)-1-(phenylacetyl)-2-pyrrolidinyl)carbonyl)amino)phenyl)-1,3-oxazol-2-yl)phenyl)-2-pyrrolidinecarboxamide;
1-acetyl-N-(4-(2-(4-((((2S)-1-(2-thienylcarbonyl)-2,5-dihydro-1H-pyrrol-2-yl)carbonyl)amino)phenyl)-1,3-oxazol-5-yl)phenyl)-L-prolinamide;
1-acetyl-N-(4-(2-(4-((((2S)-1-(2-thienylacetyl)-2,5-dihydro-1H-pyrrol-2-yl)carbonyl)amino)phenyl)-1,3-oxazol-5-yl)phenyl)-L-prolinamide;
1-acetyl-N-(4-(2-(4-((((2S)-1-(2-ethylbenzoyl)-2,5-dihydro-1H-pyrrol-2-yl)carbonyl)amino)phenyl)-1,3-oxazol-5-yl)phenyl)-L-prolinamide;
1-acetyl-N-(4-(2-(4-((((2S)-1-(5-isoxazolylcarbonyl)-2,5-dihydro-1H-pyrrol-2-yl)carbonyl)amino)phenyl)-1,3-oxazol-5-yl)phenyl)-L-prolinamide;
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-((dimethylamino)(2-fluorophenyl)acetyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-((2,4-difluorophenyl)(dimethylamino)acetyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-((2,4-difluorophenyl)(dimethylamino)acetyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-((2,4-difluorophenyl)(dimethylamino)acetyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-((4-methyl-1-piperazinyl)(phenyl)acetyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-(hydroxy(1,3-thiazol-2-yl)acetyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-(hydroxy(imidazo[1,2-a]pyridin-3-yl)acetyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-(hydroxy(2-pyridinyl)acetyl)-2-pyrrolidinecarboxamide);
(2S)-1-(hydroxy(1H-pyrrolo[2,3-b]pyridin-3-yl)acetyl)-N-(4-(2-(4-((((2S)-1-(hydroxy(7H-pyrrolo[2,3-b]pyridin-3-yl)acetyl)-2-pyrrolidinyl)carbonyl)amino)phenyl)-1,3-oxazol-5-yl)phenyl)-2-pyrrolidinecarboxamide;
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-(2-(4-chlorophenoxy)-3-(dimethylamino)propanoyl)-2-pyrrolidinecarboxamide);
(2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-(cyclopropylacetyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-((1-(cyclohexylmethyl)-2-piperidinyl)carbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-((1-benzyl-2-piperidinyl)carbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-((1-benzyl-2-methyl-5-oxo-2-pyrrolidinyl)carbonyl)-2-pyrrolidinecarboxamide);
di-tert-butyl (2S,2′S)-2,2′-(1,3-oxazole-2,5-diylbis(4,1-phenylenecarbamoyl(2S)-2,1-pyrrolidinediylcarbonyl))di(1-pyrrolidinecarboxylate);
di-tert-butyl (2R,2′R)-2,2′-(1,3-oxazole-2,5-diylbis(4,1-phenylenecarbamoyl(2S)-2,1-pyrrolidinediylcarbonyl))di(1-pyrrolidinecarboxylate);
di-tert-butyl 2,2′-(1,3-oxazole-2,5-diylbis(4,1-phenylenecarbamoyl(2S)-2,1-pyrrolidinediylcarbonyl))bis(2-methyl-1-pyrrolidinecarboxylate);
di-tert-butyl 2,2′-(1,3-oxazole-2,5-diylbis(4,1-phenylenecarbamoyl(2S)-2,1-pyrrolidinediylcarbonyl))bis(2-methyl-1-pyrrolidinecarboxylate);
di-tert-butyl(1S,3S,5S,1′S,3′S,5′S)-3,3′-(1,3-oxazole-2,5-diylbis(4,1-phenylenecarbamoyl(2S)-2,1-pyrrolidinediylcarbonyl))bis(2-azabicyclo[3.1.0]hexane-2-carboxylate);
di-tert-butyl 2,2′-(1,3-oxazole-2,5-diylbis(4,1-phenylenecarbamoyl(2S)-2,1-pyrrolidinediylcarbonyl))bis(2-benzyl-1-pyrrolidinecarboxylate);
di-tert-butyl 2,2′-(1,3-oxazole-2,5-diylbis(4,1-phenylenecarbamoyl(2S)-2,1-pyrrolidinediylcarbonyl))bis(2-benzyl-1-pyrrolidinecarboxylate);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-((2S)-2-pyrrolidinylcarbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-((2R)-2-pyrrolidinylcarbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-((2-methyl-2-pyrrolidinyl)carbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-((2-benzyl-2-pyrrolidinyl)carbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-(((2S)-1-((2R)-2-(dimethylamino)-2-phenylacetyl)-2-pyrrolidinyl)carbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-(((2R)-1-((2R)-2-(dimethylamino)-2-phenylacetyl)-2-pyrrolidinyl)carbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-(((1S,3S,5S)-2-((2R)-2-(dimethylamino)-2-phenylacetyl)-2-azabicyclo[3.1.0]hex-3-yl)carbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-((2R)-2-(dimethylamino)-2-phenylacetyl)-2-methyl-2-pyrrolidinyl)carbonyl)-2-pyrrolidinecarboxamide);
dibenzyl(2S,2′S)-2,2′-(1H-imidazole-4,5-diylbis(4,1-phenylenecarbamoyl))di(1-pyrrolidinecarboxylate);
(2S,2′S)—N,N′-(1H-imidazole-4,5-diyldi-4,1-phenylene)bis(1-(phenylacetyl)-2-pyrrolidinecarboxamide);
(2S,4S,2′S,4′S)—N,N′-(1H-imidazole-4,5-diyldi-4,1-phenylene)bis(4-hydroxy-1-(phenylacetyl)-2-pyrrolidinecarboxamide);
(2S,4S,2′S,4′S)—N,N′-(1H-imidazole-4,5-diyldi-4,1-phenylene)bis(4-hydroxy-1-(phenylacetyl)-2-pyrrolidinecarboxamide);
(2S)-1-acetyl-N-(4-(2-methyl-4-(4-((((2S)-1-(phenylacetyl)-2-pyrrolidinyl)carbonyl)amino)phenyl)-1,3-thiazol-5-yl)phenyl)-2-pyrrolidinecarboxamide;
(2S,2′S)—N,N′-((2-methyl-1,3-thiazole-4,5-diyl)di-4,1-phenylene)bis(1-acetyl-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-((2-methyl-1,3-thiazole-4,5-diyl)di-4,1-phenylene)bis(1-(phenylacetyl)-2-pyrrolidinecarboxamide);
(2)-1-acetyl-N-(4-(4-(4-((((2S)-1-(phenylacetyl)-2-pyrrolidinyl)carbonyl)amino)phenyl)-1,3-thiazol-2-yl)phenyl)-2-pyrrolidinecarboxamide;
1-acetyl-N-(4-(4-(4-(((5-oxo-1-(2-(2-thienyl)ethyl)-3-pyrrolidinyl)carbonyl)amino)phenyl)-1,3-thiazol-2-yl)phenyl)-L-prolinamide;
1-acetyl-N-(4-(4-(4-((((2S)-1-(2-thienylcarbonyl)-2,5-dihydro-1H-pyrrol-2-yl)carbonyl)amino)phenyl)-1,3-thiazol-2-yl)phenyl)-L-prolinamide;
1-acetyl-N-(4-(4-(4-((((2S)-1-(2-thienylacetyl)-2,5-dihydro-1H-pyrrol-2-yl)carbonyl)amino)phenyl)-1,3-thiazol-2-yl)phenyl)-L-prolinamide;
1-acetyl-N-(4-(4-(4-((((2S)-1-(phenylacetyl)-2,5-dihydro-1H-pyrrol-2-yl)carbonyl)amino)phenyl)-1,3-thiazol-2-yl)phenyl)-L-prolinamide;
1-acetyl-N-(4-(4-(4-((((2S)-1-(5-isoxazolylcarbonyl)-2,5-dihydro-1H-pyrrol-2-yl)carbonyl)amino)phenyl)-1,3-thiazol-2-yl)phenyl)-L-prolinamide;
1-acetyl-N-(4-(4-(4-((((2S)-1-((2R)-tetrahydro-2-furanylcarbonyl)-2,5-dihydro-1H-pyrrol-2-yl)carbonyl)amino)phenyl)-1,3-thiazol-2-yl)phenyl)-L-prolinamide;
1-acetyl-N-(4-(4-(4-((((2S)-1-((2S)-tetrahydro-2-furanylcarbonyl)-2,5-dihydro-1H-pyrrol-2-yl)carbonyl)amino)phenyl)-1,3-thiazol-2-yl)phenyl)-L-prolinamide;
1-acetyl-N-(4-(4-(4-((((2S)-1-benzoyl-2,5-dihydro-1H-pyrrol-2-yl)carbonyl)amino)phenyl)-1,3-thiazol-2-yl)phenyl)-L-prolinamide;
dibenzyl(2S,2′S)-2,2′-((5-oxo-1,5-dihydro-4H-1,2,4-triazole-3,4-diyl)bis(4,1-phenylenecarbamoyl))di(1-pyrrolidinecarboxylate);
(2S,2′S)—N,N′-(4H-1,2,4-triazole-3,4-diyldi-4,1-phenylene)bis(1-(phenylacetyl)-2-pyrrolidinecarboxamide);
(2S,4R,2′S,4′R)—N,N′-(4H-1,2,4-triazole-3,4-diyldi-4,1-phenylene)bis(4-hydroxy-1-(phenylacetyl)-2-pyrrolidinecarboxamide);
dibenzyl(2S,2′S)-2,2′-(1,3,4-oxadiazole-2,5-diylbis(4,1-phenylenecarbamoyl))di(1-pyrrolidinecarboxylate);
(2)-1-acetyl-N-(4-(5-(4-((((2S)-1-(phenylacetyl)-2-pyrrolidinyl)carbonyl)amino)phenyl)-1,3,4-oxadiazol-2-yl)phenyl)-2-pyrrolidinecarboxamide;
(2S,2′S)—N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-phenylene)bis(1-acetyl-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-phenylene)bis(1-(phenylacetyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-phenylene)bis(1-(cyclopropylacetyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-phenylene)bis(1-(cyclopropylcarbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-phenylene)bis(1-((2S)-tetrahydro-2-furanylcarbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-phenylene)bis(1-(2-thienylacetyl)-2-pyrrolidinecarboxamide);
(2)-1-acetyl-N-(4-(5-(4-((((2S)-1-(2-thienylacetyl)-2-pyrrolidinyl)carbonyl)amino)phenyl)-1,3,4-oxadiazol-2-yl)phenyl)-2-pyrrolidinecarboxamide;
(2S,2′S)—N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-phenylene)bis(1-(3-pyridinylacetyl)-2-pyrrolidinecarboxamide);
(2S)-1-acetyl-N-(4-(5-(4-((((2S)-1-(3-pyridinylacetyl)-2-pyrrolidinyl)carbonyl)amino)phenyl)-1,3,4-oxadiazol-2-yl)phenyl)-2-pyrrolidinecarboxamide;
dibenzyl(2S,2′S)-2,2′-(1H-1,2,3-triazole-4,5-diylbis(4,1-phenylenecarbamoyl))di(1-pyrrolidinecarboxylate);
(2S,2′S)—N,N′-(1H-1,2,3-triazole-4,5-diyldi-4,1-phenylene)bis(1-(phenylacetyl)-2-pyrrolidinecarboxamide);
(2S,4R,2′S,4′R)—N,N′-(1H-1,2,3-triazole-4,5-diyldi-4,1-phenylene)bis(4-hydroxy-1-(phenylacetyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(2,5-thienediyldi-4,1-phenylene)bis(1-(phenylacetyl)-2-pyrrolidinecarboxamide);
dibenzyl(2S,2′S)-2,2′-(2,5-thienediylbis(4,1-phenylenecarbamoyl))di(1-pyrrolidinecarboxylate);
(2S,2′S)—N,N′-(2,5-thienediyldi-4,1-phenylene)bis(1-acetyl-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(2,5-thienediyldi-3,1-phenylene)bis(1-(phenylacetyl)-2-pyrrolidinecarboxamide);
dibenzyl(2S,2′S)-2,2′-(1H-pyrazole-3,5-diylbis(4,1-phenylenecarbamoyl))di(1-pyrrolidinecarboxylate);
(2S,2′S)—N,N′-(1H-pyrazole-3,5-diyldi-4,1-phenylene)bis(1-(phenylacetyl)-2-pyrrolidinecarboxamide);
(2S,4R,2′S,4′R)—N,N′-(1H-pyrazole-3,5-diyldi-4,1-phenylene)bis(4-hydroxy-1-(phenylacetyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1H-pyrazole-3,5-diyldi-4,1-phenylene)bis(1-acetyl-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1H-pyrazole-3,5-diyldi-4,1-phenylene)bis(1-acetyl-2,5-dihydro-1H-pyrrole-2-carboxamide);
(2S,2′S)—N,N′-(1H-pyrazole-3,5-diyldi-4,1-phenylene)bis(1-isobutyryl-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1H-pyrazole-3,5-diyldi-4,1-phenylene)bis(1-propionyl-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1H-pyrazole-3,5-diyldi-4,1-phenylene)bis(1-(cyclobutylcarbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1H-pyrazole-3,5-diyldi-4,1-phenylene)bis(1-isonicotinoyl-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1H-pyrazole-3,5-diyldi-4,1-phenylene)bis(1-(cyclopropylcarbonyl)-2-pyrrolidinecarboxamide);
(2S)-1-acetyl-N-(4-(3-(4-((((2S)-1-(phenylacetyl)-2-pyrrolidinyl)carbonyl)amino)phenyl)-1H-pyrazol-5-yl)phenyl)-2-pyrrolidinecarboxamide;
(2S,2′S)—N,N′-(1H-pyrazole-3,5-diyldi-4,1-phenylene)bis(1-(cyclopropylcarbonyl)-2,5-dihydro-1H-pyrrole-2-carboxamide);
(2S,2′S)—N,N′-(1H-pyrazole-3,5-diyldi-4,1-phenylene)bis(1-(cyclobutylcarbonyl)-2,5-dihydro-1H-pyrrole-2-carboxamide);
(2S,2′S)—N,N′-(1H-pyrazole-3,5-diyldi-4,1-phenylene)bis(1-((3-chloro-1-isoquinolinyl)carbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1H-pyrazole-3,5-diyldi-4,1-phenylene)bis(1-((3-chloro-5-methoxy-1-isoquinolinyl)carbonyl)-2-pyrrolidinecarboxamide);
N,N′-(1H-pyrazole-3,5-diyldi-4,1-phenylene)bis(1-((2R)-2-acetamido-2-phenylacetyl)-2-pyrrolidinecarboxamide);
dibenzyl(2S,4R,2′S,4′R)-2,2′-(1H-pyrazole-3,5-diylbis(4,1-phenylenecarbamoyl))bis(4-tert-butoxy-1-pyrrolidinecarboxylate);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-((6-fluoro-2-pyridinyl)carbonyl)-2-pyrrolidinecarboxamide);
(2S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-((2R)-2-(dimethylamino)-2-phenylacetyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-((3-chloro-5-methoxy-1-isoquinolinyl)carbonyl)-2-pyrrolidinecarboxamide);
N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-((2R)-2-acetamido-2-phenylacetyl)-2-pyrrolidinecarboxamide);
(2S,4S,2′S,4′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-((2R)-2-hydroxy-2-phenylacetyl)-4-methoxy-2-pyrrolidinecarboxamide);
(2S,4S,2′S,4′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-((2R)-2-(dimethylamino)-2-phenylacetyl)-4-methoxy-2-pyrrolidinecarboxamide);
(2S,4S,2′S,4′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-(acetamido(phenyl)acetyl)-4-methoxy-2-pyrrolidinecarboxamide);
(1S,3S,5S,1′S,3′S,5′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(2-((2R)-2-acetamido-2-phenylacetyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide);
(1S,3S,5S,1′S,3′S,5′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(2-(1-isoquinolinylcarbonyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide);
(1S,3S,5S,1′S,3′S,5′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(2-((3-chloro-1-isoquinolinyl)carbonyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide);
(1S,3S,5S,1′S,3′S,5′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(2-((3-chloro-5-methoxy-1-isoquinolinyl)carbonyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide);
(1S,3S,5S,1′S,3′S,5′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(2-((2S)-2-hydroxy-2-phenylacetyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide);
(1S,3S,5S,1′S,3′S,5′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(2-((2R)-2-hydroxy-2-phenylacetyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide);
(1S,3S,5S,1′S,3′S,5′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(2-((2R)-tetrahydro-2-furanylcarbonyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide);
(1S,3S,5S,1′S,3′S,5′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(2-((2S)-2-hydroxy-2-phenylpropanoyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide);
(1S,3S,5S,1′S,3′S,5′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(2-((2R)-2-(dimethylamino)-2-phenylacetyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide);
(1S,3S,5S,1′S,3′S,5′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(2-((2R)-2-hydroxy-2-phenylpropanoyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide);
dibenzyl(2S,2′S)-2,2′-(1,3-oxazole-2,5-diylbis(4,1-phenylenecarbamoyl))di(1-pyrrolidinecarboxylate);
(2S,4R,2′S,4′R)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(4-hydroxy-1-(phenylacetyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-(phenylacetyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-(phenylacetyl)-2-piperidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-(cyclopropylcarbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-propionyl-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-(cyclobutylcarbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-isonicotinoyl-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-acetyl-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-((2S)-2-methoxy-2-phenylacetyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-((2S)-2-hydroxy-2-phenylacetyl)-2-pyrrolidinecarboxamide);
1,3-oxazole-2,5-diylbis(4,1-phenylenecarbamoyl(2S)-2,1-pyrrolidinediyl(1S)-2-oxo-1-phenyl-2,1-ethanediyl)diacetate;
(2)-1-((2S)-2-hydroxy-2-phenylpropanoyl)-N-(4-(2-(4-((((2S)-1-(2-hydroxy-2-phenylpropanoyl)-2-pyrrolidinyl)carbonyl)amino)phenyl)-1,3-oxazol-5-yl)phenyl)-2-pyrrolidinecarboxamide;
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-((2R)-2-hydroxy-2-phenylacetyl)-2-pyrrolidinecarboxamide);
1,3-oxazole-2,5-diylbis(4,1-phenylenecarbamoyl(2S)-2,1-pyrrolidinediyl(1R)-2-oxo-1-phenyl-2,1-ethanediyl)diacetate;
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-((2R)-2-methoxy-2-phenylacetyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-((2R)-2-(2-chlorophenyl)-2-hydroxyacetyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-(oxo(phenyl)acetyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-(1-benzofuran-2-ylcarbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-(1,3-benzothiazol-2-ylcarbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-(2,1-benzisoxazol-3-ylcarbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1H-pyrazole-3,5-diyldi-4,1-phenylene)bis(1-(oxo(phenyl)acetyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1H-pyrazole-3,5-diyldi-4,1-phenylene)bis(1-((2R)-2-hydroxy-2-phenylacetyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1H-pyrazole-3,5-diyldi-4,1-phenylene)bis(1-((2S)-2-hydroxy-2-phenylacetyl)-2-pyrrolidinecarboxamide);
1H-pyrazole-3,5-diylbis(4,1-phenylenecarbamoyl(2S)-2,1-pyrrolidinediyl(1S)-2-oxo-1-phenyl-2,1-ethanediyl)diacetate;
1H-pyrazole-3,5-diylbis(4,1-phenylenecarbamoyl(2S)-2,1-pyrrolidinediyl(1R)-2-oxo-1-phenyl-2,1-ethanediyl)diacetate;
(2S,2′S)—N,N′-(1H-pyrazole-3,5-diyldi-4,1-phenylene)bis(1-((2R)-2-(2-chlorophenyl)-2-hydroxyacetyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1H-pyrazole-3,5-diyldi-4,1-phenylene)bis(1-((2R)-2-methoxy-2-phenylacetyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1H-pyrazole-3,5-diyldi-4,1-phenylene)bis(1-((2S)-2-methoxy-2-phenylacetyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1H-pyrazole-3,5-diyldi-4,1-phenylene)bis(1-((2S)-2-hydroxy-2-phenylpropanoyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1H-pyrazole-3,5-diyldi-4,1-phenylene)bis(1-(1-benzofuran-2-ylcarbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1H-pyrazole-3,5-diyldi-4,1-phenylene)bis(1-(1,3-benzothiazol-2-ylcarbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1H-imidazole-4,5-diyldi-4,1-phenylene)bis(1-(oxo(phenyl)acetyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1H-imidazole-4,5-diyldi-4,1-phenylene)bis(1-((2R)-2-hydroxy-2-phenylacetyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1H-imidazole-4,5-diyldi-4,1-phenylene)bis(1-((2S)-2-hydroxy-2-phenylacetyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1H-imidazole-4,5-diyldi-4,1-phenylene)bis(1-((2S)-2-methoxy-2-phenylacetyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1H-imidazole-4,5-diyldi-4,1-phenylene)bis(1-((2S)-2-hydroxy-2-phenylpropanoyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1H-imidazole-4,5-diyldi-4,1-phenylene)bis(1-((2R)-2-hydroxy-2-phenylpropanoyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1H-imidazole-4,5-diyldi-4,1-phenylene)bis(1-(1-isoquinolinylcarbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1H-imidazole-4,5-diyldi-4,1-phenylene)bis(1-((3-chloro-1-isoquinolinyl)carbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1H-imidazole-4,5-diyldi-4,1-phenylene)bis(1-((3-chloro-5-methoxy-1-isoquinolinyl)carbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1H-imidazole-4,5-diyldi-4,1-phenylene)bis(1-(1-benzofuran-2-ylcarbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1H-imidazole-4,5-diyldi-4,1-phenylene)bis(1-(1-benzofuran-5-ylcarbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-((1-methyl-1H-pyrazole-3,5-diyl)di-4,1-phenylene)bis(1-(phenylacetyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-((1-methyl-1H-pyrazole-3,5-diyl)di-4,1-phenylene)bis(1-acetyl-2-pyrrolidinecarboxamide);
dibenzyl(2S,2′S)-2,2′-((1-methyl-1H-pyrazole-3,5-diyl)bis(4,1-phenylenecarbamoyl))di(1-pyrrolidinecarboxylate);
(2S,2′S)—N,N′-((1-methyl-1H-pyrazole-3,5-diyl)di-4,1-phenylene)bis(1-(cyclopropylcarbonyl)-2-pyrrolidinecarboxamide);
N′,N′′′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-((3R)-1-((2R)-2-hydroxy-2-phenylacetyl)-3-pyrrolidinyl)urea);
N′,N′′′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-((3R)-1-((2S)-2-hydroxy-2-phenylacetyl)-3-pyrrolidinyl)urea);
N′,N′′′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-((3R)-1-(2-hydroxy-2-phenylpropanoyl)-3-pyrrolidinyl)urea);
N′,N′′′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-((3R)-1-((2R)-2-(dimethylamino)-2-phenylacetyl)-3-pyrrolidinyl)urea);
N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(2-((2R)-2-(dimethylamino)-2-phenylacetyl)-1-pyrazolidinecarboxamide);
dibenzyl(2S,2′S)-2,2′-(1,3,4-oxadiazole-2,5-diylbis(4,1-phenylenecarbamoyl))di(1-pyrrolidinecarboxylate);
dibenzyl(2S,2′S)-2,2′-(1,3,4-oxadiazole-2,5-diylbis(4,1-phenylenecarbamoyl))bis(5-oxo-1-pyrrolidinecarboxylate);
N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-phenylene)bis(1-(phenylacetyl)-2-pyrrolidinecarboxamide);
dibenzyl(2S,2′S)-2,2′-(1,3,4-oxadiazole-2,5-diylbis(4,1-phenylenecarbamoyl))di(1-piperidinecarboxylate);
dibenzyl(2R,2′R)-2,2′-(1,3,4-oxadiazole-2,5-diylbis(4,1-phenylenecarbamoyl))di(1-piperidinecarboxylate);
(2S,2′S)—N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-phenylene)bis(1-(2-methoxybenzoyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-phenylene)bis(1-(3-methoxybenzoyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-phenylene)bis(1-(2-ethoxybenzoyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-phenylene)bis(1-(2-ethylbenzoyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-phenylene)bis(1-(2-quinolinylcarbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-phenylene)bis(1-(methoxy(phenyl)acetyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-phenylene)bis(1-((6-chloro-2-pyridinyl)carbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-phenylene)bis(1-(2-furoyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-phenylene)bis(1-((2S)-tetrahydro-2-furanylcarbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-phenylene)bis(1-((2R)-tetrahydro-2-furanylcarbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-phenylene)bis(1-((2R)-2-hydroxy-2-phenylacetyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-phenylene)bis(1-((2S)-2-hydroxy-2-phenylacetyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-phenylene)bis(1-((3-chloro-1-isoquinolinyl)carbonyl)-2-pyrrolidinecarboxamide);
(2R,2′R)—N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-phenylene)bis(1-((6-fluoro-2-pyridinyl)carbonyl)-2-pyrrolidinecarboxamide);
(3S,3′S)—N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-phenylene)bis(1-((4-methoxy-2-quinolinyl)carbonyl)-3-piperidinecarboxamide);
(2S,2′S)—N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-phenylene)bis(1-((4-chloro-2-pyridinyl)carbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-phenylene)bis(1-((2R)-2-hydroxy-2-phenylpropanoyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-phenylene)bis(1-((3-chloro-5-methoxy-1-isoquinolinyl)carbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-phenylene)bis(1-((2S)-2-(dimethylamino)-2-phenylacetyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-phenylene)bis(1-(2-chloro-6-methoxyisonicotinoyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3,4-oxadiazole-2,5-diyldi-4,1-phenylene)bis(1-((1-methyl-1H-indol-3-yl)carbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(2,5-oxazolediyldi-4,1-phenylene)bis[1-[2-(1-methyl-1H-indol-3-yl)-1,2-dioxoethyl]-2-pyrrolidinecarboxamide];
(2S,2′S)—N,N′-(2,5-oxazolediyldi-4,1-phenylene)bis[1-(3,3,3-trifluoro-2-hydroxy-1-oxopropyl)-2-pyrrolidinecarboxamide];
(2S,2′S)—N,N′-(2,5-oxazolediyldi-4,1-phenylene)bis [1-[hydroxy(1-methyl-1H-imidazol-5-yl)acetyl]-2-pyrrolidinecarboxamide];
(2S,2′S)—N,N′-(2,5-oxazolediyldi-4,1-phenylene)bis[1-[2-hydroxy-1-oxo-3-(3-pyridinyl)propyl]-2-pyrrolidinecarboxamide];
(2S,2′S)—N,N′-(2,5-oxazolediyldi-4,1-phenylene)bis[1-[2-hydroxy-3-(1H-indol-3-yl)-1-oxopropyl]-2-pyrrolidinecarboxamide];
(2S,2′S)—N,N′-(2,5-oxazolediyldi-4,1-phenylene)bis[1-(hydroxy-2-thienylacetyl)-2-pyrrolidinecarboxamide];
(2S,2′S)—N,N′-(2,5-oxazolediyldi-4,1-phenylene)bis[1-(hydroxy-3-pyridinylacetyl)-2-pyrrolidinecarboxamide];
(2S)—N,N′-(4,4′-(oxazole-2,5-diyl)bis(4,1-phenylene))bis(1-(3-(4-bromophenyl)-2-(dimethylamino)propanoyl)pyrrolidine-2-carboxamide);
(2S,2′S)—N,N′-(2,5-oxazolediyldi-4,1-phenylene)bis[1-[(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)acetyl]-2-pyrrolidinecarboxamide];
(2S,2′S)—N,N′-(2,5-oxazolediyldi-4,1-phenylene)bis[1-[2-(3-ethyl-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-oxopropyl]-2-pyrrolidinecarboxamide];
(2S,2′S)—N,N′-(2,5-oxazolediyldi-4,1-phenylene)bis[1-[(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)phenylacetyl]-2-pyrrolidinecarboxamide];
(2S)—N,N′-(4,4′-(oxazole-2,5-diyl)bis(4,1-phenylene))bis(1-(2-(dimethylamino)-3-(1H-1,2,4-triazol-1-yl)propanoyl)pyrrolidine-2-carboxamide);
(S,S,2S)—N,N′-(4,4′-(oxazole-2,5-diyl)bis(4,1-phenylene))bis(1-((2S,3S)-2-(dimethylamino)-3-hydroxy-3-phenylpropanoyl)pyrrolidine-2-carboxamide);
(S,R,2S)—N,N′-(4,4′-(oxazole-2,5-diyl)bis(4,1-phenylene))bis(1-((2S,3R)-2-(dimethylamino)-3-hydroxy-3-phenylpropanoyl)pyrrolidine-2-carboxamide);
(S,S,2S)—N,N′-(4,4′-(oxazole-2,5-diyl)bis(4,1-phenylene))bis(1-((2S,3S)-2-(dimethylamino)-3-hydroxy-3-(thiophen-3-yl)propanoyl)pyrrolidine-2-carboxamide);
(S,R,2S)—N,N′-(4,4′-(oxazole-2,5-diyl)bis(4,1-phenylene))bis(1-((2S,3R)-2-(dimethylamino)-3-hydroxy-3-(thiophen-3-yl)propanoyl)pyrrolidine-2-carboxamide);
(2S,2′S)—N,N′-(2,5-oxazolediyldi-4,1-phenylene)bis[1-[(hexahydro-5-oxopyrrolo[2,1-b]thiazol-3-yl)carbonyl]-2-pyrrolidinecarboxamide];
(2S,2′S)—N,N′-(2,5-oxazolediyldi-4,1-phenylene)bis[1-[2-(octahydro-1,3-dioxo-4,7-methano-2H-isoindol-2-yl)-1-oxopropyl]-2-pyrrolidinecarboxamide];
(2S,2′S)—N,N′-(2,5-oxazolediyldi-4,1-phenylene)bis[1-[2-(1,3,3a,4,7,7a-hexahydro-1,3-dioxo-4,7-methano-2H-isoindol-2-yl)-3-methyl-1-oxobutyl]-2-pyrrolidinecarboxamide];
(2S,2′S)—N,N′-(2,5-oxazolediyldi-4,1-phenylene)bis[1-[[(4S)-2-oxo-4-phenyl-3-oxazolidinyl]acetyl]-2-pyrrolidinecarboxamide];
(2S,2′S)—N,N′-(2,5-oxazolediyldi-4,1-phenylene)bis[1-[[(4R)-2-oxo-4-phenyl-3-oxazolidinyl]acetyl]-2-pyrrolidinecarboxamide];
(2S,2′S)—N,N′-(2,5-oxazolediyldi-4,1-phenylene)bis[1-[(2,4-dioxo-5-phenyl-3-oxazolidinyl)acetyl]-2-pyrrolidinecarboxamide];
(2)-1-((3-chloro-5-methoxy-1-isoquinolinyl)carbonyl)-N-(4-(2-(4-4-((2S)-1-((2R)-2-(dimethylamino)-2-phenylacetyl)-2-pyrrolidinyl)carbonyl)amino)phenyl)-1,3-oxazol-5-yl)phenyl)-2-pyrrolidinecarboxamide;
(2S,2′S)—N,N′-(2,5-furandiyldi-4,1-phenylene)bis(1-((2R)-2-phenylpropanoyl)-2-pyrrolidinecarboxamide);
dibenzyl(2S,2′S)-2,2′-(2,5-furandiylbis(4,1-phenylenecarbamoyl))di(1-pyrrolidinecarboxylate);
(2S,2′S)—N,N′-(2,5-furandiyldi-4,1-phenylene)bis(1-acetyl-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(2,5-furandiyldi-4,1-phenylene)bis(1-((2R)-2-hydroxy-2-phenylacetyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(2,5-furandiyldi-4,1-phenylene)bis(1-((2R)-2-hydroxy-2-phenylacetyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(2,5-furandiyldi-4,1-phenylene)bis(1-((2R)-2-hydroxy-2-phenylpropanoyl)-2-pyrrolidinecarboxamide);
(2S)-1-((2S)-2-hydroxy-2-phenylpropanoyl)-N-(4-(5-(4-((((2S)-1-(2-hydroxy-2-phenylpropanoyl)-2-pyrrolidinyl)carbonyl)amino)phenyl)-2-furyl)phenyl)-2-pyrrolidinecarboxamide;
(2S,2′S)—N,N′-(2,5-furandiyldi-4,1-phenylene)bis(1-((3-chloro-5-methoxy-1-isoquinolinyl)carbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(2,5-furandiyldi-4,1-phenylene)bis(1-((3-chloro-1-isoquinolinyl)carbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(2,5-furandiyldi-4,1-phenylene)bis(1-(1-isoquinolinylcarbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(2,5-furandiyldi-4,1-phenylene)bis(1-((2R)-2-(dimethylamino)-2-phenylacetyl)-2-pyrrolidinecarboxamide);
(2S)-1-((3-chloro-5-methoxy-1-isoquinolinyl)carbonyl)-N-(4-(5-(4-((((2S)-1-((2R)-2-hydroxy-2-phenylacetyl)-2-pyrrolidinyl)carbonyl)amino)phenyl)-2-furyl)phenyl)-2-pyrrolidinecarboxamide;
(2S)-1-((3-chloro-5-methoxy-1-isoquinolinyl)carbonyl)-N-(4-(5-(4-((((2S)-1-((2R)-2-(dimethylamino)-2-phenylacetyl)-2-pyrrolidinyl)carbonyl)amino)phenyl)-2-furyl)phenyl)-2-pyrrolidinecarboxamide;
(2S)-1-((2R)-2-(dimethylamino)-2-phenylacetyl)-N-(4-(5-(4-((((2S)-1-((2R)-2-hydroxy-2-phenylacetyl)-2-pyrrolidinyl)carbonyl)amino)phenyl)-2-furyl)phenyl)-2-pyrrolidinecarboxamide;
(2S)-1-((2R)-2-acetamido-2-phenylacetyl)-N-(4-(5-(4-((((2S)-1-((3-chloro-5-methoxy-1-isoquinolinyl)carbonyl)-2-pyrrolidinyl)carbonyl)amino)phenyl)-2-furyl)phenyl)-2-pyrrolidinecarboxamide;
(2S)-1-((3-chloro-5-methoxy-1-isoquinolinyl)carbonyl)-N-(4-(5-(4-((((2S)-1-((2S)-2-hydroxy-2-phenylacetyl)-2-pyrrolidinyl)carbonyl)amino)phenyl)-2-furyl)phenyl)-2-pyrrolidinecarboxamide;
2,5-furandiylbis(4,1-phenylenecarbamoyl(2S)-2,1-pyrrolidinediyl(1R)-2-oxo-1-phenyl-2,1-ethanediyl)diacetate;
2,5-furandiylbis(4,1-phenylenecarbamoyl(2S)-2,1-pyrrolidinediyl(1S)-2-oxo-1-phenyl-2,1-ethanediyl)diacetate;
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-(2-thienylcarbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-((1-cyanocyclopropyl)carbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-((3-methoxyphenyl)acetyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-(3-pyridinylcarbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-((dimethylamino)acetyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-(2-pyridinylcarbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-(3,5-difluorobenzoyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-((2-methoxyethoxy)acetyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-(2-methylpentanoyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-(2-fluorobenzoyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-((5-methoxy-1H-indol-3-yl)acetyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-(2-(3-chlorophenoxy)propanoyl)-2-pyrrolidinecarboxamide);
4,4′-(1,3-oxazole-2,5-diylbis(4,1-phenylenecarbamoyl(2S)-2,1-pyrrolidinediyl))bis(4-oxobutanoic acid);
(2S)-1-(1H-imidazol-4-ylacetyl)-N-(4-(2-(4-((((2S)-1-(1H-imidazol-5-ylacetyl)-2-pyrrolidinyl)carbonyl)amino)phenyl)-1,3-oxazol-5-yl)phenyl)-2-pyrrolidinecarboxamide (non-preferred name);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-(cyclohexylcarbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-((2-methylcyclopropyl)carbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-(3-chloro-2,2-dimethylpropanoyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-(tetrahydro-3-furanylcarbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-(2,2-dimethylpentanoyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-((2R)-2-phenylbutanoyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-((1-methyl-1H-imidazol-2-yl)carbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-((4-fluorophenyl)acetyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-((1-acetyl-4-piperidinyl)carbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-(cyclopropylacetyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-((3-chloro-2-thienyl)carbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-((2R)-2-methoxy-2-phenylacetyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-(4,5-dimethyl-2-furoyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-((3,5-dimethyl-4-isoxazolyl)carbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-(4-methoxybenzoyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-((2-methyl-3-pyridinyl)carbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-(tetrahydro-2-furanylcarbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-((2R)-tetrahydro-2-furanylcarbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-(1H-pyrrol-2-ylcarbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-(2,5-dimethyl-3-furoyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-((2-methoxyphenyl)acetyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-(1,3-benzodioxol-5-ylcarbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-(2-furoyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-(3-furoyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-((1-methylcyclopropyl)carbonyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-((1-methyl-1H-pyrrol-2-yl)acetyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-(1-piperidinylacetyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-((1-methyl-1H-imidazol-4-yl)acetyl)-2-pyrrolidinecarboxamide);
(2S,2′S)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-(2,5-dimethylbenzoyl)-2-pyrrolidinecarboxamide);
(2S,4R,2′S,4′R)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-(cyclopropylacetyl)-4-hydroxy-2-pyrrolidinecarboxamide);
(2S,4R,2′S,4′R)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(4-hydroxy-1-(3-pyridinylacetyl)-2-pyrrolidinecarboxamide);
(2S,4R,2′S,4′R)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-(cyclobutylcarbonyl)-4-hydroxy-2-pyrrolidinecarboxamide);
(2S,4R,2′S,4′R)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-(2-ethylbenzoyl)-4-hydroxy-2-pyrrolidinecarboxamide);
(2S,4R,2′S,4′R)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-(cyclohexylcarbonyl)-4-hydroxy-2-pyrrolidinecarboxamide);
(2S,4R,2′S,4′R)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(4-hydroxy-1-(methoxy(phenyl)acetyl)-2-pyrrolidinecarboxamide);
(2S,4R,2′S,4′R)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(4-hydroxy-1-((2R)-tetrahydro-2-furanylcarbonyl)-2-pyrrolidinecarboxamide);
(2S,4R,2′S,4′R)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(4-hydroxy-1-((3-methylphenyl)acetyl)-2-pyrrolidinecarboxamide);
(2S,4R,2′S,4′R)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(4-hydroxy-1-((3-methyl-5-isoxazolyl)acetyl)-2-pyrrolidinecarboxamide);
(2S,4R,2′S,4′R)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-((3,5-dimethyl-4-isoxazolyl)carbonyl)-4-hydroxy-2-pyrrolidinecarboxamide);
(2S,4R,2′S,4′R)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(4-hydroxy-1-(2-thienylcarbonyl)-2-pyrrolidinecarboxamide);
(2S,4R,2′S,4′R)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(4-hydroxy-1-((3-methoxyphenyl)acetyl)-2-pyrrolidinecarboxamide);
(2S,4R,2′S,4′R)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-benzoyl-4-hydroxy-2-pyrrolidinecarboxamide);
(2S,4R,2′S,4′R)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-(cyclopropylcarbonyl)-4-hydroxy-2-pyrrolidinecarboxamide);
(2S,4R,2′S,4′R)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(4-hydroxy-1-(2-pyridinylacetyl)-2-pyrrolidinecarboxamide);
dibenzyl(2S,4R,2′S,4′R)-2,2′-(1,3-oxazole-2,5-diylbis(4,1-phenylenecarbamoyl))bis(4-tert-butoxy-1-pyrrolidinecarboxylate);
(2S,4R,2′S,4′R)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(4-tert-butoxy-2-pyrrolidinecarboxamide);
(2S,4R,2′S,4′R)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(4-tert-butoxy-1-(cyclopropylacetyl)-2-pyrrolidinecarboxamide);
(2S,4R,2′S,4′R)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(4-tert-butoxy-1-(3-pyridinylacetyl)-2-pyrrolidinecarboxamide);
(2S,4R,2′S,4′R)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(4-tert-butoxy-1-(2,2-dimethylpropanoyl)-2-pyrrolidinecarboxamide);
(2S,4R,2′S,4′R)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(4-tert-butoxy-1-(cyclobutylcarbonyl)-2-pyrrolidinecarboxamide);
(2S,4R,2′S,4′R)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(4-tert-butoxy-1-(2-ethylbenzoyl)-2-pyrrolidinecarboxamide);
(2S,4R,2′S,4′R)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(4-tert-butoxy-1-(cyclohexylcarbonyl)-2-pyrrolidinecarboxamide);
(2S,4R,2′S,4′R)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(4-tert-butoxy-1-(methoxy(phenyl)acetyl)-2-pyrrolidinecarboxamide);
(2S,4R,2′S,4′R)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(4-tert-butoxy-1-((2R)-tetrahydro-2-furanylcarbonyl)-2-pyrrolidinecarboxamide);
(2S,4R,2′S,4′R)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(4-tert-butoxy-1-((3-methylphenyl)acetyl)-2-pyrrolidinecarboxamide);
(2S,4R,2′S,4′R)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(4-tert-butoxy-1-((3-methyl-5-isoxazolyl)acetyl)-2-pyrrolidinecarboxamide);
(2S,4R,2′S,4′R)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(4-tert-butoxy-1-((1-methyl-1H-pyrrol-2-yl)carbonyl)-2-pyrrolidinecarboxamide);
(2S,4R,2′S,4′R)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(4-tert-butoxy-1-((3,5-dimethyl-4-isoxazolyl)carbonyl)-2-pyrrolidinecarboxamide);
(2S,4R,2′S,4′R)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(1-benzoyl-4-tert-butoxy-2-pyrrolidinecarboxamide);
(2S,4R,2′S,4′R)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(4-tert-butoxy-1-(cyclopropylcarbonyl)-2-pyrrolidinecarboxamide);
(2S,4R,2′S,4′R)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(4-tert-butoxy-1-(2-pyridinylacetyl)-2-pyrrolidinecarboxamide);
(2S,4R,2′S,4′R)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(4-tert-butoxy-1-(2-thienylcarbonyl)-2-pyrrolidinecarboxamide); and
(2S,4R,2′S,4′R)—N,N′-(1,3-oxazole-2,5-diyldi-4,1-phenylene)bis(4-tert-butoxy-1-((3-methoxyphenyl)acetyl)-2-pyrrolidinecarboxamide).

17. A composition comprising a compound according to claim 1, or a stereoisomer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

18. A method of treating an HCV infection in a patient, comprising administering to the patient a therapeutically effective amount of a compound according to claim 1, or a stereoisomer or a pharmaceutically acceptable salt thereof.